WorldWideScience

Sample records for injectable risperidone efficacy

  1. Risperidone long-acting injection: a review of its long term safety and efficacy

    Directory of Open Access Journals (Sweden)

    Michael K Rainer

    2008-08-01

    Full Text Available Michael K RainerMemory-Clinic and Psychiatric Department, Donauspital, Vienna, AustriaAbstract: A long-acting form of the second-generation antipsychotic drug risperidone is now broadly available for the treatment of schizophrenia and closely related psychiatric conditions. It combines the advantage of previously available depot formulations for first-generation drugs with the favorable characteristics of the modern “atypical” antipsychotics, namely higher efficacy in the treatment of the negative symptoms of schizophrenia and reduced motor disturbances. Published clinical studies show an objective clinical efficacy (as per psychiatric symptom scores and relapse data that exceeds that of oral atypical antipsychotics when patients are switched to the long-acting injectable form, a low incidence of treatment-emergent extrapyramidal side effects, and very good acceptance by patients. Available data for maintenance treatment of bipolar disorder show equivalence with the oral form instead of superiority, but are still limited. As it seems likely that efficacy benefits are mostly due to the fact that the injectable form reduces the demand for patient compliance to one physician visit every 2 weeks instead of self-administration on a daily or twice-daily basis, additional potential could exist in other psychiatric disorders where atypical antipsychotic drugs are of benefit but where patient adherence to treatment schedules is typically low.Keywords: risperidone, schizophrenia, psychotic disorders, patient compliance; delayed-action preparations, injections, intramuscular

  2. Analysis of the efficacy and safety of risperidone microsphere injection in treatment of schizophrenia%注射用利培酮微球治疗精神分裂症的疗效和安全性分析

    Institute of Scientific and Technical Information of China (English)

    张东升

    2015-01-01

    Objective:To investigate the efficacy and safety of risperidone microsphere injection in the treatment of schizophrenia. Methods:90 schizophrenia patients were selected.They were divided into the experimental group and the control group average. The control group were given risperidone tablets treatment,and the experimental group were treated with injection of risperidone treatment.Results:The total treatment efficiency and the quality of life score of the patients in the experimental group was significantly higher than those of the control group(P<0.05);the incidence of the adverse reactions of the experimental group was significantly lower than that of the control group(P<0.05).Conclusion:The curative effect of risperidone microspheres in the treatment of schizophrenia is significant and the safety is high.It can improve the quality of life of patients effectively.%目的:探讨注射用利培酮微球治疗精神分裂症的疗效和安全性。方法:收治精神分裂症患者90例,将其平均分为试验组和对照组,对照组采用利培酮片治疗,试验组采用注射利培酮微球治疗。结果:试验组治疗总有效率、生活质量评分明显高于对照组(P<0.05);试验组不良反应发生率明显低于对照组(P<0.05)。结论:注射用利培酮微球治疗精神分裂症的疗效显著且安全性高,有效改善了患者的生活质量。

  3. 注射用利培酮微球治疗精神分裂症的疗效和安全性%The Efficacy and Safety of Injectable Risperidone Microspheres for Treatment of Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    杨建华

    2015-01-01

    目的:探讨注射利培酮微球治疗精神分裂症的疗效和安全性。方法将50例精神分裂症病患随机分组,给予病患注射用利培酮微球,在整个治疗过程中3、6、9、12、15周时,对照组采取口服利培酮片剂,以PANSS总分增减和不良反应数量为评定疗效的标准。结果实验组和对照组病患前后治疗PANSS总分的分值无差别变化无统计学意义,实验组与对照组在12周治疗的重点与基线相比PANSS总分有明显降低具有统计学意义(P<0.05)。35例精神分裂症病患在治疗前后血常规、血生化正常变化。实验组中大多数病患在接受25 mg/2周利培酮微球用药后病情得到控制或改善,无明显的不良反应。结论对精神分裂病患以利培酮微球注射治疗3周末即起效,治疗效果与口服利培酮片的相当。注射利培酮微球具有疗效稳定、高安全性的特点。%Objective To efficacy and safety study risperidone microsphere injection in the treatment of schizophrenia.Methods 50 cases of schizophrenic patients randomized,give patient risperidone long-acting injection,in the whole course of treatment,3,6,9,12,15 weeks,the control group took oral risperidone tablets to increase or decrease the number of total PANSS score,and adverse reaction for curative effect standard.ResultsThe experimental group and the control group before and after treatment of PANSS disease score score did not change no significant difference,the experimental group and the control group in the 12 week of treatment compared with baseline PANSS scores of key significantly decreased with statistical significance(P<0.05). 35 cases of schizophrenic patients before and after treatment of blood routine,blood biochemical changes in the normal. The majority of patients in the experimental group in an 25 mg/2 weeks risperidone microsphere obtained control or improve the disease after treatment,no significant adverse reactions

  4. Combination treatment with risperidone long-acting injection and psychoeducational approaches for preventing relapse in schizophrenia

    Directory of Open Access Journals (Sweden)

    Zhao Y

    2013-10-01

    Full Text Available Yueren Zhao,1–3 Taro Kishi,1 Nakao Iwata,1 Manabu Ikeda3,4 1Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan; 2Department of Psychiatry, Okehazama Hospital Fujita Kokoro Care Center, Toyoake, Aichi, Japan; 3Department of Neuropsychiatry, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Kumamoto, Japan; 4Department of Neuropsychiatry, Faculty of Life Sciences, Kumamoto University, Kumamoto, Kumamoto, Japan Abstract: A recent meta-analysis showed that long-acting injectable (LAI antipsychotics were not superior to oral antipsychotics for preventing relapse in patients with schizophrenia. We therefore designed a treatment strategy combining risperidone LAI and COMPASS (COMprehensive Psycho-educational Approach and Scheme Set, an original psychoeducational program supporting treatment with risperidone LAI and evaluating subjective treatment satisfaction, transition of symptoms, and effectiveness in preventing symptomatic relapse. The aim of this study was to examine whether addition of COMPASS to risperidone LAI was more effective in preventing relapse in schizophrenia patients than risperidone LAI alone, with the latter group consisting of patients enrolled in a Phase III trial of risperidone LAI in Japan. Patients were followed up for 6 months, with COMPASS continuously implemented from the transition to the observation phase. The primary efficacy measurements were relapse rate (rates of rehospitalization and discontinuation due to inefficacy. Secondary efficacy measurements were the Brief Psychiatric Rating Scale (BPRS and Global Assessment of Functioning (GAF scores. Of the 96 patients originally enrolled, 19 (19.8% were discontinued from all causes. During the 6-month study period, ten of the 96 patients (10.4% relapsed, compared with a 12.2% relapse rate in patients enrolled in a Phase III trial of risperidone LAI in Japan. Patients showed significant improvements in BPRS total

  5. Risperidone

    Science.gov (United States)

    ... bipolar disorder (manic depressive disorder; a disease that causes episodes of depression, episodes of mania, and other abnormal moods). Risperidone is also used to treat behavior problems such as aggression, self-injury, and ... repetitive behavior, difficulty interacting with others, and problems ...

  6. Risperidone Long-Acting Injections: Successful Alternative Deltoid Muscle Injections for Refractory Schizophrenia

    OpenAIRE

    Saxena, Arjun; Grace, Jeffery; Olympia, Josie L.; Trigoboff, Eileen; Watson, Thomas; Cushman, Sharon; Newcomer, David

    2008-01-01

    Treatment-resistant paranoid schizophrenia is often addressed with long-term intramuscular preparations of conventional antipsychotics (haloperidol and fluphenazine), which can be associated with the development of painful, lumpy nodules at the injection site. In this article, we present a case example of a 58-year-old male patient with paranoid schizophrenia who was treated with risperidone long-acting injection given into the deltoid muscle instead of the US Food and Drug Administration (FD...

  7. 78 FR 52777 - Draft Guidance for Industry on Bioequivalence Recommendations for Risperidone Injection...

    Science.gov (United States)

    2013-08-26

    ... on Bioequivalence Recommendations for Risperidone Injection; Availability AGENCY: Food and Drug... provides specific recommendations on the design of bioequivalence (BE) studies to support abbreviated new... availability of a draft guidance for industry entitled ``Bioequivalence Recommendations for Specific...

  8. Emerging treatments in the management of bipolar disorder – focus on risperidone long acting injection

    Directory of Open Access Journals (Sweden)

    Wissam El-Hage

    2010-07-01

    Full Text Available Wissam El-Hage1, Simon A Surguladze21Inserm U930 ERL CNRS 3106, Université François Rabelais and Clinique Psychiatrique Universitaire, CHRU de Tours, Tours, France; 2Institute of Psychiatry, King’s College London, UKAbstract: Bipolar disorder is a life-long psychiatric illness characterized by a high frequency of relapses and substantial societal costs. Almost half of the patients are prescribed second generation antipsychotics for treatment of manic states, or as the maintenance therapy. ­Risperidone long acting injection (RLAI as a monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder was approved by Food and Drug Administration (FDA in United States in May 2009. In this review we will consider the aspects of pharmacology, pharmacokinetics, metabolism, safety and tolerability, and clinical trials focusing on the efficacy of RLAI in bipolar disorder. The patients’ perspective and attitudes to long-acting injections will also be discussed.Keywords: second generation, antipsychotics, patient attitudes, lithium, valproate, monotherapy

  9. Comparing Efficacy and Side Effects of Memantine vs. Risperidone in the Treatment of Autistic Disorder.

    Science.gov (United States)

    Nikvarz, Nikvarz; Alaghband-Rad, Javad; Tehrani-Doost, Mehdi; Alimadadi, Abbas; Ghaeli, Padideh

    2017-01-01

    Introduction: This study was aimed to compare the efficacy and side effects of memantine, an antagonist of the NMDA receptor of glutamate, with risperidone given the fact that glutamate has been noted for its possible effects in the pathogenesis of autism. Risperidone, an atypical antipsychotic, has been approved by FDA for the management of irritability associated with autism. Methods: 30 children, aged 4-17 years, entered an 8-week, randomized trial. Patients were randomly assigned to receive either risperidone or memantine. Autism Behavior Checklist (ABC), Childhood Autism Rating Scale (CARS), Clinical Global Impressions - Improvement (CGI-I) and Clinical Global Impression-Severity (CGI-S) scales were used to assess behavioral symptoms of the patients. Results: Both risperidone and memantine reduced the scores of 4 subscales of ABC as well as the 10-item and the total score of CARS significantly. However, differences between the 2 drugs in the scores of each evaluating scale were not found to be significant. Relatively, larger number of patients on risperidone showed "very much improvement" when assessed by CGI-I scale when compared with those on memantine. Discussion and conclusion: The present study suggests that memantine may have beneficial effects in the treatment of many core symptoms of autism. Therefore, memantine may be considered as a potential medication in the treatment of those autistic children who do not respond or cannot tolerate side effects of risperidone.

  10. Costs and efficacy ofolanzapine and risperidone in schizophrenia

    Directory of Open Access Journals (Sweden)

    Vittorio Mapelli

    2007-06-01

    Full Text Available Introduction: schizophrenia is a serious and long lasting psychiatric disease. The new “atypical” antipsychotic drugs, introduced in the 90s, have substantially improved the effectiveness of medical treatments, compared to previous neuroleptic drugs. Nowadays they tend to be used as first choice drugs. The ddd cost of atypicals may differ by 20% and health authorities may have an incentive to deliver the less costly drug, especially if they are generic. However the various drugs show differential effectiveness rates and a rational choice should consider both cost and effectiveness.
Objective: the purpose of this analysis is to review the existing evidence on cost-effectiveness studies of olanzapine and risperidone, the two most prescribed drugs in Italy. Six published studies were identified, but attention was focused on two articles that reported consistent and methodologically sound results.
Results: most reviewed studies are cost-minimization analyses, since effectiveness indicators show no significant statistical difference between the two drugs, and are inconclusive since the results depend on the evaluation setting. However one observational retrospective study showed a significant severity reduction over 12 months for patients treated with olanzapine (-2.46 on HoNOS scale; p<0.05, compared to a smaller non significant reduction of the risperidone group (-0.57. Despite the higher drug cost, the average total cost per reduced severity score was lower for olanzapine than for risperidone patients (€ 4,554 vs. € 10,897. The only medical and related health care costs for risperidone patients were higher than total costs for olanzapine patients. Another study comparing cohorts of patients with similar starting severity showed a significant severity reduction and global functioning increase over 12 months for olanzapine but no significant increase for risperidone patients (-0.35, p<0.01 on CGI scale; +3.66, p <0.05 on GAF scale

  11. Efficacy of ziprasidone and risperidone in treatment of vagrants with schizophrenia

    Institute of Scientific and Technical Information of China (English)

    Zhan-Hua Li; Zhi-Xiang Li

    2016-01-01

    Objective:To explore the clinical efficacy of ziprasidone and risperidone in the treatment of vagrants with schizophrenia.Methods:A total of 70 vagrants with schizophrenia who were admitted in our hospital from December, 2014 to December, 2015 were included in the study and divided into the observation group (ziprasidone) and the control group (risperidone) according to different treatment protocols. In the observation group, the initial dosage of ziprasidone was 20 mg/d, and was gradually increased to 80-160 mg/d within 10 d, with an average dosage of (105.6±38.7) mg/d. In the control group, the initial dosage of risperidone was 1 mg/d, and was gradually increased to 3-5 mg/d within 10 d, with an average dosage of (3.6±0.9) mg/d. Eight-week treatment was regarded as one course. PANSS was used for grading before and after treatment. The levels of FBG, TG, TC, and HDL-C before and after treatment were detected. The adverse reactions after treatment were observed.Results:With the extending of treatment time, PANSS positive symptoms, negative symptoms, psychosis symptoms, and total scores in the two groups were significantly reduced when compared with before treatment (P0.05). After treatment, the levels of FBG, TG, TC, and HDL-C in the observation group were not significantly different from those before treatment (P>0.05), while those levels in the control group were significantly elevated when compared with before treatment (P<0.05), and those in the observation group were significantly superior to those in the control group (P<0.05). After treatment, the occurrence rate of adverse reactions in the observation was significantly lower than that in the control group (P<0.05).Conclusions: The clinical efficacy of ziprasidone and risperidone in the treatment of vagrants with schizophrenia is equal, but ziprasidone has a small effect on the blood sugar and lipid, with less adverse reactions and preferable compliance; therefore, it deserves to be widely recommended in

  12. 利培酮微球和利培酮治疗精神分裂症对照研究%A comparative study of risperidone long-acting injection and risperidone in treatment for patients with schizophrenia

    Institute of Scientific and Technical Information of China (English)

    苏磊; 孙自豪; 冯凡; 李龙飞

    2015-01-01

    Objective To explore the efficacy and safety of risperidone long-acting injection and risperidone in treatment for patients with schizophrenia.Methods A total of 160 patients with schizophrenia were randomly divided into study group ( 80 cases) with risperidone long-acting injection and control group(80 cases) with risperidone for treatment of 3 months.They were assessed with Positive and Negative Syndrome Scale(PANSS), Clinical Global Impression-Severity of Illness(CGI-S), Clinical Global Impression-Global Improvement(CGI-I) and Extrapyramidal Symptom Rating Scale(ESRS) at baseline , 1st month end, 2nd month end and 3rd month end of treatment.Results At 1st month end, 2nd month end and 3rd month end of treatment, the factors and total scores of PANSS in two groups were all significantly lower than those at baseline(P<0.05).At 2nd month end and 3rd month end of treatment, the factors and total scores of PANSS and CGI in study group were all significantly lower than those in control group(P<0.05).At 1st month end, 2nd month end and 3rd month end of treatment, the scores of ESRS in study group were significantly lower than those in control group(P<0.05).Conclusion It’s effective and safe for risperidone long-acting injection to treat the patients with schizophrenia.%目的:探寻利培酮微球和利培酮治疗精神分裂症患者的疗效和安全性。方法将160例精神分裂症患者随机分为研究组和对照组各80例,研究组用利培酮微球系统治疗,对照组用利培酮系统治疗,共3个月,在基线和治疗后1、2、3个月末应用阳性和阴性综合征量表( PANSS)、临床疗效总评量表-病情严重程度( CGI-S)、临床疗效总评量表-疗效总评( CGI-I)、锥体外系症状评定量表( ESRS)评价。结果两组在治疗后第1、2、3个月末的PANSS评分均低于基线时相应评分(P<0.05)。在治疗后第2、3个月末,研究组PANSS评分以及CGI

  13. An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia

    Directory of Open Access Journals (Sweden)

    Pandina Gahan

    2012-06-01

    Full Text Available Abstract Background Data on the long-term efficacy, safety, and tolerability of risperidone in adolescents with schizophrenia are limited. The objective of this study was to evaluate the efficacy and safety of maintenance risperidone treatment in adolescents with schizophrenia. Methods This open-label study of adolescents aged 13 to 17 years with schizophrenia was a single extension study of two short-term double-blind risperidone studies and also enrolled subjects directly in open-label risperidone treatment. The risperidone dose was flexible and ranged from 2 to 6 mg/day. Most subjects enrolled for 6 months; a subset enrolled for 12 months. Assessment tools included the Positive and Negative Syndrome Scale total and factor scores, Clinical Global Impressions, Children’s Global Assessment Scale, adverse event (AE monitoring, vital signs, laboratory testing, and extrapyramidal symptom rating scales. Results A total of 390 subjects were enrolled; 48 subjects had received placebo in a previous double-blind study; 292 subjects had received risperidone as part of their participation in one of two previous controlled studies; and 50 subjects were enrolled directly for this study. A total of 279 subjects enrolled for 6 months of treatment, and 111 subjects enrolled for 12 months of treatment. Overall, 264 (67.7% subjects completed this study: 209 of the 279 subjects (75% in the 6-month group and 55 of the 111 subjects (50% in the 12-month group. The median mode dose was 3.8 mg/day. At 6 months, all three groups experienced improvement from open-label baseline in symptoms of schizophrenia as well as general assessments of global functioning. Improvements were generally maintained for the duration of treatment. The most common AEs (≥10% of subjects were somnolence, headache, weight increase, hypertonia, insomnia, tremor, and psychosis. Potentially prolactin-related AEs (PPAEs were reported by 36 (9% subjects. The AE profile in this study was

  14. Worsening of myasthenia gravis after administration of injectable long-acting risperidone for treatment of schizophrenia; first case report and a call for caution.

    Science.gov (United States)

    Al-Hashel, Jasem Y; Ismail, Ismail Ibrahim; John, John K; Ibrahim, Mohammed; Ali, Mahmoud

    2016-01-01

    Myasthenia gravis is an autoimmune disease characterized by muscle weakness due to autoantibodies affecting the neuromuscular junction. Co-occurrence of myasthenia gravis and schizophrenia is very rare and raises a challenge in management of both diseases. Antipsychotic drugs exhibit anticholinergic side effects and have the potentials of worsening myasthenia. Long-acting risperidone is an injectable atypical antipsychotic drug that has not been previously reported to worsen myasthenia gravis in literature. We report the first case report of worsening of myasthenia after receiving long-acting risperidone injection for schizophrenia in a 29-year-old female with both diseases. She started to have worsening 2 weeks following the first injection and her symptoms persisted despite receiving plasma exchange. This could be explained by the pharmacokinetics of the drug. We recommend that long-acting risperidone should be used with caution in patients with myasthenia gravis, and clinicians must be aware of the potential risks of this therapy.

  15. Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America

    Directory of Open Access Journals (Sweden)

    Mario Louzã

    2010-12-01

    Full Text Available Rogelio Apiquian1, Rodrigo Córdoba2, Mario Louzã31Americas University, Behavior and Development Sciences Division, Mexico City, Mexico; 2Nervous System Research Center-CISNE, Bogota, Colombia; 3Schizophrenia Research Program, Institute of Psychiatry, Faculty of Medicine, University of São Paulo, BrazilBackground: Risperidone long-acting injection (RLAI has been shown to be efficacious, improve compliance, and increase long-term retention rate on therapy. The aim of this work was to determine the effect of RLAI on clinical outcome and hospitalization rate in patients with schizophrenia or schizoaffective disorder enrolled in the electronic Schizophrenia Treatment Adherence Registry in Latin America.Methods: Data were collected at baseline, retrospectively for the 12 months prior to baseline, and prospectively every three months for 24 months. Hospitalization prior to therapy was assessed by a retrospective chart review. Efficacy and functioning were evaluated using Clinical Global Impression of Illness Severity (CGI-S, Personal and Social Performance (PSP, and Global Assessment of Functioning (GAF scores. Relapse and treatment were also registered.Results: Patients were recruited in Mexico (n = 53, Brazil (n = 11, and Colombia (n = 15. Sixty-five percent (n = 52 were male, and mean age was 32.9 years. Patients were classified as having schizophrenia (n = 73 or schizoaffective disorder (n = 6. The mean dose of RLAI at six months was 34.1 mg (standard deviation = 10.2 mg. The percentage of hospitalized patients before treatment was 28.2% and 5.1% at six months after initiating RLAI (P < 0.001. Significant changes were registered on CGI-S, GAF, and PSP scores.Conclusions: RLAI was associated with an improvement in clinical symptoms and functioning, and a greater reduction in hospitalization.Keywords: long-acting, risperidone, schizophrenia, schizoaffective disorder, Latin America

  16. Clinical utility of the risperidone formulations in the management of schizophrenia

    Directory of Open Access Journals (Sweden)

    Madaan V

    2011-10-01

    Full Text Available Vishal Madaan1, Durga P Bestha2, Venkata Kolli2, Saurabh Jauhari2, Roger C Burket1 1University of Virginia Health System, Charlottesville, VA, USA; 2Creighton University Medical Center, Omaha, NE, USA Abstract: Risperidone is one of the early second-generation antipsychotics that came into the limelight in the early 1990s. Both the oral and long-acting injectable formulations have been subject to numerous studies to assess their safety, efficacy, and tolerability. Risperidone is currently one of the most widely prescribed antipsychotic medications, used for both acute and long-term maintenance in schizophrenia. Risperidone has better efficacy in the treatment of psychotic symptoms than placebo and possibly many first-generation antipsychotics. Risperidone fares better than placebo and first-generation antipsychotics in the treatment of negative symptoms. Risperidone's long acting injectable preparation has been well tolerated and is often useful in patients with medication nonadherence. Risperidone has a higher risk of hyperprolactinemia comparable to first-generation antipsychotics (FGAs but fares better than many second-generation antipsychotics with regards to metabolic side effects. In this article, we briefly review the recent literature exploring the role of risperidone formulations in schizophrenia, discuss clinical usage, and highlight the controversies and challenges associated with its use. Keywords: risperidone, schizophrenia, formulation, antipsychotic, side effects

  17. Efficacy of Risperidone Augmentation with Ondansetron in the Treatment of Negative and Depressive Symptoms in Schizophrenia: A Randomized Clinical Trial

    Directory of Open Access Journals (Sweden)

    Roya Samadi

    2017-01-01

    Full Text Available Background: Given the potential role of the 5-hydroxytryptamine-3 receptor in the pathogenesis of schizophrenia, this study was performed to determine whether ondansetron plus risperidone could reduce the negative and depressive symptoms in patients with treatment-resistant schizophrenia. Methods: In a double-blinded, placebo-controlled, randomized trial (IRCT registration # 201112125280N7, in 2012–2013 in Mashhad, Iran, 38 patients with treatment-resistant schizophrenia received risperidone either combined with a fixed dose (4–8 mg/d of ondansetron (n=18 or with a placebo (n=20 for 12 weeks. The patients were evaluated using the Positive and Negative Syndrome Scale (PANSS, Wechsler’s Adult Intelligence Scale-Revised (WAIS-R, and Hamilton’s Rating Scale for Depression (HRSD at baseline and 12 weeks later. Changes in the inventories were used to evaluate the efficacy of the treatment. The t test, Chi-square test, and SPSS (version 16 were used to analyze the data. The statistical significance was set at P<0.05. Results: Ondansetron plus risperidone was associated with a significantly larger improvement in the PANSS overall scale and subscales for negative symptoms and cognition than was risperidone plus placebo (P<0.001. The WAIS-R scale results indicated significant differences between the 2 groups before and after administrating the medicine and the placebo. The administration of ondansetron significantly improved visual memory based on the subtests of the WAIS (P<0.05. Ondansetron had no positive effects on depressive symptoms (effect size=0.13. Conclusion: This study confirmed that ondansetron, as an adjunct treatment, reduces negative symptoms in patients with schizophrenia and can be used as a potential adjunctive strategy particularly for negative symptoms and cognitive impairments. Trial Registration Number: IRCT201112125280N7

  18. Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America

    Science.gov (United States)

    Apiquian, Rogelio; Córdoba, Rodrigo; Louzã, Mario

    2011-01-01

    Background Risperidone long-acting injection (RLAI) has been shown to be efficacious, improve compliance, and increase long-term retention rate on therapy. The aim of this work was to determine the effect of RLAI on clinical outcome and hospitalization rate in patients with schizophrenia or schizoaffective disorder enrolled in the electronic Schizophrenia Treatment Adherence Registry in Latin America. Methods Data were collected at baseline, retrospectively for the 12 months prior to baseline, and prospectively every three months for 24 months. Hospitalization prior to therapy was assessed by a retrospective chart review. Efficacy and functioning were evaluated using Clinical Global Impression of Illness Severity (CGI-S), Personal and Social Performance (PSP), and Global Assessment of Functioning (GAF) scores. Relapse and treatment were also registered. Results Patients were recruited in Mexico (n = 53), Brazil (n = 11), and Colombia (n = 15). Sixty-five percent (n = 52) were male, and mean age was 32.9 years. Patients were classified as having schizophrenia (n = 73) or schizoaffective disorder (n = 6). The mean dose of RLAI at six months was 34.1 mg (standard deviation = 10.2 mg). The percentage of hospitalized patients before treatment was 28.2% and 5.1% at six months after initiating RLAI (P < 0.001). Significant changes were registered on CGI-S, GAF, and PSP scores. Conclusions RLAI was associated with an improvement in clinical symptoms and functioning, and a greater reduction in hospitalization. PMID:21326651

  19. Preparation and in-vitro characterization of Risperidone-cyclodextrin inclusion complexes as a potential injectable product

    Directory of Open Access Journals (Sweden)

    D Shukla

    2009-12-01

    Full Text Available "n  "n Background and the purpose of the study: This investigation deals with risperidone cyclodextrin (CD complexation for parenteral administration to improve its aqueous solubility which would be beneficial over immediate and sustained release formulations available in market especially for agitated and non-cooperative psychotic patients. "nMethods: The phase solubility study of the drug with β-CD, hydroxypropyl (HP-β-CD and γ-CD was conducted and CDs with higher stability constants were selected for complexation. The complexes of Risperidone with β-CD and HP-β-CD were prepared by precipitation and vacuum drying methods, respectively. Fourier transform-infrared, X-ray diffraction and differential scanning calorimetry techniques were used for characterization of complexes. Drug precipitation study of complex's solution in water for injection and 100 ml of 0.1 M pH 7.4 phosphate buffer saline and stability study in accelerated condition were also carried out. "nResults: The stability constants of the CD were in the following order: β-CD (341.953±11.87 M-1 > HP-β-CD (170.817± 5.93 M-1 > γ-CD (93.716 ± 3.25 M-1. CDs with high stability constants were selected to prepare the drug CD complex. The complexation efficiencies of β-CD and HP-β-CD were 95.23 ± 2.27% and 97.59 ±1.97%, respectively. Both types of CDs exhibited complexation at 1:2 molar stoichiometric ratio. The drug precipitation study indicated complete solubility (100% drug dissolution without a trace of precipitate within 5 mins. The complexes were found to be stable for a period of 3 months under accelerated stability conditions. Major conclusion:Stable complexes of risperidone were successfully formulated using both β-CD and HP-β-CD by simple and highly efficient methods of complexation for parenteral administration.

  20. Efficacy of Risperidone Augmentation with Ondansetron in the Treatment of Negative and Depressive Symptoms in Schizophrenia: A Randomized Clinical Trial

    Science.gov (United States)

    Samadi, Roya; Soluti, Susan; Daneshmand, Reza; Assari, Shervin; Manteghi, Ali Akhoundpour

    2017-01-01

    Background: Given the potential role of the 5-hydroxytryptamine-3 receptor in the pathogenesis of schizophrenia, this study was performed to determine whether ondansetron plus risperidone could reduce the negative and depressive symptoms in patients with treatment-resistant schizophrenia. Methods: In a double-blinded, placebo-controlled, randomized trial (IRCT registration # 201112125280N7), in 2012–2013 in Mashhad, Iran, 38 patients with treatment-resistant schizophrenia received risperidone either combined with a fixed dose (4–8 mg/d) of ondansetron (n=18) or with a placebo (n=20) for 12 weeks. The patients were evaluated using the Positive and Negative Syndrome Scale (PANSS), Wechsler’s Adult Intelligence Scale-Revised (WAIS-R), and Hamilton’s Rating Scale for Depression (HRSD) at baseline and 12 weeks later. Changes in the inventories were used to evaluate the efficacy of the treatment. The t test, Chi-square test, and SPSS (version 16) were used to analyze the data. The statistical significance was set atPWAIS-R scale results indicated significant differences between the 2 groups before and after administrating the medicine and the placebo. The administration of ondansetron significantly improved visual memory based on the subtests of the WAIS (P<0.05). Ondansetron had no positive effects on depressive symptoms (effect size=0.13). Conclusion: This study confirmed that ondansetron, as an adjunct treatment, reduces negative symptoms in patients with schizophrenia and can be used as a potential adjunctive strategy particularly for negative symptoms and cognitive impairments. Trial Registration Number: IRCT201112125280N7 PMID:28293046

  1. Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium

    Directory of Open Access Journals (Sweden)

    Macfadden Wayne

    2011-04-01

    Full Text Available Abstract Background Because wide variations in mental health care utilization exist throughout the world, determining long-term effectiveness of psychotropic medications in a real-world setting would be beneficial to physicians and patients. The purpose of this analysis was to describe the effectiveness of injectable risperidone long-acting therapy (RLAT for schizophrenia across countries. Methods This was a pragmatic analysis of data from two prospective observational studies conducted in the US (Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation [SOURCE]; ClinicalTrials.gov registration number for the SOURCE study: NCT00246194 and Spain, Australia, and Belgium (electronic Schizophrenia Treatment Adherence Registry [eSTAR]. Two separate analyses were performed to assess clinical improvement during the study and estimate psychiatric hospitalization rates before and after RLAT initiation. Clinical improvement was evaluated using the Clinical Global Impressions-Severity (CGI-S and Global Assessment of Functioning (GAF scales, and change from baseline was evaluated using paired t tests. Psychiatric hospitalization rates were analyzed using incidence densities, and the bootstrap resampling method was used to examine differences between the pre-baseline and post-baseline periods. Results The initial sample comprised 3,069 patients (US, n = 532; Spain, n = 1,345; Australia, n = 784; and Belgium, n = 408. In all, 24 months of study participation, completed by 39.3% (n = 209, 62.7% (n = 843, 45.8% (n = 359, and 64.2% (n = 262 of patients from the US, Spain, Australia, and Belgium, respectively, were included in the clinical analysis. Improvements compared with baseline were observed on both clinical assessments across countries (P P P Conclusions RLAT in patients with schizophrenia was associated with improvements in clinical and functional outcomes and decreased hospitalization rates in the US, Spain, Australia, and Belgium, despite

  2. Comparison between the efficacies of Risperidone with Haloperidol in the treatment of attention-deficit hyperactivity disorder (ADHD) among preschoolers: a randomized double-blind clinical trial

    Science.gov (United States)

    Riahi, Forough; Tashakori, Ashraf; Abdi, Leila

    2016-01-01

    Background Attention-deficit hyperactivity disorder (ADHD) is a common psychiatric disease with a worldwide pooled prevalence of 5.29%. Objective To compare the efficacy of Risperidone with Haloperidol in the treatment of attention-deficit hyperactivity disorder (ADHD) among 3- to 6-year-old children. Methods In a 6-week double-blind clinical trial, the efficacy of Risperidone 0.5–2 mg with a dose of maximum Haloperidol 0.075 mg/kg was assessed in 39 children aged 3–6 years. This study was conducted at the Golestan Psychiatric Clinic (Ahvaz, Iran). Measurement tools included the Conners’ Parent Rating Scale (CPRS-48), Children’s Global Assessment Scale (CGAS), and the Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS). Data were analyzed using the Wilcoxon, Mann-Whitney, and Fisher’s exact tests in the SPSS 19. Results During the 6 weeks, the decline in points was seen in Conner’s rating scale and in ADHD-RS score in Risperidone and Haloperidol groups (p0.05). Conclusions Haloperidol and Risperidone possibly can be an acceptable treatment choice in the ADHD treatment of 3- to 6-year-old children. Trial registration The trial was registered at the Iranian Registry of Clinical Trials (http://www.irct.ir) with the Irct ID: IRCT2015082623766N1. Funding This work was financially supported by grant (ref. no.: U-93130) from the vice chancellor for Research Affairs of Ahvaz Jundishapur University of Medical Sciences. PMID:27790334

  3. Effect of Smoking on Pharmacokinetics and Clinical Efficacy of Risperidone%吸烟对利培酮药代动力学及疗效的影响

    Institute of Scientific and Technical Information of China (English)

    曹民佑

    2014-01-01

    目的:探讨吸烟对利培酮药代动力学和血药浓度的影响,以及利培酮血药浓度与临床疗效及不良反应之间的关系。方法采用反相高效液相色谱法测定利培酮及9-羟利培酮血药浓度,并进行药代动力学参数研究,采用简明精神病症状评定量表(BPRS)、阳性和阴性症状量表(SAPS、SANS)和副反应量表(TESS)评定临床疗效和不良反应。结果吸烟者的利培酮和9-羟利培酮的消除速率较非吸烟者快[消除速率常数(K)更高],且其消除半衰期(T1/2)较短,达峰浓度(Cmax)和第2周末稳态浓度谷值均较低(P<0.05或P<0.01)。利培酮血药浓度及利培酮+9-羟利培酮总浓度与TESS增分值呈正相关(r=0.42~0.62,均P<0.01),与BPRS、SANS和SAPS的减分率无显著相关性(P>0.05)。以治疗8周BPRS总分减分率≥25%为界,划分有效组和无效组进行血药浓度比较,无效组利培酮及利培酮+9-羟利培酮血药浓度低于有效组(P<0.05)。结论吸烟可加快利培酮的代谢,利培酮和9-羟利培酮总的血药浓度在20~60μg·L-1范围内较为适宜,疗效较好,不良反应较少。%Objective To evaluate the influence of smoking on the pharmacokinetics and plasma concentrations of risperidone, and to investigate the relationships of blood risperidone concentrations to clinical efficacies and adverse reactions. Methods The plasma concentrations of risperidone and 9-hydroxyrisperidone were measured by RP-HPLC and pharmacokinetic studies were performed in patients. Clinical efficacies and adverse reactions were evaluated with Brief Psychiatric Reacting Scale (BPRS),Scale for the Assessment of Positive Symptoms (SAPS),Scale for the Assessment of Negative Symptoms(SANS) and Treatment Emergent Symptom Scale(TESS). Results Compared with patients who do not smoke, elimination rate constant of risperidone and 9-hydroxyrisperidone increased and

  4. Risperidone versus pimozide in Tourette's disorder : A comparative double-blind parallel-group study

    NARCIS (Netherlands)

    Bruggeman, R; van der Linden, C.; Buitelaar, JK; Gericke, GS; Hawkridge, SM; Temlett, JA

    2001-01-01

    Background: The treatment of Tourette's disorder with classical neuroleptics is limited by their side effects. Risperidone is a new efficacious antipsychotic with a low propensity for extrapyramidal side effects. To establish risperidone's therapeutic potential in Tourette's disorder, we studied the

  5. Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews

    Directory of Open Access Journals (Sweden)

    Tamara Melnik

    Full Text Available CONTEXT AND OBJECTIVE: According to some cohort studies, the prevalence of refractory schizophrenia (RS is 20-40%. Our aim was to evaluate the effectiveness and safety of aripiprazole, paliperidone, quetiapine and risperidone for treating RS. METHODS: This was a critical appraisal of Cochrane reviews published in the Cochrane Library, supplemented with reference to more recent randomized controlled trials (RCTs on RS. The following databases were searched: Medical Literature Analysis and Retrieval System Online (Medline (1966-2009, Controlled Trials of the Cochrane Collaboration (2009, Issue 2, Embase (Excerpta Medica (1980-2009, Literatura Latino-Americana e do Caribe em Ciências da Saúde (Lilacs (1982-2009. There was no language restriction. Randomized controlled trials, systematic reviews and meta-analyses evaluating atypical antipsychotics for treating RS were included. RESULTS: Seven Cochrane systematic reviews and 10 additional RCTs were included in this review. The data generally showed minor differences between the atypical antipsychotics evaluated and typical antipsychotics, regarding improvement in disease symptoms, despite better adherence to treatment with atypical antipsychotics. Risperidone was specifically evaluated in patients with RS in one of the systematic reviews included, with favorable outcomes, but without definitive superiority compared with other drugs of proven efficacy, like amisulpride, clozapine and olanzapine. CONCLUSIONS: The findings underscore the difficulty in treating these patients, with high dropout rates and treatment patterns of modest improvement in assessments of effectiveness. Atypical antipsychotics have advantages over typical antipsychotics mainly through their better safety profile, which leads to better adherence to treatment. A combination of antipsychotics may also be an option for some refractory patients.

  6. Efficacy and safety analysis of Ziprasidone and Risperidone in treatment of schizophrenic patients%齐拉西酮与利培酮治疗精神分裂症患者的疗效及安全性分析

    Institute of Scientific and Technical Information of China (English)

    文卫

    2015-01-01

    目的::探讨齐拉西酮与利培酮两种药物在精神分裂症患者治疗中的临床效果。方法:将64例精神分裂症患者分为齐拉西酮组和利培酮组,每组各32例。分别给予两组患者齐拉西酮或利培酮治疗,观察两组患者的疗效和安全性。结果:在治疗4周后,两组患者的两项量表评估有明显差异(P<0.05);齐拉西酮组患者不良反应率为9.38%低于利培酮组的18.75%,差异有统计学意义(P<0.05)。结论:齐拉西酮治疗精神分裂症患者的临床效果优于利培酮治疗。%Objective:To investigate clinical effects of Ziprasidone and Risperidone in treatment of schizophrenia. Methods:64 schizophrenic patients were divided into Ziprasidone group ( treated with Ziprasidone) and Risperidone group ( treated with Risperi-done) . The efficacies of safety of the two groups were observed. Results:In 4 weeks after treatment, there were significant differences in the two scales between the two group (P<0. 05). The adverse reaction rates of Ziprasidone group and Risperidone group were 9. 38% and 18. 75%. Conclusions: In the treatment of schizophrenia, Ziprasidone has good clinical effects and higher safety than Risperidone.

  7. Interpreting serum risperidone concentrations.

    Science.gov (United States)

    Boerth, Joel M; Caley, Charles F; Goethe, John W

    2005-02-01

    Risperidone is an atypical antipsychotic commonly used for treatment of schizophrenia and other psychotic disorders. Although therapeutic drug monitoring is not routine for any of the atypical antipsychotics, serum antipsychotic concentrations are measured routinely to assess treatment nonadherence. In humans, risperidone is metabolized by cytochrome P450 2D6 to 9-hydroxyrisperidone; together these constitute the active moiety. Dose-proportional increases in serum concentrations have not been reported for the parent drug, but have been reported for 9-hydroxyrisperidone and the active moiety (i.e., the combined concentrations of risperidone and 9-hydroxyrisperidone). We describe a 34-year-old Caucasian man of Sicilian descent with a history of schizophrenia, disorganized type. He was suspected to be noncompliant with his risperidone therapy. Initially, active moiety risperidone concentrations increased linearly with prescribed dosage increases. However, with continued increases, active moiety concentrations adjusted downward and remained 17-36% below anticipated levels. We propose a method for estimating target active moiety concentrations of risperidone based on dosage-a method that may be used to guide clinicians in assessing nonadherence to risperidone treatment.

  8. Efficacy and adverse reactions of Aripiprazole and Risperidone in treatment of patients with schizophrenia%阿立哌唑与利培酮治疗精神分裂症患者的疗效及不良反应

    Institute of Scientific and Technical Information of China (English)

    臧双九

    2015-01-01

    目的::观察阿立哌唑、利培酮治疗精神分裂症患者的疗效、不良反应及安全性。方法:将60例符合CCMD-3诊断标准的精神分裂症患者随机分为两组,分别给予患者阿立哌唑、利培酮治疗8周,于治疗前以及治疗2、4和8周采用阳性与阴性症状量表( PANSS)评定患者的疗效,不良反应量表( TESS)评定患者的不良反应。结果:两组患者治疗的疗效相当。利培酮组患者的锥体外系反应、内分泌以及体重增加多于阿立哌唑组。结论:阿立哌唑治疗精神分裂症患者的疗效与利培酮相似,但不良反应更少。%Objective: To observe efficacy, adverse reactions and safety of Aripiprazole and Risperidone in treatment of pa-tients with schizophrenia. Methods: 60 cases meeting CCMD3 diagnostic criteria for schizophrenia were randomly divided into 2 groups. They were treated with Aripiprazole and Risperidone for 8 weeks, respectively. Before and 2, 4 and 8 weeks after the treat-ment, PANSS (positive and negative symptom scale) and TESS (treatment emergent symptom scale) were used to evaluate the efficacy and adverse reactions. Results:The two groups had a similar efficacy;however, the extrapyramidal system reactions, endocrine, and weight gain in Risperidone group were more than those of Aripiprazole group. Conclusions:Aripiprazole in the treatment of the patients with schizophrenia has a similar efficacy with Risperidone, but has fewer adverse reactions.

  9. Effect of acute and chronic treatment with risperidone on the serotonin and dopamine receptors in the rat brain

    Energy Technology Data Exchange (ETDEWEB)

    Choi, Yun Young; Moon, Dae Hyuk; Son, Hye Kyung; Kim, Chang Yoon; Lee, Chul; Lee, Hee Kyung [College of Medicine, Ulsan Univ., Seoul (Korea, Republic of)

    1997-03-01

    The therapeutic efficacy of antipsychotic drugs is generally attributed to their ability to block dopamine D{sub 2} receptors. Classical D{sub 2} antagonists are not effective to treat negative symptoms and produce extrapyramidal side effects. On the other hand, atypical antipsychotic agents ameliorate negative symptoms without producing extrapyramidal side effects, and it is reported to be associated with blockade of serotonin 5-HT{sub 2} receptors. The purpose of this study was to evaluate the effect of risperidone on neuroreceptors in the rat brain by quantitative autoradiography method. In acute treatment group, risperidone was injected into peritoneal cavity of male Wistar rats with dose of 0, 0.1, 0.25, 0.5, 1.0 and 2.0mg/kg in each group (5/group), and they were decapitated after 2 hours. In chronic treatment group, risperidone was injected with dose of 0, 0.1, and 1m/kg (I.P.) for 21 ays and decapitated after 24 hours following last treatment. The effect of risperodone on the binding of [{sup 3}H) spiperone to 5-HT{sub 2} and D{sub 2} receptors were analysed in 4 discrete regions of the striatum, nucleus accumbens, and frontal cortex by quantitative autoradiography. Acute treatment with risperidone reduced cortical 5-HT{sub 2} specific [{sup 3}H]spiperone binding to 32% of vehicle-treated control. Subcortical 5-HR{sub 2} specific [{sup 3}H]spiperone binding was not affected at all dose groups whereas a significant reduction (57%) in D{sub 2} specific [{sup 3}H]spiperone binding was observed in risperidone treated group at doses of 1-2mg/kg. Chronic treatment with risperidone produced a decrease in the maximal number of cortical 5-HT{sub 2} receptors to 51% and 46% of control in 0.1mg/kg and 1mg/kg treated group respectively. In conclusion, risperidone is a cortical serotonin receptor antagonist with relatively weak antagonistic action on dopamine receptors. These effects on neuroreceptors may explain the therapeutic effect of risperidone as a atypical

  10. 喹硫平与利培酮治疗精神分裂症的疗效与安全性研究%Study on efficacy and safety of Quetiapine and Risperidone in treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    吴雪娥

    2015-01-01

    Objective To observe efficacy and safety of quetiapine and risperidone to patients with schizophrenia.Methods Participants included 80 patients with schizophrenia ,accepted quetiapine(496 ±65) mg/d and risperidone ( 3.1 ±0.3 ) mg/d respectively for eight weeks, and curative effect and safety were observed.Results The total efficiency rate of quetiapine group and risperidone group was 72.5% and 75%respectively, the effects of quetiapine and risperidone in schizophrenic patients had no significantly difference( p>0.05).The incidence of postural hypotension in quetiapine group was higher than that in risperidone group, but the incidence of extrapyramidal side effects and weight gain in quetiapine group was lower than that in risperidone group, there was significantly difference (P<0.05).Conclusions Quetiapine and risperidone have similar efficiency in the treatment of schizophrenic patients, and are safe and generally well-tolerated.%目的:研究喹硫平与利培酮治疗精神分裂症的疗效及安全性。方法按随机数字表法将2013年在本院精神病科住院的精神分裂症患者随机分为喹硫平组和利培酮组,每组各40例。喹硫平组给予喹硫平(496±65) mg/d治疗,利培酮组给予利培酮(3.1±0.3) mg/d治疗。疗程8周,从PANSS减分率评价其疗效,同时以不良反应症状量表(TESS)评定副反应。结果喹硫平组总有效率为72.5%,利培酮组总有效率为75.0%,两组疗效差异无统计学意义( P>0.05)。喹硫平组体位性低血压发生率明显高于利培酮组,利培酮组体重增加及锥体外系反应发生率显著高于喹硫平组,组间比较差异有统计学意义( P<0.05)。结论喹硫平与利培酮治疗精神分裂症疗效相当,安全性良好。

  11. Medication adherence in patients with psychotic disorders: an observational survey involving patients before they switch to long-acting injectable risperidone

    Directory of Open Access Journals (Sweden)

    Baylé FJ

    2015-09-01

    Full Text Available Franck Jean Baylé,1 Arnaud Tessier,2,3 Sophie Bouju,4 David Misdrahi2,3 1Sainte-Anne Hospital (SHU, Paris V-Descartes University, Paris, 2Hôpital Charles Perrens, Pôle de Psychiatrie Adulte, 3CNRS UMR 5287-INCIA, Bordeaux University, Bordeaux, 4Janssen-Cilag France, Issy Les Moulineaux, Paris, France Background: Maintaining antipsychotic therapy in psychosis is important in preventing relapse. Long-acting depot preparations can prevent covert non-adherence and thus potentially contribute to better patient outcomes. In this observational survey the main objective is to evaluate medication adherence and its determinants for oral treatment in a large sample of patients with psychosis.Methods: In this cross-sectional survey medication adherence for oral treatment was assessed by patients using the patient-rated Medication Adherence Questionnaire (MAQ. Data were collected by physicians on patients with a recent acute psychotic episode before switching to long-acting injectable risperidone. Other evaluations included disease severity (Clinical Global Impression – Severity, patients’ insight (Positive and Negative Syndrome Scale item G12, treatment acceptance (clinician-rated Compliance Rating Scale, and therapeutic alliance (patient-rated 4-Point ordinal Alliance Scale.Results: A total of 399 psychiatrists enrolled 1,887 patients (mean age 36.8±11.9 years; 61.6% had schizophrenia. Adherence to oral medication was “low” in 53.2% of patients, “medium” in 29.5%, and “high” in 17.3%. Of patients with psychiatrist-rated active acceptance of treatment, 70% had “medium” or “high” MAQ scores (P<0.0001. Medication adherence was significantly associated with therapeutic alliance (4-Point ordinal Alliance Scale score; P<0.0001. Patient age was significantly associated with adherence: mean age increased with greater adherence (35.6, 36.7, and 38.6 years for patients with “low”, “medium”, and “high” levels of adherence

  12. Efficacy observation of Aripiprazole and Risperidone in treatment of schizophrenia%阿立哌唑和利培酮治疗精神分裂症的疗效观察

    Institute of Scientific and Technical Information of China (English)

    曲秀颖

    2015-01-01

    目的::探讨阿立哌唑与利培酮治疗精神分裂症的疗效及安全性。方法:选取76例符合CCMD-3精神分裂症诊断标准的患者随机分为阿立哌唑组和利培酮组,每组38例。两组患者分别给予阿立哌唑和利培酮治疗,6周后进行临床疗效评价及不良反应评定。结果:阿立哌唑组患者总有效率为89.47%,利培酮组患者总有效率为86.84%,两组患者总体疗效相当(P>0.05)。两组患者治疗前后PANSS评分比较,差异有统计学意义(P0.05)。治疗6周,阿立哌唑组患者不良反应发生率低于利培酮组(P0. 05). There was a statistical difference in the PANSS score between the two group before and after the treatment (P0. 05). Six weeks after the treatment, the inci-dence rates of adverse reactions of Aripiprazole group were lower than those of Risperidone group (P<0. 05). Conclusions: In the treatment of schizophrenia, Aripiprazole has a similar efficacy with Risperidone, but is superior in influences on extrapyramidal reac-tions, endocrine and weight than Risperidone.

  13. Observation of the clinical efficacy of aripiprazole and risperidone in the treatment of schizophrenia%阿立哌唑与利培酮治疗精神分裂症的临床疗效观察

    Institute of Scientific and Technical Information of China (English)

    刘卫平

    2015-01-01

    目的:探讨阿立哌唑与利培酮治疗精神分裂症的疗效。方法:收治精神分裂症患者60例,随机分为对照组和观察组,对照组采用利培酮治疗,观察组采用阿立哌唑治疗,比较两组治疗效果。结果:对照组总有效率86.7%,观察组总有效率90.0%,P>0.05;对照组出现不良反应18例(60.0%),观察组出现不良反应6例(20.0%),P<0.05。结论:在精神分裂症的治疗中利培酮与阿立哌唑均具有显著的疗效,然而相对于利培酮而言,阿立哌唑具有较低的不良反应发生率,因此其具有较高的安全性。%Objective:To explore the clinical efficacy of aripiprazole and risperidone in the treatment of schizophrenia.Methods:60 patients with schizophrenia were selected.They were randomly divided into the control group and the observation group.The control group was treated with risperidone,and the observation group was treated with aripiprazole.We compared the treatment effect of the two groups.Results:In the control group,the total efficiency was 86.7%;in the observation group,the total efficiency was 90%,P>0.05.In the control group,18 cases(60%) had adverse reactions;in the observation group,6 cases(20%) had adverse reactions,P<0.05.Conclusion:In the treatment of schizophrenia,risperidone and aripiprazole all had significant curative effect,but compared with risperidone,aripiprazole had low adverse reaction rate,so it had a high safety.

  14. Local analgesic efficacy of tramadol following intraplantar injection.

    Science.gov (United States)

    Mert, Tufan; Gunes, Yasemin; Gunay, Ismail

    2007-03-08

    Several studies have suggested that systemic tramadol, an opioid, can represent a valuable treatment in severe pain conditions because of their effects on central pain pathways. However, there are not enough studies supporting that tramadol is efficacious when administered locally. Therefore, we studied the potential local analgesic effects of tramadol in peripheral nociception. In addition, we tested the antinociceptive effects of tramadol-CaCl(2) or naloxone combinations after subcutaneous intraplantar injection in a validated rat model of acute thermal nociception. Local analgesic effects of tramadol were compared with those of lidocaine. The effects of tramadol on thermal paw withdrawal latencies were monitored using the plantar test. The antinociceptive potency of tramadol is higher and long-lasting than that of lidocaine. Naloxone was unable to inhibit the increased antinociceptive response produced by tramadol. Ca(2+) modified the effect of tramadol. When Ca(2+) dose was increased in the solution, thermal antinociceptive potency of tramadol, but not lidocaine was prolonged. Thermal nociceptive responses were not affected in the non-injected paws, indicating a lack of systemic effects with doses of tramadol and lidocaine that elicited local analgesia. These results suggest that intraplantar tramadol administration can produce local analgesic effect with a different action mechanism than that of lidocaine. In addition, extracellular Ca(2+) may play an important role in the local analgesic action of tramadol.

  15. 利培酮治疗不同型精神分裂症患者疗效及安全性研究%Study on efficacy and safety of risperidone in treatment of different kinds of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    王继禹; 白丽娟; 段媛卿; 原洁; 李志锐; 李新义

    2013-01-01

    目的 探讨利培酮治疗不同型精神分裂症的疗效及安全性.方法 收集100例偏执型及未分化型精神分裂症患者,分别给予利培酮治疗,观察8周,分别于治疗前及治疗第1,2,4,6,8周末分别进行阳性和阴性症状量表(PANSS)、临床总体印象量表、不良反应量表、锥体外系不良反应量表评分,比较不同型精神分裂症患者对利培酮的疗效及不良反应.结果 不同型精神分裂症患者治疗后同一时间点PANSS评分比较差异无统计学意义(P>0.05);不同型精神分裂症患者同一时间点所用剂量比较差异无统计学意义(P>0.05);利培酮治疗前后PANSS评分比较差异有统计学意义(P<0.01);入组前体重基线值为(63.91±11.75) kg,治疗8周后为(65.48±10.92) kg,差异有统计学意义(P<0.01).结论 利培酮对偏执型及未分化型精神分裂症疗效肯定,并具有较好的安全性及耐受性.%Objective To explore the safety and efficacy of risperidone in treatment of different kinds of schizophrenia.Methods Collected 100 cases of paranoid and undifferentiated schizophrenia patients,all patients were given risperidone treatment and observed for 8 weeks.Before treatment and at the 1st,2nd,4th,6th,8th weeks respectively by means of positive and negative symptom scale (PANSS),the Clinical Global Impression scale,adverse reaction scale,extrapyramidal system adverse reactions to scale score,comparison of different types of schizophrenia patients on risperidone' s efficacy and adverse reaction.Results The total PANSS score of different kinds of schizophrenia didn' t have great difference (P>0.05); the dose also didn' t have great statistical difference between different kinds of schizophrenia (P>0.05); the total PANSS score had great statistical difference between treatment (P<0.01); the group before the baseline weight value was (63.91 ± 11.75) kg,after 8 weeks of treatment it was (65.48 ± 10.92) kg,the difference was

  16. Formulation, in vitro and in vivo evaluation of transdermal patches containing risperidone.

    Science.gov (United States)

    Aggarwal, Geeta; Dhawan, Sanju; Hari Kumar, S L

    2013-01-01

    The efficacy of oral risperidone treatment in prevention of schizophrenia is well known. However, oral side effects and patient compliance is always a problem for schizophrenics. In this study, risperidone was formulated into matrix transdermal patches to overcome these problems. The formulation factors for such patches, including eudragit RL 100 and eudragit RS 100 as matrix forming polymers, olive oil, groundnut oil and jojoba oil in different concentrations as enhancers and amount of drug loaded were investigated. The transdermal patches containing risperidone were prepared by solvent casting method and characterized for physicochemical and in vitro permeation studies through excised rat skin. Among the tested preparations, formulations with 20% risperidone, 3:2 ERL 100 and ERS 100 as polymers, mixture of olive oil and jojoba oil as enhancer, exhibited greatest cumulative amount of drug permeated (1.87 ± 0.09 mg/cm(2)) in 72 h, so batch ROJ was concluded as optimized formulation and assessed for pharmacokinetic, pharmacodynamic and skin irritation potential. The pharmacokinetic characteristics of the optimized risperidone patch were determined using rabbits, while orally administered risperidone in solution was used for comparison. The calculated relative bioavailability of risperidone transdermal patch was 115.20% with prolonged release of drug. Neuroleptic efficacy of transdermal formulation was assessed by rota-rod and grip test in comparison with control and marketed oral formulations with no skin irritation. This suggests the transdermal application of risperidone holds promise for improved bioavailability and better management of schizophrenia in long-term basis.

  17. Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial

    DEFF Research Database (Denmark)

    Lublin, Henrik; Haug, Hans-Joachim; Koponen, Hannu

    2009-01-01

    The efficacy, safety and tolerability of ziprasidone versus the comparators olanzapine, risperidone or quetiapine were investigated in adult patients with chronic schizophrenia, schizoaffective and schizophreniform disorders, with lack of efficacy or intolerance to their previous antipsychotic tr...

  18. 注射用利培酮微球与非经典抗精神病药治疗精神分裂症的对照研究%A comparative study between long-acting risperidone microsphere injection for treatment of patients with schizophrenia

    Institute of Scientific and Technical Information of China (English)

    谷德康; 杨楠; 白录东

    2010-01-01

    Objective To investigate clinical efficacy and side effects of long-acting risperidone microsphere injection for treatment of patients with schizophrenia. Methods A total of 82 patients with schizophrenia were randomly divided into two groups,study group with long-acting risperidone microsphere injection and control group with atypical antipsychotics treatment for 24 weeks. The Positive and Negative Syndrome Scale (PANSS),The Personal and Social Performance (PSP) and Treatment Emergent Symptoms Scale (TESS) were used to evaluate efficacy and adverse effects of treatment at the end of 1st ,2nd,4th, 12nd and 24th week. Results The therapeutic efficacy in control group was similar to that in study group,and there was no significant difference between the two groups (P> 0.05 ). But the therapeutic efficacy in study group was better than that in control group at the end of the 4nd week (P<0.05 ) , and study group was more likely to improve social function(P < 0. 05 ). Incidence of adverse effects in study group was lower than that in control group , but the difference was not significant (P >0.05 ). The incidence of akathisia symptom in study group was higher than that in control group,but the difference was not significant (P>0.05). The incidence of drowsiness symptom in study group was significantly lower than that in control group(P<0.05 ). Conclusion Long-acting risperidone microsphere injection is as effective as atypical antipsychotics for treatment of patients with schizophrenia, but it has better efficacy in improving social function of the schizophrenia with lower side effects.%目的 探讨注射用利培酮微球治疗精神分裂症的疗效和安全性.方法 符合诊断标准的82名精神分裂症患者分成2组,分别给予注射用利培酮微球和非经典抗精神病药物利培酮、喹硫平、奥氮平治疗24周.于治疗前及治疗后2,4,12,24周末分别采用阳性与阴性症状量表(PANSS)、个体和社会功能量表(PSP)

  19. Comparison of efficacy and safety of amisulpride ang risperidone in treating patients with schizophrenia%氨黄必利与利培酮治疗患者精神分裂症患者的对照研究

    Institute of Scientific and Technical Information of China (English)

    杨奎娟; 刘超

    2013-01-01

    目的比较氨黄必利与利培酮治疗精神分裂症患者的疗效与不良反应。方法 120例符合中国精神障碍分类与诊断标准第3版精神分裂症诊断标准的患者随机分为两组,每组60例,分别给予氨黄必利和利培酮治疗8周,采用阳性与阴性症状量表(PANSS)评定疗效,治疗中出现的症状量表(TESS)评定不良反应,用世界卫生组织编制的生活质量量表(WHOQOL-100)评定生活质量。结果 治疗8周后,氨黄必利组显效率73.3%,有效率90%,利培酮组显效率66.7%,总有效率86.7%,两组疗效比较差异无统计学意义(P>0.05);两组WHOQOL-100各领域评分较治疗前均明显差异(P>0.01);氨黄必利组不良反应发生率16.7%,利培酮组为13.3%两组差异无统计学意义(P>0.05)。结论 氨黄必利与利培酮治疗精神分裂症患者的疗效相当,不良反应小,明显改善患者生活质量。%Objective: To compare the efficacy and safety between amisulpride and rispeeidone in treatment of schizophrenia. Method: one hundred and twenty Patients with schizophrenia who met the schizophrenia critetion of Chinese classification of mental disorders were devided into two groups ramdomly and treated with amisulpride or riseridone for 8weeks respectively .The positive and negative scale (PANSS) and treatment Emergent side effect scale (TESS) were used to evaluate the efficacy and adverse effect respectively, the quality of life was measured by World Health Organization quality of life questionnaire (WHOQOL-100). Results:The significant efficacy rate of amisulpride group Was 73.3%and the efficacy rate was 90.0% after 8 weeks, while 66.7% and 86.7% in risperidone group . There were no statistical difference between two groups (P>0.05).The two groups showed similar improvement on quality of life. The incidence rate of adverse effect was 16.7% in amisulpride group and that was 13.3% in risperidone group, without

  20. 齐拉西酮和利培酮治疗精神分裂症的临床疗效及安全性评价%Clinical efficacy and safety of ziprasidone and risperidone in the treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    陈统献; 闫耀宇; 鲍佑元

    2015-01-01

    Objective To evaluate the efficacy and safety of ziprasidone versus risperidone in the treatment of schizophrenia .Methods A total of 120 patients with schizophrenia were randomly divided into treatment group (n=62) and control group(n=58).Patients in the control group were administered risperidone 0.25 mg・ d-1 initially with maximum of 4.0 mg・ d-1 orally, qd. And patients in the treatment group were administered of ziprasidone 40 mg・ d -1 initially with maximum of 160 mg・ d-1 orally, bid.All the patients received 8 weeks treatment.After treatment, the clinical efficacy ,quality of life score and side effects were compared between the two groups.Results After treatment, the clinical efficacy were 89.66% and 91.94% in control and treatment group respectively, with no statistical difference(P>0.05).The score evalua-ted by the short from health survey ( SF-36 ) was significant higher in treatment group compared with control group ( P <0.05 ) . The side effects incidence rate were 20.69% in control group and 8.06% in treatment group, which was significantly difference ( P <0.05 ) . Conclusion The clinical efficacy was not different between ziprasidone and risperidone.But ziprasidone can improve patients′quality of life much more significantly with and less adverse events .%目的:评价齐拉西酮和利培酮治疗精神分裂症的临床疗效及安全性。方法将120例精神分裂症患者随机分为对照组58例和试验组62例。对照组予以利培酮起始给药剂量为0.25 mg・ d-1,最大给药剂量4.0 mg・ d-1,每日1次;试验组予以齐拉西酮初始剂量为40 mg・ d-1开始,分2次服用,按照控制情况逐渐加量,根据患者病情和耐受情况,1周之内达到最大剂量160 mg・ d-1,2组均治疗8周。比较2组的临床疗效、生活质量评分及不良反应发生率有无差别。结果对照组临床总有效率为89.66%,试验组临床总有效率为91.94%,2组比

  1. Evidence based administration of risperidone and paliperidone for the treating conduct disorder

    Directory of Open Access Journals (Sweden)

    Ahmad Ghanizadeh

    2013-01-01

    Full Text Available Background: This study evaluates the evidence-based administration of risperidone and paliperidone for the treating children and adolescents with conduct disorder (CD. Materials and Methods: A review of the current literature from clinical trials that investigated the efficacy of risperidone and paliperidone on CD considering the inclusion criteria and search strategies was performed by a search of PubMed and Google Scholar databases. Results: Out of 53 titles, 31 were irrelevant. The abstract of 22 potentially related articles were studied. Only six articles reported the results of clinical trial. However, one of them reported the effect of risperidone on conduct behaviors in autistic disorders. One study was a re-analysis of two previous studies, one study reported the effects of maintenance versus withdrawal of risperidone treatment and two studies included children with sub-average intelligence. Headache, somnolence and increased appetite are among the most common reported adverse effects. No study examined the effect of paliperidone on CD was found. Conclusion: Current literature suggests that risperidone could be effective for treating some conduct behaviors in children and adolescents. The effect of risperidone on CD is not a well-researched area. There is no well-controlled evidence based reports about the safety and efficacy of risperidone for the treatment of CD. Further trials should examine the efficacy of these medications on CD rather than conduct behaviors or disruptive behavior disorders.

  2. Comparison of efficacy and safety of ziprasidone hydrochloride and risperidone in treatment of schizophrenia%盐酸齐拉西酮与利醅酮治疗精神分裂症的疗效及安全性比较

    Institute of Scientific and Technical Information of China (English)

    卢殿军; 宁洁; 吴胜

    2011-01-01

    Objective To evaluate clinical efficacy and safety of ziprasidone hydrochloride and risperidone in treatment of schizophrenia. Methods 60 patients with schizophrenia in hospital were selected and randomly divided into ziprasidone group (n=30,ziprasidone administrated orally) and risperidone group(n=30 ,risperidone tablet administrated orally), with a 6 week course of treatment. Positive and negative syndrome scale(PANSS) was used to assess their clinical efficacy and the treatment emergent symptom scale(TESS) was adopted to investigate their safety. Results At the end of treatment, PANSS reduced score rate of ziprasidone group was(60.98±24.04)% ,and that of risperidone group was (62.03±28.29)% ,with no statistically significant difference between the two groups(P>0.05). Compared incidence rate of side effects of patients in ziprasidone group with that in risperidone group,no statistically significant difference was found between the two groups(P>0.05). Conclusion Ziprasidone hydrochloride is an effective and safe antipsychotic agent with similar curative efficacy and adverse reaction to risperidone.%目的 评价盐酸齐拉西酮与利培酮治疗精神分裂症的临床疗效及安全性.方法 选择住院精神分裂症患者60例,随机分为齐拉西酮组(n=30,口服盐酸齐拉西酮片)与利培酮组(n=30,口服利培酮片),疗程6周.采用精神分裂症阳性与阴性症状评定量表(PANSS)评价其临床疗效,不良反应量表(TESS)评价其安全性.结果 治疗结束时,齐拉西酮组PANSS减分率为(60.98±24.04)%,利培酮组PANSS减分率为(62.03±28.29)%,组间比较差异无统计学意义(P>0.05);齐拉西酮组不良反应发生率与利培酮组比较差异无统计学意义(P>0.05).结论 盐酸齐拉西酮的疗效及不良反应与利培酮相当,是有效、安全的抗精神病药物.

  3. Risperidone Improves Behavioral Symptoms in Children with Autism in a Randomized, Double-Blind, Placebo-Controlled Trial

    Science.gov (United States)

    Pandina, Gahan J.; Bossie, Cynthia A.; Youssef, Eriene; Zhu, Young; Dunbar, Fiona

    2007-01-01

    Subgroup analysis of children (5-12 years) with autism enrolled in an 8-week, double-blind, placebo-controlled trial of risperidone for pervasive developmental disorders. The primary efficacy measure was the Aberrant Behavior Checklist-Irritability (ABC-I) subscale. Data were available for 55 children given risperidone (n = 27) or placebo (n =…

  4. Risperidone Dosing in Children and Adolescents with Autistic Disorder: A Double-Blind, Placebo-Controlled Study

    Science.gov (United States)

    Kent, Justine M.; Kushner, Stuart; Ning, Xiaoping; Karcher, Keith; Ness, Seth; Aman, Michael; Singh, Jaskaran; Hough, David

    2013-01-01

    Efficacy and safety of 2 risperidone doses were evaluated in children and adolescents with autism. Patients (N = 96; 5-17 years), received risperidone (low-dose: 0.125 mg/day [20 to 45 kg] or high-dose: 1.25 mg/day [20 to 45 kg]) or placebo. Mean baseline (range 27-29) to endpoint change…

  5. Efficacy of Clozapine Combined with Risperidone in Refractory Schizophrenia%氯氮平联合利培酮治疗难治性精神分裂症的疗效

    Institute of Scientific and Technical Information of China (English)

    李晓波; 韦伟香

    2014-01-01

    Objective To explore the efficacy and safety of clozapine combined with risperidone in the treatment of refractory schizophrenia.Methods A total of 118 patients with refractory schizophrenia were randomly treated with clozapine tablets alone(control group,n = 59)or in combination with risperidone tablets(observation group,n=59).Clinical efficacy and adverse re-actions were observed in both groups.Patients were scored using the Positive and Negative Syn-drome Scale(PANSS)before and after treatment for 2,4,8 and 12 weeks.Results PANSS scores significantly decreased in both groups after treatment for 8 and 12 weeks(P <0.05),and the de-crease in observation group was more obvious than that in control group(P <0.05).In addition, the total effective rate in observation group was significantly higher than that in control group (96.6% vs 81.4%,P < 0.05),and the incidence of adverse reactions in observation group was significantly lower than that in control group(15.3% vs 27.1%,P < 0.05).Conclusion The combination of clozapine and risperidone is an effective,safe and reliable treatment and can reduce adverse reactions in the treatment of refractory schizophrenia.%目的:探讨氯氮平联合利培酮治疗难治性精神分裂症的临床疗效和安全性。方法将118例难治性精神分裂症患者按入院的先后顺序分为2组:观察组和对照组,每组59例。2组均采用氯氮平片治疗。在此基础上,观察组加用利培酮片治疗。观察2组临床疗效以及不良反应发生的情况,并对2组治疗前及治疗2、4、8和12周后采用阳性与阴性症状量表(PANSS)进行评分。结果2组治疗8、12周后 PANSS 得分均较治疗前明显降低(均 P <0.05),观察组治疗8、12周后 PANSS 得分均较对照组下降更明显(均 P <0.05)。观察组总有效率明显高于对照组(96.6%比81.4%,P <0.05),不良反应发生率明显低于对照组(15.3%比27.1%,P <0.05

  6. Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis

    Directory of Open Access Journals (Sweden)

    Schooler Nina

    2011-02-01

    Full Text Available Abstract Background To compare the efficacy and tolerability of paliperidone extended-release (ER with risperidone immediate-release using propensity score methodology. Methods Six double-blind, randomized, placebo-controlled, short-term clinical trials for acute schizophrenia with availability of individual patient-level data were identified (3 per compound. Propensity score pairwise matching was used to balance observed covariates between the paliperidone ER and risperidone patient populations. Scores were generated using logistic regression models, with age, body mass index, race, sex, baseline Positive and Negative Syndrome Scale (PANSS total score and baseline Clinical Global Impressions–Severity (CGI-S score as factors. The dosage range of paliperidone ER (6-12 mg/day was compared with 2 risperidone dosage ranges: 2-4 and 4-6 mg/day. The primary efficacy measure was change in PANSS total score at week 6 end point. Tolerability end points included adverse event (AE reports and weight. AEs with rates ≥5% and with a ≥2% difference between paliperidone ER and risperidone were identified. Results Completion rates for placebo-treated subjects in paliperidone ER trials (n = 95 and risperidone trials (n = 122 groups were 36.8% and 51.6%, respectively; end point changes on PANSS total scores were similar (p = 0.768. Completion rates for subjects receiving paliperidone ER 6-12 mg/day (n = 179, risperidone 2-4 mg/day (n = 113 or risperidone 4-6 mg/day (n = 129 were 64.8%, 54.0% and 66.7%, respectively (placebo-adjusted rates: paliperidone ER vs risperidone 2-4 mg/day, p = 0.005; paliperidone ER vs risperidone 4-6 mg/day, p = 0.159. PANSS total score improvement with paliperidone ER was greater than with risperidone 2-4 mg/day (difference in mean change score, -6.7; p Conclusions This indirect database analysis suggested that paliperidone ER 6-12 mg/day may be more efficacious than risperidone 2-4 mg/day and as efficacious as risperidone 4-6 mg

  7. 二甲双胍联合行为干预治疗利培酮所致的代谢紊乱%Efficacy of metformin combined behavior intervention in the treatment of metabolic disorders caused by risperidone

    Institute of Scientific and Technical Information of China (English)

    夏金校; 王一冰; 甘建光; 曹世林; 段迪; 钱佩华; 沈妃

    2011-01-01

    目的 观察二甲双胍(降血糖药)联合行为干预治疗利培酮(抗精神分裂症药)所致体质量增加及糖、脂代谢紊乱的临床疗效.方法 对口服利培酮所致肥胖的150例精神分裂症患者,随机分为A组(75例)和B组(75例),2组均给予行为干预;但A组加服二甲双胍,治疗6个月,测相关生化指标并进行比较.结果 除DBP、HDL-C和PRL外,A组余各指标,6个月末与入组时比较有极显著性差异;除DBP、TC、PRL、HDL-C外,B组余各指标,做相应地比较也有显著性差异.6个月末,除血压、脂蛋白、AST、PRL外,余各指标,A组与同期B 组比较有显著性差异;不良反应(主要为轻度恶心)发生率,A、B 2组分别为8%,7%,2组比较无显著性差异.结论 二甲双胍与行为干预单一或联合治疗利培酮所致体质量增加及代谢紊乱均有较好效果,尤以二甲双胍联合行为干预效果更好.%Objective To explore the clinical efficacy of metformin combined behavior intervention in treating metabolic disorders caused by risperidone, such as weight gain, glucose and lipid metabolism disorders.Methods A total of 150 schizophrenia patients who become obese after treated with risperidone were randomly divided into groups A (n =75) and B (n = 75).Both groups were given the same behavioral intervention for 6 months, but patients in group A also received treatment with metformin.At the point of baseline and the 6th month end, patients in both two groups received physical examination as well as a series of serological tests followed by statistic analysis.Results All the examine indexes except diastolic blood pressure, HDL -C and PRL were different between the point of baseline and the 6th month end in group A.All the examine indexes in addition to diastolic blood pressure, TC, PRL and HDL - C were different between the point of baseline and the 6th month end in group B.A lot of exam indexes were definitely different between two groups at the 6th month end

  8. 阿立哌唑与利培酮治疗精神分裂症的疗效与安全性对比分析%Analysis of Efficacy and Safety of Aripiprazole and Risperidone in the Treatment of Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    程道猛; 刘靖雯; 黄鹏; 徐世超; 王春江

    2013-01-01

    目的:探讨阿立哌唑与利培酮治疗精神分裂症的收益和风险,优化临床治疗效果与安全性,指导临床合理治疗。方法:将60例符合入组标准的精神分裂症按随机数字表分为阿立哌唑组与利培酮组,各30例,分别给予阿立哌唑与利培酮,8周为1个疗程,治疗前、后观察患者症状,进行阳性症状量表和阴性症状量表(PANSS)评分及不良反应量表(T ESS )评分,评价两组患者的临床疗效与安全性。结果:阿立哌唑组和利培酮组的总有效率均为93.33%,P>0.05;阿立哌唑组和利培酮组的阳性症状量表(PANSS)评分、阴性症状量表(PANSS)评分及量表总评分差异均无统计学意义,均 P>0.05;阿立哌唑组和利培酮组头痛、口干、血压降低、失眠差异无统计学意义,均 P>0.05,但阿立哌唑组锥体外系反应、体质量增加、闭经溢乳的发生率明显低于利培酮,差异具有统计学意义,均 P<0.05。结论:阿立哌唑起效速度、安全性、依从性明显优于利培酮,尤其能明显降低现锥体外系反应、体质量增加、闭经溢乳的副反应,是治疗精神分裂症的首选药物。%Objective :To investigate benefits and risks of aripiprazole and risperidone in the treatment of schizophreni-a ,to optimize clinical efficacy and safety ,guide clinical treatment .Methods :60 schizophrenia patients met the inclusion criteria were randomly divided into aripiprazole group and risperidone group ,30 cases of each group ,each group were given aripiprazole and risperidone ,8 weeks for an effect ,observed symptoms ,made a positive and negative symptom scale symptom scale (PANSS) scores and adverse reactions scale (TESS) scores ,to evaluate the clinical efficacy and safety .Results:The total effective rate of aripiprazole group and risperidone group was 93 .33% ,P>0 .05 ;the positive symptom scale (PANSS) score ,negative

  9. Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability – a review

    Directory of Open Access Journals (Sweden)

    González-Rodríguez A

    2015-05-01

    Full Text Available Alexandre González-Rodríguez,1 Rosa Catalán,1–4 Rafael Penadés,1–4 Clemente Garcia-Rizo,1,3,4 Miquel Bioque,1,4 Eduard Parellada,1,3–5 Miquel Bernardo1–4 1Barcelona Clinic Schizophrenia Unit (BCSU, Neuroscience Institute, Hospital Clinic of Barcelona, 2Department of Psychiatry and Clinical Psychobiology, University of Barcelona, 3Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS, Barcelona, Spain; 4Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM, Madrid, Spain; 5Department of Pharmacology, University of Barcelona, Barcelona, Spain Background and objectives: Short-term studies focused on once-monthly paliperidone palmitate (PP at doses of 25 mg eq, 50 mg eq, 75 mg eq, 100 mg eq, or 150 mg eq have shown its efficacy and tolerability in the treatment of schizophrenia patients. However, few open-label and long-term studies are available regarding this new pharmacological formulation. Thus, our main aim was to review the scientific evidence on efficacy, safety, tolerability, and preference of PP in these populations. Method: Electronic searches were conducted by using PubMed and ISI Web of Knowledge databases. All relevant studies published from 2009 until January 2015 were included without any language restriction if patients met diagnostic criteria for schizophrenia, and adequate information on efficacy, safety, and tolerability of once-monthly PP was available. Results: Nineteen studies were identified irrespective of the study design and duration of the follow-up period. Randomized, double-blind, placebo-controlled trials found that schizophrenia patients receiving PP showed a significant improvement in psychotic symptoms and similar adverse events compared to placebo and suggested that all doses of PP were efficacious and well tolerated. Other studies demonstrated noninferiority of PP compared to risperidone long-acting injectable in recently diagnosed schizophrenia patients, chronically

  10. Efficacy and executive function of olanzapine and risperidone in the treatment of elderly patients with schizophrenia%奥氮平与利培酮治疗老年精神分裂症患者疗效及执行功能比较

    Institute of Scientific and Technical Information of China (English)

    杭荣华; 程万良; 王瑞权; 吴明飞

    2012-01-01

    AIM: To explore the difference on efficacy and executive function between olanzapine and risperidone in treatment of elderly patients with schizophrenia. METHODS: 84 eider-ly patients with schizophrenia were randomly divided into olanzapine group (43 cases) and ris-peridon group (41 cases) treated for 8 weeks. The efficacy was assessed with the positive and negative symptoms scale (PANSS) and the executive function was evaluated with Wisconsin Card Sorting Test (WCST) in baseline and after 8 weeks of treatment. RESULTS: After 8 weeks of treatment, the efficacy rate of olanzapine was 90. 6 % . in which 67. 4% was improved markedly. The efficacy rate of risperidon was 92. 6%, in which 68.3% were improved markedly. There were no differences between two groups (P>0. 01). The score of negative symptom of olanzapine group was significantly lower than that of risperidon group(P<0. 05). The score of categories control in risperidon group was significantly lower than that in olanzapine group, persistent errors and response error were higher than that in olanzapine group(P<0. 01). CONCLUSION; Both olanzapine and risperidon can improve the symptom and executive function of elderly patients with schizophrenia. Olanzapine is better than risperidon in improving negative symptom and executive function.%目的:比较奥氮平与利培酮治疗老年精神分裂症的疗效及对执行功能的影响.方法:84例老年精神分裂症患者随机分为奥氮平组(43例)和利培酮组(41例),于治疗前及治疗后第8周末采用阳性与阴性症状量表(PANSS)和威斯康星卡片分类测验( WCST)评定疗效和执行功能,分别比较每组治疗前后及两组间的结果.结果:治疗后奥氮平组的有效率及显效率分别为90.6%和67.4%,利培酮组的有效率及显效率分别为92.6%和68.3%,两者差异无统计学意义(P>0.05).治疗后奥氮平组的阴性症状分低于利培酮组(P<0.01).利培酮组WCST的完成分类数低于奥氮平组,

  11. 认知行为与利培酮联合治疗精神分裂症残留型的临床疗效分析%Analysis of the Clinical Efficacy of Cognitive Behavior Combined With Risperidone in the Treatment of Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    王永良

    2015-01-01

    目的:分析认知行为配合利培酮治疗残留型精神分裂症的疗效。方法将72名残留型精神分裂症患者分成Og(观察)组和Cg(对照)组。Cg组单纯用利培酮治疗,Og组用利培酮时配合认知行为治疗。结果 Og组治疗后阴性症状、语言记忆、表达流畅、HAMD、HAMA等得分比治疗前降低,同时也比Cg组治疗后降低,而PSP得分增加。病理状态、阳性症状、SES得分及总分治疗前后无明显差别。结论认知行为疗法配合利培酮对于治疗残留型精神分裂患者获得的疗效比单纯服用药物好。%Objective To analyze the effect of cognitive behavior combined with risperidone in the treatment of residual type of schizophrenia.Methods 72 patients with schizophrenia were divided into Og (observation) group and Cg(control) group. Cg group was treated with risperidone alone, while the Og group was treated with the cognitive behavioral therapy and risperidone. ResultsThe negative symptoms,language memory, expression, HAMA and HAMD in the Og group were significantly less than those in Cg group,while the PSP score increased after treatment. There was no obvious difference in the pathological status, positive symptoms,SES score and total score.Conclusion Cognitive behavior therapy combined with risperidone in the treatment of residual type of schizophrenia patients has good efficacy.

  12. EFFICACY OF TRANSFORAMINAL EPIDURAL STEROID INJECTION IN LUMBOSACRAL RADICULOPATHY

    Directory of Open Access Journals (Sweden)

    Saheel

    2016-02-01

    Full Text Available BACKGROUND Lumbosacral radiculopathy is a common medical and socioeconomic problem with a lifetime prevalence estimated to be around 40%-60%. In 1930, Evans reported that sciatica could be treated by epidural injection. The use of epidural corticosteroid injection for the treatment of axial and radicular back pain was first reported in 1953. Lumbar Transforminal Epidural Steroid Injections (TFESIs are performed to provide symptomatic relief in patients with radicular pain. A transforaminal epidural steroid injection (TFESI using a small volume of local anaesthetic will anaesthetize the spinal nerve and also partially anaesthetize the dura, the posterior longitudinal ligament, the intervertebral disc and facet joint. For these reasons, fluoroscopy-guided TFESI has become the preferred approach to epidural space. AIMS AND OBJECTIVES To study the role of transforaminal epidural steroid injection in management of radiculopathy. SETTINGS AND DESIGN This prospective study was conducted in the Department of Orthopaedics, SKIMS Medical College and Hospital, Bemina, Srinagar, J and K, India, for a 2-year period from November 2012 to October 2014; 110 cases, both male and female in the age group of 20-60 years having back pain with radiculopathy of varied types and duration without neurodeficit were enrolled in the study. MATERIALS AND METHODS After selecting a patient for giving transforaminal block, we used a local anaesthetic (2% Xylocaine. Contrast media, e.g. Iohexol was used to demarcate the correct positioning of the needle. A spinal needle (20-25 gauge and 5mL syringe were used to deliver the drug. CONCLUSION Transforaminal epidural steroid injections with long acting anaesthetic is an excellent form of conservative treatment in management of low back ache with radicular pain. It is relatively safe, simple, economical and shortens the time of recovery from severe pain, avoids risks and complications of surgery and also avoids long periods of bed

  13. Clinical Efficacy of Risperidone and Olanzapine in the Treatment of first Episode Schizophrenia%利培酮与奥氮平治疗首发精神分裂症患者的临床疗效与安全性

    Institute of Scientific and Technical Information of China (English)

    任丽

    2015-01-01

    Objective To investigate the effect of risperidone and olanzapine in the treatment of first-episode clinical eficacy and safety in patients with schizophrenia.Methods Methods 68 patients with first episode schizophrenia were randomly divided into risperidone group in 34 cases and 34 cases of olanzapine group, risperidone group were treated with oral risperidone treatment,olanzapine group were treated with oral olanzapine treatment,after 8 weeks of treatment with PANSS reduction rate of curative effect evaluation.Results Risperidone group of patients,the total effective rate was 94.1%(32/34),olanzapine group of patients,the total effective rate was 91.2%(31/34),the difference between the two groups had no statistical significance(P>0.05).Olanzapine group drowsiness,dry mouth and body mass increase adverse effects than risperidone group,risperidone group akathisia, insomnia and headache adverse reactions than olanzapine group(P<0.05).Conclusion Equivalent efficacy of olanzapine and risperidone on schizophrenia,but the adverse reactions of two different,clinicians should take according to the regimen of according to the clinical characteristics of the patients with.%目的:探讨利培酮与奥氮平治疗首发精神分裂症患者的临床疗效与安全性。方法将68例首发精神分裂症患者随机分为利培酮组34例及奥氮平组34例,利培酮组患者给予口服利培酮进行治疗,奥氮平组患者给予口服奥氮平进行治疗,治疗8周后采用阳性和阴性症状量表(PANSS)减分率评估疗效。结果利培酮组患者总有效率为94.1%(32/34),奥氮平组患者总有效率为91.2%(31/34),两组比较差异无统计学意义(P>0.05)。奥氮平组嗜睡、口干和体质量增加不良反应多于利培酮组,利培酮组静坐不能、失眠和头痛不良反应多于奥氮平组(P<0.05)。结论奥氮平与利培酮对首发精神分裂症的疗效相当,但二者不良反应不同,临床

  14. A Comparative Study between Olanzapine and Risperidone in the Management of Schizophrenia

    Directory of Open Access Journals (Sweden)

    Saeed Shoja Shafti

    2014-01-01

    Full Text Available Introduction. Since a variety of comparisons between risperidone and olanzapine have resulted in diverse outcomes, so safety and efficacy of them were compared again in a new trial. Method. Sixty female schizophrenic patients entered into one of the assigned groups for random allocation to olanzapine or risperidone (n=30 in each group in a double-blind, 12-week clinical trial. Scale for Assessment of Positive Symptoms (SAPS and Scale for Assessment of Negative Symptoms (SANS were used as the primary outcome measures. Clinical Global Impressions-Severity Scale (CGI-S, Schedule for Assessment of Insight (SAI, and finally Simpson Angus Scale (SAS as well were employed as secondary scales. Results. While both of olanzapine and risperidone were significantly effective for improvement of positive symptoms (P<0.0001, as regards negative symptoms, it was so only by means of olanzapine (P<0.0003. CGI-S and SAI, as well, were significantly improved in both of the groups. SAS increment was significant only in the risperidone group (P<0.02. Conclusion. While both of olanzapine and risperidone were equally effective for improvement of positive symptoms and insight, olanzapine showed superior efficacy with respect to negative symptoms, along with lesser extrapyramidal side effects, in comparison with risperidone.

  15. Aripiprazole versus risperidone for treating children and adolescents with tic disorder: a randomized double blind clinical trial.

    Science.gov (United States)

    Ghanizadeh, Ahmad; Haghighi, Alireza

    2014-10-01

    There are some uncontrolled studies about the efficacy and safety of both aripiprazole and risperidone for treating tic disorder. Moreover, the efficacy of these medications has never been compared. This is the first double blind randomized clinical trial comparing the safety and efficacy of aripiprazole and risperidone for treating patients with tic disorder. Sixty children and adolescents with tic disorder were randomly allocated into one of the two groups to receive either aripiprazole or risperidone for 2 months. The primary outcome measure was the score of Yale Global Tic Severity Scale. In addition, health related quality of life and adverse events were assessed. Both aripiprazole and risperidone decreased the Yale Global Tic Severity Scale score during this trial. Moreover, both medications increased the health related quality of life score. Both aripiprazole and risperidone were tolerated well. Aripiprazole [3.22 (1.9) mg/day] decreased tic score as much as risperidone [0.6 (0.2) mg/day]. Their adverse effects and their effects on health related quality of life were comparable. However, risperidone increased the patients' social functioning more than aripiprazole in short term.

  16. Celecoxib and omega-3 fatty acids alone and in combination with risperidone affect the behavior and brain biochemistry in amphetamine-induced model of schizophrenia.

    Science.gov (United States)

    El-Sayed El-Sisi, Alaa; Sokkar, Samia Salem; El-Sayed El-Sayad, Magda; Sayed Ramadan, Ehab; Osman, Enass Yossef

    2016-08-01

    The implications of oxidative stress and neuro-inflammation in the pathogenesis of schizophrenia have been elucidated. Despite their effectiveness against positive symptoms of schizophrenia, antipsychotics have limited effectiveness against negative and cognitive symptoms and are associated with remarkable adverse effects. The use of celecoxib or omega-3 in schizophrenia may have beneficial effects. This study aimed to evaluate the possible efficacies of celecoxib, omega-3 or the combination of celecoxib+risperidone and omega-3+ risperidone compared to risperidone on the behavior and brain biochemistry in rats. In the present study, an amphetamine-induced model of schizophrenia in adult male rats was used to evaluate the effects of celecoxib, omega-3, celecoxib+risperidone and omega-3+ risperidone on the behavior of animals and on brain lipid peroxidation or tumor necrosis factor-alpha. In the water maze task, celecoxib, omega-3, celecoxib+risperidone, omega-3+ risperidone significantly decreased the latency time compared to amphetamine-treated group. Celecoxib, omega-3, celecoxib+risperidone, omega-3+risperidone also significantly reversed the decreased spontaneous alternation induced by amphetamine in the Y-maze task. In the social interaction task, groups treated with celecoxib, omega-3, celecoxib+risperidone, omega-3+ risperidone spent less time to recognize foreign animals than animals in the amphetamine-treated group. Increased brain MDA and TNF-α levels due to amphetamine were significantly reduced in groups treated with celecoxib+risperidone or omega-3+ risperidone. The present findings showed that celecoxib or omega-3 can attenuate amphetamine- induced behavioral impairment and these effects may be associated with their ability to decrease lipid peroxidation and cytokine release. Celecoxib or omega-3 may be promising candidates as adjuvant therapy for schizophrenia.

  17. Clinical efficacy of Risperidone combined with Paroxetine in treatment of methamphetamine-induced mental disorder patients%利培酮合并帕罗西汀治疗甲基苯丙胺所致精神障碍患者的临床疗效

    Institute of Scientific and Technical Information of China (English)

    文卫

    2015-01-01

    目的::对比分析利培酮单用与利培酮合并帕罗西汀治疗甲基苯丙胺所致精神障碍患者的治疗效果。方法:将68例甲基苯丙胺所致精神障碍患者的临床资料,采用数字单双号的模式随机分为对照组(利培酮)与治疗组(利培酮合并帕罗西汀),每组各34例。结果:对照组患者的总有效率为82.35%,治疗组患者的总有效率为94.12%,治疗组明显高于对照组,(P0.05)。结论:针对甲基苯丙胺所致精神障碍患者,采用利培酮合并帕罗西汀进行治疗能够显著改善患者的精神病性状态和抑郁、焦虑情绪,临床疗效明显,值得临床推广应用。%Objective: To comparatively analyze effects of Risperidone alone and Risperidone combined with Paroxetine in treatment of methamphetamine-induced mental disorder patients. Methods: A retrospective analysis of clinical data of 68 cases with methamphetamine-induced mental disorder was done by using digital odd and even numbers modes, and these cases were randomly di-vided into control group ( Risperidone) and treatment group ( Risperidone merger Paroxetine) , 34 cases in each group. Results:The total effective rates of control group and treatment group were 82. 35% and 94. 12%, and the difference was statistically significant (P0. 05). Conclusions:For the methamphetamine-induced mental disorder patients, Paroxetine combined with Risperidone can significantly improve the patient's mental state and de-pression and anxiety emotions with a significant clinical efficacy, and is worthy of clinical application and promotion.

  18. Efficacy of tramadol and butorphanol pretreatment in reducing pain on propofol injection: A placebo-controlled randomized study

    Directory of Open Access Journals (Sweden)

    Arvinderpal Singh

    2016-01-01

    Conclusion: Pretreatment with both butorphanol and tramadol significantly reduced pain on propofol injection; however, they exhibited comparable efficacy among each other. Thus, either of these two drugs can be considered for pretreatment to reduce propofol injection pain.

  19. Efficacy of Epidural Injections in the Treatment of Lumbar Central Spinal Stenosis: A Systematic Review

    OpenAIRE

    Manchikanti, Laxmaiah; Kaye, Alan David; Manchikanti, Kavita; Boswell, Mark; Pampati, Vidyasagar; Hirsch, Joshua

    2015-01-01

    Context: Lumbar central spinal stenosis is common and often results in chronic persistent pain and disability, which can lead to multiple interventions. After the failure of conservative treatment, either surgical or nonsurgical modalities such as epidural injections are contemplated in the management of lumbar spinal stenosis. Evidence Acquisition: Recent randomized trials, systematic reviews and guidelines have reached varying conclusions about the efficacy of epidural injections in the man...

  20. A Case of Priapism with Risperidone

    Directory of Open Access Journals (Sweden)

    Almari Ginory

    2014-01-01

    Full Text Available Priapism is a urologic emergency defined as a prolonged, possibly painful, penile erection. There are several known causes of priapism including psychotropic medications. One of the mechanisms by which antipsychotics are believed to induce priapism is through alpha-1 antagonism. This is case of a 50-year-old male with a history of schizophrenia with previous priapism related to trazodone, who presents with new onset priapism associated with risperidone. In this case, the treatment of priapism includes discontinuation of the offending agent and drainage of the corpus cavernosum twice along with intracavernosal phenylephrine injections. It is important to educate patients on priapism as a possible side effect of medications. It is also important to consider previous episodes of medication-induced priapism when prescribing psychotropic medications as this may increase the patient’s future risk of priapism.

  1. 利培酮治疗儿童孤独症谱系障碍11例疗效分析%Clinical efficacy of risperidone in 11 children with autism spectrum disorders

    Institute of Scientific and Technical Information of China (English)

    焦云; 刘李燕; 蔡小凡

    2013-01-01

    目的 观察利培酮治疗孤独症谱系障碍患儿的疗效.方法 11例入选患儿在原有综合治疗的基础上服用利培酮,剂量0.5~1.0 mg/d,分别在接受利培酮治疗前、治疗半年后进行孤独症治疗评定量表(ATEC)评估.结果 治疗后与治疗前比较,患儿在社交、感知觉、行为等方面均有显著改善(P<0.01),疗效明显.结论 利培酮治疗孤独症谱系障碍患儿在不良行为控制的基础上能明显改善认知,提高社交能力,而且副作用轻微,值得推广.%Objective To analyze the effect of risperidone to treat autism spectrum disorders in children. Methods Eleven children with autism spectrum disorders were treated with risperidone for 6 months. Autism treatment evaluation checklist ( ATEC) before and after the treatment was analyzed. The adverse events related to risperidone treatment were observed. Results The score of severity of illness and the ATEC total scores were significantly reduced after 6 month treatment. Great improvements had been shown on the apperception and behavioural symptoms. No severe adverse events related to risperidone treatment were observed. Conclusions Risperidone can significantly improve the behavioral disorders in children with autism spectrum disorders.

  2. Ethanol injection of ornamental trees facilitates testing insecticide efficacy against ambrosia beetles (Coleoptera: Curculionidae: Scolytinae).

    Science.gov (United States)

    Reding, Michael E; Oliver, Jason B; Schultz, Peter B; Ranger, Christopher M; Youssef, Nadeer N

    2013-02-01

    Exotic ambrosia beetles are damaging pests in ornamental tree nurseries in North America. The species Xylosandrus crassiusculus (Motshulsky) and Xylosandrus germanus (Blandford) are especially problematic. Management of these pests relies on preventive treatments of insecticides. However, field tests of recommended materials on nursery trees have been limited because of unreliable attacks by ambrosia beetles on experimental trees. Ethanol-injection of trees was used to induce colonization by ambrosia beetles to evaluate insecticides and botanical formulations for preventing attacks by ambrosia beetles. Experiments were conducted in Ohio, Tennessee, and Virginia. Experimental trees injected with ethanol had more attacks by ambrosia beetles than uninjected control trees in all but one experiment. Xylosandrus crassiusculus and X. germanus colonized trees injected with ethanol. In most experiments, attack rates declined 8 d after ethanol-injection. Ethanol-injection induced sufficient pressure from ambrosia beetles to evaluate the efficacy of insecticides for preventing attacks. Trunk sprays of permethrin suppressed cumulative total attacks by ambrosia beetles in most tests. Trunk sprays of the botanical formulations Armorex and Veggie Pharm suppressed cumulative total attacks in Ohio. Armorex, Armorex + Permethrin, and Veggie Pharm + Permethrin suppressed attacks in Tennessee. The bifenthrin product Onyx suppressed establishment of X. germanus in one Ohio experiment, and cumulative total ambrosia beetle attacks in Virginia. Substrate drenches and trunk sprays of neonicotinoids, or trunk sprays of anthranilic diamides or tolfenpyrad were not effective. Ethanol-injection is effective for inducing attacks and ensuring pressure by ambrosia beetles for testing insecticide efficacy on ornamental trees.

  3. THE EFFICACY OF ORAL GLUCOSE FOR RELIEVING PAIN FOLLOWING INTRAMUSCULAR INJECTION IN TERM NEONATES

    Directory of Open Access Journals (Sweden)

    F. Sajedi

    2006-09-01

    Full Text Available Pain in neonates can be associated with various risks and it seems essential to find a simple and acceptable method for relieving pain. Pharmacologic agents are not recommended in neonates for pain relief in minor procedures but orally administered glucose solution is found to be effective. The objective of this study was to assess the efficacy of oral 30% glucose during intramuscular injection in term neonates. Sixty-four healthy term neonates were recruited for this study during 1 month. The inclusion criteria were gestational age 37-42 weeks, birth weight 2500-4000 gr, and Apgar score > 7. The intervention consists of administration of either 2 ml of oral 30% glucose or 2ml of sterile water 2 minutes before injection. The primary out come measure was the cumulative Neonatal Infant Pain Scale (NIPS score at 3 minutes after injection. Thirty-two neonates received 30% glucose and 32 neonates received sterile water. The cumulative NIPS score at 3 minutes after injection for neonates given 30% glucose was significantly (P = 0.000 lower than for neonates given sterile water. The heart rate immediately after injection for neonates given 30% glucose was significantly (P = 0.002 lower than for neonates given sterile water. Oral 30% glucose given 2 minutes before injection was effective in reducing neonatal pain following injection. It is a simple, safe and fast acting analgesic and should be considered for minor invasive procedures in term neonates.

  4. Efficacy of acupuncture versus local methylprednisolone acetate injection in De Quervain's tenosynovitis: a randomized controlled trial.

    Science.gov (United States)

    Hadianfard, Mohammadjavad; Ashraf, Alireza; Fakheri, Maryamsadat; Nasiri, Aref

    2014-06-01

    There is no consensus on the management of De Quervain's tenosynovitis, but local corticosteroid injection is considered the mainstay of treatment. However, some patients are reluctant to take steroid injections. This study was performed to compare the efficacy of acupuncture versus corticosteroid injection for the treatment of this disease. Thirty patients were consequently treated in two groups. The acupuncture group received five acupuncture sessions of 30 minutes duration on classic points of LI-5, LU-7, and LU-9 and on ahshi points. The injection group received one methylprednisolone acetate injection in the first dorsal compartment of the wrist. The degree of disability and pain was evaluated by using the Quick Disabilities of the Arm, Shoulder, and Hand (Q-DASH) scale and the Visual Analogue Scale (VAS) at baseline and at 2 weeks and 6 weeks after the start of treatment. The baseline means of the Q-DASH and the VAS scores were 62.8 and 6.9, respectively. At the last follow-up, the mean Q-DASH scores were 9.8 versus 6.2 in the acupuncture and injection groups, respectively, and the mean VAS scores were 2 versus 1.2. We demonstrated short-term improvement of pain and function in both groups. Although the success rate was somewhat higher with corticosteroid injection, acupuncture can be considered as an alternative option for treatment of De Quervain's tenosynovitis.

  5. 氨磺必利与利培酮治疗精神分裂症疗效和安全性的Meta分析%Meta-analysis on the Efficacy and Safety of Amisulpride and Risperidone in the Treatment of Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    陈志强; 周峰; 陈惠萍

    2015-01-01

    Objective:To evaluate the efficacy and safety of amisulpride and risperidone in the treatment of schizophrenia. Meth-ods:The RCTs literatures on amisulpride and risperidone in the treatment of schizophrenia were retrieved and screened, and the quali-fied ones were analyzed by meta-analysis. Results:A total of 10 literatures were included involving 802 patients. Meta-analysis results showed that the difference between the two groups after the treatment was not statistically significant by comparing the clinical efficien-cy, PANSS score and TESS score. About the incidence of adverse reactions, amisulpride was better than risperidone in the endocrine function, extrapyramidal symptoms, weight gain and cardiovascular system. The incidence of nausea and vomiting of amisulpride was more than that of risperidone. There was no statistical significance in insomnia, headache, dizziness and the others. Conclusion:Ex-isting literature analysis shows that amisulpride is safe and effective in the treatment of schizophrenia.%目的::评价氨磺必利与利培酮治疗精神分裂症的疗效和安全性。方法:检索氨磺必利与利培酮治疗精神分裂症相关的随机对照研究文献,纳入合格文献进行Meta分析。结果:共纳入10篇文献,802例患者纳入分析。 Meta分析结果显示:两组治疗后临床有效率、阳性和阴性症状量表( PANSS)评分及治疗中出现的症状量表( TESS)评分比较,差异无统计学意义(P>0.05);药品不良反应发生率:内分泌功能、锥体外系症状、体重增加及心血管系统不良反应比较,氨磺必利少于利培酮(P0.05)。讨论:现有文献分析结果表明,氨磺必利治疗精神分裂症安全、有效。

  6. 利培酮和氯氮平治疗精神分裂症疗效评价及其对糖、脂代谢的影响分析%Clinical efficacy of risperidone and clozapine treatment for schizophrenia and the impact on glucose and lipid metabolism

    Institute of Scientific and Technical Information of China (English)

    刘洪光; 曾志强; 王元彬; 叶昌斌

    2013-01-01

    目的 探讨利培酮和氯氮平治疗精神分裂症初诊患者的临床疗效及其对糖脂代谢的影响.方法 94例精神分裂症初诊患者分为利培酮组和氯氮平组,治疗8周后评价临床疗效,测定并比较治疗前后患者总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白(LDL)、高密度脂蛋白(HDL)、空腹血糖(FBG)、空腹胰岛素(Fins)、胰岛素抵抗指数(IRI)及胰岛素敏感指数(ISI)水平.结果 两组患者治疗总有效率无统计学差异(P>0.05).两组患者治疗后血浆TC、TG、LDL、FBG、Fins、IRI水平升高,HDL、ISI水平降低(P<0.05),氯氮平组TC、TG、LDL水平升高幅度、HDL降低幅度大于利培酮组(P<0.05).结论 氯氮平和利培酮对精神分裂症初诊患者临床疗效确切,二者均对患者糖、脂代谢有影响;利培酮对患者脂代谢的影响相对较小,可作为患者临床治疗的首选用药.%Objective To investigate the clinical efficacy of risperidone and clozapine for treating patients with first-case schizophrenia and the impact on glucose and lipid metabolism.Methods 94 patients with first-case schizophrenia were randomly divided into risperidone group and clozapine group.After treatment of 8 weeks, clinical efficacy was evaluated.The pre-treatment and pro-treatment total cholesterol(TC),triacylglycerol(TG),low density lipoprotein(LDL) ,high density lipoprotein(HDL),fasting blood glucose(FBG) and fasting insulin(Fins), insulin resistance index(IRI) .insulin sensitivity index(ISI) levels of the two groups were detected and compared.Results The total effective rate of the two groups was with no statistical difference(PX).05).After treatment, the plasma TC,TG,LDL,FBG,Fins and IRI levels of two groups significantly increased,the HDL,ISI levels significantly de-creased(P<0.05),and the increase extent of TC,TG and LDL level and the decrease extent of HDL level of the clozapine group was more obvious than the risperidone group(P<0.05).Conclusion The

  7. Comparison of Efficacy of Ziprasidone and Risperidone in Patients with First-episode Schizophrenia%齐拉西酮与利培酮对首发精神分裂症患者对照研究

    Institute of Scientific and Technical Information of China (English)

    刘娜

    2016-01-01

    目的::探讨齐拉西酮与利培酮治疗首发精神分裂症疗效及不良反应。方法:将100例首发精神分裂症患者随机分为齐拉西酮组和利培酮组各50例,分别于治疗前、治疗12周评定 PANSS 量表,评估不良反应发生率。结果:齐拉西酮组和利培酮组疗效相仿,差异无统计学意义(P >0.05)。齐拉西酮组的不良反应显著少于利培酮组,差异有统计学意义(P 0.05),which has no statis-tical significance.The adverse reactions of ziprasidone group were significantly less than that of the risperi-done group(P <0.05),which is statistically significant.Conclusion:Ziprasidone and risperidone have equal effect in the treatment of First-episode schizophreni,however,the clinical safety and adverse reactions of zi-prasidone are superior to those of the risperidone.Therefore,ziprasidone is worth widely used in the clinical practice.

  8. Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome.

    Directory of Open Access Journals (Sweden)

    Sheng-Mou Hsiao

    Full Text Available To analyze the predictors of therapeutic efficacy after intravesical botulinum toxin A injection for overactive bladder syndrome (OAB refractory to antimuscarinic therapy.All consecutively OAB patients, who visited the urologic outpatient clinics of a medical center and refractory to antimuscarinic treatment, were prospectively enrolled. All enrolled patients received intravesical injection of 100 U onabotulinumtoxinA (Botox. The Global Response Assessment (GRA score ≥ 2 at 3 months after Botox injection was defined as a successful treatment, otherwise failed.Overall, 89 patients received intravesical injection. Eighty patients, including 42 men and 38 women, had received follow-up at 3 months. The overall success rate was 63.8%. The global response assessment, urgency severity score, urgency, urgency urinary incontinence and frequency episodes, and functional bladder capacity improved after treatment. However, post-void residual volume (PVR increased, and voiding efficiency (VE decreased after treatment. Female gender (odds ratio = 3.75 was the only independent factor associated with the success. Female gender (coefficient = 0.74, low baseline overactive bladder symptoms score (coefficient = -0.12 and the presence of OAB-wet (coefficient = 0.79 were independent factors associated with therapeutic efficacy (i.e., GRA score. VE (odds ratio = 0.062 was the only predictor for a large PVR at 3 months. The optimum cutoff value of VE was <87% with the area under the ROC curve being 0.64 (sensitivity = 63.8%, specificity = 57.1%.The therapeutic effects of Botox can persist till 6 months after treatment. Female gender, low overactive bladder symptoms score and OAB-wet are associated better therapeutic efficacy, and low baseline VE is associated with large PVR. These findings can serve as an initial guide or assist in consultation regarding the treatment of OAB patients with Botox injection.ClinicalTrials.gov NCT01657409.

  9. NINE-YEAR EFFICACY OF HEPATITIS B VACCINATION WITHLOW-DOSE IN THE THIRD INJECTION

    Institute of Scientific and Technical Information of China (English)

    2000-01-01

    Objective In order to observe the efficacy of low-dose in the third injection of hepatitis B vaccine. Methods 126 children aged 5~9 years were enrolled in a double-blind, place-controlled and randomized field trial. They were randomly divided into 10μg and 20μg dose group, and were redivided into 2μg, 5μg, 10μg, 20μg or non-in jected subgroups when the third booster injections were given. Results During the 9 years follow-up, the differences of the anti-HBs levels(GMT) among the groups were not significant at every time (P > 0. 05). The GMTs at the ninth year(T108) were 7. 0, 6. 4, 9.9, 6.1, 9.7, 5. 4 and 7.4, respectively (P> 0. 05). The HBV infection rates among the groups had no significant difference (P > 0. 05). The protective rates in the groups were all higher than 75% at T108. Conclusion According to the data, it can be concluded that the third injection with low-dose has no influence on the vaccine efficacy(either short-term or long-term efficacy).

  10. Postmortem Femoral Blood Concentrations of Risperidone

    DEFF Research Database (Denmark)

    Linnet, Kristian; Johansen, Sys Stybe

    2014-01-01

    Postmortem femoral blood concentrations of the antipsychotic drug risperidone and the active metabolite 9-hydroxyrisperidone were determined by an achiral LC-MS/MS method in 38 cases. The cause of death was classified as unrelated to risperidone in 30 cases, in which the sum of the concentration ...

  11. Cisplatin Tumor Biodistribution and Efficacy after Intratumoral Injection of a Biodegradable Extended Release Implant

    Directory of Open Access Journals (Sweden)

    Ariella Shikanov

    2011-01-01

    Full Text Available Local delivery of chemotherapeutic drugs has long been recognized as a potential method for reaching high drug doses at the target site while minimizing systemic exposure. Cisplatin is one of the most effective chemotherapeutic agents for the treatment of various tumors; however, its systemic toxicity remains the primary dose-limiting factor. Here we report that incorporation of cisplatin into a fatty acid-based polymer carrier followed by a local injection into the solid tumor resulted in a successful tumor growth inhibition in heterotopic mouse bladder tumor model in mice. Platinum concentration in the tumor tissue surrounding the injected implant remained above the therapeutic level up to 14 days after the injection, while the plasma levels were several orders of magnitude lower comparing to systemic delivery. The reported delivery system increased the maximum tolerated dose of cisplatin 5 times compared to systemic delivery, thus potentially improving antitumor efficacy of cisplatin in solid tumor model.

  12. Injecting drugs of abuse and immunity: implications for HIV vaccine testing and efficacy.

    Science.gov (United States)

    Ugen, Kenneth E; Nyland, Susan B

    2006-11-01

    The recreational use of legal and illegal drugs has significant effects on immune responses and can potentially modulate susceptibility to infection by a number of pathogens. A number of agents including cannabinoids (marijuana), cocaine opiates, amphetamines, nicotine and alcohol were demonstrated to have potentially adverse effects on the susceptibility to infections, mediated most likely, by adverse effects on immunity. As such, these drugs of abuse could have significant and potentially adverse effects on the vaccination efficacy of a number of vaccines currently on the market and on potential experimental vaccines currently in the pipeline. This review will present an overview on how drugs of abuse potentially impacts immune responses and vaccination efficacy. The emphasis of this review will be the effects of opiate abuse, as exemplified by injecting/intravenous drug users (IDU), on HIV/AIDS and its potential impact on vaccine efficacy trials against this devastating infection/syndrome.

  13. 利培酮或阿立哌唑替换奋乃静治疗分裂症疗效与副反应研究%Risperidone or Aripiprazole Replace Perphenazine Treatment Efficacy and Side Effects of Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    汪津洋

    2013-01-01

    目的评价利培酮或阿立哌唑替换奋乃静治疗精神分裂症的疗效与不良反应。方法将257例服用奋乃静治疗的分裂症患者逐渐替换为利培酮和阿立哌唑治疗,采用自然观察研究方法,对研究对象进行1年跟踪研究,评价疗效及副反应。结果治疗终点利醅酮和阿立哌唑组有效率分别为62.5%和69.8%,差异无统计学意义(P>0.05),跟踪中其他时点(2、4、6、8个月)两组有效率差异亦无统计学意义。12个月末利培酮组和阿立哌唑组的复发率(14.3%、12.3%)、持续治疗时间(9.4±3.7月、9.6±3.7月)、复发时间(4.1±2.8月、5.2±2.7月)等差异均无统计学意义(均P>0.05)。不良反应方面,利培酮组锥体外系反应比例高于阿立哌唑组,阿立哌唑组镇静作用弱。结论替换奋乃静后,利培酮与阿立哌唑治疗精神分裂症疗效均好,利培酮组锥体外系反应发生较多,阿立哌唑组镇静作用弱。%Objective To evaluate the ef icacy and adverse reaction of Aripirazole or risperidone in the original treatment of perphenazine. Methods 257 patients with original treatment of perphenazine assigned to Aripirazole group (n=131) or risperidone group(n=126), a 12 months fol ow up was used to evaluate the ef icacy and adverse ef ect. Results The response rates at the end of 12 months of Risperidone group and Aripirazole group were 62.5% and 69.8% respectively (P>0.05). There were no dif erence for the response rates between two groups at any other fol ow-up times.There were no dif erence between Risperidone and Aripirazole groups for the relapse rate (14.5%,12.5%,respectively),the time from response to relapse(9.5±3.8 months,9.7±3.8 months,respectively)and the time to treatment discontinuation for any reason(4.0± 2.9 months,5.1 ±2.8 months,respectively)at the end of 12 month.Aripirazole was associated with lower sedative ef ect and risperidone with more EPS (extrapyramidal syndrome). Conclusion Both

  14. Association between polymorphisms of rs194072,rs187269 in GABRB2 gene and first-episode schizophrenia and the efficacy of risperidone%GABRB2基因 rs194072和 rs187269位点遗传多态性与首发精神分裂症及利培酮疗效的关联性研究

    Institute of Scientific and Technical Information of China (English)

    刘延辉; 寇海燕; 王福华; 田博; 张心华

    2015-01-01

    Objective To explore the association between polymorphisms of Gamma-aminobutyric acid receptor subunit beta-2 (GABRB2 ) gene and first-episode schizophrenia,as well as the association with efficacy of risperidone.Methods Polymorphisms of rs194072 and rs187269 in GABRB2 gene was genotyped by using a SYBR Green based real time PCR assay in 277 schizophrenic patients (study group)and 315 healthy controls (control group).Patients in study group were treated with risperidone for 8 weeks and were assessed with Positive and negative Syndrome Scale (PANSS)at baseline and at the end of the treatment.Results There were significant differences in genotypic frequency and allelic frequency of rs194072 (χ2 =7.93,8.64 respectively;P =0.02,0.003 respectively)and rs187269 (χ2 =9.79,8.23 respectively;P =0.008,0.004 respectively) between study group and control group.The haplotype frequency of CC in study group was significantly higher than that in control group (P =0.003)and the haplotype frequency of TT in study group was significantly lower than that in control group (P =0.004).There were significant differences in distribution of genotypes and alleles of rs187269 between patients response to risperidone and patients invalid to risperidone (P =0.003,0.004 respectively).Conclusion The polymorphisms of rs194072 and rs187269 in GABRB2 gene are likely associated with the pathogenesis of schizophrenia and polymorphism of rs187269 is likely associated with the efficacy of risperidone.%目的:探讨γ-氨基丁酸β2受体(GABRB2)基因多态性与首发精神分裂症及其利培酮疗效的相关性。方法采用 SYBR Green I 荧光等位基因特异性实时 PCR 基因分型法完成277例精神分裂症患者(研究组)和315例正常对照者(对照组)的 GABRB2基因 rs194072和 rs187269两个位点多态性的测定。研究组采用利培酮治疗8周,于治疗前及治疗后第8周末用阳性和阴性综合征量表(PANSS)评估疗效。结果两组 rs

  15. Paediatric European Risperidone Studies (PERS) : context, rationale, objectives, strategy, and challenges

    NARCIS (Netherlands)

    Glennon, Jeffrey; Purper-Ouakil, Diane; Bakker, Mireille; Zuddas, Alessandro; Hoekstra, Pieter; Schulze, Ulrike; Castro-Fornieles, Josefina; Santosh, Paramala J.; Arango, Celso; Koelch, Michael; Coghill, David; Flamarique, Itziar; Penzol, Maria J.; Wan, Mandy; Murray, Macey; Wong, Ian C. K.; Danckaerts, Marina; Bonnot, Olivier; Falissard, Bruno; Masi, Gabriele; Fegart, Joerg M.; Vicari, Stefano; Carucci, Sara; Dittmann, Ralf W.; Buitelaar, Jan K.

    2014-01-01

    In children and adolescents with conduct disorder (CD), pharmacotherapy is considered when non-pharmacological interventions do not improve symptoms and functional impairment. Risperidone, a second-generation antipsychotic is increasingly prescribed off-label in this indication, but its efficacy and

  16. Long-term effects of risperidone in children with autism spectrum disorders : A placebo discontinuation study

    NARCIS (Netherlands)

    Troost, PW; Lahuis, BE; Steenhuis, MP; Ketelaars, CEJ; Buitelaar, JK; Van Engeland, H; Scahill, L; Minderaa, RB; Hoekstra, PJ

    2005-01-01

    Objective: The short-term benefit of risperidone in ameliorating severe disruptive behavior in pediatric patients with autism spectrum disorders is well established; however, only one placebo-controlled, long-term study of efficacy is available. Method: Thirty-six children with an autism spectrum di

  17. Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia

    Directory of Open Access Journals (Sweden)

    Jeffrey R Bishop

    2008-03-01

    Full Text Available Jeffrey R Bishop1,2, Mani N Pavuluri21Department of Pharmacy Practice, University of Illinois at Chicago College of Pharmacy, Chicago, IL, USA; 2Department of Psychiatry, Pediatric Mood Disorders Program and Center for Cognitive Medicine, University of Illinois at Chicago College of Medicine, Chicago, IL, USAAbstract: Risperidone is a commonly used medication for the treatment of bipolar disorder and schizophrenia in children and adolescents. It has been studied as a monotherapy treatment in early onset schizophrenia and as both monotherapy and combination therapy for pediatric bipolar disorder. Studies to date indicate that risperidone is an effective treatment for positive and negative symptoms of schizophrenia and mania symptoms of bipolar disorder. In young patient populations, side effects such as weight gain, extrapyramidal side effects, and prolactin elevation require consideration when evaluating the risk benefit ratio for individual patients. Here we review published studies of risperidone for the treatment of bipolar disorder and schizophrenia in children and adolescents to provide practitioners with an overview of published data on the efficacy and safety of risperidone in these patient populations.Keywords: risperidone, bipolar disorder, schizophrenia, children, adolescents

  18. Efficacy and safety of puerarin injection in curing acute ischemic stroke

    Science.gov (United States)

    Zheng, Qing-Hua; Li, Xiao-Li; Mei, Zhi-Gang; Xiong, Li; Mei, Qing-Xian; Wang, Jin-Feng; Tan, Ling-Jing; Yang, Song-Bai; Feng, Zhi-Tao

    2017-01-01

    Abstract Background: Previous studies indicated that the puerarin injection has been widely employed in China for the treatment of acute ischemic stroke. We aim to evaluate the efficacy and safety of the puerarin injection for the treatment of acute ischemic stroke. Methods: A systematic literature search was performed in PUBMED, EMBASE, SPRINGER LINK, Scopus, Cochrane Library, China National Knowledge Infrastructure (CNKI), VIP Journals Database, Wanfang database and the China Biological Medicine database before November 2016, randomized controlled clinical trials (RCTs) of puerarin injection treating acute ischemic stroke were included. In addition, we searched reference lists of relevant retrieved articles. Two authors extracted data independently. The effective rate, the neurologic deficit score, the blood rheology indexes, and fibrinogen were assessed and analyzed by the Review Manager 5.3 software. The continuous variables were expressed as MD with 95% CI and dichotomous data used RR or ORs. Adverse reactions related to the puerarin injection were also examined. Results: Thirty-five RCTs with a total of 3224 participants were identified in the meta-analysis. The combined results of 32 trials indicated that the puerarin injection was better than control drugs at the clinical effective rate (RR 1.22, 95% CI 1.17 to 1.28, P < 0.001) and 16 studies showed the neurological deficit was significantly improved (MD –3.69, 95% CI –4.67 to –2.71, P < 0.001); the hemorheology index and fibrinogen were much lower with the puerarin injection when compared with western conventional medicines (WCM) or other control drugs (the whole blood viscosity: MD –0.89, 95% CI –1.37 to –0.41, P < 0.001; the HCT: MD –0.04, 95% CI –0.06 to –0.02, P < 0.001; the fibrinogen: MD –0.64, 95% CI –0.96 to –0.31, P < 0.001). Eleven trials reported that the adverse reactions related to the puerarin injection included facial flushing, dizziness, vomiting

  19. Long-Term Efficacy and Safety of Botulinum Toxin Injections in Dystonia

    Directory of Open Access Journals (Sweden)

    Juan Ramirez-Castaneda

    2013-02-01

    Full Text Available Local chemodenervation with botulinum toxin (BoNT injections to relax abnormally contracting muscles has been shown to be an effective and well-tolerated treatment in a variety of movement disorders and other neurological and non-neurological disorders. Despite almost 30 years of therapeutic use, there are only few studies of patients treated with BoNT injections over long period of time. These published data clearly support the conclusion that BoNT not only provides safe and effective symptomatic relief of dystonia but also long-term benefit and possibly even favorably modifying the natural history of this disease. The adverse events associated with chronic, periodic exposure to BoNT injections are generally minor and self-limiting. With the chronic use of BoNT and an expanding list of therapeutic indications, there is a need to carefully examine the existing data on the long-term efficacy and safety of BoNT. In this review we will highlight some of the aspects of long-term effects of BoNT, including efficacy, safety, and immunogenicity.

  20. 阿立哌唑与利培酮治疗痴呆精神行为症状的疗效及安全性比较%Comparison of efficacy and safety of aripiprazole and risperidone treating behavioral and psychological symptoms of dementia

    Institute of Scientific and Technical Information of China (English)

    罗克勇; 刘克祥; 王瑞超; 付华斌

    2013-01-01

    by patients in risperidone group with a starting dose of 0.5 mg/d and less than the maximum dose 3 mg/d.Two groups were treated for 8 weeks.BEHAVE-AD and treatment emergent symptom scale (TESS) were used to evaluate the efficacy and adverse effect respectively before and at the ends of 8 weeks treatment.The levels of blood glucose,total cholesterol(TC),triglyceride(TG),high density lipoproteincholesterol (HDL-C),low density lipoprotein-cholesterol (LDL-C) and weight were measured at baseline and after 8 weeks.Results After 8 weeks treatment,the scores of BEHAVE-AD in both groups significantly reduced [aripiprazole group:(14.8 ± 4.2),(10.2 ± 3.6),(6.8 ± 2.6) scores vs (16.4 ± 4.6) scores ; risperidone group:(15.2 ±3.9),(11.8 ±3.8),(7.2 ±3.0)scores vs (17.2 ±5.0)scores,P<0.05 or P<0.01],but there were no significantly differences between the two groups (P > 0.05) ; there were few side effects in both groups [both 8.8% (3/34)],but the weight gaining,TC and LDL-C in risperidone group were higher than those before treatment [(71-±6)kg vs (66 ±6)kg,(1.62 ± 0.46) mmol/L vs (0.96 ± 0.29) mmol/L,(3.82±0.86)mmol/L vs (3.08 ± 0.74)mmol/L,all P < 0.05].Conclusion The results suggest that aripiprazole is as effective and safe as risperidone for the treatment of BPSD,but aripiprazole has less effect on blood glucose,lipids and weight than risperidone.

  1. Injectable fipronil for cattle: Plasma disposition and efficacy against Rhipicephalus microplus.

    Science.gov (United States)

    Cid, Yara P; Ferreira, Thais P; Magalhães, Viviane S; Correia, Thais R; Scott, Fábio B

    2016-04-15

    Fipronil is a phenylpyrazole class insecticide. It is widely used as an insecticide in agriculture and in the control of ectoparasites in veterinary medicine. The application of fipronil in an injectable form (subcutaneously) becomes an innovation, since there is no commercially available preparation containing fipronil herein. The present study aimed at fipronil usage, applied subcutaneously in cattle, to control Rhipicephalus microplus. The assessing criteria used in the research have been the construction of the plasma concentration curve and efficacy studies. A method using High Performance Liquid Chromatograph with ultraviolet detection was developed for determination of fipronil in bovine plasma samples, providing a fast and simple process with good reproducibility and low limit of quantification. The validation of the analytical method showed linearity, selectivity, precision, accuracy, sensitivity and stability, thus proving it as suitable for routine analysis. This method showed to be an important investigative tool in the analysis of fipronil plasma concentration in cattle. Fipronil administered via subcutaneous in bovine reached the systemic circulation (Cmax=378.06±137.44 ng/mL), was quickly absorbed (t(max)=10±0.87 h), and its elimination occurred slowly (t(1/2)=12 days), while maintaining quantifiable blood plasma levels (23.79±12.16 ng/mL) for up to 21 days after the treatment with a 1 mg/kg dosage. The in vivo efficacy tests proved that fipronil applied subcutaneously in a single dose of 1 mg/kg in cattle exhibited a mean efficacy of 82.41% against R. microplus. The potential of subcutaneous injection as an alternative treatment route in cattle encourage the development of an injectable formulation of fipronil.

  2. Development of Risperidone PLGA Microspheres

    Directory of Open Access Journals (Sweden)

    Susan D’Souza

    2014-01-01

    Full Text Available The aim of this study was to design and evaluate biodegradable PLGA microspheres for sustained delivery of Risperidone, with an eventual goal of avoiding combination therapy for the treatment of schizophrenia. Two PLGA copolymers (50 : 50 and 75 : 25 were used to prepare four microsphere formulations of Risperidone. The microspheres were characterized by several in vitro techniques. In vivo studies in male Sprague-Dawley rats at 20 and 40 mg/kg doses revealed that all formulations exhibited an initial burst followed by sustained release of the active moiety. Additionally, formulations prepared with 50 : 50 PLGA had a shorter duration of action and lower cumulative AUC levels than the 75 : 25 PLGA microspheres. A simulation of multiple dosing at weekly or 15-day regimen revealed pulsatile behavior for all formulations with steady state being achieved by the second dose. Overall, the clinical use of Formulations A, B, C, or D will eliminate the need for combination oral therapy and reduce time to achieve steady state, with a smaller washout period upon cessation of therapy. Results of this study prove the suitability of using PLGA copolymers of varying composition and molecular weight to develop sustained release formulations that can tailor in vivo behavior and enhance pharmacological effectiveness of the drug.

  3. Combination treatment of tamoxifen with risperidone in breast cancer.

    Directory of Open Access Journals (Sweden)

    Wei-Lan Yeh

    Full Text Available Tamoxifen has long been used and still is the most commonly used endocrine therapy for treatment of both early and advanced estrogen receptor-positive breast cancer in pre- and post-menopause women. Tamoxifen exerts its cytotoxic effect primarily through cytostasis which is associated with the accumulation of cells in the G0/G1 phase of the cell cycle. Apoptotic activity can also be exerted by tamoxifen which involves cleavage of caspase 9, caspase 7, caspase 3, and poly-ADP-ribose polymerase (PARP. Down-regulation of anti-apoptotic proteins Bcl-2 and Bcl-xL and up-regulation of pro-apoptotic proteins Bax and Bak have also been observed. In addition, stress response protein of GRP 94 and GRP 78 have also been induced by tamoxifen in our study. However, side effects occur during tamoxifen treatment in breast cancer patients. Researching into combination regimen of tamoxifen and drug(s that relieves tamoxifen-induced hot flushes is important, because drug interactions may decrease tamoxifen efficacy. Risperidone has been shown to be effective in reducing or eliminating hot flushes on women with hormonal variations. In this present study, we demonstrated that combination of tamoxifen with risperidone did not interfered tamoxifen-induced cytotoxic effects in both in vitro and in vivo models, while fluoxetine abrogated the effects of tamoxifen. This is the first paper suggesting the possibility of combination treatment of tamoxifen with risperidone in breast cancer patients, providing a conceivable resolution of tamoxifen-induced side effects without interfering the efficacy of tamoxifen against breast cancer.

  4. 利培酮治疗痴呆患者精神行为的临床疗效及护理效果分析%Risperidone in the treatment of dementia in patients with clinical efficacy and behavioral and psychological care benefits analysis

    Institute of Scientific and Technical Information of China (English)

    冉海珍

    2015-01-01

    目的:探讨利培酮治疗痴呆患者精神行为的临床疗效及护理效果。方法:选取2014年2月至2015年3月我院收治的痴呆患者80例,随机分成两组,每组40例,观察组采用利培酮治疗,对照组采用氟哌啶醇治疗,观察两组治疗效果。结果:经治疗后,观察组患者的治疗有效率明显高于对照组,且观察组患者出现胃肠道反应症状以及锥体外系反应症状的不良反应发生率明显低于对照组(P <0.05),有统计学意义。结论:对痴呆患者实施利培酮治疗以及必要的护理干预,能够有效提升患者的治疗有效率,降低患者的不良反应发生率,效果显著,值得临床推广。%To investigate the risperidone in the treatment of dementia in patients with clinical efficacy and behavioral and psychological care benefits. Methods:patients with dementia from February 2014 to March 2015 in our hospital,80 patients were randomly divided into two groups of40 patients treated with risperidone observation group,the control group,haloperidol,observe two group therapy.Results:After treatment,the treatment of patients in the observation group was significantly higher efficiency,and the observation group were gastrointestinal reactions symptoms and extrapyramidal symptoms of adverse reactions were significantly lower than the control group (P <0.05)there was statistically significant.Conclusion:Risperidone treatment for patients with dementia and the necessary nursing intervention can effectively improve the patient's treatment efficiency,reduce incidence of adverse reactions in patients,the effect is signifi-cant,worthy of promotion.

  5. Efficacy and safetycomparison on the Amisulpride and risperidone in the treatment offirst-episode schizophrenia%氨磺必利与利培酮治疗首发精神分裂症疗效和安全性对照研究

    Institute of Scientific and Technical Information of China (English)

    唐小辉

    2015-01-01

    目的:对照研究氨磺必利与利培酮治疗首发精神分裂症疗效和安全性。方法选取某院2013年6月至2015年3月的首发精神分裂症患者40例,平均分成试验组和对照组,试验组采用氨磺必利的治疗方式,对照组采用利培酮的治疗方式,比较两组的总有效率和不良反应率。结果试验组的总有效率为90%,不良反应率为50%,与对照组对比差异具有统计学意义(P<0.05)。结论氨磺必利在首发精神分裂症的治疗中,较之利培酮疗效更加明显,但副作用较大,需要在临床应用中根据病人的情况将维持剂量调整到最小有效剂量。%ObjectiveTo compare theefficacy and safety on the amisulpride and risperidone in thetreatment of first-episode schizophrenia.Methods To select 40 cases offirst-episode schizophrenia from June 2013 to March 2015 in a hospital and divide them into experiment group(treated with amisulpride) and control group(treated with risperidone). Compare their total efficiency and the rates of adverse reactions.Results The total effective rate of the experimental group was 50%, the adverse reaction rate was 90%, and the difference was statistically significant (P<0.05).Conclusion Amisulpride in first-episode schizophrenia treatment, compared with risperidone efficacy isbetter, yet the side effects is larger. It is need to adjust maintain dose to the minimum effective dose in clinical application according to the patient’s condition.

  6. Risperidone for Aggressive Behavior in ADHD

    Directory of Open Access Journals (Sweden)

    J Gordon Millichap

    2007-05-01

    Full Text Available The effects of risperidone augmentation for treatment-resistant aggression in children with ADHD were evaluated in a placebo-controlled pilot study at the University of Miami Miller School of Medicine, FL.

  7. Alterations in brain extracellular dopamine and glycine levels following combined administration of the glycine transporter type-1 inhibitor Org-24461 and risperidone.

    Science.gov (United States)

    Nagy, Katalin; Marko, Bernadett; Zsilla, Gabriella; Matyus, Peter; Pallagi, Katalin; Szabo, Geza; Juranyi, Zsolt; Barkoczy, Jozsef; Levay, Gyorgy; Harsing, Laszlo G

    2010-12-01

    The most dominant hypotheses for the pathogenesis of schizophrenia have focused primarily upon hyperfunctional dopaminergic and hypofunctional glutamatergic neurotransmission in the central nervous system. The therapeutic efficacy of all atypical antipsychotics is explained in part by antagonism of the dopaminergic neurotransmission, mainly by blockade of D(2) dopamine receptors. N-methyl-D-aspartate (NMDA) receptor hypofunction in schizophrenia can be reversed by glycine transporter type-1 (GlyT-1) inhibitors, which regulate glycine concentrations at the vicinity of NMDA receptors. Combined drug administration with D(2) dopamine receptor blockade and activation of hypofunctional NMDA receptors may be needed for a more effective treatment of positive and negative symptoms and the accompanied cognitive deficit in schizophrenia. To investigate this type of combined drug administration, rats were treated with the atypical antipsychotic risperidone together with the GlyT-1 inhibitor Org-24461. Brain microdialysis was applied in the striatum of conscious rats and determinations of extracellular dopamine, DOPAC, HVA, glycine, glutamate, and serine concentrations were carried out using HPLC/electrochemistry. Risperidone increased extracellular concentrations of dopamine but failed to influence those of glycine or glutamate measured in microdialysis samples. Org-24461 injection reduced extracellular dopamine concentrations and elevated extracellular glycine levels but the concentrations of serine and glutamate were not changed. When risperidone and Org-24461 were added in combination, a decrease in extracellular dopamine concentrations was accompanied with sustained elevation of extracellular glycine levels. Interestingly, the extracellular concentrations of glutamate were also enhanced. Our data indicate that coadministration of an antipsychotic with a GlyT-1 inhibitor may normalize hypofunctional NMDA receptor-mediated glutamatergic neurotransmission with reduced

  8. Effectiveness of the behavior change intervention to improve harm reduction self-efficacy among people who inject drugs in Thailand

    Directory of Open Access Journals (Sweden)

    Pawa D

    2016-09-01

    Full Text Available Duangta Pawa,1 Chitlada Areesantichai1,2 1College of Public Health Sciences, Chulalongkorn University, 2Drug Dependence Research Center WHO Collaborating Centre for Research and Training in Drug Dependence, Bangkok, Thailand Background: People who inject drugs (PWID in Thailand reported unsafe injection practices resulting in injection-related health consequences. Harm reduction self-efficacy plays an important role and could be improved to reduce harm associated with injecting drugs. Evidence-based interventions targeting PWID are needed. This study sought to evaluate the effectiveness of the behavior change intervention within the PWID population. Methods: The behavior change intervention, Triple-S, was designed to improve harm reduction self-efficacy among PWID. This quasi-experimental study was a pre- and post-comparison with a control group design. Participants were PWID, aged 18–45 years, and located in Bangkok. Changes in harm reduction self-efficacy of the intervention group were compared with the control group using paired and independent t-test. Results: Most of PWID were male (84%, had a secondary school and lower education (71%, were single, and had a mean age of 41 years. They had been injecting drugs for an average of 20 years, and the median of drug injections per week was ten times in the past month. Pre- and post-intervention effects were measured and results showed that the intervention group reported improvement in harm reduction self-efficacy in negative emotional conditions (P=0.048. Conclusion: Our findings suggest that Triple-S intervention can significantly improve harm reduction self-efficacy in negative emotional conditions. The results may suggest the importance of behavior change intervention, especially when integrated with services provided by drop-in centers. The intervention can be further developed to cover other harm reduction behaviors and improve harm reduction self-efficacy. Keywords: drug injection, harm

  9. Risperidone-induced symptomatic hyperprolactinaemia in adolescents.

    Science.gov (United States)

    Holzer, Laurent; Eap, Chin B

    2006-04-01

    Studies performed in adult patients unambiguously demonstrate a marked effect of risperidone on prolactin blood levels, with possible clinical effects related to hyperprolactinemia, such as gynecomastia and galactorrhea. However, the largest study performed in children and adolescents showed a weak effect of risperidone on prolactin concentrations during short-term treatment and a negligible effect during long-term treatment, which was probably because of the relatively low dosages of risperidone used [approximately 0.04 mg/(kg x d)]. Among the 10 psychotic adolescents treated with risperidone in our unit, we had 3 cases of gynecomastia in 3 male patients and 2 cases of galactorrhea in 2 female patients. The prolactin blood levels in these cases and in 3 other patients without apparent prolactin-related side effects were all above the normal range (median, 59 ng/mL; range, 30-123 ng/mL). Thus, risperidone administered to adolescents at doses commonly used for the treatment of psychotic symptoms can strongly increase prolactin levels, with clinical consequences such as gynecomastia and/or galactorrhea. Given that the long-term effects of antipsychotic drug-induced hyperprolactinemia are not well documented, especially regarding osteopenia, infertility, growth, and pubertal delay, risperidone should be administered with caution to children and adolescents.

  10. Efficacy of submucosal injection of different solutions inclusive blood components on mucosa elevation for endoscopic resection

    Directory of Open Access Journals (Sweden)

    Al-Taie OH

    2012-04-01

    Full Text Available Oliver H Al-Taie1, Yildiz Bauer2, Christoph G Dietrich3, Wolfgang Fischbach21Department of Internal Medicine, Sankt Elisabeth-Hospital, Gütersloh, 2Department of Internal Medicine II, Klinikum Aschaffenburg, Aschaffenburg, 3Department of Internal Medicine, Bethlehem-Hospital, Stolberg, GermanyBackground: Endoscopic resection has become the standard treatment for noninvasive gastrointestinal malignancies. In flat mucosal tumors, normal saline is frequently used for submucosal fluid injection in order to reduce the risk of complications during endoscopic resection. Recent studies have demonstrated longer-lasting mucosa elevation by injection of agents such as hyaluronic acid or glyceol, rather than normal saline. We investigated the efficacy of different blood components in comparison with other solutions for use as a submucosal fluid cushion.Methods: Normal saline, sodium hyaluronate, glyceol, hydroxyethyl starch, serum, plasma, and whole blood were evaluated for their effectiveness in creating a submucosal cushion. One milliliter of each solution was injected into the submucosa of 5 × 5 cm specimens of resected porcine stomach. Mucosa elevation was measured before and up to 60 minutes after injection.Results: The shortest duration of mucosa elevation was observed after injection of normal saline, glyceol, and 0.125% hyaluronic acid. A significantly longer duration was obtained after injection of hydroxyethyl starch, 0.25% and 0.5% hyaluronic acid, serum, and plasma. However, whole blood generated a longer-lasting mucosa elevation than all other agents.Conclusion: The results of the current study suggest that whole blood is more effective in generating long-lasting mucosa elevation than any other commonly used solution. Because autologous blood is readily available at almost no cost, this seems to be an optimal agent for creating the mucosa elevation needed for endoscopic resection. Further in vivo studies in humans are needed to clarify the

  11. 帕利哌酮缓释片对精神分裂症疗效及安全性的对照研究%A Controlled Study on the Efficacy and Safety of Paley Risperidone Sustained-release Tablets in the treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    姜雪晶

    2015-01-01

    目的:对照研究帕利哌酮缓释片对精神分裂症的疗效以及安全性。方法选取某院2014年2月至2015年2月收治的46例精神分裂症患者作为研究对象。按照收治顺序将其随机分为对照组和实验组各23例。对照组患者采用利培酮进行治疗,实验组患者采用帕利哌酮缓释片进行治疗。对比基线、治疗2周后与治疗4周后两组患者的阳性和阴性症状,以及一般精神病理。结果在治疗2周与4周后,实验组患者的阳性症状、阴性症状以及一般精神病理均低于基线时和对照组,差异具有统计学意义(P<0.05)。同时,实验组与对照组均未出现严重的不良反应事件。结论帕利哌酮缓释片对于精神分裂症患者的阳性症状、阴性症状、一般精神病理能够起到明显的改善作用。%ObjectiveTo take a control study on the efficacy andsafety of Paley risperidone sustained-release tablets in the treatment of schizophrenia.Methods 46 cases of schizophrenia patients from Feb.2014 to Feb.2014 are selected and randomly divided into the control group and the experimental group according to the treatment order. Control group were treated by risperidone treatment and the experimental group were treated by Paley risperidone sustained-release tablets for treatment. Compare the baseline, the positive and negative symptomstreatment and general psychopathology of the two groups after 2 weeks and 4 weeks after treatment. Results After treatment for 2 weeks and 4 weeks, the positive symptoms, negative symptoms and general psychopathology of experiment group are lower than the baseline and the control group, whichdifference has statistical significance (P<0.05). And the experimental group and control group has no serious adverse events occurred. Conclusion Paley risperidone sustained-release tablets can obviously improve the positive symptoms, negative symptoms, general psychopathology of schizophrenia patients.

  12. A Comparison of Risperidone and Buspirone for Treatment of Behavior Disorders in Children with Phenylketonuria

    Directory of Open Access Journals (Sweden)

    Afshin FAYYAZI

    2014-12-01

    and Lang W .Neurobehavioral Problems Associated with Phenylketonuria. Psychiatry (Edgemont 2009; 7(12:29–32.Luciana M, Hanson K L,Whitley C B.A preliminary report on dopamine system reactivity in PKU: acute effects of haloperidol on neuropsychological, physiological, and neuroendocrine functions. Psychopharmacology 2004;175: 18–25.Pappadopulos E, Woolston S, Chait A, Perkins M, Connor DF, Jensen P S. Pharmacotherapy of Aggression in Children and Adolescents: Efficacy and Effect Size. J CDN ACAD Child Adolesc Psychiatry 2006; 15(1:27-39.Shea S, Turgay A, Carroll A, Schulz M, Orlik H ,Smith I and et al. Risperidone in the Treatment of Disruptive Behavioral Symptoms in Children With Autistic and Other Pervasive Developmental Disorders. Pediatrcs 2004; 114:634-641.Miral S, Gencer O, Inal-Emiroglu F.N, Baykara B, Baykara A, Dirik E. Risperidone versus haloperidol in children and adolescents with AD: a randomized, controlled, doubleblind trial. Eur Child Adolesc Psychiatry 2008; 17:1–8.Aman M.G, Hollway J.A, McDougle C.J, Scahill L, Tierney E, McCracken J.T and et al. Cognitive effects of risperidone in children with autism and irritable behavior. J. Child Adolesc. Psychopharmacol 2008; 18:227–236.Pandina G.J, Bossie C.A, Youssef E, Zhu Y, Dunbar F. Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebocontrolled trial. J Autism Dev Disord 2007; 37:367–373.Luby J, Mrakotsky C, Stalets M.M, Belden A, Heffelfinger A, Williams M and et al. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J. Child Adolesc. Psychopharmacol 2006; 16:575–587.Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism: randomized, placebo controlled, double blind study. J. Child Neurol 2006; 21:450–455.Haas M, Karcher K, Pandina GJ. Treating Disruptive Behavior Disorders with Risperidone: A 1-Year, Open-Label Safety Study in Children and Adolescents. Journal of Child and

  13. 精神分裂症患者HTR2A基因多态性与帕利哌酮和利培酮临床疗效及安全性的关联研究%Association study of the HTR2A polymorphisms with efficacy and safety of risperidone or paliperidone in Chinese schizophrenic patients

    Institute of Scientific and Technical Information of China (English)

    杜波; 刘永桥; 刘飞虎; 肖卫东; 卢天兰; 李玲芝; 黄兰; 宓为峰; 张鸿燕

    2011-01-01

    目的 观察中国汉族精神分裂症患者的5-羟色胺2A受体(HTR2A)基因多态性与帕利哌酮和利培酮治疗精神分裂症患者临床疗效与安全性的关联.方法 入组201名精神分裂症患者,133例门诊或住院患者,随机接受12周帕利哌酮棕榈酸盐(50~150 mg/4周)或利培酮长效注射针剂(25~50 mg/4周)治疗,每2周进行1次疗效和安全性的评定;68例住院患者,接受4周利培酮片(2~6 mg·d-1)治疗,每周进行1次疗效和安全性评定;以试验结束时阳性阴性症状评定量表(PANSS)总减分率为主要疗效评价指标.共选择3个多态性位点,采用限制性酶切片段长度多态性或直接测序,获得基因型.结果 rs7997012各基因型可能与I临床疗效相关联(P<0.05),位点rs6313和rs6311的各基因型间临床疗效的差别无统计学意义(P>0.05);位点rs6313和rs6311的各基因型与BARS、SAS评分变化及血AST、ALT升高的水平相关联(P<0.05).结论 HTR2A 基因与帕利哌酮及利培酮治疗的临床疗效和安全性可能有关联.%Objective To study the relationship between gene polymorphisms of 5 - hydroxytryptamine receptor 2A (HTR2A) genes and the clinical efficacy and safety in Han Chinese schizophrenic patients who were treated with risperidone or paliperidone. Methods Two hundreds and one schizophrenic patients were included in this study, one hundred and thirty thee inpatients or outpatients were randomized to take paliperidone palmitate (50 - 150 mg/4 week) or risperidone LAI (25 -50 mg/2 week) for 12 weeks' therapy, efficacy and safety examines were taken at every visit. Sixty eight inpatients or outpatients who were treated with risperidone tablets (2 - 6 mg· d - 1 ) for 4 weeks were chosen. Efficacy and security examines was taken by every week. The main effect assessment was the final and baseline positive and negative syndrome scale(PANSS)total score reduced rate. The trial had chosen 3 SNPs, genotypes were detected by PCR

  14. Double-blind comparison of ziprasidone and risperidone in the treatment of Chinese patients with acute exacerbation of schizophrenia

    Directory of Open Access Journals (Sweden)

    Hongyan Zhang

    2011-03-01

    Full Text Available Hongyan Zhang1, Huafang Li2, Liang Shu1, Niufan Gu2, Gang Wang3, Yongzhen Weng3, Shiping Xie4, Xinbao Zhang4, Ting Li5, Cui Ma5, Wei Yu6, Bruce Parsons7, Manjula Schou81Institute of Mental Health, Peking University, Beijing, China; 2Shanghai Mental Health Center, Shanghai, China; 3Capital Medical University, Beijing An Ding Hospital, Beijing, China; 4Nanjing Brain Hospital, Nanjing, China; 5Guangzhou Brain Hospital, Guangzhou, China; 6Pfizer China, Beijing, China; 7Pfizer Inc, New York, NY, USA; 8Pfizer Australia, Sydney, AustraliaBackground: The aim of the study was to evaluate the efficacy and safety of ziprasidone versus risperidone in Chinese subjects with acute exacerbation of schizophrenia.Methods: In patients meeting the Chinese Classification of Mental Disorders criteria for schizophrenia and with a Positive and Negative Syndrome Scale (PANSS total score ≥60 were randomly assigned to six weeks of double-blind treatment with ziprasidone 40–80 mg twice daily or risperidone 1–3 mg bid, flexibly dosed. Noninferiority was demonstrated if the upper limit of the two-sided 95% confidence interval (CI for the difference in PANSS total score improvement from baseline in the evaluable population was smaller than the prespecified noninferiority margin of 10 units.Results: The intent-to-treat population comprised 118 ziprasidone-treated and 121 risperidone-treated subjects. Improvement (reduction from baseline to week 6 in PANSS total score was (-35.6 [95% CI: -38.6, -32.6] for ziprasidone and (-37.1 [95% CI: -39.9, -34.4] for risperidone. Noninferiority was demonstrated in the evaluable population with a difference score of 1.5 [95% CI: -2.5, 5.5]. Mean prolactin levels decreased at week 6 compared with baseline for ziprasidone (-3.5 ng/mL, but significantly increased for risperidone (61.1 ng/mL; P < 0.001. More risperidone-treated subjects (14.9% than ziprasidone-treated subjects (4.2% reported weight gain ≥7%. Akathisia and somnolence in

  15. Risperidone use in a teaching hospital during its first year after market approval: economic and clinical implications.

    Science.gov (United States)

    Carter, C S; Mulsant, B H; Sweet, R A; Maxwell, R A; Coley, K; Ganguli, R; Branch, R

    1995-01-01

    Risperidone, a new antipsychotic drug, was recently approved by the Food and Drug Administration (FDA) on the basis of its having comparable efficacy and less toxicity than haloperidol. In a preliminary study to evaluate the therapeutic efficiency of this drug, we conducted a survey of resperidone utilization, cost, and safety during its first year of availability at an academic psychiatric hospital. Data were obtained from a computerized, centralized medical record system, from an adverse drug reaction monitoring system, and from pharmacy purchasing records. In its first year of availability, risperidone became the second most widely used antipsychotic agent at our institution. Most of this use extended beyond the adult schizophrenia population, for whom pre-marketing safety and efficacy data are available. The direct institutional cost of risperidone treatment exceeded the entire budget for antipsychotic drugs during the year before its release. Results from the adverse drug reaction reporting system did not indicate a strong advantage of risperidone over more established antipsychotic agents with respect to extrapyramidal side effects. Furthermore, the mean dose of risperidone associated with extrapyramidal symptoms was 3.5 mg/day, considerably lower than that suggested by pre-marketing studies in a more select patient group. These results confirm that new pharmacological agents are generally used in much broader patient populations than those for which efficacy and safety have been established prior to FDA approval. This study also raises questions about the therapeutic efficiency of risperidone compared with other antipsychotic drugs. We conclude that systematic studies of outcome, safety, and cost of new pharmaceuticals in naturalistic settings are needed to provide the data necessary to establish local standards of cost-effective care.

  16. Efficacy of oral, injectable and pour-on formulations of moxidectin against gastrointestinal nematodes in cattle in New Zealand.

    Science.gov (United States)

    Leathwick, D M; Miller, C M

    2013-01-31

    The efficacy of moxidectin administered by different routes, against naturally acquired infections of gastrointestinal nematode parasites of cattle, was compared using faecal egg count reduction tests on 14 commercial farms throughout New Zealand. On each farm, groups of 15 calves were sampled for faecal nematode egg count and then treated with ivermectin administered orally, or with moxidectin administered either by the oral, subcutaneous injection or topical (pour-on) route. Samples were again collected 14 days after treatment and efficacy was calculated as the percentage reduction in-group mean egg count between the pre- and post-treatment samples. In addition, efficacy was calculated for individual animals, in order to compare the variability of the different treatments. On four farms untreated control groups were run and five animals from each of the control and all of the moxidectin-treated groups were bled over time to estimate plasma-moxidectin concentrations. Averaged across all tests, the reduction in faecal egg count was significantly greater after treatment with moxidectin oral (91.1%) than following treatment with moxidectin injection (55.5%) or with moxidectin pour-on (51.3%). Low efficacies were invariably against Cooperia oncophora. The oral treatments were significantly less variable in efficacy than the injection and pour-on treatments. Moxidectin concentrations in plasma were highest following subcutaneous injection and lowest following pour-on administration. Plasma levels following oral administration were intermediate, being significantly lower than post-injection and significantly higher than post-pour-on. There was no evidence of transfer of moxidectin to untreated animals through licking. Based on these results, along with those of other studies, it is proposed that oral administration of macrocyclic lactone anthelmintics results in higher concentrations of active reaching the target worms in the gastrointestinal tract than following either

  17. Gynecomastia with risperidone-fluoxetine combination.

    Science.gov (United States)

    Benazzi, F

    1999-01-01

    Gynecomastia (breast enlargement) is a side effect of neuroleptic antipsychotic drugs, related to prolactin elevation caused by dopamine D2 receptor blockade (Richelson, 1996). The atypical antipsychotic risperidone is less likely to cause gynecomastia at low doses (Casey, 1996). It can cause a dose-dependent increase in serum prolactin concentration (Peuskens, 1995), by blocking dopamine D2 receptors (Richelson, 1996). I would like to describe a patient who did not have gynecomastia with risperidone at a dose of 3 mg/day, but had it when risperidone, at a dose of 0.5 mg/day, was combined with fluoxetine. A MEDLINE search failed to find any reports about such an interaction.

  18. Risperidone associated paralytic ileus in schizophrenia

    Directory of Open Access Journals (Sweden)

    Parthasarathy Ramamourthy

    2013-01-01

    Full Text Available A 32-year-old man, diagnosed with catatonic schizophrenia, was treated with risperidone and lorazepam in the general hospital psychiatry setup. He developed signs of intestinal obstruction, which was diagnosed as paralytic ileus and was treated conservatively along with stopping the offending drug. Risperidone is said to be devoid of anticholinergic side effects, but prevalence of these varies from 7% to 13% in patients receiving treatment for schizophrenia. Constipation has been reported but fatal adverse effect like paralytic ileus with risperidone is rarely reported. Timely diagnosis can save the need for surgical interventions and fatal complications. This predisposition in schizophrenia could be due to neurodevelopmentally shared abnormality of brain and gut nervous system.

  19. Efficacy of multimodal cocktail periarticular injection with or without steroid in total knee arthroplasty

    Institute of Scientific and Technical Information of China (English)

    YUE De-bo; WANG Bai-liang; LIU Kun-peng; GUO Wan-shou

    2013-01-01

    Background Multimodal cocktail periarticular injection (MCPI) with a large volume of low concentration local anesthetics,adrenaline,and anti-inflammatory agents such as non-steroidal anti-inflammatory drug or steroids have shown good pain control and improvement in range of motion after surgery.This study compares the efficacy of pain control after total knee arthroplasty,using multimodal cocktail periarticular injection with steroid or without steroid.Methods This is a prospective,double-blinded,randomized and control study.Seventy-two patients with osteoarthritis that met clinical criteria for total knee arthroplasty were recruited into the study,and were randomized to receive either multimodal cocktail periarticular injection with steroid or without steroid.Pain was assessed by visual analogue scale (VAS) at preoperative and postoperative at rest,and during activity.The range of motion was recorded preoperatively and postoperatively.The amount of daily and cumulative morphine consumption were measured by patient-controlled analgesia in the first 72 hours postoperatively.The duration of celecoxib usage was also recorded at the last follow-up.Results There were no differences between the non-steroid and steroid groups with regard to VAS at rest and during activity,or range of motion,at any postoperative observation time.The postoperative Knee Society Knee Score in the steroid group improved significantly as compared with that in non-steroid group at the one-month (84.1±13.1 and 65.9±12.1; P <0.0045),three-month follow-up (90.2±16.3 and 72.5±16.6; P <0.0027),but after postoperative six-month the Knee Society Knee Score showed no significant difference between the groups.There was no significant difference in consumption of the morphine about daily or total consumption within 72 hours between the two groups.The duration of celecoxib usage in patients in the steroid group was significantly shorter than that in the non-steroid group ((7.2±0.7) compared with

  20. An association study of the cytochromes P4502D6, the dopamine D2 receptor gene polymorphisms and efficacy of risperidone%细胞色素P4502D6及多巴胺D2受体基因多态性与利培酮疗效的关联

    Institute of Scientific and Technical Information of China (English)

    杨鸽; 李文强; 张红星; 吕路线

    2012-01-01

    目的 探讨细胞色素P450 2D6(cytochromes P450 2D6,CYP2D6)基因多态性、多巴胺D2受体(dopamine D2 receptor,DRD2)基因多态性与利培酮疗效的相关性.方法 对199例首发精神分裂症患者给予利培酮治疗8周,治疗前后采用阳性和阴性症状量表(Positive and Negative Syndrome Scale,PANSS)评定疗效,同时收集198例正常对照进行病例-对照分析.采用聚合酶链反应序列特异性引物扩增技术检测CYP2D6/C188T、DRD2 TaqIA基因型,分析二者与利培酮临床效应的相关性.结果 病例组和对照组CYP2D6/C 188T的基因型和等位基因频率相比,差异有统计学意义(CC:40.7% vs.21.2%,CT:25.6% vs.45.5%,TT:33.7%vs.33.3%,P<0.05;C:53.5% vs.43.9%,T:46.5% vs.56.1%,P<0.05),病例组和对照组DRD2 TaqIA的基因型和等位基因频率相比,差异有统计学意义(A1A1:29.1% vs.35.9%,A1A2:37.7% vs.47.5%,A2A2:33.2% vs.16.6%,P<0.05; A1:48.0% vs.59.6%,A2:52.0% vs.40.4%,P<0.05);CYP2D6/C 188T与DRD2TaqIA的交互作用对PANSS减分率的影响没有统计学意义(F=0.735,P>0.05);CYP2D6/C188T,DRD2TaqIA与性别的交互作用对PANSS减分率的影响具有统计学意义(F=3.214,P<0.05).结论 CYP2D6基因C188T多态性和DRD2基因TaqIA多态性不是影响精神分裂症患者利培酮临床疗效的易感因素,但是在协变量性别的作用下,上述基因多态性的交互作用可能影响利培酮的疗效.%Objective To investigate the correlation of polymorphisms of cytochromes P450 2D6, dopamine D2 receptor and efficacy of risperidone treatment. Methods One hundred ninety-nine first episode schizophrenics were treated with Risperidone for 8 weeks and 198 healthy people served as controls. Positive and Negative Syndrome Scale was used to evaulate the efficacy of risperidone. PCR-RFLP was used to detect the polymorphisms of the CYP2D6 C/T188and DRD2TaqIA genotypes. Results There were significant differences in the ratio of

  1. Efficacy of injections of phosphatidylcholine into fat deposits-a non-surgical alternative to liposuction in body-contouring

    Directory of Open Access Journals (Sweden)

    Karl-G Heinrich

    2005-01-01

    Full Text Available Injecting phosphatidylcholine has been used in South America as a non-surgical treatment in body contouring. The objective of this study was to demonstrate the efficacy of injecting phosphatidylcholine in the reduction of localised fat deposits. 86 patients were included in the study. Patients received 1-3 treatments in localised fat deposits in various areas of the body using phosphatidylcholine. After treatment with phosphatidylcholine (250 mg / 5 ml, fat deposits show an average circumferential reduction per application of 2.70 cm. No patient showed irregularities, dimples or any serious side effect after treatment. Results remained stable during the time of follow up. All patients showed remarkable reductions of the fat deposits treated with phosphatidylcholine. Using the correct technique, injecting phosphatidylcholine may be a safe and efficacious alternative to liposuction in patients objecting to surgery.

  2. Choline acetyltransferase expression in rat prefrontal cortex and hippocampus after acute and chronic exposure to amisulpride, haloperidol, and risperidone.

    Science.gov (United States)

    Huang, Guang-Biao; Zhao, Tong; Li, Chun-Rong; Sui, Zhi-Yan; Kang, Nam-In; Han, Eui-Hyeog; Chung, Young-Chul

    2012-10-24

    Recently, there has been an increasing concern that atypical antipsychotics as well as typical ones may cause detrimental effects on cognitive function. Supporting evidence comes from many preclinical studies demonstrating that long-term administration of haloperidol, risperidone, and ziprasidone reduced choline acetyltransferase (ChAT) expression in rat hippocampus (HIP). However, to the best of our knowledge, no studies have examined the effects of amisulpride on ChAT expression in rats. Therefore, the aim of this study was to investigate the effects of acute and chronic administration of amisulpride, haloperidol, and risperidone on ChAT expression in the rat prefrontal cortex (PFC) and HIP. Animals received daily intraperitoneal (i.p.) injections of amisulpride (5 or 100mg/kg), haloperidol (1 or 2mg/kg), risperidone (1 or 2mg/kg) or vehicle for 7 or 45 days. One day after the last injection, rats were sacrificed. ChAT immunoreactivity was assessed with immunofluorescence staining. Target areas of brain were PFC and HIP (CA1, CA3 and DG). The short-term administration of haloperidol and risperidone produced significant decrease of ChAT immunoreactivity in the PFC and HIP compared to vehicle whereas amisulpride had no effects on ChAT immunoreactivity in the PFC and HIP. In long-term study, haloperidol and risperidone decreased ChAT-positive cells and/or fiber pixel density in the PFC and HIP whereas amisulpride decreased ChAT-positive cells in the PFC and had no effects on fiber pixel density of ChAT in the HIP. The results suggest that both short-term and long-term administration of haloperidol and risperidone, and long-term administration of amisulpride may produce detrimental effects on cognitive function by reducing ChAT expression in the PFC and/or HIP.

  3. Efficacy of Ligustrazine Injection as Adjunctive Therapy for Angina Pectoris: A Systematic Review and Meta-Analysis.

    Science.gov (United States)

    Shao, Huikai; Zhao, Lingguo; Chen, Fuchao; Zeng, Shengbo; Liu, Shengquan; Li, Jiajia

    2015-11-29

    BACKGROUND In the past decades, a large number of randomized controlled trials (RCTs) on the efficacy of ligustrazine injection combined with conventional antianginal drugs for angina pectoris have been reported. However, these RCTs have not been evaluated in accordance with PRISMA systematic review standards. The aim of this study was to evaluate the efficacy of ligustrazine injection as adjunctive therapy for angina pectoris. MATERIAL AND METHODS The databases PubMed, Medline, Cochrane Library, Embase, Sino-Med, Wanfang Databases, Chinese Scientific Journal Database, Google Scholar, Chinese Biomedical Literature Database, China National Knowledge Infrastructure, and the Chinese Science Citation Database were searched for published RCTs. Meta-analysis was performed on the primary outcome measures, including the improvements of electrocardiography (ECG) and the reductions in angina symptoms. Sensitivity and subgroup analysis based on the M score (the refined Jadad scores) were also used to evaluate the effect of quality, sample size, and publication year of the included RCTs on the overall effect of ligustrazine injection. RESULTS Eleven RCTs involving 870 patients with angina pectoris were selected in this study. Compared with conventional antianginal drugs alone, ligustrazine injection combined with antianginal drugs significantly increased the efficacy in symptom improvement (odds ratio [OR], 3.59; 95% confidence interval [CI]: 2.39 to 5.40) and in ECG improvement (OR, 3.42; 95% CI: 2.33 to 5.01). Sensitivity and subgroup analysis also confirmed that ligustrazine injection had better effect in the treatment of angina pectoris as adjunctive therapy. CONCLUSIONS The 11 eligible RCTs indicated that ligustrazine injection as adjunctive therapy was more effective than antianginal drugs alone. However, due to the low quality of included RCTs, more rigorously designed RCTs were still needed to verify the effects of ligustrazine injection as adjunctive therapy for

  4. Association of multidrug resistance 1 gene polymorphism with the clinical efficacy of paliperidone and risperidone in schizophrenic patients%精神分裂症患者多药耐药基因多态性与帕利哌酮和注射用利培酮微球临床疗效的关联研究

    Institute of Scientific and Technical Information of China (English)

    宓为峰; 张鸿燕; 杜波; 刘永桥; 刘飞虎; 肖卫东; 卢天兰; 李玲芝; 黄兰; 岳伟华

    2010-01-01

    Objective To explore the association between multidrug resistance 1gene (MDR1)polymorphisms with the therapeutic efficacy of paliperidone (9-hydroxyrisperidone) and risperidone in Han Chinese schizophrenic patients. Methods One hundred and thirty-three schizophrenic patients were given paliperidone or risperidone LAI for a 12-week treatment. The PANSS was used to assess the main therapeutic efficacy, and the Clinical Global Impression-Severity (CGI-S) scale and the Personal and Social Function scale (PSP) were used to as the secondary therapeutic efficacy assessments. The patients were evaluated every 2 weeks. The polymerase chain reaction-based-restriction fragment length polymorphisms (PCRRFLP) and DNA sequencing were used to detect the genotypes of 5 candidate single nucleotide polymorphisms (SNPs). The association between MDR1 genotypes with the therapeutic efficacy was analyzed using the chi-square and ANOVA tests. Results There were no statistical significant differences between MDR1 gene polymorphism and the PANSS reduction rate or clinical efficacy rate(P >0.05). Non-parameter tests revealed that, patients carrying CC genotype of locus rs1045642 had better efficacy in negative symptom item ' difficulty in abstract thinking' ( Z = - 2. 62, P = 0. 009 ) and positive symptom item ' grandiosity '(Z = -2. 84,P =0. 005), and GG genotype of locus rs2032582 carriers had worse improvements in general psychopathology item 'tension' (Z = -2.50,P =0. 012), and as to patient who carried A allele of locus rs1202169 had better improvements in general psychopathology item 'active societal avoidance'(Z = -2. 09,P =0. 036), and CC genotype of locus rs13233308 carriers had worse improvements in items ' guilt feelings' (Z = - 2. 09, P = 0. 036) and ' lack of spontaneity and flow of conversation' (Z = - 2.73,P = 0. 006) ,TT genotype carriers had a better improvement in item ' tension' ( Z = - 2. 54, P = 0. 011).Secondary clinical efficacy analysis showed that locus C allele

  5. Efficacy of two injection-site localisation techniques for botulinum toxin injections: a single-blind, crossover, randomised trial protocol among adults with hemiplegia due to stroke

    Science.gov (United States)

    Morel, Claire; Hauret, Isabelle; Andant, Nicolas; Bonnin, Armand; Pereira, Bruno; Coudeyre, Emmanuel

    2016-01-01

    Introduction Botulinum toxin injections are an effective treatment for limb spasticity following stroke. Different tracking techniques are used for this purpose: palpation, electrostimulation, electromyography and ultrasound. Yet very few studies have compared these different techniques, and none has successfully proved the superior efficacy of ultrasound-guided injections compared to another tracking method. The primary objective of our study was therefore to compare the efficacy of botulinum toxin injections depending on the tracking technique used: ultrasound versus electrostimulation. Methods and analysis This is a clinical, single-centre, prospective, interventional, single-blind, crossover, randomised trial. In total, 30 patients aged between 18 and 80 years presenting with triceps surae spasticity (evaluated >1 on the modified Ashworth scale) associated with hemiplegia sequelae due to stroke will be included. The patients will be selected among those who attend for consultation the Physical Medicine and Rehabilitation Department of the Clermont-Ferrand University Hospital. One group will receive the abobotulinumtoxinA (BoNT-A) injection guided by electrostimulation then ultrasound, and the second group's botulinum toxin injections will be guided by ultrasound then electrostimulation. For each patient, the duration of study participation is 5 months. The primary end point is variation in passive ankle dorsiflexion range of motion at slow and high speeds (Tardieu scale) with the knee straight. Ethics and dissemination This study received ethics approval form the CPP of Rhônes-Alpes region. Results will be published in a peer-reviewed journal. Trial registration number NCT01935544; pre-results. PMID:27852706

  6. Efficacy and Safety of Intravesical OnabotulinumtoxinA Injection in Patients with Detrusor Hyperactivity and Impaired Contractility

    Directory of Open Access Journals (Sweden)

    Chung-Cheng Wang

    2016-03-01

    Full Text Available We investigated the efficacy and safety of intravesical onabotulinumtoxinA injection in patients with detrusor hyperactivity and impaired contractility (DHIC. Twenty-one patients with urodynamically proven DHIC and 21 age-matched patients with overactive bladder (OAB with urodynamic detrusor overactivity were treated with intravesical injections of 100 U of onabotulinumtoxinA. The overactive bladder symptom score, urgency severity score, patient perception of bladder condition, global response assessment, voiding diary, and procedure-related adverse events (AE at baseline, two weeks, one, three, and six months after treatment were assessed. The results showed that the subjective symptom scores improved significantly in both groups, and the scores did not differ between the groups. The decrease in urgency episodes and urgency urinary incontinence were noted in OAB patients but not in DHIC patients. Although the incidence of AEs was comparable between the groups, the therapeutic efficacy lasted for a mean of 4.9 ± 4.8 months in DHIC patients and 7.2 ± 3.3 months in OAB patients (p = 0.03. We concluded that the efficacy of intravesical onabotulinumtoxinA injection for DHIC patients was limited and short-term. Nevertheless, AEs did not increase in DHIC. Intravesical onabotulinumtoxinA might not be a good indication in patients with DHIC and high post-voiding residual urine. Physicians should inform patients of the potential benefits and risks of onabotulinumtoxinA injection for treatment of DHIC.

  7. Treatment Efficacy of Electromyography versus Fiberscopy-Guided Botulinum Toxin Injection in Adductor Spasmodic Dysphonia Patients: A Prospective Comparative Study

    Directory of Open Access Journals (Sweden)

    Jae Wook Kim

    2014-01-01

    Full Text Available Introduction. This study prospectively evaluates and compares the treatment efficacy of botulinum toxin injection under electromyography guidance (EMG group and percutaneous botulinum toxin injection under flexible fiberscopic guidance (fiberscopy group. Methods. Thirty patients with adductor spasmodic dysphonia (ADSD, who had never received treatment, were randomly allocated into EMG- or fiberscopy-guided botulinum toxin injections between March 2008 and February 2010. We assessed acoustic and aerodynamic voice parameters, and the voice handicap index (VHI before injection and at 1, 3, and 6 months after injection. Results. The mean total dosage of botulinum toxin was similar for both groups: 1.7 ± 0.5 U for the EMG group and 1.8 ± 0.4 U for the fiberscopy group (P>0.05. There were no significant differences in outcomes between the two groups in either the duration of effectiveness or complications such as breathy voice and aspiration. Conclusion. Botulinum toxin injection under fiberscopic guidance is a viable alternative to EMG-guided botulinum toxin injection for the treatment of adductor spasmodic dysphonia when EMG equipment is unavailable.

  8. 11 Efficacy and Tolerability of HDM Injective Immunotherapy With Monomeric Allergoid

    Science.gov (United States)

    Compalati, Enrico; Atzeni, Isabella; Cabras, Sergio; Fancello, Paolo; Gaspardini, Giulio; Longo, Rocco; Patella, Vincenzo; Tore, Giorgio

    2012-01-01

    Background Subcutaneous immunotherapy (SCIT) is an effective treatment of respiratory allergy and carbamylated monomeric allergoids (monoids), by virtue of their reduced IgE-binding activity, resulted clinically safe by sublingual administration. Purpose of this study was to investigate the efficacy and tolerability of immunotherapy with house dust mites (HDM) monoid administered by injective route in patients with allergic rhinoconjunctivitis (AR). Methods A preparation of 0.70 mL of 10 BU/mL containing modified extract with 50% Dermatophagoides pteronyssinus and 50% Dermatophagoides farinae (amount of major allergen: 4 μg of group 1 per milliliter) was delivered monthly for 12 months, following a 5-week build-up induction phase (0.10–0.20–0.30–0.50–0.70 mL), to 58 patients (60% males, mean age 25.1 ± 12.7) suffering from AR due to mites for at least 2 years, whereas 60 patients with similar baseline characteristics were observed as controls. All patients were allowed to assume traditional drug therapy for their condition. At the end of the study changes from baseline in symptoms scores, in number of days with drug assumption, in severity of AR (according to ARIA classification) were compared between the 2 groups; moreover an overall assessment of clinical efficacy and tolerability was based on patients' and physicians' judgements (unsatisfactory, mild, good, optimal). Results In respect to baseline both groups showed, after 1 year, an improvement in symptoms score (P < 0.001) with a significant difference in favour of SCIT group (P < 0.05). Days of drug intake were significantly lower in patients receiving SCIT (P < 0.05). The number of patients with severe AR decreased in the first group while no variation was observed in controls. The subjective clinical overall assessment was optimal in 31 cases and good in 24 according to physicians' and patients' judgements; similarly 38 patients judged tolerability as optimal and 18 as good, whereas according to

  9. Risperidone treatment increases CB1 receptor binding in rat brain

    DEFF Research Database (Denmark)

    Secher, Anna; Husum, Henriette; Holst, Birgitte

    2010-01-01

    , the ghrelin receptor, neuropeptide Y, adiponectin and proopiomelanocortin. We investigated whether the expression of these factors was affected in rats chronically treated with the antipsychotic risperidone. METHODS: Male Sprague-Dawley rats were treated with risperidone (1.0 mg/kg/day) or vehicle (20......% hydroxypropyl beta-cyclodextrin) for 28 days. Expression of the aforementioned factors were examined together with plasma prolactin and ghrelin levels. RESULTS: No difference in body weight gained during treatment was observed between risperidone and vehicle treated rats, but plasma risperidone levels...... positively correlated with visceral fat mass. Risperidone treatment increased CB(1) receptor binding in the arcuate nucleus (40%), hippocampus (25-30%) and amygdala (35%) without concurrent alterations in the CB(1) receptor mRNA. Risperidone treatment increased adiponectin mRNA. CONCLUSION: The present study...

  10. Association study of IL-10 gene promoter polymorphisms and efficacy of risperidone treatment of schizophrenic patients with first episode%白介素10基因启动子多态性与首发精神分裂症及利培酮疗效的关联

    Institute of Scientific and Technical Information of China (English)

    刘延辉; 张立霞; 张心华

    2014-01-01

    目的 探讨白介素10(interleukin-10,IL-10)基因启动子多态性与首发精神分裂症患者及利培酮疗效的关系.方法 513例首发精神分裂症患者(患者组)和627个健康对照(对照组)为研究对象,通过聚合酶链式反应与限制性片段长度多态性基因分型技术对IL-10基因标签单核酸多态性位点-592A/C(rs1800872)、-1082A/G(rs 1800896)、-819T/C(rs1800871)进行基因分型.513例患者使用利培酮治疗8周,以阳性与阴性症状量表(Positive and Negative Syndrome Scale,PANSS)评定疗效.结果 在rs1800896患者组与对照组在基因型(332:166:15,453:161:13;x2 =7.55,df=2,P=0.02)与等位基因(830:196,1067:187;x2=7.09,df=1,P=0.008,OR=1.35,95% CI=1.08~1.68)差异有统计学意义,但是在Bonferroni多重校正后仅等位基因差异有统计学意义(P=0.024).在rs1800872与rs1800871患者组与对照组在基因型与等位基因均差异无统计学意义(P>0.05).单倍型频率在患者组与对照组差异无统计学意义(P>0.05).利培酮总疗效有效组(381例)与无效组(132例)相比,rs1800872、rs1800896、rs1800871在基因型[分别为134:209:38,61:59:12;x2=5.16,df=2,P=0.08;244:129:8,88:37:7;x2 =4.57,df=2,P=0.10;188:158:35,54:64:14;x2=2.80,df=2,P=0.25]与等位基因[分别为477:285,181:83;x2=3.03,f=1,P=0.08;617:145,213:51;x2=0.01,df=1,P=0.92; 534:228,172:92;x2=2.22,df=1,P=0.14]频率分布均差异无统计学意义(P>0.05),但在ATC单倍型差异有统计学意义(x2=7.501,P=0.006,OR(95% CI)=2.420[1.262~4.640]).结论 IL-10基因rs1800896多态性可能与精神分裂症的易感性有关,利培酮治疗精神分裂症的临床疗效与ATC单倍型有关,ATC单倍型可能是利培酮总体疗效好的预测因子.%Objective To investigate association of IL-10 gene promoter polymorphisms with first episode schizophrenic and efficacy of risperidone.Methods 513 schizophrenic patients with first episode(patient group) and 627 health controls(control group

  11. 小剂量利培酮强化抗抑郁剂治疗双相抑郁发作的疗效和安全性研究%Efficacy and safety of low dosage risperidone added on valproate and citalopram in the treatment of acute bipolar depression

    Institute of Scientific and Technical Information of China (English)

    王健; 王刚; 马辛

    2014-01-01

    目的考察小剂量利培酮强化抗抑郁剂治疗对双相抑郁发作的疗效和安全性。方法符合入组标准的住院患者,先接受2周的丙戊酸钠( valproate,VPA)合并西酞普兰( citalopram,CIT)治疗。2周末相对于基线的蒙哥马利抑郁量表( Montgomery and Asberg Depression Scale,MADRS)减分率0.05)。 CGI-I 2组对比,差异具有统计学意义(P0.05)。随机治疗第1周末BPRS阳性因子评分VPA+CIT+RIS组较VPA+CIT组明显降低,差异有统计学意义(P<0.05),显示VPA+CIT+RIS组较VPA+CIT组在改善阳性精神病性症状方面起效更快。在随机治疗第2周,VPA+CIT+RIS组有效率为66.0%,VPA+CIT组为33.3%,显示VPA+CIT+RIS组较VPA+CIT组起效更快。结论 VPA+CIT+RIS与VPA+CIT治疗双相抑郁发作均安全有效。在快速起效及降低转相风险方面,VPA+CIT+RIS组优于VPA+CIT组。%Objective To evaluate the augmentation efficacy and safety of low dosage risperidone, added on the usual treatment ( valproate and citalopram) in the acute treatment of bipolar depression. Methods A total of 46 inpatients with a diagnostic criteria for acute depression episode with bipolar disorder according to DSM-IV-TR were first given valproate and citalopram treatment. The subjects who achieve little clinical response( i. e. reduction from baseline in total MADRS score by<50%) at the end of 2-week will enter into the randomized open-label 6-week treatment phase. The eligible subjects will be randomized to treatment with valproate & citalopram or valproate & citalopram & risperidone in a 1:1 ratio. Efficacy rating scales to be used in the study include MADRS, YMRS, BPRS( total score and positive subscale), CGI-S, and CGI-I. The evaluations of safety and tolerability include SAS, treatment-emergent mania, clinical laboratory tests, vital signs , ECG, and adverse events reports. Results At the end of treatment, the scores of MADRS, BPRS, GIC-I, and CGI-S in both treatment groups decreased significantly compared

  12. Efficacy of a single ultrasound-guided injection for the treatment of hip osteoarthritis.

    LENUS (Irish Health Repository)

    Atchia, Ismaël

    2011-01-01

    Intra-articular injection is effective for osteoarthritis, but the best single injection strategy is not known, nor are there established predictors of response. The objectives of this study were to assess and predict response to a single ultrasound-guided injection in moderate to severe hip osteoarthritis.

  13. Efficacy of moxidectin 1% injectable and 0.2% oral drench against natural infection by Dictyocaulus filaria in sheep.

    Science.gov (United States)

    Hidalgo-Argüello, M R; Díez-Baños, N; Rojo-Vázquez, F A

    2002-07-29

    Two separate trials (I and II) with 34 and 32 Churra ewes, respectively, and distributed into two groups, have been carried out to evaluate the efficacy of two different formulations of moxidectin at a dose rate of 0.2mg/kg body weight (b.w.) against natural infection by Dictyocaulus filaria in sheep. Trial I was designed to evaluate a 1% moxidectin injectable formulation, whereas in trial II a 0.2% moxidectin oral drench formulation was used. The efficacy was measured on the basis of the reduction of the faecal larval counts and of adult worm recoveries at slaughter. In each trial, a group of animals was treated on day 0 with moxidectin 1% injectable or moxidectin 0.2% oral drench and the other group acted as untreated control. When the faecal larval counts was compared within the treated groups, the efficacy was over 95% until day +13, and 100% at the remainder of the sampling dates after the application of injectable moxidectin, whereas in trial II, the larvae per gram (lpg) of faeces increased until the first sampling time post treatment (p.t.), day +6, and zero counts were recorded for all animals by the following days. On the basis of adult worm recoveries at necropsy, the efficacy of the treatment was 100% in both trials, however, adult worms were detected at slaughter for all control sheep. These results indicate that moxidectin 1% injectable and moxidectin 0.2% oral drench, administered at 0.2mg/kg b.w., were 100% effective against D. filaria infection in sheep. No adverse reactions to the treatments were observed in the animals.

  14. The Efficacy of Local Injection of Methylprednisolone and Lidocaine with and Without Splint, in Treating Patients with De Quervain's Tenosynovitis

    OpenAIRE

    Saleh,, M. a.; Dehghan; Sherafat

    2012-01-01

    Introduction: Suffering from de Quervain's tenosynovitis due to repetitive and routine activities leads to considerable referrals to orthopedic clinics and increasing health care costs and wasting of patients' time. The present study aimed to compare the efficacy of local injection of methylprednisolone with and without splint for treatment of patients suffering from de Quervain's tenosynovitis. Methods: In a clinical trial study, 72 patients with de Quervain's tenosynovitis were selected in ...

  15. A pharmacogenetic study of risperidone on histamine H3 receptor gene (HRH3) in Chinese Han schizophrenia patients.

    Science.gov (United States)

    Wei, Zhiyun; Wang, Lei; Zhang, Mengmeng; Xuan, Jiekun; Wang, Yang; Liu, Baocheng; Shao, Liyan; Li, Jun; Zeng, Zhen; Li, Tao; Liu, Jie; Wang, Ti; Zhang, Ming; Qin, Shengying; Xu, Yifeng; Feng, Guoyin; He, Lin; Xing, Qinghe

    2012-06-01

    Evidence suggests that the human histamine H3 receptor (HRH3) may be involved in the pharmacodynamics of risperidone and influence clinical efficacy. More information on the pharmacogenetics of this receptor may therefore be useful in developing individualized therapy. However, to our knowledge, no study has been reported in this area. The aim of this investigation was to clarify whether H3 receptor polymorphism could affect risperidone efficacy. We genotyped tag single nucleotide polymorphisms (SNPs) of the HRH3 gene (rs3787429 and rs3787430) and analyzed their association with the reduction of Brief Psychiatric Rating Scale (BPRS) score in Chinese Han schizophrenia patients (N = 129), following an eight-week period of risperidone monotherapy. The confounding effects of non-genetic factors were estimated, and then the significant one was included as the covariate for adjustment in statistical analysis. Baseline symptom score was the only significant confounding effect and thus the covariate. After adjustment, significant association of HRH3 with antipsychotic efficacy was detected (for rs3787429, p = 0.013, 0.087 after 4 weeks and 8 weeks of treatment, respectively; for rs3787430, p = 0.024, 0.010 after 4 weeks and 8 weeks of treatment, respectively) and stood up to conservative Bonferroni correction. Our results demonstrate that polymorphism of the HRH3 gene may be a potential genetic marker for predicting the therapeutic effect of risperidone, and suggest novel pharmacological links between HRH3 and risperidone. Further studies with larger samples and different ethnic populations are warranted to confirm our results.

  16. Effects of Environmental Manipulations and Treatment with Bupropion and Risperidone on Choice between Methamphetamine and Food in Rhesus Monkeys.

    Science.gov (United States)

    Banks, Matthew L; Blough, Bruce E

    2015-08-01

    Preclinical and human laboratory choice procedures have been invaluable in improving our knowledge of the neurobiological mechanisms of drug reinforcement and in the drug development process for candidate medications to treat drug addiction. However, little is known about the neuropharmacological mechanisms of methamphetamine vs food choice. The aims of this study were to develop a methamphetamine vs food choice procedure and determine treatment effects with two clinically relevant compounds: the monoamine uptake inhibitor bupropion and the dopamine antagonist risperidone. Rhesus monkeys (n=6) responded under a concurrent schedule of food delivery (1-g pellets, fixed-ratio (FR) 100 schedule) and intravenous methamphetamine injections (0-0.32 mg/kg/injection, FR10 schedule) during 7-day bupropion (0.32-1.8 mg/kg/h) and risperidone (0.001-0.0056 mg/kg/h) treatment periods. For comparison, effects of removing food pellets or methamphetamine injections and FR response requirement manipulations were also examined. Under saline treatment conditions, food was preferred over no methamphetamine or small unit methamphetamine doses (0.01-0.032 mg/kg/injection). Larger methamphetamine doses resulted in greater methamphetamine preference and 0.32 mg/kg/injection methamphetamine maintained near exclusive preference. Removing food availability increased methamphetamine choice, whereas removing methamphetamine availability decreased methamphetamine choice. Methamphetamine choice was not significantly altered when the FR response requirements for food and drug were the same (FR100:FR100 or FR10:FR10). Risperidone treatment increased methamphetamine choice, whereas bupropion treatment did not alter methamphetamine choice up to doses that decreased rates of operant behavior. Overall, these negative results with bupropion and risperidone are concordant with previous human laboratory and clinical trials and support the potential validity of this preclinical methamphetamine vs food

  17. Efficacy of sofosbuvir-based therapies in HIV/HCV infected patients and persons who inject drugs.

    Science.gov (United States)

    Puoti, Massimo; Panzeri, Claudia; Rossotti, Roberto; Baiguera, Chiara

    2014-12-15

    In the era of Directly Acting anti HCV Antivirals treatment of hepatitis C is successful in the majority of persons treated. However, treatment of persons with HIV or who inject drugs remains challenging because of special issues: drug-drug interactions with antiretroviral, psychiatric and drug substitution therapies, treatment adherence, impact of treatment on HIV disease course or on risk of bacterial infections. Sofosbuvir induced sustained virologic response in 91% of 23 HIV/HCV coinfected persons treated in combination with ribavirin and pegylated interferon, in 83% of 497 treated in combination with ribavirin and in all 50 patients infected with HCV GT1 treated in combination with ledipasvir and ribavirin. The rates of efficacy in HCV-HIV coinfected were almost the same as those observed in HCV monoinfected suggesting that the efficacy of sofosbuvir is not reduced by HIV coinfection. There are no data on the efficacy of sofosbuvir in injection drugs users. The pangenotypic activity, the high barrier to resistance, the modest potential for drug-drug interactions makes sofosbuvir a reference drug for the treatment of these two special populations.

  18. RISPERIDONE - INDUCED TARDIVE DYSKINESIA : CASE REPORT AND REVIEW OF LITERATURE

    OpenAIRE

    Kumar, P.N. Suresh; Andrade, Chittaranjan

    2001-01-01

    Risperidone is an atypical antipsychotic with broad spectrum of antipsychotic activity and lower potential for extrapyramidal side effects at therapeutic doses. This case report illustrates the development of tardive dyskinesia with therapeutic dose of risperidone in a paranoid schizophrenic patient who was not on any antipsychotic medication previously.

  19. Euprolactinemic gynecomastia and galactorrhea with risperidone-fluvoxamine combination.

    Science.gov (United States)

    Pratheesh, P J; Praharaj, Samir Kumar; Srivastava, Ashish

    2011-01-01

    Risperidone is associated with hyperprolactinemia and its consequent symptoms such as gynecomastia, galactorrhea and sexual dysfunction in adults, and less so in adolescents. Rarely, serotonin reuptake inhibitors are also associated with such adverse effects. We report a case of gynecomastia and galactorrhea in an adolescent male while on a combination of risperidone and fluvoxamine, although the serum prolactin was within normal range.

  20. Cervical interlaminar epidural steroid injection for unilateral cervical radiculopathy: Comparison of midline and paramedian approaches for efficacy

    Energy Technology Data Exchange (ETDEWEB)

    Yoon, Ji Young; Kwon, Jong Won; Yoon, Young Cheol [Dept. of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (Korea, Republic of); Lee, Jong Seok [School of Business Administration, Hallym University, Chuncheon (Korea, Republic of)

    2015-06-15

    The objective of this study was to compare the clinical outcomes of the cervical interlaminar epidural steroid injection (CIESI) for unilateral radiculopathy by the midline or paramedian approaches and to determine the prognostic factors of CIESI. We retrospectively analyzed 182 patients who underwent CIESI from January 2009 to December 2012. Inclusion criteria were no previous spinal steroid injection, presence of a cross-sectional image, and presence of follow-up records. Exclusion criteria were patients with bilateral cervical radiculopathy and/or dominant cervical axial pain, combined peripheral neuropathy, and previous cervical spine surgery. Short-term clinical outcomes were evaluated at the first follow-up after CIESI. We compared the clinical outcomes between the midline and paramedian approaches. Possible prognostic factors for the outcome, such as age, gender, duration of radiculopathy, and cause of radiculopathy were also analyzed. Cervical interlaminar epidural steroid injections were effective in 124 of 182 patients (68.1%) at the first follow-up. There was no significant difference in the clinical outcomes of CIESI, between midline (69.6%) and paramedian (63.7%) approaches (p = 0.723). Cause of radiculopathy was the only significant factor affecting the efficacy of CIESI. Patients with disc herniation had significantly better results than patients with neural foraminal stenosis (82.9% vs. 56.0%) (p < 0.001). There is no significant difference in treatment efficacy between the midline and paramedian approaches in CIESI, for unilateral radiculopathy. The cause of the radiculopathy is significantly associated with the treatment efficacy; patients with disc herniation experience better pain relief than those with neural foraminal stenosis.

  1. Observation on Efficacy of Astragalus Injection in Treating Diabetic Nephrotic Edema

    Institute of Scientific and Technical Information of China (English)

    胡仲仪; 刘迟; 陈以平; 沈玲妹; 金亚明

    2002-01-01

    @@ At the mid-late stage of diabetic nephropathy massive proteinuria, hypoproteinemia and anasarca would develop which is nephrotic syndrome. Diuretics are often insensitive and treatment is very difficult. From January 1995 to December 1998, the authors adopted intravenous dripping infusion of Astragalus injection (AI) for patients with nephrotic syndrome due to diabetic nephropathy (DN). The control group was treated by Salvia injection (SI). The result was that the group treated by AI showed obvious diuretic and detumescent effect.

  2. A Double-Blind, Placebo-Controlled Study of Risperidone for the Treatment of Adolescents and Young Adults with Anorexia Nervosa: A Pilot Study

    Science.gov (United States)

    Hagman, Jennifer; Gralla, Jane; Sigel, Eric; Ellert, Swan; Dodge, Mindy; Gardner, Rick; O'Lonergan, Teri; Frank, Guido; Wamboldt, Marianne Z.

    2011-01-01

    Objective: The purpose of this double-blind, placebo-controlled exploratory pilot study was to evaluate the safety and efficacy of risperidone for the treatment of anorexia nervosa. Method: Forty female subjects 12 to 21 years of age (mean, 16 years) with primary anorexia nervosa in an eating disorders program were randomized to receive…

  3. A retrospective study of risperidone oral solution versus risperidone tablets in treating schizophrenia%利培酮口服液与片剂治疗精神分裂症的回顾性分析

    Institute of Scientific and Technical Information of China (English)

    钟智勇; 吴小立; 韩自力; 张晋碚

    2011-01-01

    AIM To retrospectively evaluate the efficacy and safety of risperidone oral solution and risperidone tablets in treating schizophrenia. METHODS A total of 204 patients, who met diagnostic criteria of CCMD-3 for schizophrenia and were hospitalized in our department of psychiatry from May 2007 to May 2011, included 85 patients in risperidone oral solution group and 119 patients in risperidone tablets group. Before the treatment and at the end of the 4 th week of the treatment, all patients were assessed by Brief Psychiatric Rating Scale (BPRS), Scale for the Assessment of Negative Symptoms (SANS), Scale for the Assessment of Positive Symptoms (SAPS), Treatment Emergent Symptom Scale (TESS) and laboratory tests. RESULTS There were significant differences in total scales of TESS and the rates of ECG abnormalities and extrapyramidal side effects between the risperidone oral solution group and risperidone tablets group (6.62 ± 3.65 vs. 7.97 ± 4.93, 16.5%vs. 28.6%, 23.5% vs. 40.3%, P0.05) in the total scales of BPRS, SANS, SAPS and other index of safety. CONCLUSION The efficacy of risperidone oral solution and risperidone tablets in treating schizophrenia was equal, but risperidone oral solution is superior to risperidone tablets on the safety.%目的 比较利培酮口服液与利培酮片剂治疗精神分裂症的疗效与安全性.方法 回顾性分析2007年5月至201 1年5月在本科室住院4 wk以上,符合CCMD-3精神分裂症诊断标准的患者共204例,其中利培酮口服液组85例,利培酮片剂组119例.比较2组患者治疗前与治疗4 wk末简明精神病评定量表、阳性症状量表、阴性症状量表、副反应量表总分以及实验室检查的差异.结果 2组治疗4 wk末简明精神病评定量表、阳性症状量表、阴性症状量表分值无显著差异(P>0.05).利培酮口服液组副反应量表总分、心电图异常发生率以及锥体外系反应发生率明显低于利培酮片剂组(6.62±3.65 vs.7.97±4.93,16.5

  4. 利培酮口服液与奥氮平治疗老年痴呆精神行为症状的疗效比较%Comparison efficacy of risperidone oral solution and olanzapine in the treatment of elderly dementia behavioral and psychological symptoms

    Institute of Scientific and Technical Information of China (English)

    曲春晖; 孙平; 孙忠国

    2016-01-01

    Objective To discuss the clinical value and safety of risperidone oral solution and olanzapine in treatment of elderly dementia behavioral and psychological symptoms (BPSD).Methods 120 patients with BPSD were randomly divided into research group and control group ,each of 60 cases.Research group were treated with risperidone oral solution ,control group were treated with olanzapine ,the treatment course was 8 weeks.Used BEHAVE-AD to evaluate the efficacy ,evaluated the agitated behavior improvement by CMAI , assessed the adverse drug reactions by TESS assessment , observed the medication compliance by self compliance scale .Results 4 weeks after treatment ,the BEHAVE-AD score and CMAI scores of two groups than before treatment decreased ,but the difference was not statistically significant (P>0.05),8 weeks after treatment,the BE-HAVE-AD score and CMAI scores of two groups decreased significantly ,compared with before treatment difference was statisti-cally significant(P0.05).The incidence rate of weight gain,lethargy in research group were lower than control group ,the difference was statistically significant (P0.05),4 weeks,8 weeks after treatment the compliance of research group was better than control group ,the difference was statistically significant(P<0.05).Conclusion Risperidone oral solu-tion is applied to the clinical treatment of elderly dementia with BPSD effective and relatively safe ,patients with better compli-ance .%目的:比较利培酮口服液与奥氮平治疗老年痴呆精神行为症状( BPSD )的疗效和安全性。方法将120例BPSD患者随机分为研究组和对照组各60例。研究组患者给予利培酮口服液治疗,对照组患者给予奥氮平治疗,疗程为8周。2组患者均采用痴呆病理行为评定量表(BEHAVE-AD)评定疗效,Cohan Mansfield 激越行为量表(CMAI)评定激越行为的改善程度,副反应量表(TESS)评定药物不良反应,自编依从性量表观察患者服药

  5. Comparison of efficacy after adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia between different gender%阿立哌唑治疗利培酮所致高催乳素血症效果的性别差异

    Institute of Scientific and Technical Information of China (English)

    陈景旭; 梁雪梅; 卞清涛; 刘可智; 张立刚; 张荣珍; 李伟; 刘艳红

    2015-01-01

    Objective To compare the efficacy and safety of adjunctive treatment with aripiprazole on hyperprolactinemia induced ky risperidone ketween different gender. Methods By using a stratified randomization protocol,116 schizophrenic patients with risperi=done- induced hyperprolactinemia were assigned to research group(28 male and 31 female)and control group(26 male and 31 female), and received 20mg·d-1 aripiprazole or placeko for adjunctive treatment respectively. Serum prolactin levels was measured at kaseline, the end of the 2nd,4th and 8th weed and UKU Side Effects Rating Scale(UKU)were assessed at kaseline and the end of 8th weed. Re-sults Compared with the kaseline,koth male and female in research group showed statistical difference in serum prolactin at the end of the 2nd,4th and 8th weed(P﹤0.001),kut here were no significant difference ketween the 2nd,4th and 8th weed in research group ketween and after treatment in control group(P﹥0. 05). At the end of the 8th weed,there was no statistical deference ketween male and female in research group in the decline rate of serum prolactin levels[(79. 61 ± 17. 81)%(,75. 54 ± 12. 96)%],and the normal ratio of male pa=tients were significantly higher(92. 9%)than that of female patients in research group(58. 1%)(χ2 =9. 39,P﹤0. 001). Conclusion Adjunctive aripiprazole treatment may ke effective for treating risperidone -induced hyperprolactinemia and achieved almost all of its effects after the 2nd weed. The effects on male patients was ketter than female patients with the same e dosage of aripiprazole.%目的探讨阿立哌唑治疗利培酮所致高催乳素血症的效果是否存在性别差异。方法采用分层随机方法将116例利培酮所致高催乳素血症的精神分裂症患者分为研究组(男性28例,女性31例)和对照组(男性26例,女性31例)。维持原有利培酮治疗方案不变,研究组合并用阿立哌唑20mg·d-1,对照组合并安慰剂治

  6. Efficacy of 2% Lidocaine Injection as a Topical Agent in Cataract Surgery

    Institute of Scientific and Technical Information of China (English)

    Wenyong Huang; Bin Liu; Jiewei Liu; Jinxing Xu; Zhende Lin

    2003-01-01

    Purpose: To determine whether 2% Lidocaine injection is an effective topical anesthetic agent for non-phaco small incision cataract surgery.Setting: Charity eye clinic supported by Hellen Keller International.Methods:One hundred and twenty-five consecutive cataract surgery patients received topical anesthesia with 2% Lidocaine injection solution just 1 and 0.5 minutes prior to non-phaco small incision cataract extraction and intraocular lens implantation. Each patient was asked about pain or piessure sensation during the operation.Results: The surgeon felt ease in the operations. Many patients (93/125) were comfort during the whole surgery. Only 9 patients′ score was above level 3,mostly complained during the nucleus extraction; Among those whose score was level 1~2, 82.6%(19/23)claimed discomfort at middle of the operation (nucleus extraction) or the beginning (creating the conjunctival flap).Conclusion: Lidocaine injection solution(2%) was an effective topical anesthesia agent in cataract surgery.

  7. Discovering risperidone: the LSD model of psychopathology.

    Science.gov (United States)

    Colpaert, Francis C

    2003-04-01

    In the 1970s and 1980s, Janssen Pharmaceutica Research, which had a broad interest in central nervous system disorders and nurtured intellectual freedom, developed original, and at times heretical, concepts. It took decades for the scientific community to endorse some of these concepts. Among them were such notions as an elementary particle of behaviour, the introduction of response quality in receptor theory, and the idea that tolerance does not develop to opioids. These concepts enabled the discovery of the antipsychotic risperidone, a unique full antagonist of the interoceptive effects of LSD.

  8. P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug-drug interaction experiments

    DEFF Research Database (Denmark)

    Ejsing, Thomas B.; Pedersen, Anne D.; Linnet, Kristian

    2005-01-01

    P-glycoprotein, risperidone, nortriptyline, cyclosporine A, drug-drug interaction, blood-brain barrier, knock-out mice......P-glycoprotein, risperidone, nortriptyline, cyclosporine A, drug-drug interaction, blood-brain barrier, knock-out mice...

  9. Prolactin levels and adverse events in patients treated with risperidone.

    Science.gov (United States)

    Kleinberg, D L; Davis, J M; de Coster, R; Van Baelen, B; Brecher, M

    1999-02-01

    Hyperprolactinemia is a common clinical disorder that may lead to sexual dysfunction or galactorrhea. It may arise from a variety of etiologies, including the use of antipsychotic agents, presumably because of a dopamine receptor blockade. This analysis was designed to characterize the relationship between risperidone, serum prolactin levels, and possible clinical sequelae. All data from randomized, double-blind studies of risperidone in patients with chronic schizophrenia were analyzed. The two largest studies (the North American and multinational trials) included 841 patients (259 women, 582 men) with paired prolactin level data and 1,884 patients (554 women, 1,330 men) with data on six adverse events possibly associated with increased prolactin levels (amenorrhea, galactorrhea, and decreased libido in women; erectile dysfunction, ejaculatory dysfunction, gynecomastia, and decreased libido in men). Both risperidone and haloperidol produced dose-related increases in plasma prolactin levels in men and women. Among women, the risperidone dose was not correlated with adverse events, nor were the adverse events correlated with endpoint prolactin levels. Among men, the incidence of adverse events was positively correlated with risperidone dose; however, at risperidone doses of 4 to 10 mg/day the incidence of adverse events was not significantly higher than that observed in patients receiving placebo. Furthermore, adverse events in men were unrelated to plasma prolactin levels. Risperidone-associated increase in serum prolactin levels was not significantly correlated to the emergence of possible prolactin-related side effects.

  10. Synthesis, characterization of novel injectable drug carriers and the antitumor efficacy in mice bearing Sarcoma-180 tumor.

    Science.gov (United States)

    Guo, Wen-xun; Huang, Kai-xun; Tang, Rong; Xu, Hui-bi

    2005-10-20

    New unsaturated polyesters of poly(fumaric acid-glycol-dodecanedioic acid) P(FA-GLY-DDDA) copolymers, poly(fumaric acid-glycol-brassylic acid) P(FA-GLY-BA) copolymers, poly(fumaric acid-glycol-tetradecanedioic acid) P(FA-GLY-TA) copolymers and poly(fumaric acid-glycol-pentadecanedioic acid) P(FA-GLY-PA) copolymers were prepared by melt polycondensation of the corresponding mixed monomers: fumaric acid, glycol and one of C(12-15) dibasic acids. The copolymers were characterized by FT-IR, gel permeation chromatography (GPC), and the surface structure of unsaturated polyesters after solidify were studied by atomic force microscopy (AFM). The molecular structure and composition of the unsaturated polyesters were determined by 1H NMR spectroscopy. In vitro studies showed that some of the copolymers are degradable in phosphate buffer at 37 degrees C and have properly drug release rate as drug carriers. The biocompatibility of P(FA-GLY-DDDA) and P(FA-GLY-BA) copolymers under mice skin was also evaluated, macroscopic observation and microscopic analysis demonstrated that the copolymer is biocompatible and well tolerated in vivo. Antitumor efficacy of P(FA-GLY-DDDA) copolymers and P(FA-GLY-BA) copolymers containing 5% adriamycin hydrochloride (ADM) in mice bearing Sarcoma-180 tumor exhibited increased volume doubling time (VDT) (22+/-1.5 days and 24+/-2.5 days) compared to plain subcutaneous injection of ADM (7+/-0.9 days). The antitumor efficacy of injecting P(FA-GLY-DDDA)-ADM inside tumor twice intervened in 22 days exhibited an especially increased cytotoxic effect as revealed by increased VDT (33+/-2.5 days), and the antitumor efficacy of injecting P(FA-GLY-BA)-ADM inside tumor twice intervened in 24 days exhibited an especially increased cytotoxic effect as revealed by increased VDT (35+/-1.5 days). The studies suggested that P(FA-GLY-DDDA) copolymers and P(FA-GLY-BA) copolymers as effective and injectable carriers for antineoplastic drug like adriamycin hydrochloride

  11. Lack of efficacy of injectable ketamine with xylazine or diazepam for anesthesia in chickens.

    Science.gov (United States)

    Varner, Jack; Clifton, Kelli R; Poulos, Stacy; Broderson, J Roger; Wyatt, Roger D

    2004-05-01

    Compared to other laboratory animals, little is known about the use of anesthetics in birds, potentially resulting in the use of improper dosing regimens. The authors compared two commonly used ketamine combinations with isoflurane and concluded that the injectable doses were ineffective for induction of surgical anesthesia in chickens.

  12. Control study of efficacy and safety of Paliperidone and Risperidone in treatment of alcohol-induced mental disorder%帕利哌酮与利培酮治疗酒精所致精神障碍疗效及安全性对照研究

    Institute of Scientific and Technical Information of China (English)

    田文聪

    2014-01-01

    目的:探讨帕利哌酮缓释片与利培酮片治疗酒精所致精神障碍的临床疗效及安全性。方法:共纳入40例酒精所致精神障碍患者进行6周的研究。将患者分为帕利哌酮缓释片组(研究组)和利培酮组(对照组)各20例。在患者治疗前及治疗第1、2、4、6周末采用阳性和阴性症状量表( PANSS)评定临床疗效;治疗中需处理的不良反应量表( TESS)评定不良反应;两组患者均入院即使用相同护肝药物,定期检测肝功能,监测肝功能各项指标变化。结果:两药对酒精所致精神障碍的疗效无显著性差异(P>0.05);在不良反应方面,帕利哌酮缓释片组患者低于利培酮组,两组患者比较有显著差异(P0. 05). The study group had significant less side effects than control group, and the difference was significant (P<0. 05). The study group had more significant improvement in liver function compared to control group 2 weeks after the treatment, and the difference was significant (P<0. 05). Conclusions: Paliperidone ER has good efficacy in the treatment of alcohol-induced mental disorder. It has less side effects than Risperidone and helps the improvement of liver function. Paliperidone ER is worth further clinical application.

  13. Cisplatin Tumor Biodistribution and Efficacy after Intratumoral Injection of a Biodegradable Extended Release Implant

    OpenAIRE

    Ariella Shikanov; Sergey Shikanov; Boris Vaisman; Jacob Golenser; Domb, Abraham J.

    2011-01-01

    Local delivery of chemotherapeutic drugs has long been recognized as a potential method for reaching high drug doses at the target site while minimizing systemic exposure. Cisplatin is one of the most effective chemotherapeutic agents for the treatment of various tumors; however, its systemic toxicity remains the primary dose-limiting factor. Here we report that incorporation of cisplatin into a fatty acid-based polymer carrier followed by a local injection into the solid tumor resulted in a ...

  14. Comparison of Efficacy and Prolactin Concentrations between Aripiprazole and Risperidone Treat-ments in Patients with Schizophrenia%阿立哌唑替换利培酮治疗对精神分裂症患者血清催乳素水平的影响

    Institute of Scientific and Technical Information of China (English)

    马筠; 李轶琛; 李毅; 房茂胜; 钟宝亮

    2013-01-01

    Objective: To compare the prolactin concentrations between aripiprazole and risperidone treatment in patients with schizophrenia. Methods: One hundred and twenty-eight schizophrenic patients with hy-perprolactinemia were randomly divided into risperidone group and aripiprazole group. Patients in the risperidone group were treated with risperidone and in the aripiprazole group were treated with aripiprazol instead of risperidone for 8 weeks. The prolactin concentrations were assessed and compared between two groups at weeks 0, 1,2, 4, 6, and 8. The clinical status was assessed by using the positive and negative syndrome scale (PANSS) and the clinical global impressions scale (CGIS) atweeks0 and 8. Results: Fifty-three in the risperidone group and 48 in the aripiprazole group were available for analyzing. Shift risperidone to aripiprazole was effective in reducing serum prolactin levels. The serum prolactin levels in the risperidone group was significantly lower than that in the aripiprazole group at week 8 (P<0.001). No significant changes was found in the PANSS and CGI-S scores between the two groups. Conclusion: Shift risperidone to aripiprazole was effective in reducing serum prolactin levels of schizophrenia patients with hyperprolactinemia.%目的:研究阿立哌唑替换利培酮治疗对精神分裂症患者血清催乳素水平的影响.方法:伴有高催乳素血症的精神分裂症患者128 例,随机分为利培酮组(维持利培酮治疗)和阿立哌唑(阿立哌唑替代利培酮治疗)组,治疗8 周.于第0、1、2、4、6 及8 周测血清催乳素水平及身体质量指数(BMI);在入组时和治疗8 周时采用阳性与阴性症状量表(PANSS)和临床总体印象量表(CGIS)测定疗效.结果:可用于评估的数据101 例,利培酮组53 例,阿立哌唑组48 例.阿立哌唑组替换治疗后第1 周血清催乳素水平即明显下降,第8 周时,显著低于利培酮组(P<0.001);2 组BMI 、PANSS 及CGIS 评分及变化差异无统计

  15. Efficacy and safety of motherwort injection and oxytocin in preventing postpartum hemorrhage after vaginal delivery: a Meta analysis

    Directory of Open Access Journals (Sweden)

    Lin-miao ZENG

    2015-11-01

    Full Text Available Objective To evaluate the clinical efficacy and safety of motherwort injection and oxytocin in preventing postpartum hemorrhage after vaginal delivery. Methods Data of randomly controlled trials (RCTs of motherwort injection and oxytocin in preventing postpartum hemorrhage after vaginal delivery were collected by searching PubMed (1980-2013.9, Wiley Online Library (1990-2013.9, Embase (1990-2013.9, CNKI (1990-2013.9, VIP database (1990-2013.9 and WanFang Data (1990-2013.9. The amount and incidence of postpartum hemorrhage and quantity of blood loss, as well as the incidence of postpartum morbidity were then collected in those puerperal women treated with motherwort injection and oxytocin. The quality of included studies was assessed according to Cochrane Systematic Review, and Meta-analysis was conducted by RevMan 5.1 software. Results A total of 13 studies involving 2186 patients were included. Compared with oxytocin group, motherwort and oxytocin decreased the amount of vaginal bleeding within 2 hours after delivery and 24 hours after delivery. Furthermore, motherwort and oxytocin significantly decreased the incidence of postpartum hemorrhage (RR=0.30, 95%CI 0.19-0.47, P<0.00001. No difference was found between the two groups in the postpartum adverse reaction rate (RR=0.63, 95%CI 0.37-1.05, P=0.08. Conclusions Motherwort injection and oxytocin are effective in preventing postpartum hemorrhage after vaginal delivery, and they can effectively reduce incidence of postpartum hemorrhage and the amount of blood loss without increasing the side effects in patients. DOI: 10.11855/j.issn.0577-7402.2015.10.11

  16. Clinical Observation of Risperidone in the Treatment of Postoperative Delirium in Elderly Orthopedics Patients%利培酮治疗老年骨科患者术后谵妄的临床观察

    Institute of Scientific and Technical Information of China (English)

    吴晓; 王利宏

    2013-01-01

    目的:观察利培酮治疗老年骨科患者术后谵妄的临床疗效和安全性.方法:将符合标准的骨科术后并发谵妄的老年患者68例按年龄、性别、病种、手术种类为条件均分为对照组和观察组.对照组肌肉注射氟哌啶醇注射液,起始剂量为2.0 mg/d,经调整剂量后平均用量(7.0±0.4)mg/d,每日1~2次;观察组口服利培酮片,起始剂量为0.5 mg/d,经调整剂量后平均用量(1.5±0.3)mg/d,每日1~2次.两组患者均治疗7d.治疗过程中采用谵妄分级量表进行谵妄症状(DRS)评分,并观察不良反应发生情况.结果:两组患者治疗期间DRS评分较治疗前均显著下降(P<0.05),但两组患者同期DRS评分比较差异无统计学意义(P>0.05);对照组2例患者出现锥体外系反应,而观察组未见不良反应发生,两组患者不良反应发生率比较差异有统计学意义(P<0.05).结论:利培酮治疗老年骨科患者手术后谵妄与氟哌啶醇疗效相近,但利培酮较氟哌啶醇更安全.%OBJECTIVE:To observe clinical efficacy and safety of risperidone in the treatment of delirium in elderly orthopedic patients after surgery.METHODS:68 elderly patients with delirium after orthopedic surgery met criteria were randomly divided into control group and observation group according to age,gender,disease type and operation tyes.Control group was given Haloperidol injection intramuscularly with starting dose of 2.0 mg/d,1 to 2 times a day,average dose of (7.0 ± 0.4) mg/d after adjustment; observation group was given Risperidone tablet orally with t starting dose of 0.5 mg/d,1 to 2 times a day,average dose of (1.5 + 0.3) mg/d after adjustment.Treatment course of 2 groups both were 7 days.The symptems was scored by using Delirium Rating Scale (DRS) score and adverse drug reactions were observed during treatment.RESULTS:DRS scores of two groups were decreased significantly during treatment (P<0.05),there was no statistical significance between 2

  17. Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review

    Directory of Open Access Journals (Sweden)

    Mravčík V

    2013-10-01

    Full Text Available Viktor Mravčík,1,2 Lisa Strada,3 Josef Štolfa,4,5 Vladimir Bencko,6 Teodora Groshkova,7 Jens Reimer,3 Bernd Schulte3 1National Monitoring Centre for Drugs and Drug Addiction, 2Department of Addictology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic; 3Centre for Interdisciplinary Addiction Research, University of Hamburg, Hamburg, Germany; 4Department of General Practice, Institute for Postgraduate Medical Education in Prague, 5Department of General Practice, Second Faculty of Medicine, 6Institute of Hygiene and Epidemiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic; 7European Monitoring Centre for Drugs and Drug Addiction, Lisbon, Portugal Introduction and methods: Hepatitis C virus (HCV infections are highly prevalent amongst people who inject drugs (PWID. Despite well documented evidence of its effectiveness, suggested cost-effectiveness, and potential to reduce HCV prevalence rates, the uptake of antiviral HCV treatment by PWID is low. This nonsystematic literature review describes factors associated with the uptake, adherence, and efficacy of HCV treatment among PWID and discusses strategies to increase their uptake of treatment. Results: Low HCV treatment uptake among PWID is associated with a number of patient-related and provider-related barriers. Beliefs and fears about low efficacy and adverse effects on the patient’s part are common. A substantial number of factors are associated with the chaotic lifestyle and altered social functioning of PWID, which are often associated with decompensation or relapsing into drug addiction. This may lead to perceived low adherence with treatment and low efficacy on the provider’s part too, where lack of support, inadequate management of addiction, and other drug-related problems and poor treatment of side effects have been described. Practical issues such as the accessibility of treatment and finances also play a role

  18. A Numerical study for the efficacy of flow injection on the diminution of rudder cavitation

    Science.gov (United States)

    Seo, Dae Won; Lee, Seung-Hee; Kim, Hyo Chul; Oh, Jung Keun

    2010-06-01

    The complete avoidance of cavitation, as a result of gap flow between the fixed and movable portion of a horn type rudder system, is difficult. To reduce gap flow, it is a common practice to attach a half round prismatic bar that protrudes beyond the concave surface of the horn facing the gap and laid along the centerplane of the rudder. However the employment of such a device does not always yield satisfactory results. Previously, the authors have shown that a pair of blocking bars, attached on the convex surface of the movable portion, better enhance the blocking ability of gap flow to that of a single centre bar installed on the concave surface. This also circumvents difficulties that might occur in practical applications. In the present study, a series of numerical computations show that flow injected into the gap of a rudder may also block the flow within, without employment of any physical devices, such as a half circular bar. This study also shows that the combination of flow injection and blocking bars may result in the synergic augmentation of blocking efficiency of gap flow, as demonstrated in computations for a three dimensional rudder system.

  19. A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study

    Directory of Open Access Journals (Sweden)

    Galynker Igor I

    2009-05-01

    Full Text Available Abstract Background Because a large proportion of patients with panic attacks receiving approved pharmacotherapy do not respond or respond poorly to medication, it is important to identify additional therapeutic strategies for the management of panic symptoms. This article describes a randomized, rater-blind study comparing low-dose risperidone to standard-of-care paroxetine for the treatment of panic attacks. Methods Fifty six subjects with a history of panic attacks were randomized to receive either risperidone or paroxetine. The subjects were then followed for eight weeks. Outcome measures included the Panic Disorder Severity Scale (PDSS, the Hamilton Anxiety Scale (Ham-A, the Hamilton Depression Rating Scale (Ham-D, the Sheehan Panic Anxiety Scale-Patient (SPAS-P, and the Clinical Global Impression scale (CGI. Results All subjects demonstrated a reduction in both the frequency and severity of panic attacks regardless of treatment received. Statistically significant improvements in rating scale scores for both groups were identified for the PDSS, the Ham-A, the Ham-D, and the CGI. There was no difference between treatment groups in the improvement in scores on the measures PDSS, Ham-A, Ham-D, and CGI. Post hoc tests suggest that subjects receiving risperidone may have a quicker clinical response than subjects receiving paroxetine. Conclusion We can identify no difference in the efficacy of paroxetine and low-dose risperidone in the treatment of panic attacks. Low-dose risperidone appears to be tolerated equally well as paroxetine. Low-dose risperidone may be an effective treatment for anxiety disorders in which panic attacks are a significant component. Trial Registration ClinicalTrials.gov Identifier: NCT100457106

  20. Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database

    Directory of Open Access Journals (Sweden)

    Lambert Tim

    2012-03-01

    Full Text Available Abstract Background This observational study was designed to collect treatment outcomes data in patients using the electronic Schizophrenia Treatment Adherence Registry (e-STAR. Methods Patients with schizophrenia or schizoaffective disorder in Australia who were prescribed risperidone long-acting injection (RLAI between 2003 and 2007 were assessed 12-months retrospectively, at baseline and 24-months prospectively at 3-monthly intervals. The intent-to-treat population, defined as all patients who received at least one dose of RLAI at baseline, was used for the efficacy and safety analyses. Results At total of 784 patients (74% with schizophrenia, 69.8% male with a mean age of 37.1 ± 12.5 years and 10.6 ± 9.5 years since diagnosis were included in this Australian cohort. A significant improvement in mean Clinical Global Impression - severity score was observed at 24-months (4.52 ± 1.04 at baseline, 3.56 ± 1.10 at 24-months. Most of this improvement was seen by 3-months and was also reflected in mean Global Assessment of Functioning score, which improved significantly at 24-months (42.9 ± 14.5 at baseline, 59 ± 15.4 at 24-months. For patients still receiving RLAI at 24-months there was an increase from a mean baseline RLAI dose of 26.4 ± 5 mg to 43.4 ± 15.7 mg. Sixty-six percent of patients discontinued RLAI before the 24-month period--this decreased to 46% once patients lost to follow-up were excluded. Conclusion Over the 24-month period, initiation of RLAI was associated with improved patient functioning and illness severity in patients with schizophrenia or schizoaffective disorder. Improved outcomes were observed early and sustained throughout the study. Trial Registration Clinical Trials Registration Number, NCT00283517.

  1. The efficacy of an ivermectin/closantel injection against experimentally induced infections and field infections with gastrointestinal nematodes and liver fluke in cattle

    NARCIS (Netherlands)

    Borgsteede, F.H.M.; Taylor, S.; Gaasenbeek, C.P.H.; Couper, A.; Cromie, L.

    2008-01-01

    Three studies were performed to test the efficacy of an ivermectin/closantel injection (200 ¿g/kg¿1 ivermectin and 5 mg/kg¿1 closantel) in cattle. Two were experimentally induced infections of Ostertagia ostertagi, Cooperia oncophora and Fasciola hepatica in calves, and the third had natural field i

  2. Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo.

    Science.gov (United States)

    Wong, So C; Klein, Jason J; Hamilton, Holly L; Chu, Qili; Frey, Christina L; Trubetskoy, Vladimir S; Hegge, Julia; Wakefield, Darren; Rozema, David B; Lewis, David L

    2012-12-01

    Effective in vivo delivery of small interfering (siRNA) has been a major obstacle in the development of RNA interference therapeutics. One of the first attempts to overcome this obstacle utilized intravenous injection of cholesterol-conjugated siRNA (chol-siRNA). Although studies in mice revealed target gene knockdown in the liver, delivery was relatively inefficient, requiring 3 daily injections of 50 mg/kg of chol-siRNA to obtain measurable reduction in gene expression. Here we present a new delivery approach that increases the efficacy of the chol-siRNA over 500-fold and allows over 90% reduction in target gene expression in mice and, for the first time, high levels of gene knockdown in non-human primates. This improved efficacy is achieved by the co-injection of a hepatocyte-targeted and reversibly masked endosomolytic polymer. We show that knockdown is absolutely dependent on the presence of hepatocyte-targeting ligand on the polymer, the cognate hepatocyte receptor, and the cholesterol moiety of the siRNA. Importantly, we provide evidence that this increase in efficacy is not dependent on interactions between the chol-siRNA with the polymer prior to injection or in the bloodstream. The simplicity of the formulation and efficacy of this mode of siRNA delivery should prove beneficial in the use of siRNA as a therapeutic.

  3. Effects of Risperidone on Cognitive-Motor Performance and Motor Movements in Chronically Medicated Children

    Science.gov (United States)

    Aman, Michael G.; Hollway, Jill A.; Leone, Sarah; Masty, Jessica; Lindsay, Ronald; Nash, Patricia; Arnold, L. Eugene

    2009-01-01

    This study was designed to explore the placebo-controlled effects of risperidone on cognitive-motor processes, dyskinetic movements, and behavior in children receiving maintenance risperidone therapy. Sixteen children aged 4-14 years with disruptive behavior were randomly assigned to drug order in a crossover study of risperidone and placebo for 2…

  4. Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults

    Directory of Open Access Journals (Sweden)

    Kim S

    2012-07-01

    Full Text Available Shiyun Kim,1 Hugo Solari,2 Peter J Weiden,2 Jeffrey R Bishop11Department of Pharmacy Practice, University of Illinois at Chicago College of Pharmacy, 2Department of Psychiatry, University of Illinois at Chicago College of Medicine, Chicago, IL, USAPurpose: To review the use of paliperidone palmitate in treatment of patients with schizophrenia.Methods: Published clinical trial data for the development and utilization of paliperidone palmitate for the treatment of schizophrenia were assessed in this review. Four short-term, randomized, double-blind, placebo-controlled trials investigated the efficacy of paliperidone palmitate in acute exacerbation of schizophrenia. Paliperidone palmitate was also studied as a maintenance treatment to prevent or delay relapse in stable schizophrenia. In addition, paliperidone palmitate was compared to risperidone long-acting injection for noninferiority in three studies.Results: Paliperidone palmitate has been shown to be effective in reducing symptoms as measured by the Positive and Negative Syndrome Scale total scores in the four acute treatment studies. In the maintenance treatment studies, paliperidone palmitate was found to be more effective than placebo in preventing or delaying the time to first relapse in stable schizophrenia patients. In addition, paliperidone palmitate was shown to be noninferior to risperidone long-acting injection in two studies. It was shown to be reasonably well tolerated in all clinical trials. Acute treatment phase should be initiated with a dose of 234 mg on day one and 156 mg on day eight, followed by a recommended monthly maintenance dose of 39–234 mg based on efficacy and tolerability results from the clinical studies.Conclusion: Providing an optimal long-term treatment can be challenging. Paliperidone palmitate can be used as an acute treatment even in outpatient setting, and it has shown to be well tolerated by patients. Also, it does not require overlapping oral

  5. Clinical efficacy of intra-articular injections in knee osteoarthritis: a prospective randomized study comparing hyaluronic acid and betamethasone

    Directory of Open Access Journals (Sweden)

    Trueba Davalillo CA

    2015-01-01

    Full Text Available Cesáreo Ángel Trueba Davalillo,1,2 Cesáreo Trueba Vasavilbaso,2 José Mario Navarrete Álvarez,2 Pilar Coronel Granado,3 Ozcar Alejandro García Jiménez,2 Mercedes Gimeno del Sol,3 Félix Gil Orbezo2 1School of Medicine (UNAM, México DF, Mexico; 2Orthopedic Service, Hospital Español de México, México DF, Mexico; 3Scientific Department, TEDEC-MEIJI FARMA,SA, Alcalá de Henares, Spain Background: Osteoarthritis (OA is the most common joint disease and leading cause of disability. Intra-articular (IA administration of hyaluronic acid (HA or corticosteroids (CS have been previously studied, though using insufficient number of patients or short follow-up periods.Objective: We evaluate HA and CS in patients with knee OA in terms of clinical efficacy over 12 months.Methods: We used a prospective, randomized study with parallel groups. Randomized patients received IA injections of HA or betamethasone (BM. The primary outcomes were improvement in pain using Visual Analog Scale and function in the Western Ontario and McMaster University Osteoarthritis Index (Likert scale. Follow-up visits were scheduled at 3 months, 6 months, 9 months, and 12 months.Results: A total of 200 patients were included. Pain was significantly reduced in both groups at the first follow-ups. At 12 months, the mean pain reduction in the HA group was 33.6% (95% CI: 31.1–36.1 compared to 8.2% (95% CI: 5.2–11.1 in BM (P<0.0001. Function improvement was higher in HA through every visit, and mean improvement at 12 months was 47.5% (95% CI: 45.6–49.3 in HA patients vs 13.2% (95% CI: 11.4–14.9 in the BM group (P<0.0001. All patients from both groups achieved the Minimal Clinically Important Improvement (MCII for both pain and function up to 6 months. At 9 months and 12 months, the MCII figures were higher in HA group with ≥80% compared to ≤10% in BM group (P<0.0001. Adverse reactions were rare and related to the administration procedure.Conclusion: Both treatments

  6. Clinical efficacy of intra-articular injections in knee osteoarthritis: a prospective randomized study comparing hyaluronic acid and betamethasone

    Science.gov (United States)

    Trueba Davalillo, Cesáreo Ángel; Trueba Vasavilbaso, Cesáreo; Navarrete Álvarez, José Mario; Coronel Granado, Pilar; García Jiménez, Ozcar Alejandro; Gimeno del Sol, Mercedes; Gil Orbezo, Félix

    2015-01-01

    Background Osteoarthritis (OA) is the most common joint disease and leading cause of disability. Intra-articular (IA) administration of hyaluronic acid (HA) or corticosteroids (CS) have been previously studied, though using insufficient number of patients or short follow-up periods. Objective We evaluate HA and CS in patients with knee OA in terms of clinical efficacy over 12 months. Methods We used a prospective, randomized study with parallel groups. Randomized patients received IA injections of HA or betamethasone (BM). The primary outcomes were improvement in pain using Visual Analog Scale and function in the Western Ontario and McMaster University Osteoarthritis Index (Likert scale). Follow-up visits were scheduled at 3 months, 6 months, 9 months, and 12 months. Results A total of 200 patients were included. Pain was significantly reduced in both groups at the first follow-ups. At 12 months, the mean pain reduction in the HA group was 33.6% (95% CI: 31.1–36.1) compared to 8.2% (95% CI: 5.2–11.1) in BM (P<0.0001). Function improvement was higher in HA through every visit, and mean improvement at 12 months was 47.5% (95% CI: 45.6–49.3) in HA patients vs 13.2% (95% CI: 11.4–14.9) in the BM group (P<0.0001). All patients from both groups achieved the Minimal Clinically Important Improvement (MCII) for both pain and function up to 6 months. At 9 months and 12 months, the MCII figures were higher in HA group with ≥80% compared to ≤10% in BM group (P<0.0001). Adverse reactions were rare and related to the administration procedure. Conclusion Both treatments effectively controlled OA symptoms. BM showed higher short-term effectiveness, while HA showed better long-term effectiveness, maintaining clinical efficacy in a large number of patients 1 year after administration.

  7. 氯硝西泮对偏执型精神分裂症的辅助治疗作用%An efficacy study of risperidone combined with clonazepam injection in the treatment of paranoid schizophrenia

    Institute of Scientific and Technical Information of China (English)

    王小全; 王晓峰; 周海晓

    2003-01-01

    目的:评价利培酮配合氯硝西泮注射液治疗偏执型精神分裂症的疗效.方法:对病程<3年的80例首次住院,选用利培酮治疗的偏执型精神分裂症患者,随机分为合用氯硝西泮(合用组)和未合用氯硝西泮(对照组)各40例,进行8周治疗.采用阳性症状与阴性症状量表(PANSS)评定疗效,副反应量表(TESS)评定不良反应.结果:合用组治疗2周后PANSS量表总分、阳性症状分、精神病理因子分及症状群中激活性、偏执、攻击性分值均显著下降;治疗4周末时利培酮剂量合用组显著低于对照组.结论:利培酮配合氯硝西泮注射液治疗偏执型精神分裂症可缩短疗程,改善其阳性症状及攻击行为.

  8. RP-HPLC estimation of risperidone in tablet dosage forms

    Directory of Open Access Journals (Sweden)

    Bladania S

    2008-01-01

    Full Text Available A simple, specific, accurate, and precise reverse phase liquid chromatographic method was developed and validated for the estimation of risperidone in tablet dosage forms. A Phenomenex Gemini C-18, 5 µm column having 250x4.6 mm i.d. in isocratic mode, with mobile phase containing methanol: acetonitrile: 50 mM potassium dihydrogen orthophosphate (80:10:10 v/v was used. The flow rate was 1.3 ml/min and effluents were monitored at 234 nm. Clozapine was used as an internal standard. The retention time of risperidone and clozapine were 2.5 min and 3.3 min, respectively. The method was validated for linearity, accuracy, precision, specificity, limit of quantification, limit of detection, robustness and stability. The limit of detection and limit of quantification for estimation of risperidone was found to be 500 ng/ml and 990 ng/ml, respectively. Recovery of risperidone was found to be in the range of 99.02-101.68%. Proposed method was successfully applied for the quantitative determination of risperidone in tablet formulations.

  9. Efficacy of perioperative parecoxib injection on postoperative pain relief after laparoscopic cholecystectomy: A prospective,randomized study

    Institute of Scientific and Technical Information of China (English)

    Thawatchai Akaraviputh; Charay Leelouhapong; Varut Lohsiriwat; Somkiat Aroonpruksakul

    2009-01-01

    AIM: To determine the efficacy of perioperative parecoxib injection on postoperative pain relief after laparoscopic cholecystectomy.METHODS: A prospective, double-blind, randomized,placebo-controlled study was conducted on 70 patients who underwent elective laparoscopic cholecystectomy under general anesthesia at Siriraj Hospital, Bangkok,from January 2006 to December 2007. Patients were randomized to receive either 20 mg parecoxib infusion 30 min before induction of anesthesia and at 12 h after the first dose (treatment group), or normal saline infusion, in the same schedule, as a placebo (control group). The degree of the postoperative pain was assessed every 3 h in the first 24 h after surgery, and then every 12 h the following day, using a visual analog scale. The consumption of analgesics was also recorded.RESULTS: There were 40 patients in the treatment group, and 30 patients in the control group. The pain scores at each time point, and analgesic consumption did not differ between the two groups. However,there were fewer patients in the treatment group than placebo group who required opioid infusion within the first 24 h (60% vs 37%, P = 0.053).

  10. Clinical result of intra-arterial lymphocyte injection therapy for treatment of lymphedema and the evaluation of the efficacy of the therapy. Quantitative analysis by an injection of {sup 111}In-labeled lymphocytes and by MR imaging

    Energy Technology Data Exchange (ETDEWEB)

    Yoshizumi, Masanori; Kitagawa, Tetsuya; Hori, Takaki; Katoh, Itsuo; Harada, Masashi; Matsumoto, Takahiro; Nishitani, Hiromu [Tokushima Univ. (Japan). School of Medicine

    1995-11-01

    We have employed the intra-arterial lymphocytes injection therapy for treatment of lymphedema of the limbs with various causes. In the present study, we observed the clinical outcome of our therapy in 38 patients with lymphedema of the limbs. Results showed that the therapy was effective in 26 of 38 patients (68% of the total). Moreover, a marked efficacy was obtained in 13 of 38 patients (34% of the total). In the latest 5 patients, to evaluate the efficacy of our therapy, we examined the distribution of the {sup 111}In-oxine labeled lymphocytes injected into the proximal artery of the affected limb. The radioactivities of the affected limbs were apparently higher than that of the healthy limbs in effective cases. Moreover, MR imaging showed that the reduction of STIR ratio and T{sub 2} ratio well correlate with the results of clinical course. Thus, the efficacy of the lymphocyte injection therapy is able to be evaluated by radiolabeled lymphocytes and MR imaging. (author).

  11. Ultrasound-guided retro-calcaneal bursa corticosteroid injection for refractory Achilles tendinitis in patients with seronegative spondyloarthropathy: efficacy and follow-up study.

    Science.gov (United States)

    Srivastava, Puja; Aggarwal, Amita

    2016-06-01

    Ultrasound (US)-guided corticosteroid injection has been shown to be safe and effective for varied causes of plantar fasciitis; however, its use for Achilles tendinitis is controversial. We studied the efficacy and changes in US findings at Achilles enthesitis after corticosteroid injection in patients with spondyloarthropathy (SpA). Patients with SpA with symptomatic Achilles enthesitis, refractory to 6 weeks of full-dose NSAIDs, were offered US-guided local corticosteroid injection. Injected entheses were examined by US (both B mode and power Doppler) at baseline and 6 weeks after injection. Standard OMERACT definitions were used to define enthesitis. Achilles tendon thickness >5.29 mm, 2 cm proximal to insertion in long axis, was considered thickened. Twenty-seven symptomatic Achilles tendons (in 18 patients) were injected with 20 mg methylprednisolone under US guidance baseline, and 6-week follow-up US features were compared. All patients reported improvement in pain (VAS) in the affected tendon after injection (p < 0.0001). Simultaneously, improvement in local inflammatory changes were noted, in the form of significant reduction in tendon thickness (p < 0.0001), vascularity (p < 0.0001), peritendinous oedema (p = 0.001), bursitis and bursal vascularity (p < 0.001 and < 0.0001, respectively). There was no change in bone erosions and enthesophyte. None of the patients had tendon rupture or other injection-related complications at 6 weeks of follow-up. US-guided local corticosteroid injection is an effective and safe modality for refractory Achilles enthesitis in patients with SpA and leads to reversion of acute changes at entheseal site.

  12. Risperidone and lorazepam concomitant use in clonazepam refractory catatonia: a case report.

    Science.gov (United States)

    Grenier, Ernesto; Ryan, Molly; Ko, Elizabeth; Fajardo, Karina; John, Vineeth

    2011-12-01

    The DSM-IV recognizes catatonia as a subtype of schizophrenia characterized by at least two of the following: motor immobility, excessive motor activity not influenced by external stimuli, and peculiarities of voluntary movement. Catatonia may also occur secondary to mania, depression, or a general medical condition including encephalitis, focal neurological lesions, metabolic disturbances, and drug intoxications and withdrawals. Benzodiazepines remain the first line of treatment; up to 80% of patients respond promptly to Lorazepam challenge; failure to respond to lorazepam may be followed by electroconvulsive therapy. Atypical antipsychotics may be a new alternative in the treatment of catatonia. Successful reduction of the catatonic symptoms has been demonstrated with atypical antipsychotics. A possible mechanism of action for the efficacy of this class of drugs involves the antagonism of the 5-HT2A receptor. We are now reporting a case of treatment response to risperidone in a patient with chronic catatonia resistant to benzodiazepines.

  13. Safety and efficacy of a novel injectable filler in the treatment of nasolabial folds: polymethylmethacrylate and cross-linked dextran in hydroxypropyl methylcellulose.

    Science.gov (United States)

    Lee, Young Bok; Song, Eun Jong; Kim, Sang Seok; Kim, Jin Wou; Yu, Dong Soo

    2014-08-01

    Nasolabial folds are a sign of aging and increasing number of people want filler injections in their nasolabial folds to look younger. Various dermal fillers are used for the correction of nasolabial folds. Recently, a novel injectible filler, polymethylmethacrylate (PMMA) and cross-linked dextran in hydroxypropyl methylcellulose, was introduced for facial contouring. This study was designed as a six-month, prospective, single-blinded, and open-label study in two centers located in Korea. Nineteen Korean patients received the novel filler injections on both nasolabial folds. At Weeks 4, 12, and 24, the efficacy and safety of the dermal filler were evaluated by blinded-investigators using clinical photographs. The mean Wrinkle Severity Rating Scale revealed significant decrease after dermal filler injections at each study visit. The decreased Wrinkle Severity Rating Scale was maintained for 6 months (p < 0.0001). The Global Aesthetic Improvement score showed an improvement greater than 2 in 95% of the per-proto col population 24 weeks after the injections. All patients (100%) experienced an improvement of their nasolabial folds at Week 24. There were no complications related to the novel filler injection. The novel dermal filler, PMMA, and cross-linked dextran in hydroxylpropyl methylcellulose, can be another safe and effective treatment option in the treatment of nasolabial folds.

  14. Does Reduction of Number of Intradetrusor Injection Sites of aboBoNTA (Dysport® Impact Efficacy and Safety in a Rat Model of Neurogenic Detrusor Overactivity?

    Directory of Open Access Journals (Sweden)

    Amélie Huynh Le Maux

    2015-12-01

    Full Text Available Intradetrusor injections of Botulinum toxin A—currently onabotulinumtoxinA—is registered as a second-line treatment to treat neurogenic detrusor overactivity (NDO. The common clinical practice is 30 × 1 mL injections in the detrusor; however, protocols remain variable and standardization is warranted. The effect of reducing the number of injection sites of Dysport® abobotulinumtoxinA (aboBoNTA was assessed in the spinal cord-injured rat (SCI. Nineteen days post-spinalization, female rats received intradetrusor injections of saline or aboBoNTA 22.5 U distributed among four or eight sites. Two days after injection, continuous cystometry was performed in conscious rats. Efficacy of aboBoNTA 22.5 U was assessed versus aggregated saline groups on clinically-relevant parameters: maximal pressure, bladder capacity, compliance, voiding efficiency, as well as amplitude, frequency, and volume threshold for nonvoiding contractions (NVC. AboBoNTA 22.5 U significantly decreased maximal pressure, without affecting voiding efficiency. Injected in four sites, aboBoNTA significantly increased bladder capacity and compliance while only the latter when in eight sites. AboBoNTA significantly reduced NVC frequency and amplitude. This preclinical investigation showed similar inhibiting effects of aboBoNTA despite the number of sites reduction. Further studies are warranted to optimize dosing schemes to improve the risk-benefit ratio of BoNTA-based treatment modalities for NDO and further idiopathic overactive bladder.

  15. Does Reduction of Number of Intradetrusor Injection Sites of aboBoNTA (Dysport®) Impact Efficacy and Safety in a Rat Model of Neurogenic Detrusor Overactivity?

    Science.gov (United States)

    Huynh Le Maux, Amélie; Pignol, Bernadette; Behr-Roussel, Delphine; Blachon, Jean-Luc; Chabrier, Pierre-Etienne; Compagnie, Sandrine; Picaut, Philippe; Bernabé, Jacques; Giuliano, François; Denys, Pierre

    2015-01-01

    Intradetrusor injections of Botulinum toxin A—currently onabotulinumtoxinA—is registered as a second-line treatment to treat neurogenic detrusor overactivity (NDO). The common clinical practice is 30 × 1 mL injections in the detrusor; however, protocols remain variable and standardization is warranted. The effect of reducing the number of injection sites of Dysport® abobotulinumtoxinA (aboBoNTA) was assessed in the spinal cord-injured rat (SCI). Nineteen days post-spinalization, female rats received intradetrusor injections of saline or aboBoNTA 22.5 U distributed among four or eight sites. Two days after injection, continuous cystometry was performed in conscious rats. Efficacy of aboBoNTA 22.5 U was assessed versus aggregated saline groups on clinically-relevant parameters: maximal pressure, bladder capacity, compliance, voiding efficiency, as well as amplitude, frequency, and volume threshold for nonvoiding contractions (NVC). AboBoNTA 22.5 U significantly decreased maximal pressure, without affecting voiding efficiency. Injected in four sites, aboBoNTA significantly increased bladder capacity and compliance while only the latter when in eight sites. AboBoNTA significantly reduced NVC frequency and amplitude. This preclinical investigation showed similar inhibiting effects of aboBoNTA despite the number of sites reduction. Further studies are warranted to optimize dosing schemes to improve the risk-benefit ratio of BoNTA-based treatment modalities for NDO and further idiopathic overactive bladder. PMID:26694464

  16. 肌注利培酮微球与口服利培酮治疗精神分裂症疗效研究%Studies on the Eficacy of Intramuscular Risperidone Microspheres and Oral Risperidone in the Treatment of Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    梁松新; 王秋琴; 麦以成; 邓良华

    2013-01-01

      目的探讨肌注利培酮微球与口服利培酮治疗精神分裂症的疗效,为临床选择药物提供依据.方法将80例精神分裂症患者随机分成肌注利培酮微球(RLAI)组及口服利培酮片组,治疗12周.在治疗第1、4、8、12周用阳性与阴性症状量表(PANSS)、临床疗效总评量表(CGI-SI)、不良反应量表(TESS)评定疗效和不良反应.结果两组PANSS总分及CGI-SI评分均比治疗前显著下降(P<0.01),与基线比较,PANSS评分自4周末以后均出现显著差异,两组疗效相当.RLAI组的不良反应明显低于口服利培酮片组(P<0.05).结论肌注利培酮微球与口服利培酮片治疗精神分裂症的疗效相当,RLAI组的不良反应较口服利培酮少而轻.肌注利培酮微球治疗精神分裂症安全有效,患者对治疗依从性比口服利培酮更好.%Objective To investigate the efficacy of intramuscular risperidone microspheres and oral risperidone in the treatment of schizophrenia, and to provide the basis for clinical drug of choice. Methods 80 cases of patients with schizophrenia were randomly divided into intramuscular risperidone microspheres(RLAI) group and the oral risperidone piece group, 12 weeks of treatment. Evaluate the efficacy and adverse reactions in the treatment of 1, 4, 8 and 12 weeks using the Positive and Negative Syndrome Scale(PANSS), the Clinical Global Impression(CGI-SI), adverse reactions Scale(TESS). Results The PANSS total score and CGI-SI score in both groups was significantly decreased(P<0.01) than before treatment. Compared with baseline, there are significant differences in the PANSS score after 4 weeks. Treatment efficiency in two group is very close to. The adverse drug reactions of RLAI group was significantly lower than the oral risperidone group(P<0.05). Conclusion The efficacy of intramuscular risperidone microspheres and oral risperidone tablets in the treatment of schizophrenia is very close to, The RLAI group adverse reactions are

  17. Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine

    NARCIS (Netherlands)

    Schillevoort, I; de Boer, A; Herings, R M; Roos, R A; Jansen, P A; Leufkens, H G

    2001-01-01

    OBJECTIVE: To compare the risk of extrapyramidal syndrome (EPS) between risperidone, olanzapine, and haloperidol, taking into account patients' past antipsychotic drug use and past EPS. METHODS: Data were obtained from the PHARMO-database, containing filled prescriptions of 450,000 community-dwellin

  18. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.

    Science.gov (United States)

    Laux, Gerd; Heeg, Bart; van Hout, Ben A; Mehnert, Angelika

    2005-01-01

    Schizophrenia is one of the most expensive psychiatric conditions because of high direct and indirect costs associated with the nature of the illness, its resistance to treatment and the consequences of relapse. Long-acting risperidone is a new formulation of an atypical antipsychotic drug that also offers the improvements in compliance associated with haloperidol depot. The aim of this simulation study was to compare the benefits and costs of three pharmacological treatment strategies comprising first-line treatment with long-acting risperidone injection, a haloperidol depot or an oral atypical antipsychotic agent, over a 5-year period in Germany. A discrete event simulation model was developed to compare three treatment scenarios from the perspective of major third-party payers (sickness funds and social security 'Sozialversicherung'). The scenarios comprised first-line treatment with haloperidol depot (scenario 1), long-acting risperidone (scenario 2) and oral olanzapine (scenario 3). Switches to second or third-line options were allowed when side-effects occurred or a patient suffered more than a fixed number of relapses. The model accounted for fixed patient characteristics, and on the basis of these, simulated patient histories according to several time-dependent variables. The time horizon for this model was limited to 5 years, and in accordance with German guidelines, costs and effects were discounted by between 3 and 10%. Direct costs included medication, type of physician visits and treatment location. Indirect costs were not included. Information on treatment alternatives, transition probabilities, model structure and healthcare utilization were derived from the literature and an expert panel. Outcomes were expressed in terms of the number and duration of psychotic episodes, cumulative symptom scores, costs, and quality-adjusted life-years (QALY). Univariate sensitivity analyses were carried out, as were subgroup analyses based on disease severity and

  19. The Efficacy and Safety of Concurrent Collagenase Clostridium Histolyticum Injections for 2 Dupuytren Contractures in the Same Hand

    DEFF Research Database (Denmark)

    Gaston, R. G.; Larsen, Søren; Pess, G. M.

    2015-01-01

    participated in a 60-day, multicenter, open-label, phase 3b study. Two 0.58 mg CCH doses were injected into 1 or 2 cords in the same hand (1 injection per affected joint) during the same visit. Finger extension was performed approximately 24, 48, or 72 or more hours later. Changes in FFC and range of motion...

  20. The Efficacy of Botulinum Toxin Type a Injection in the Hamstring and Calf Muscles With and Without Serial Foot Casting in Gait Improvement in Children With Cerebral Palsy

    Directory of Open Access Journals (Sweden)

    Shamsodini A

    2011-11-01

    Full Text Available Background: The goal of this study was to compare the efficacy of botulinum toxin type A (BTX-A injection in the hamstring and calf muscles with and without ankle serial casting in the improvement of gait in children with cerebral palsy (CP.Methods : This double-blind prospective clinical trial was performed on 25, 2 to 8-year-old children with hemiplegic or diplegic CP in Tehran, Iran in 2010. The participants were chosen by simple randomized sampling and were matched for age, gross motor function classification system (GMFCS and type of CP and were randomly divided into two groups: children in the first group (13 only received BTX-A injection, but the second group (12 received BTX-A and serial foot casting starting one week after the injection.Results : Comparison of the gross motor function, right and left knee spasticities and passive ROM of both knees between the two groups before and 1, 3, 6 and 12 months after the injections were not statistically significant (P>0.1. Furthermore, comparison of the right and left ankle spasticities and passive ROM before the injections and in1 and 3-month follow-ups did not show a statistically significant difference (P>0.1, but the differences were significant in 6 and 12-month follow-ups (P<0.05.Conclusion: BTX-A injection with serial foot casting vs. BTX-A alone was more effective in decreasing spasticity and improving passive ROM in the ankle of children with CP, but such injections in the hamstrings were not useful in these regards.

  1. Efficacy and safety of cross-linked hyaluronic acid single injection on osteoarthritis of the knee: a post-marketing phase IV study

    Directory of Open Access Journals (Sweden)

    Bashaireh K

    2015-04-01

    Full Text Available Khaldoon Bashaireh,1 Ziad Naser,2 Khaled Al Hawadya,2 Sorour Sorour,2 Rami Nabeel Al-Khateeb3 1Department of Orthopedics Surgery, King Abdullah University Hospital, Jordan University of Science and Technology, Irbid, Jordan; 2Private Clinic, 3Elaf Medical Supplies Company, Amman, Jordan Purpose: The primary objective of this study was to evaluate the efficacy, safety, and duration of action of viscosupplementation with Crespine® Gel over a 9-month period.Materials and methods: The study was a post-marketing phase IV study. A total of 109 participants with osteoarthritis of the knee (grades 1–4 in the tibio–femoral compartment were recruited in Jordan. Data were collected from each participant during the baseline visit. Each participant received Crespine® Gel injection, and follow-up visits took place at 3 months, 6 months, and 9 months post-injection.Main outcome measure(s: An assessment of participants by phone was conducted at 1 month, 2 months, 4 months, 5 months, 7 months, and 8 months post-injection. Western Ontario and McMaster Universities Arthritis Index questionnaires were completed during each visit. A 72-hour visit questionnaire was used to assess the safety of the injection. Statistical analysis included a two-sided 95% confidence interval for the difference between pain scores across visits, and the percent change from baseline was calculated.Main results: The full analysis included 84 participants who gave their informed consent and finished the necessary baseline and follow-up visits needed to assess efficacy and safety. Peak improvement was noted at 5 months post-injection, when pain and physical performance scores had decreased to 2.60 and 9.90, respectively, and the stiffness score was 0.33. The peak improvement in stiffness was noted at 8 months post-injection, when the stiffness score had decreased to 0.32. Significant improvements were still apparent at 9 months post-injection, when the pain score was 3

  2. Risperidone-induced enuresis in a 12-year-old child

    Directory of Open Access Journals (Sweden)

    Reetika Dikshit

    2017-01-01

    Full Text Available Risperidone has been documented to be effective in the management of behavior problems, aggression, and conduct disorder in children. While metabolic side effects like weight gain and obesity have been attributed to Risperidone use in children, side effects of the drug related to the urinary bladder are rare. We present a case of Risperidone-induced enuresis in a 12-year-old boy with conduct disorder that resolved completely after stopping the medication.

  3. Risperidone-induced Enuresis in a 12-year-old Child

    Science.gov (United States)

    Dikshit, Reetika; Karia, Sagar; De Sousa, Avinash

    2017-01-01

    Risperidone has been documented to be effective in the management of behavior problems, aggression, and conduct disorder in children. While metabolic side effects like weight gain and obesity have been attributed to Risperidone use in children, side effects of the drug related to the urinary bladder are rare. We present a case of Risperidone-induced enuresis in a 12-year-old boy with conduct disorder that resolved completely after stopping the medication. PMID:28149096

  4. Using Glycopyrrolate as an alternative option in case of Risperidone induced sialorrhoea

    Directory of Open Access Journals (Sweden)

    Dr. Hemanta Dutta

    2015-03-01

    Full Text Available Drug induced hypersalivation has been playing an unique factor in terms of noncompliance of antipsychotics. Hypersalivation has been described commonly with clozapine. Although Risperidone is also seen to be notorious to be causing hypersalivation. Use of Glycopyrrolate in Risperidone induced hypersalivation has not been covered though reported studies till yet. Here we are depicting the use of Glycopyrrolate as an alternative treatment option for hypersalivation induced by Risperidone.

  5. A comparative study between risperidone and ritalin in the treatment of attention deficit hyperactivity disorder%利培酮治疗注意缺陷障碍对照观察

    Institute of Scientific and Technical Information of China (English)

    兰利明; 薛漳

    2001-01-01

    目的:观察小剂量利培酮治疗注意缺陷障碍(ADHD) 的疗效和安全性。 方法:前瞻性研究,以利他林作为对照,采用 康纳多动症评定量表及不良反应症状量表(TESS)评定,观察4周。 结果:利培酮有效率为77%,利他林为78%;未见锥体外系副反应。 结论:利培酮与利他林的疗效相似,小剂量使用时安全有效。%Objective:To observe the efficacy and security of small doses risperidone in the treatment of attention deficit hyperactivity diso rder(ADHD). Method:Compared with ritalin group,the patients wer e treated with small doses risperidone for 4 weeks.Conner hyperactivety rating s cale (CHRS) and the treatment emergent symptom scale (TESS) were completed by th em. Results:The efficacy rate in risperidone group was 77%, a nd in ritalin group was 78%. No extrapyramidal side effect was found. C onclusion:It suggests that small doses risperidone is effective and safe in the treatment of ADHD, being similar to ritalin.

  6. Comparison of Hemostatic Efficacy of Argon Plasma Coagulation with and without Distilled Water Injection in Treating High-Risk Bleeding Ulcers

    Directory of Open Access Journals (Sweden)

    Yuan-Rung Li

    2014-01-01

    Full Text Available Background. Argon plasma coagulation (APC is useful to treat upper gastrointestinal bleeding, but its hemostatic efficacy has received little attention. Aims. This investigation attempted to determine whether additional endoscopic injection before APC could improve hemostatic efficacy in treating high-risk bleeding ulcers. Methods. From January 2007 to April 2011, adult patients with high-risk bleeding ulcers were included. This investigation compared APC plus distilled water injection (combined group to APC alone for treating high-risk bleeding ulcers. Outcomes were assessed based on initial hemostasis, surgery, blood transfusion, hospital stay, rebleeding, and mortality at 30 days posttreatment. Results. Totally 120 selected patients were analyzed. Initial hemostasis was accomplished in 59 patients treated with combined therapy and 57 patients treated with APC alone. No significant differences were noted between these groups in recurred bleeding, emergency surgery, 30-day mortality, hospital stay, or transfusion requirements. Comparing the combined end point of mortality plus the failure of initial hemostasis, rebleeding, and the need for surgery revealed an advantage for the combined group (P=0.040. Conclusions. Endoscopic therapy with APC plus distilled water injection was no more effective than APC alone in treating high-risk bleeding ulcers, whereas combined therapy was potentially superior for patients with poor overall outcomes.

  7. Controlled clinical treatment of the domestic Ziprasidone and risperidone%国产齐拉西酮与维思通的临床对照治疗

    Institute of Scientific and Technical Information of China (English)

    李永强; 冯金河

    2013-01-01

    Objective:comparison curative effect and untoward effect between Ziprasidone and risperidone. Methods:Sixty patients with schizophrenia were randomly divided into two groups: thirty patients were in Ziprasidone's group and the other thirty patients were in risperidone's group, after treatment for six weekends, used positive and negative symptom scale (PANSS) and treatment emergent symptoms scale (TESS) to evaluate the efficacy. Results: Ziprasidone and risperidone have equal therapy, but the incidence of adverse reaction and symptom severity of Ziprasidone was significantly lower than risperidone, especially, Ziprasidone has a small influence in mammotropic hormone and weight. Conclusion: Ziprasidone for schizophrenia have a good efficacy, few untoward effects and good compliance.%目的对比国产齐拉西酮与维思通的疗效和不良反应。方法对60例精神分裂症患者随机分为国产齐拉西酮组30例和维思通组30例,进行相应的药物治疗,疗程6周,采用PANSS量表和TESS副反应量表进行评价。结果国产齐拉西酮和维思通疗效相当,但国产齐拉西酮的不良反应发生率和症状严重程度显著低于维思通,特别对催乳素和体重的影响明显较小,同时具有良好的依从性。结论国产齐拉西酮治疗精神分裂症疗效确切,不良反应少,依从性好。

  8. Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia

    Institute of Scientific and Technical Information of China (English)

    Zhi-ling ZHOU; Qiu-xiong LIN; Chuan-yue WANG; Wen-biao LI; Shu-guang LIN; Huan-de LI; Xin LI; Huai-yan PENG; Xi-yong YU; Ming YANG; Feng-li SU; Feng WANG; Rong-hua ZHU; Chun-yu DENG

    2006-01-01

    Aim: To study the multiple dose clinical pharmacokinetics of risperidone and its main active metabolite, 9-hydroxyrisperidone, in Chinese female patients with schizophrenia. Methods: The subjects were 23 Chinese female inpatients aged 18-65 years who met the CCMD-Ⅲ (third revision of the Chinese Criteria of Mental Disorders) criteria for schizophrenia. Subjects were tested after 17 d of treatment with 2 mg risperidone twice daily. Plasma concentrations of risperidone and 9-hydroxy-risperidone were assayed by using validated high performance liquid chromatography-mass spectrometry (HPLC-MS) methods. Results: Risperidone was rapidly absorbed (Tmax was 1.6 h) and its Tin in plasma was short (3.2 h).9-hydroxy-risperidone was quickly metabolized from the parent drug with a mean Tmax of 2.5 h. It had a long half-life of 24.7 h. The Cssav of risperidone and 9-hydroxyrisperidone were 36.9±33.1 and 110.6±30.5 μg·h·L-1, respectively, and the AUCss0-12 were 443.2±397.4 and 1327.2±402.3 μg·h·L-1, respectively. CL/F and V/F of risperidone were 8.7±6.2 L/h and 34.1±24.3 L, respectively. Interindividual variations for pharmacokinetic parameters were quite large for risperidone. All 23 subjects experienced high prolactin levels when treated with risperidone. However there was no correlation between prolactin level and the concentration of risperidone, 9-hydroxy-risperidone, or the active moiety. Conclusion: Risperidone showed large interindividual variations in pharmacokinetics. Administration of risperidone resulted in high serum prolactin levels. The results indicate that systemic exposure to risperidone and 9-hydroxy-risperidone in female Chinese schizophrenic patients is higher relative to published data for white Caucasian patients. Larger studies regarding the PK/PD relationship may be required to develop a reasonable clinical dosage regimen for Chinese female patients.

  9. 利培酮的臨床應用與進展%Clinical Application and Advancement of Risperidone

    Institute of Scientific and Technical Information of China (English)

    查彩慧; 肖計劃

    2001-01-01

    Objective This article reviews the mechanism, pharmcokinetics and the clinical use ofrisperidone.Materials The data base on updated literature recently. Conclusion Risperidone, a benzisoxazol derivative, is a novel typical antipsychotic agent which combines 5-hydroxytryptamine-2 (5-HT2) and dopamine-2 (D2) receptors antagonism. It can improve both positive and negative symptoms of schizophrenia. The efficacy of risperidone is well positive and effective in patients with chronic schizophrenia who had been resistant to or intolerant of conventiona neuroleptics. Risperidone can be used to treat mood disorder, obsessive-compulsive disorder, metal retardation,brain injury associated behavioral and psychiatric disorder and now it is already used in clinic widely. Risperidone is absorbed rapidly when taken orally and mainly metabolized in the liver .The principal active metabolite is 9-hydroxyrisperidone which has obvious pharmacological function. The metabolized production of risperidone is mainly discharged via urine. Risperidone has high efficacy and good safety. Now it is already used in clinic widely.%目的本文對利培酮的作用機制、藥代動力學、臨床應用和不良反應作一綜述,供同道們參考.資料所有資料均來自近幾年最新的相關文獻.結論利培酮是苯異惡唑衍生物,是一種新型的非典型抗精神病藥物.利培酮對5羥色胺Ⅱ型和多巴胺Ⅱ型受體均有拮抗作用,能有效改善精神分裂症陽性和陰性症狀,對於傳統抗精神病藥物治療失敗的難治性精神分裂症患者可首選利培酮治療.利培酮還可用於治療心境障礙、強迫症、精神發育遲滯及腦損害伴發的行為和精神障礙.利培酮口服吸收迅速,主要經肝臟代謝,在體內的代謝産物為9-羥基利培酮,亦具有藥理活性.利培酮主要通過尿液排出.利培酮的常見副反應為激越、頭痛、失眠、噁心、嗜睡等,較少出現錐體外系副反應,惡性綜合徵發

  10. Efficacy and safety of vitamin D3 B.O.N intramuscular injection in Korean adults with vitamin D deficiency

    Directory of Open Access Journals (Sweden)

    Han Seok Choi

    2016-12-01

    Conclusion: Intramuscular injection of vitamin D3 200,000 IU was superior to placebo in terms of its impact on serum 25(OHD concentrations, and is considered to be safe and effective in Korean adults with vitamin D deficiency.

  11. Neuroleptic malignant syndrome due to risperidone misdiagnosed as status epilepticus

    Directory of Open Access Journals (Sweden)

    Ali Ertug Arslankoylu

    2011-06-01

    Full Text Available Neuroleptic malignant syndrome (NMS is a rare but potentially fatal disease characterized by fever, muscle rigidity, delirium and autonomic instability. Here we report a child, with NMS due to the risperidone misdiagnosed as status epilepticus. Nine year old boy, who had been under high dose risperidone treatment for 8 weeks, admitted to the emergency room because of the contractions (evaluated as status epilepticus persisting for 7 hours. Since there was neuroleptic treatment in the past medical history and, unconsciousness, muscular rigidity, diaphoresis, hypertermi and, hypotension in physical examination, leucocytosis and elevated creatininphosphokinase levels in laboratory tests, the patient was evaluated as NMS and discharged without any complications. We reported this case to point out that; NMS may be misdiagnosed as status epilepticus in children when EEG monitoring is unavailable. When a child admitted to the emergency room because of suspicious convulsion neuroleptic drug use must surely be asked.

  12. A comparison between augmentation with olanzapine and increased risperidone dose in acute schizophrenia patients showing early non-response to risperidone.

    Science.gov (United States)

    Hatta, Kotaro; Otachi, Taro; Sudo, Yasuhiko; Kuga, Hironori; Takebayashi, Hiroshi; Hayashi, Hideaki; Ishii, Ryusuke; Kasuya, Masataka; Hayakawa, Tatsuro; Morikawa, Fumiyoshi; Hata, Kazuya; Nakamura, Mitsuru; Usui, Chie; Nakamura, Hiroyuki; Hirata, Toyoaki; Sawa, Yutaka

    2012-07-30

    We examined whether augmentation with olanzapine would be superior to increased risperidone dose among acute schizophrenia patients showing early non-response to risperidone. We performed a rater-blinded, randomized controlled trial at psychiatric emergency sites. Eligible patients were newly admitted patients with acute schizophrenia. Early response was defined as Clinical Global Impressions-Improvement Scale score ≤3 following 2 weeks of treatment. Early non-responders were allocated to receive either augmentation with olanzapine (RIS+OLZ group) or increased risperidone dose (RIS+RIS group). The 78 patients who completed 2 weeks of treatment were divided into 52 early responders to risperidone and 26 early non-responders to risperidone (RIS+OLZ group, n=13; RIS+RIS group, n=13). No difference in the achievement of ≥50% improvement in Positive and Negative Syndrome Scale total score was observed between RIS+OLZ and RIS+RIS groups. Although time to treatment discontinuation for any cause was significantly shorter in the RIS+RIS group (6.8 weeks [95% confidence interval, 5.2-8.4]) than in early responders to risperidone (8.6 weeks [7.9-9.3]; P=0.018), there was no significant difference between the RIS+OLZ group (7.9 weeks [6.3-9.5]) and early responders to risperidone. Secondary outcomes justify the inclusion of augmentation arms in additional, larger studies comparing strategies for early non-responders.

  13. Efficacy of hyaluronic acid or steroid injections for the treatment of a rat model of rotator cuff injury.

    Science.gov (United States)

    Yamaguchi, Takeshi; Ochiai, Nobuyasu; Sasaki, Yu; Kijima, Takehiro; Hashimoto, Eiko; Sasaki, Yasuhito; Kenmoku, Tomonori; Yamazaki, Hironori; Miyagi, Masayuki; Ohtori, Seiji; Takahashi, Kazuhisa

    2015-12-01

    This study evaluated dorsal root ganglia from C3-C7, analyzed gait, and compared the expression of calcitonin gene-related peptide (CGRP) which was a marker of inflammatory pain in a rat rotator cuff tear model in which the supraspinatus and infraspinatus tendons were detached; comparisons were made to a sham group in which only the tendons were exposed. Fluorogold was injected into the glenohumeral joint 21 days after surgery in both groups, and saline, steroids, or hyaluronic acid was injected into the glenohumeral joint in the rotator cuff tear group 26 days after surgery. The proportions of CGRP-immunoreactive neurons were higher and the gait parameters were impaired in the rotator cuff tear group compared to in the sham group. However, the CGRP expression was reduced and the gait was improved with steroid or hyaluronic acid injection compared to saline, suggesting that both hyaluronic acid and steroid injections suppressed of inflammation which thought to be provided pain relief. While there were no significant differences, the suppression of CGRP expression and the improved gait after hyaluronic acid and steroid injections suggested that both methods were effective for rat rotator cuff tear model.

  14. 利培酮合并氯氮平治疗难治性精神分裂症对照研究%Comparative Study on Risperidone Combined Clozapine and Risperidone in the Treatment of Refractory Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    高亚娇; 安红伟; 靳红强

    2011-01-01

    Objective To compare the efficacy and safety of clozapine combined with risperidone in the treatment of refractory schizophrenia. Methods 63 cases were divided into two groups randomly,32 cases of treatment-refractory schizophrenia were treated with risperidone combined clozapine( the treatment group ) and 31 cases were treated with risperidone( the control group ). The clinical effect of patients were measured with positive and negative symptoms scale( PANSS ), and side effects were assessed with treatment emergent symptoms scale( TESS )respectively before and after 4,8,12 week treatment. Results There were significant differences in the curative effect between the two groups( P <0.05 ). After eight weeks treatment, total score of PANSS in two groups were much lower than before,the treatment group had greater decreases. After twelve weeks treatment,total score of PANSS in the treatment group was lower than that in the control group. There were statistical differences between the two groups( P <0. 05 ). Conclusion Clozapine combined with risperidone has curative effect affirmation to treat TRS,this deserves utilization in the clinical area.%目的 探讨利培酮联合氯氮平治疗难治性精神分裂症(TRS)的疗效及安全性.方法 将63例TRS患者随机分为利培酮合并氯氮平组(治疗组)32例和利培酮组(对照组)31例,两组治疗后4、8、12周均以阳性与阴性症状量表(PANSS)评定疗效,治疗意外症状量表(TESS)评定不良反应.结果 治疗组和对照组治疗TRS的疗效比较差异有统计学意义(P<0.05).治疗后8周,两组PANSS总分均较治疗前下降,治疗组下降更明显.两组治疗12周后PANSS总分比较,治疗组明显低于对照组,差异有统计学意义(P<0.05).结论 利培酮联合氯氮平治疗TRS的疗效肯定,值得临床应用.

  15. 阿立哌唑与利培酮治疗精神分裂症疗效比较%Aripiprazole and Risperidone in the Treatment of Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    赵辉

    2014-01-01

    目的:比较阿立哌唑与利培酮治疗精神分裂症的疗效。方法将我院2012年10月-2013年6月收治的40例精神分裂症患者按随机数字表法随机分为阿立哌唑组和利培酮组各20例,分别使用阿立哌唑和利培酮对两组患者进行治疗,将两组治疗效果按照CCMD-3精神分裂症的诊断标准进行评价,依据副反应量表( TESS )评定副反应,以阳性与阴性症状量表( PANSS)减分率对疗效进行评定。结果阿立哌唑组痊愈9例,7例显著好转,3例好转,1例无效;利培酮组痊愈10例,5例显著好转,3例好转,2例无效。两组间的疗效比较无显著性差异。阿立哌唑组5例出现不良反应,占25%;利培酮组出现不良反应的有12例,占60%,阿立哌唑组不良反应总发生率显著低于利培酮组(χ2=5.013, P<0.05)。结论阿立哌唑与利培酮治疗精神分裂症的疗效显著,在治疗过程中,两种药物各有千秋,但在不良反应发生率方面,阿立哌唑低于利培酮,阿立哌唑的安全性高于利培酮。%Objective To analyze and compare aripiprazole and risperidone in the treatment of schizophrenia treatment .Methods 40 cases of patients with schizophrenia in hospital from October 2012 to June 2013 were randomly divided into aripiprazole group and the risperidone group,respectively,the two groups of patients were evaluated according to CCMD -3 diagnostic criteria,TESS and PANSS. Results In aripiprazole group ,9 cases recure ,7 cases were significantly improved ,3 cases improved ,and one case was invalid .In risper-idone group,10 cases cured,5 cases were significantly improved,3 cases improved,2 cases were ineffective.There was no significant difference in the efficacy between the two groups (P>0.05).Aripiprazole group had 5 cases of adverse reactions (25%),risperidone group had 12 cases of adverse reactions (60%),incidence of adverse reactions in aripiprazole group was

  16. Clinical Analysis of Oxiracetam combined with Risperidone Treatment of Schizophrenia.%奥拉西坦与利培酮联合治疗精神分裂症的临床分析

    Institute of Scientific and Technical Information of China (English)

    崔会欣; 赵龙; 张娜; 尹艳芳

    2013-01-01

    Objective:To investigate the efficacy of Oxiracetam combined with Risperidone in the treatment of Schizophrenia. Methods:The schizophrenia patients were divided into study group and control group randomly. Study group were given Oxiracetam combined with Risperidone. Control group given Risperidone only for the treatment of 8 weeks. The efficacy and side effects were evaluated with scores of PANSS and TESS. Result:the effective rates were 86.17% in study group and 63.33% in control group. There are statistically difference between the two groups(P<0.05). The adverse reaction of two groups was rare and mild .Conclusion:Oxiracetam combined with Risperidone in the treatment of Schizophrenia were effective and safe and take effects better than single Risperidone.%目的探讨奥拉西坦与利培酮联合治疗精神分裂症的临床效果。方法将我院比例符合标准的精神分裂症患者随即分为研究组和对照组,研究组给予奥拉西坦合并利培酮治疗,对照组单用利培酮,疗程8周。用PANSS,TESS量表评定疗效和安全性。结果研究组有效率86.17%,对照组有效率63.33%。两组比较鉴别有统计学意义(P<0.05),两组不良反应少且轻。结论奥拉西坦合并利培酮治疗精神分裂症疗效可靠,安全性好,优于单用利培酮。

  17. Association studies of COMT gene polymorphisms with risperidone treatment in first-episode schizophrenia%首发精神分裂症患者利培酮疗效与COMT基因多态性关联研究

    Institute of Scientific and Technical Information of China (English)

    李波; 黎雪松; 龚道元; 谢国军; 陈家强; 彭艳; 王晓娟

    2013-01-01

    目的:探讨首发精神分裂症患者COMT基因多态性与利培酮疗效的关系.方法:100例首发精神分裂症患者使用利培酮治疗8周,以PANSS量表评定疗效;SNaPshot SNP检测COMT基因rs4680和rs4818多态性.结果:利培酮有效组与无效组相比,精神分裂症患者rs4680基因型G/G与A/G、A/A的分布差异具有显著性(x2=5.334,P<0.05),rs4680 G/G基因型与利培酮疗效之间存在明显关联(OR=1.78,P<0.05).结论:rs4680多态性与利培酮治疗首发精神分裂症的临床疗效相关.%Objective To investigate the association of catechol-O-methyltransferase (COMT) gene polymorphisms with response of risperidone treatment in first-episode schizophrenia. Methods One hundred cases of schizophrenic patients were chosen to treat with risperidone for 8 weeks. The efficacy of antipsychotic medication was evaluated by PANSS scale. Allelic typing of COMT was detected by SNaPshot SNP technique. Results The distribution of rs4680 genotype G/G, A/G and A/A had significant difference between risperidone responder group and nonresponder group (X2 = 5.334,P < 0.05) and rs4680 G/G genotype was correlated with the efficacy of risperidone (OR = 1.78,P< 0.05). Conclusion The polymorphisms of rs4680 related with effects of risperidone on first-episode schizophrenia.

  18. A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning

    NARCIS (Netherlands)

    Knegtering, H; Boks, M; Blijd, C; Castelein, S; Van den Bosch, RJ; Wiersma, D

    2006-01-01

    The objective of this study was to compare sexual functioning in patients treated with olanzapine or risperidone. This open-label trial included 46 patients randomized to olanzapine (5-15mg/d) or risperidone (1-6mg/d) for 6 weeks. We used sexual dysfunction was assessed by a semistructured interview

  19. Risperidone in the management of agitation and aggression associated with psychiatric disorders.

    NARCIS (Netherlands)

    Deyn, P.P. de; Buitelaar, J.K.

    2006-01-01

    OBJECTIVE: This review provides an overview of the prevalence and treatment of agitation and aggression, and focuses on the use of risperidone to treat these symptoms in patients from different age groups. METHODS: MEDLINE and EMBASE databases were used to identify controlled studies of risperidone

  20. Prolactin release in children treated with risperidone - Impact and role of CYP2D6 metabolism

    NARCIS (Netherlands)

    Troost, Pieter W.; Lahuis, Bertine E.; Hermans, Mirjam H.; Buitelaar, Jan K.; van Engeland, Herman; Scahill, Lawrence; Minderaa, Ruud B.; Hoekstra, Pieter J.

    2007-01-01

    Objective: Little is known about the role of CYP2136 polymorphism in risperidone-induced prolactin release in children. Method: Twenty-five children (aged 5-15 years) with pervasive developmental disorders were genotyped for CYP2D6 polymorphisms. Serum prolactin, risperidone, and 9-hydroxyrisperidon

  1. Comparison of risperidone and aripiprazole in the treatment of preschool children with disruptive behavior disorder and attention deficit-hyperactivity disorder: A randomized clinical trial

    Directory of Open Access Journals (Sweden)

    Parvin Safavi

    2016-01-01

    Full Text Available Although pharmacotherapy with atypical antipsychotics is common in child psychiatry, there has been little research on this issue. To compare the efficacy and safety of risperidone and aripiprazole in the treatment of preschool children with disruptive behavior disorders comorbid with attention deficit-hyperactivity disorder (ADHD. Randomized clinical trial conducted in a university-affiliated child psychiatry clinic in southwest Iran. Forty 3-6-year-old children, diagnosed with oppositional defiant disorder comorbid with ADHD, were randomized to an 8-week trial of treatment with risperidone or aripiprazole (20 patients in each group. Assessment was performed by Conners′ rating scale-revised and clinical global impressions scale, before treatment, and at weeks 2, 4, and 8 of treatment. The data were analyzed by SPSS version 16. Mean scores between the two groups were compared by analysis of variance and independent and paired t-test. Mean scores of Conners rating scales were not different between two groups in any steps of evaluation. Both groups had significantly reduced scores in week 2 of treatment (P = 0.00, with no significant change in subsequent measurements. Rates of improvement, mean increase in weight (P = 0.894, and mean change in fasting blood sugar (P = 0.671 were not significantly different between two groups. Mean serum prolactin showed a significant increase in risperidone group (P = 0.00. Both risperidone and aripiprazole were equally effective in reducing symptoms of ADHD and oppositional defiant disorder, and relatively safe, but high rates of side effects suggest the cautious use of these drugs in children.

  2. Augmentation by escitalopram, but not citalopram or R-citalopram, of the effects of low-dose risperidone: behavioral, biochemical, and electrophysiological evidence.

    Science.gov (United States)

    Marcus, Monica M; Jardemark, Kent; Malmerfelt, Anna; Gertow, Jens; Konradsson-Geuken, Asa; Svensson, Torgny H

    2012-04-01

    Antidepressant drugs are frequently used to treat affective symptoms in schizophrenia. We have recently shown that escitalopram, but not citalopram or R-citalopram, increases firing rate and burst firing of midbrain dopamine neurons, potentiates cortical N-methyl-D-aspartate (NMDA) receptor-mediated transmission and enhances cognition, effects that might influence the outcome of concomitant antipsychotic medication. Here, we studied, in rats, the behavioral and neurobiological effects of adding escitalopram, citalopram, or R-citalopram to the second-generation antipsychotic drug risperidone. We examined antipsychotic efficacy using the conditioned avoidance response (CAR) test, extrapyramidal side effect (EPS) liability using a catalepsy test, dopamine outflow in the medial prefrontal cortex (mPFC) and nucleus accumbens using in vivo microdialysis in freely moving animals, and NMDA receptor-mediated transmission in the mPFC using intracellular electrophysiological recording in vitro. Only escitalopram (5 mg/kg), but not citalopram (10 mg/kg), or R-citalopram (10 mg/kg), dramatically enhanced the antipsychotic-like effect of a low dose of risperidone (0.25 mg/kg), without increasing catalepsy. Given alone, escitalopram, but not citalopram or R-citalopram, markedly enhanced both cortical dopamine output and NMDA receptor-mediated transmission. Addition of escitalopram and to some extent R-citalopram, but not citalopram, significantly enhanced both cortical dopamine output and cortical NMDA receptor-mediated transmission induced by a suboptimal dose/concentration of risperidone. These results suggest that adjunct treatment with escitalopram, but not citalopram, may enhance the effect of a subtherapeutic dose of risperidone on positive, negative, cognitive, and depressive symptoms in schizophrenia, yet without increased EPS liability.

  3. 利培酮与阿立哌唑治疗精神分裂症的效果比较%Clinical effects and security of aripiprazole and risperidone on the treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    李正发

    2010-01-01

    Objective To assess the efficacy and safety of aripiprazole and risperidone on the treatment of schizophrenia. Method 80 patients with schizophrenia were randomly divided into risperidone group ( n = 40) and aripiprazole group( n= 40). According to random, controlled principles, all patients were treated for 8 weeks. The positive and negative syndrome scale ( PANSS ), clinical global impression ( CGI ), treatment emergent symptom scale (TESS) and laboratory examinations were used to assess the effectiveness and the safety of the treatment. Results By the end of the 8 weeks treatment,the scores of PANSS in both groups decreased significantly compared to the baseline ( P 0. 05 ). Total clinical effective rates was 90% in risperidone group and 80% in aripiprazole group, without significant difference between two groups. Digestion adverse reactions in aripiprazole group were significantly more than in risperidone group (P 0.05).治疗后,利培酮组有效率90%,阿立哌唑组有效率80%,两组差异无统计学意义(P>0.05).阿立哌唑组消化道反应发生率明显高于利培酮组(P<0.05).结论 利培酮治疗精神分裂症的疗效较阿立哌唑略好,安全性高.

  4. Anesthetic efficacy of the supplemental X-tip intraosseous injection using 4% articaine with 1:100,000 adrenaline in patients with irreversible pulpitis: An in vivo study

    Directory of Open Access Journals (Sweden)

    Atool Chandra Bhuyan

    2014-01-01

    Full Text Available Introduction: Pain management remains the utmost important qualifying criteria in minimizing patient agony and establishing a strong dentist-patient rapport. Symptomatic irreversible pulpitis is a painful condition necessitating immediate attention and supplemental anesthetic techniques are often resorted to in addition to conventional inferior alveolar nerve block. Aim: The purpose of the study was to evaluate the anesthetic efficacy of X-tip intraosseous injection in patients with symptomatic irreversible pulpitis, in mandibular posterior teeth, using 4% Articaine with 1:100,000 adrenaline as local anesthetic, when the conventional inferior alveolar nerve block proved ineffective. Materials and Methods: X-tip system was used to administer 1.7 ml of 4% articaine with 1:100,000 adrenaline in 30 patients diagnosed with irreversible pulpitis of mandibular posterior teeth with moderate to severe pain on endodontic access after administration of an inferior alveolar nerve block. Results: The results of the study showed that 25 X-tip injections (83.33% were successful and 5 X-tip injections (16.66% were unsuccessful. Conclusion: When the inferior alveolar nerve block fails to provide adequate pulpal anesthesia, X-tip system using 4% articaine with 1:100,000 adrenaline was successful in achieving pulpal anesthesia in patients with irreversible pulpitis.

  5. Efficacy and safety of metronidazole injection for the treatment of infectious peritonitis, abdominal abscess and pelvic inflammatory diseases in Japan.

    Science.gov (United States)

    Mikamo, Hiroshige; Matsumizu, Miyako; Nakazuru, Yoshiomi; Nagashima, Masahito

    2015-02-01

    Although metronidazole (MNZ) has been used worldwide for more than 4 decades as a standard therapy for trichomoniasis, anaerobic and amebic infections, resistance to MNZ is still low. MNZ is available as oral, intravenous, and vaginal formulations, but the intravenous formulation of MNZ has not been approved in Japan. We conducted a phase 3 study to evaluate the efficacy and safety of intravenous MNZ combined with ceftriaxone (CTRX) in Japanese subjects with infectious peritonitis, abdominal abscess or pelvic inflammatory diseases (PIDs) to obtain regulatory approval. A combination of MNZ/CTRX at doses of 500 mg 3 or 4 times a day/1 or 2 g twice a day was administered intravenously to a total of 38 hospitalized subjects. MNZ/CTRX was well tolerated and exhibited excellent clinical and bacteriological efficacy with clinical efficacy rates of 100% (20/20) in infectious peritonitis or abdominal abscess subjects and 90.0% (9/10) in PID subjects, and the eradication rates in infectious peritonitis or abdominal abscess subjects and PID subjects were 100% (16/16) and 100% (4/4), respectively, at the test of cure. MNZ/CTRX was effective in 1 subject in whom a metallo-β-lactamase-producing Bacteroides fragilis strain (MIC of MNZ, 2 μg/ml) was identified. The most common treatment-related adverse event was diarrhea (23.7%), followed by nausea (5.3%). No new safety signals were identified. MNZ/CTRX demonstrated excellent efficacy and was well tolerated in Japanese infectious peritonitis, abdominal abscess and PID subjects. This treatment regimen can be useful for anaerobic infections. Clinical registration number: NCT01473836.

  6. Pain and efficacy rating of a microprocessor-controlled metered injection system for local anaesthesia in minor hand surgery.

    Science.gov (United States)

    Nimigan, André S; Gan, Bing Siang

    2011-01-01

    Purpose. Little attention has been given to syringe design and local anaesthetic administration methods. A microprocessor-controlled anaesthetic delivery device has become available that may minimize discomfort during injection. The purpose of this study was to document the pain experience associated with the use of this system and to compare it with use of a conventional syringe. Methods. A prospective, randomized clinical trial was designed. 40 patients undergoing carpal tunnel release were block randomized according to sex into a two groups: a traditional syringe group and a microprocessor-controlled device group. The primary outcome measure was surgical pain and local anaesthetic administration pain. Secondary outcomes included volume of anaesthetic used and injection time. Results. Analysis showed that equivalent anaesthesia was achieved in the microprocessor-controlled group despite using a significantly lower volume of local anaesthetic (P = .0002). This same group, however, has significantly longer injection times (P microprocessor controlled methods of administering local anaesthetic showed similar levels of discomfort in both groups. While the microprocessor-controlled group used less volume, the total time for the administration was significantly greater.

  7. Efficacy of imidacloprid, trunk-injected into Acer platanoides, for control of adult Asian longhorned beetles (Coleoptera: Cerambycidae).

    Science.gov (United States)

    Ugine, Todd A; Gardescu, Sana; Lewis, Phillip A; Hajek, Ann E

    2012-12-01

    Feeding experiments with Asian longhorned beetles (Anoplophora glabripennis (Motschulsky)) in a quarantine laboratory were used to assess the effectiveness of imidacloprid in reducing adult fecundity and survival. The beetles were fed twigs and leaves cut between June-September 2010 from Norway maples (Acer platanoides L.) in the beetle-infested area of Worcester, MA. Treated trees had been trunk-injected once with imidacloprid in spring 2010 under the U.S. Department of Agriculture-Animal and Plant Health Inspection Service operational eradication program. The 21 d LC50 value for adult beetles feeding on twig bark from imidacloprid-injected trees was 1.3 ppm. Adult reproductive output and survival were significantly reduced when beetles fed on twig bark or leaves from treated trees. However, results varied widely, with many twig samples having no detectable imidacloprid and little effect on the beetles. When twigs with > 1 ppm imidacloprid in the bark were fed to mated beetles, the number of larvae produced was reduced by 94% and median adult survival was reduced to 14 d. For twigs with 1 ppm). When given a choice of control twigs and twigs from injected trees, beetles did not show a strong preference.

  8. Persistent efficacy of a long acting injectable formulation of moxidectin against natural infestations of the sheep nasal bot (Oestrus ovis) in Spain.

    Science.gov (United States)

    Rugg, Douglas; Ferrer, Luis Miguel; Sarasola, Patxi; Figueras, Luis; Lacasta, Delia; Liu, Bo; Bartram, David

    2012-09-10

    Cydectin(®) 2% LA Solution for Injection for Sheep (Pfizer Animal Health) is a long-acting (LA) formulation of moxidectin for the treatment and prevention of mixed infections of gastro-intestinal nematodes, respiratory nematodes and certain arthropod parasites in sheep. To evaluate the duration of persistent efficacy against nasal bots (Oestrus ovis), a natural exposure study was conducted in Spain during the summer of 2011. One hundred and twenty nasal bot-free, Rasa Aragonesa sheep were randomly allocated to eight groups of 15 animals each. On Day 0, four groups were treated at the recommended dose rate of 1 mg moxidectin/kg bodyweight. Four groups remained untreated as negative controls. All animals were held in nasal bot-proof housing except for exposure to natural challenge when one group of treated sheep and one of group of control animals were transferred to a local pasture at either 0-20, 20-40, 40-60, or 60-80 days after treatment. Following challenge, sheep were scored for clinical signs of bot infestation, necropsied and the heads sectioned for larval recovery. Nasal bot larvae were retrieved from 7 to 11 control sheep following each exposure period indicating that adult bots were active throughout the study. In the first challenge up to 20 days after treatment, when sheep were slaughtered immediately after exposure, the majority of larvae were first instar (L1) and only 3 of the 15 control sheep were infested with second instars (L2). There was 100% efficacy against L2 and 38.1% reduction in the number of live L1 in the treated sheep but mean counts were not significantly different between treatment and control groups (P ≥ 0.05). For the subsequent exposure periods 20-80 days after treatment (necropsies 7-9 days after challenge), 6-10 sheep were infested with L1 and 9-11 control sheep were infested with L2 and third instars (L3). There was negligible efficacy against L1, but treatment with moxidectin resulted in 100% control of L2 and L3. These

  9. Clinical efficacy of bone cement injectable pedicle screw system combined with intervertebral fusion in treatment of lumbar spondylolysis and osteoporosis

    Directory of Open Access Journals (Sweden)

    Peng-yi DAI

    2016-10-01

    Full Text Available Objective  To observe the therapeutic effect of bone cement injectable pedicle screw system combined with intervertebral fusion for lumbar spondylolysis and osteoporosis. Methods  The clinical data were analyzed retrospectively of 21 patients with lumbar spondylolysis and osteoporosis who received treatment of bone cement injectable pedicle screw system and intervertebral fusion from Aug. 2013 to Nov. 2015. The 21 patients (9 males and 12 females aged from 60 to 80 years (mean 64 years old; 6 of them presented degenerative spondylolysis, 15 with isthmic spondylolisthesis; 2 cases had I degree slippage, 13 had Ⅱdegree slippage, 6 had Ⅲdegree slippage, and all the cases were unisegmental slippage including 9 cases in L4 and 12 cases in L5. Bone mineral density of lumbar vertebrae (L2-L5 was measured with dual-energy X-ray absorptiometry, and T values conforming to the diagnostic criteria of osteoporosis were less than or equal to -2.5; All patients were operated with whole lamina resection for decompression, bone cement injectable pedicle screws system implantation, propped open reduction and fixation intervertebral fusion. The clinical outcomes were determined by the radiographic evaluation including intervertebral height, height of intervertebral foramen, slip distance, slip rate and slip angle, and Oswestry disability index (ODI on preoperative, 3 months after operation and the end of the time, and the interbody fusion were followed up. Results  Cerebrospinal fluid leakage of incision was observed in two cases after operation, compression and dressing to incision, Trendelenburg position, dehydration and other treatments were taken, and the stitches of incisions were taken out on schedule. Slips in the 21 patients were reset to different extent, and lumbar physiological curvatures were recovered. The intervertebral height and height of intervertebral foramen were obviously higher 3 months after operation than that before operation (P0

  10. COMPARATIVE STUDY OF EFFICACY OF LOCAL STEROID INJECTION AND EXTRACORPOREAL SHOCKWAVE THERAPY IN THE TREATMENT OF PLANTAR FASCITIS

    Directory of Open Access Journals (Sweden)

    Rajan

    2014-04-01

    Full Text Available INTRODUCTION: Plantar fasciitis is a common condition causing misery to lot of patients. The etiology and treatment of plantar fasciitis are poorly understood. The results from such treatments vary considerably, and there is no consensus of opinion on the best method. MATERIAL AND METHODS: We conducted a controlled trial in our institute to compare the results of local steroid injections & the use of Extra-corporeal shock wave therapy (ESWT for managing plantar fasciitis. 200 patients with 240 painful heels were evaluated. All patients with moderate to severe heel pain who had already taken ten days of unsatisfactory treatment with oral NSAIDS were divided in two main groups. Group A of 100 patients received 1000 impulses of shock waves in three sessions at weekly interval. In Group B of 100 patients up to three local injections of 40 mg methyl prednisone mixed with 1 ml. of 2% lignocaine were given at biweekly interval. Pain assessment was done using VAS scale and the results were evaluated at six weeks, three months and six months after the completion of the therapy. CONCLUSIONS: There was a significant difference between two groups of patients being treated. The group B patients had significantly greater improvement in pain scale and early return to daily activities

  11. 利培酮联合喹硫平治疗老年痴呆精神行为症状的研究%Study on risperidone combined with quetiapine for treating psychiatric and behavioral disturbances in senile dementia

    Institute of Scientific and Technical Information of China (English)

    赵新民; 李远

    2016-01-01

    Objective To investigate the efficacy and safety of risperidone combined with quetiapine in the treatment behavioral and psychiatric symptoms of dementia (BPSD). Methods Ninety cases of BPSD in the geriatric department of our hospital from January 2013 to December 2015 were randomly divided into the combination group , risperidone group and quetiap-ine group according to the completely random method ,30 cases in each group. The combination group was given risperidone com-bined with quetiapine, the risperidone group was given the risperidone therapy and quetiapine group received the quetiapine therapy. The treatment effects were evaluated by using the BEHAVE-AD before treatment and after 2-,4-,8-week treatment. The side effects scale(TESS) was used to evaluate the adverse reactions occurrence situation. Results The AD-BEHAVE scores after 2-,4-,8-week treatment in 3 groups were significantly lower than those before treatment ,the difference was statistically significant (P0.05),but the effect in the combination group was significantly superior to that in the quetiapine group(χ2=15.39,P0.05),但明显优于喹硫平组,差异有统计学意义(χ2=15.39,P<0.01)。利培酮组不良反应发生率明显高于联合组、喹硫平组,差异均有统计学意义(P<0.05)。结论利培酮联合喹硫平治疗老年痴呆BPSD具有较好疗效,不良反应小,更适于老年痴呆患者的治疗。

  12. 利培酮与氯氮平治疗精神分裂症对照研究%Effect of risperidone and clozapine on the treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    李月霞

    2009-01-01

    目的 比较利培酮和氯氮平治疗精神分裂症的疗效和不良反应.方法 将40例精神分裂症患者随机分成两组,利培酮组和氯氮平组各20例,于治疗前和治疗第2、4、6周末采用症状量表(PANSS)及副反应量表(TESS)评定疗效及不良反应.结果 两组PANSS减分率比较差异无统计学意义(P>0.05),利培酮组不良反应少.结论 利培酮与氯氮平治疗精神分裂症疗效相当,但利培酮不良反应少.%Objective To comparie effect of risperidone and clozapine on the treatment of schizophrenia and adverse reactions. Methods 40 cases were randomly divided into two groups of patients with schizophrenia, risperi-done and clozapine group 20 cases, pre-treatment and treatment in the first weekend 2,4,6 Symptom Rating Scale (PANSS) and the reaction volume Table (TESS) were used to assess the efficacy and adverse reactions. Results Comparison of reduction rate PANSS, there was no significant difference(P > 0. 05), compared with clozapine group, risperidone group had less adverse reactions. Conclusion Risperidone and clozapine group had considerable effect in the treatment of schizophrenia, but risperidone had fewer adverse reactions.

  13. A literature review on the efficacy and safety of botulinum toxin: An injection in post-stroke spasticity

    Directory of Open Access Journals (Sweden)

    Majid Ghasemi

    2013-01-01

    Full Text Available Background: A variety of techniques for the management of spasticity have been suggested, including positioning, cryotherapy, splinting and casting, biofeedback, electrical stimulation, and medical management by pharmacological agents, Botulinum toxin A (BTA is now the pharmacological treatment of choice in focal spasticity. BTA by blocking acetylcholine release at neuromuscular junctions accounts for its therapeutic action to relieve spasticity. Methods: A computerized search of Pub Med was carried out to find the latest result about efficacy of BTA in management of post stroke spasticity. Result: Among 84 articles were found, frothy of them included in this review and divided to lower and upper extremity. Conclusions: BTA is a treatment choice in reducing tone and managing post stroke spasticity .

  14. Comparative Study on the Efficacy and Safety of Olanzapine and Risperidone in the Treatment of Behavioral and Psychological Symptoms of Dementia%奥氮平与利培酮治疗痴呆精神行为症状的疗效及安全性比较研究

    Institute of Scientific and Technical Information of China (English)

    梁静涛; 吴丽娟

    2016-01-01

    目的探讨奥氮平与利培酮治疗痴呆精神行为症状的临床效果以及安全性。方法将我院2013年1月~2014年1月收治的70例患有痴呆精神行为症状的患者随机分成对照组和治疗组,对照组行利培酮进行治疗,治疗组行奥氮平进行治疗,比较两组患者的治疗效果。结果治疗后,治疗组总有效率为85.71%,对照组为91.43%,对比显示差异无统计学意义(>0.05);与治疗前相比,两组患者治疗2、4、8w后的BEHAVE-AD评分均有明显改善,且差异显示具有统计学意义(0.05);治疗组不良反应率为11.43%,明显低于对照组的31.43%,且差异显示具有统计学意义( 0.05); compared with before treatment, the two groups of patients after treatment BEHAVE 2,4,8w -AD scores showed significant improvement, and show a statistically significant difference ( 0.05); adverse reaction rate was 11.43% in treatment group was significantly 31.43% lower than the control group, and the difference was statistically significant display ( <0.05). Conclusion Olanzapine and risperidone behavioral and psychological symptoms of dementia have some clinical effect, but Olanzapine security even more significant, can reduce the incidence of adverse events, help patients get better treatment, worthy of promotion.

  15. Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life

    Directory of Open Access Journals (Sweden)

    Montemagni C

    2016-04-01

    Full Text Available Cristiana Montemagni,1,2 Tiziana Frieri,1,2 Paola Rocca1,2 1Department of Neuroscience, Unit of Psychiatry, University of Turin, 2Department of Mental Health, Azienda Sanitaria Locale (ASL Torino 1 (TO1, Azienda Ospedaliero-Universitaria (AOU Città della Salute e della Scienza di Torino, Turin, Italy Abstract: Long-acting injectable antipsychotics (LAIs were developed to make treatment easier, improve adherence, and/or signal the clinician when nonadherence occurs. Second-generation antipsychotic LAIs (SGA-LAIs combine the advantages of SGA with a long-acting formulation. The purpose of this review is to evaluate the available literature concerning the impact of SGA-LAIs on patient functioning and quality of life (QOL. Although several studies regarding schizophrenia patients’ functioning and QOL have been performed, the quantity of available data still varies greatly depending on the SGA-LAI under investigation. After reviewing the literature, it seems that SGA-LAIs are effective in ameliorating patient functioning and/or QOL of patients with schizophrenia, as compared with placebo. However, while methodological design controversy exists regarding the superiority of risperidone LAI versus oral antipsychotics, the significant amount of evidence in recently published research demonstrates the beneficial influence of risperidone LAI on patient functioning and QOL in stable patients and no benefit over oral treatment in unstable patients. However, the status of the research on SGA-LAIs is lacking in several aspects that may help physicians in choosing the correct drug therapy. Meaningful differences have been observed between SGA-LAIs in the onset of their clinical efficacy and in the relationships between symptoms and functioning scores. Moreover, head-to-head studies comparing the effects of SGA-LAIs on classical measures of psychopathology and functioning are available mainly on risperidone LAI, while those comparing olanzapine LAI with other

  16. Critical appraisal of the efficacy, safety, and patient acceptability of hydroxyprogesterone caproate injection to reduce the risk of preterm birth

    Directory of Open Access Journals (Sweden)

    Vidaeff AC

    2013-07-01

    Full Text Available Alex C Vidaeff, Michael A BelfortDivision of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, USAAbstract: Prevention of preterm delivery is a major desiderate in contemporary obstetrics and a societal necessity. The means to achieve this goal remain elusive. Progesterone has been used in an attempt to prevent preterm delivery since the 1970s, but the evidence initially accumulated was fraught by mixed results and was based on mostly underpowered studies with variable eligibility criteria, including history of spontaneous abortion as an indication for treatment. More recent randomized controlled clinical trials restimulated the interest in progesterone supplementation, suggesting that progesterone may favorably influence the rate of preterm delivery. Preterm delivery is a complex disorder and consequently it is unlikely that one generalized prevention strategy will be effective in all patients. Further, an additional impediment in accepting progesterone as the "magic bullet" in the prevention of preterm delivery is that its mechanism of action is not fully understood and the optimal formulations, route of administration, and dose have yet to be established. We have concerned ourselves in this review with the most recent status of 17 alpha-hydroxyprogesterone caproate (17OH-PC supplementation for prevention of preterm delivery. Our intention is to emphasize the efficacy, safety, and patient acceptability of this intervention, based on a comprehensive and unbiased review of the available literature. Currently there are insufficient data to suggest that 17OH-PC is superior or inferior to natural progesterone. Based on available evidence, we suggest a differential approach giving preferential consideration to either 17OH-PC or other progestins based on obstetric history and cervical surveillance. Progestin therapy for risk factors other than a history of preterm

  17. Efficacy of caudal epidural injection of lidocaine, xylazine and xylazine plus hyaluronidase in reducing discomfort produced by electroejaculation in bulls.

    Science.gov (United States)

    Pagliosa, Ronaldo C; Derossi, Rafael; Costa, Deiler S; Faria, Fabio J C

    2015-11-01

    To test the hypothesis that epidural administration of lidocaine, xylazine or xylazine plus hyaluronidase provides reduced pain and stress during electroejaculation in bulls, eight 30-month-old Nellore bulls received saline solution (control), 2% lidocaine, 2% xylazine or 2% xylazine plus hyaluronidase injected into the first intercoccygeal (Co1-Co2) epidural space in randomized order. Heart rate, respiratory rate, mean arterial pressure, analgesia, animal behavior and motor blockade were evaluated before treatment and at predetermined intervals during and after treatment. Pain and stress were scored subjectively, and semen quality was evaluated. The onset of anesthetic action was significantly faster with lidocaine (3.0 ± 1.2 min) than with xylazine or xylazine plus hyaluronidase (8.9 ± 1.5 and 5.5 ± 2.6 min, P=0.021 and P=0.012, respectively), and the onset of anesthesia with xylazine plus hyaluronidase was significantly faster than that with xylazine alone (P=0.032). Treatment with xylazine or xylazine plus hyaluronidase resulted in less discomfort than treatment with lidocaine, as indicated by animal behavior. Changes in heart rate, respiratory rate and arterial pressure were within acceptable limits. Penile protrusion and semen emission occurred in all animals during all four treatments. Our results suggest that xylazine plus hyaluronidase reduced discomfort during electroejaculation more effectively than xylazine or lidocaine alone. Further experiments are necessary to determine whether electroejaculation with xylazine plus hyaluronidase is feasible for obtaining semen from Nellore bulls unaccustomed to being handled or restrained.

  18. A case study: neuroleptic malignant syndrome with risperidone and CYP2D6 gene variation.

    Science.gov (United States)

    Ochi, Shinichiro; Kawasoe, Koichiro; Abe, Masao; Fukuhara, Ryuji; Sonobe, Kantaro; Kawabe, Kentaro; Ueno, Shu-ichi

    2011-01-01

    We present a schizophrenic patient who experienced neuroleptic malignant syndrome with risperidone treatment due to variants of the CYP2D6 gene with reduced function. Clinicians need to be aware of this potential complication.

  19. Serum prolactin levels and sexual dysfunctions in antipsychotic medication, such as risperidone : a review

    NARCIS (Netherlands)

    Knegtering, H; Lambers, PA; Prakken, G; ten Brink, C

    2000-01-01

    Classical antipsychotic drugs increase the level of serum prolactin. The atypical antipsychotic clozapine barely increases prolactin levels. An open naturalistic study in the University Hospital of Groningen suggests that treatment with risperidone in comparison to classical antipsychotics seems to

  20. Induction of Drug Transporters Alters Disposition of Risperidone - A Study in Mice

    Directory of Open Access Journals (Sweden)

    David Holthoewer

    2010-06-01

    Full Text Available Pharmacokinetic interactions, e.g. modulation of drug transporters like P-glycoprotein at the blood-brain barrier, can be a reason for treatment non-response. This study focuses on the influence of induction of drug transporters on the disposition of the antipsychotic drugs risperidone and 9-hydroxyrisperidone. Brain and serum concentrations of risperidone and its active metabolite 9-hydroxyrisperidone, which are known P-glycoprotein substrates, were measured after drug transporter induction with rifampicin, dexamethasone or 5-pregnene-3beta-ol-20-on-16alpha-carbonitrile using high performance liquid chromatography. Disposition of risperidone and 9-hydroxyrisperidone was dramatically decreased in mouse brain and serum after drug transporter induction. The metabolism of risperidone was also affected.

  1. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels

    NARCIS (Netherlands)

    Knegtering, R; Baselmans, P; Castelein, S; Bosker, F; Bruggeman, R; van den Bosch, RJ

    2005-01-01

    Objective: The atypical antipsychotic risperidone significantly raises plasma prolactin levels in patients, but clozapine, olanzapine, and quetiapine do not. The differences in neuroendocrine response may be connected with the metabolism of the medications. The authors examined the contributory role

  2. A Comparison of Risperidone and Buspirone for Treatment of Behavior Disorders in Children with Phenylketonuria

    OpenAIRE

    FAYYAZi, Afshin; Salari, Elham; Ali KHAJEH; GAJARPOUR, Abdi

    2014-01-01

    How to Cite This Article: Fayyazi A, Salari E, Khajeh A, Ghajarpour A. A Comparison of Risperidone and Buspirone for Treatment ofBehavior Disorders in Children with Phenylketonuria. Iran J Child Neurol. 2014 Autumn; 8(4):33-38.AbstractObjectiveMany patients with late-diagnosed phenylketonuria (PKU) suffer from severe behavior problems. This study compares the effects of buspirone and risperidone on reducing behavior disorders in these patients.Materials & MethodsIn this crossover clinical...

  3. In Vitro-In Vivo Correlation of Parenteral Risperidone Polymeric Microspheres

    OpenAIRE

    2015-01-01

    The objective of the present study was to determine whether an in vitro-in vivo correlation (IVIVC) can be established for polymeric microspheres that are equivalent in formulation composition but prepared with different manufacturing processes. Risperidone was chosen as a model therapeutic and poly(lactic-co-glycolic acid) (PLGA) with similar molecular weight as that used in the commercial product Risperdal® Consta® was used to prepare risperidone microspheres. Various manufacturing processe...

  4. Development of novel risperidone implants using blends of polycaprolactones and in vitro in vivo correlation studies

    OpenAIRE

    2014-01-01

    The objective of this study was to develop a novel implant containing risperidone intended for long-term treatment in Schizophrenia utilizing in vitro in vivo correlation (IVIVC) studies. Different implants (F1-F8) containing an antipsychotic drug, risperidone, were prepared using a hot melt extrusion technique by taking polycaprolactones of different molecular weights (Mwt. 15000, 45000, 80000) either alone or as their blends, and PLGA (75:25). The implants contained 40% of the drug. After f...

  5. 利培酮、氯氮平合并碳酸锂治疗躁狂症的临床对照研究%Clinical control study of risperidone,clozapine combined with lithium carbonate in the treatment of mania

    Institute of Scientific and Technical Information of China (English)

    孙锦红

    2014-01-01

    目的:观察利培酮与氯氮平分别合并碳酸锂治疗有精神病性症状躁狂症的疗效及安全性。方法:将符合DSM-Ⅳ诊断标准的躁狂症患者60例,随机分为两组,在使用碳酸锂的同时,分别合并利培酮或氯氮平平进行为期8周的治疗。采用躁狂量表(BRMS)评定疗效,采用不良反应量表(TESS)评定不良反应。结果:利培酮与氯氮平平疗效相当,利培酮起效时间迟于氯氮平,但不良反应较轻,依从性好。结论:利培酮合并碳酸锂与氯氮平合并碳酸锂治疗躁狂症总体疗效相当,但安全性较高。%Objective:To observe the effects of risperidone and clozapine both combined with lithium in treatment efficacy and safety of psychotic symptoms of mania.Methods:60 patients with mania were selected,all of them meet the DSM-Ⅳ diagnostic criteria on mania.They were randomly divided into 2 groups,at the same time of the use of lithium carbonate combined with risperidone or clozapine respectively,the treatment time is 8 weeks.The treatment efficacy assessed by Mania Rating Scale(BRMS), the adverse reactions assessed by side effects scale(TESS).Results:The treatment efficacy of risperidone and clozapine is equalized,the onset time of risperidone later than clozapine,but the adverse reaction of risperidone less than clozapine,and the former has better compliance.Conclusion:The efficacy of risperidone combine with lithium carbonate and clozapine combined with lithium in treatment of mania are equivalent,but risperidone has higher security.

  6. In vitro-in vivo correlation of parenteral risperidone polymeric microspheres.

    Science.gov (United States)

    Shen, Jie; Choi, Stephanie; Qu, Wen; Wang, Yan; Burgess, Diane J

    2015-11-28

    The objective of the present study was to determine whether an in vitro-in vivo correlation (IVIVC) can be established for polymeric microspheres that are equivalent in formulation composition but prepared with different manufacturing processes. Risperidone was chosen as a model therapeutic and poly(lactic-co-glycolic acid) (PLGA) with similar molecular weight as that used in the commercial product Risperdal® Consta® was used to prepare risperidone microspheres. Various manufacturing processes were investigated to produce the risperidone microspheres with similar drug loading (approx. 37%) but distinctly different physicochemical properties (e.g. porosity, particle size and particle size distribution). In vitro release of the risperidone microspheres was investigated using different release testing methods (such as sample-and-separate and USP apparatus 4). In vivo pharmacokinetic profiles of the risperidone microsphere formulations following intramuscular administration were determined using a rabbit model. Furthermore, the obtained pharmacokinetic profiles were deconvoluted using the Loo-Riegelman method and the calculated in vivo release was compared with the in vitro release of these microspheres. Level A IVIVCs were established and validated for the compositionally equivalent risperidone microspheres based on the in vitro release data obtained using USP apparatus 4. The developed IVIVCs demonstrated good predictability and were robust. These results showed that the developed USP apparatus 4 method was capable of discriminating PLGA microspheres that are equivalent in formulation composition but with manufacturing differences and predicting their in vivo performance in the investigated animal model.

  7. Treatment with the antipsychotic agent, risperidone, reduces disease severity in experimental autoimmune encephalomyelitis.

    Science.gov (United States)

    O'Sullivan, David; Green, Laura; Stone, Sarrabeth; Zareie, Pirooz; Kharkrang, Marie; Fong, Dahna; Connor, Bronwen; La Flamme, Anne Camille

    2014-01-01

    Recent studies have demonstrated that atypical antipsychotic agents, which are known to antagonize dopamine D2 and serotonin 5-HT2a receptors, have immunomodulatory properties. Given the potential of these drugs to modulate the immune system both peripherally and within the central nervous system, we investigated the ability of the atypical anti-psychotic agent, risperidone, to modify disease in the animal model of multiple sclerosis (MS)4, experimental autoimune encephalomyelitis (EAE). We found that chronic oral administration of risperidone dose-dependently reduced the severity of disease and decreased both the size and number of spinal cord lesions. Furthermore, risperidone treatment substantially reduced antigen-specific interleukin (IL)-17a, IL-2, and IL-4 but not interferon (IFN)-γ production by splenocytes at peak disease and using an in vitro model, we show that treatment of macrophages with risperidone alters their ability to bias naïve T cells. Another atypical antipsychotic agent, clozapine, showed a similar ability to modify macrophages in vitro and to reduce disease in the EAE model but this effect was not due to antagonism of the type 1 or type 2 dopamine receptors alone. Finally, we found that while risperidone treatment had little effect on the in vivo activation of splenic macrophages during EAE, it significantly reduced the activation of microglia and macrophages in the central nervous system. Together these studies indicate that atypical antipsychotic agents like risperidone are effective immunomodulatory agents with the potential to treat immune-mediated diseases such as MS.

  8. Galactorrhea - side effect of risperidone in combination with depakine chrono in a patient with bipolar disorder.

    Science.gov (United States)

    Peitl, Marija Vucić; Peitl, Vjekoslav; Grahovac, Tanja; Pavlović, Eudard

    2010-03-01

    Risperidone, as all atypical antipsychotics, can cause hyperprolactinemia which can in turn lead to galactorrhea. Mood stabilizers, one of which is valproic acid and its derivate "Depakine Chrono", are rarely linked with symptomatic hyperprolactinemia and do not alter prolactin concentrations. This case is based around a patient suffering from a bipolar disorder that has been psychiatrically treated in an outpatient clinic during four years. Bipolar disorder treatment was started with carbamazepine, but later it was discontinued due to adverse events and extreme increase of liver transaminases. Treatment was continued with introduction of lithium, but the patient stated that she could not tolerate it. Subsequently, her endocrinologist advised for lithium discontinuation due to very severe osteoporosis. At the beginning of 2009, lithium was discontinued and Depakine Chrono was introduced. Due to patient's psychotic decompensation it was necessary to introduce risperidone into treatment and soon afterwards her psychotic symptoms settled. After several months of treatment her mood lowered, she began to feel sedated, psychomotorically retarded and that lead to dose lowering of Depakine Chrono and risperidone, at which point galactorrhea as a serious adverse event occurred. Occurrence of galactorrhea at lower risperidone doses in this case might be partially explained by recent studies that showed that lower doses of risperidone can also improve psychic state, but could also cause adverse events. Although galactorrhea, as a direct consequence of hyperprolactinemia caused by risperidone has mainly been researched with higher doses of this atypical antipsychotic, we have to keep in mind that lower doses could also cause serious adverse events.

  9. Early onset of treatment effects with oral risperidone

    Directory of Open Access Journals (Sweden)

    Naber Dieter

    2007-01-01

    Full Text Available Abstract Background The dogma of a delayed onset of antipsychotic treatment effects has been maintained over the past decades. However, recent studies have challenged this concept. We therefore performed an analysis of the onset of antipsychotic treatment effects in a sample of acutely decompensated patients with schizophrenia. Methods In this observational study, 48 inpatients with acutely decompensated schizophrenia were offered antipsychotic treatment with oral risperidone. PANSS-ratings were obtained on day 0, day 1, day 3, day 7 and day 14. Results Significant effects of treatment were already present on day 1 and continued throughout the study. The PANSS positive subscore and the PANSS total score improved significantly more than the PANSS negative subscore. Conclusion Our results are consistent with the growing number of studies suggesting an early onset of antipsychotic treatment effects. However, non-pharmacological effects of treatment also need to be taken into consideration.

  10. Therapeutic Efficacy and Safety of Percutaneous Ethanol Injection with or without Combined Radiofrequency Ablation for Hepatocellular Carcinomas in High Risk Locations

    Energy Technology Data Exchange (ETDEWEB)

    Cha, Dong Ik; Lee, Min Woo; Rhim, Hyunchul; Choi, Dongil; Kim, Young-sun; Lim, Hyo K. [Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710 (Korea, Republic of)

    2013-07-01

    To evaluate the therapeutic efficacy and safety of percutaneous ethanol injection (PEI) alone and combined with radiofrequency ablation (RFA) for hepatocellular carcinomas (HCCs) in high risk locations. We performed PEI for HCCs in RFA-high risk locations, either alone or in combination with RFA. There were 20 HCCs (1.7 ± 0.9 cm) in 20 patients (PEI group: n = 12; PEI + RFA group: n = 8). We evaluated technical success, local tumor progression and complications in both groups. Technical success was achieved in all HCCs in both groups. During follow-up, local tumor progression was found in 41.7% (5/12) in the PEI group, whereas 12.5% (1/8) for the PEI + RFA group (p = 0.32). Bile duct dilatation was the most common complication, especially when the tumors were in periportal locations; 55% (5/9) in the PEI group and 50% (2/4) in the PEI + RFA group (p = 1.00). One patient in the PEI group developed severe biliary stricture and upstream dilatation that resulted in atrophy of the left hepatic lobe. One patient treated with PEI + RFA developed cholangitis and an abscess. Combined PEI and RFA treatment has a tendency to be more effective than PEI alone for managing HCCs in high risk locations, although the difference is not statistically significant. Even though PEI is generally accepted as a safe procedure, it may cause major biliary complications for managing HCCs adjacent to the portal vein.

  11. Influence of aripiprazole, risperidone, and amisulpride on sensory and sensorimotor gating in healthy 'low and high gating' humans and relation to psychometry.

    Science.gov (United States)

    Csomor, Philipp A; Preller, Katrin H; Geyer, Mark A; Studerus, Erich; Huber, Theodor; Vollenweider, Franz X

    2014-09-01

    Despite advances in the treatment of schizophrenia spectrum disorders with atypical antipsychotics (AAPs), there is still need for compounds with improved efficacy/side-effect ratios. Evidence from challenge studies suggests that the assessment of gating functions in humans and rodents with naturally low-gating levels might be a useful model to screen for novel compounds with antipsychotic properties. To further evaluate and extend this translational approach, three AAPs were examined. Compounds without antipsychotic properties served as negative control treatments. In a placebo-controlled, within-subject design, healthy males received either single doses of aripiprazole and risperidone (n=28), amisulpride and lorazepam (n=30), or modafinil and valproate (n=30), and placebo. Prepulse inhibiton (PPI) and P50 suppression were assessed. Clinically associated symptoms were evaluated using the SCL-90-R. Aripiprazole, risperidone, and amisulpride increased P50 suppression in low P50 gaters. Lorazepam, modafinil, and valproate did not influence P50 suppression in low gaters. Furthermore, low P50 gaters scored significantly higher on the SCL-90-R than high P50 gaters. Aripiprazole increased PPI in low PPI gaters, whereas modafinil and lorazepam attenuated PPI in both groups. Risperidone, amisulpride, and valproate did not influence PPI. P50 suppression in low gaters appears to be an antipsychotic-sensitive neurophysiologic marker. This conclusion is supported by the association of low P50 suppression and higher clinically associated scores. Furthermore, PPI might be sensitive for atypical mechanisms of antipsychotic medication. The translational model investigating differential effects of AAPs on gating in healthy subjects with naturally low gating can be beneficial for phase II/III development plans by providing additional information for critical decision making.

  12. A control study of olanzapine and risperidone in the treatment of senile delirium%奥氮平与利培酮治疗老年期谵妄患者的对照研究

    Institute of Scientific and Technical Information of China (English)

    冼易平; 王英

    2011-01-01

    Objective; To compare the efficacy and safety of olanzapine and risperidone in the treatment of senile delirium. Method: Fifty patients with senile delirium were randomly divided into olanzapine treatment group (n = 25 ) and risperidone treatment group ( n = 25). They were prospectively observed and assessed with the Chinese revision of confusion assessment method (CAM-CR) .clinical global impression severity scale (CGI-SI) and treatment emergent symptom scales (TESS). Results:The effective rate of olanzapine treatment group and risperidone treatment group were 64. 0% and 68. 0% respectively (P > 0. 05). CGI-SI total scores of olanzapine treatmeng group and that of risperidone treatmen group were both reduced significantly after treatment (t=5. 19,6. 95 ;P 0.05 ). The total incidence rate of side effects in the risperidone group was significantly higher than that in olanzapine group ( χ2 = 5. 88, P < 0. 05). Conclusion; Olanzapine and risperidone have similar effects in treating senile delirium,ahd has fewer side effects.%目的:比较奥氮平和利培酮治疗老年期谵妄的疗效和安全性. 方法:将50例老年期谵妄患者随机分成奥氮平治疗组(n=25),利培酮治疗组(n=25),疗程2周.治疗前后以谵妄评定方法中文修订版(CAM-CR)及临床疗效总评量表-病情严重程度(CGI-SI)评定疗效;以治疗中出现的症状量表(TESS)评定药物不良反应. 结果:奥氮平组和利培酮组显效率分别为64.0%和68.0% (P >0.05).两组CGI-SI总分治疗后均较治疗前明显降低(t=5.19、6.95,P均<0.01);两组间比较,差异无统计学意义(P>0.05).利培酮组不良反应明显高于奥氮平组(x2=5.88,P<0.05). 结论:奥氮平和利培酮治疗老年期谵妄疗效相当,不良反应轻.

  13. A Randomized Open Label Comparison of the Effects ofRisperidone and Haloperidol on Sexual Function

    Directory of Open Access Journals (Sweden)

    S. Jaber Mousavi

    2009-12-01

    Full Text Available "n Objective: "nSexual dysfunction in patients who take antipsychotics causes adecline in their quality of life and medication acceptance. Considering the restrictions in cross sectional design of many earlier researches, we used a clinical trial aimed at assessing sexual dysfunction by substituting Risperidone, an atypical antipsychotic drug, with Haloperidol, a typical one . "n "n "nMethod: This clinical trial was conducted on 51 patients who had been using Risperidone with a minimum dose of 2 mg/daily for at least 2 months. The patients were randomly divided into 2 groups. The first group continued taking Risperidone, whereas the second group was given Haloperidol. Sexual function prior to and after the drug substitution was assessed using a sexual questionnaire designed to assess four stages of sexual function . "nResults: Compared to those who changed their medication to Haloperidol, the patients who remained on Risperidone therapy suffered from more sexual dysfunction, especially in their tendency towards having sexual activities (P= 0.01, post menstrual sexual activity (P= 0.002, and reaching orgasm in their sexual activities (P= 0.04; however in the Haloperidol group, no significant difference was observed before and after the change in medication . "nConclusion: Although Risperidone and Haloperidol can both disturb patients'sexual function, the side effects of Risperidone are stronger. Hence toprevent the decline of medication acceptance or irregular consumption by patients which may lead to possible relapse, substitution of Risperidone withanother drug with fewer side effects on sexual activities is definitely to the advantage of the patients .

  14. CYP2D6 polymorphisms and their influence on risperidone treatment

    Directory of Open Access Journals (Sweden)

    Puangpetch A

    2016-12-01

    Full Text Available Apichaya Puangpetch,1 Natchaya Vanwong,1 Nopphadol Nuntamool,2 Yaowaluck Hongkaew,1 Monpat Chamnanphon,1 Chonlaphat Sukasem1 1Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, 2Molecular Medicine, Faculty of Science, Mahidol University, Bangkok, Thailand Abstract: Cytochrome P450 enzyme especially CYP2D6 plays a major role in biotransformation. The interindividual variations of treatment response and toxicity are influenced by the polymorphisms of this enzyme. This review emphasizes the effect of CYP2D6 polymorphisms in risperidone treatment in terms of basic knowledge, pharmacogenetics, effectiveness, adverse events, and clinical practice. Although the previous studies showed different results, the effective responses in risperidone treatment depend on the CYP2D6 polymorphisms. Several studies suggested that CYP2D6 polymorphisms were associated with plasma concentration of risperidone, 9-hydroxyrisperidone, and active moiety but did not impact on clinical outcomes. In addition, CYP2D6 poor metabolizer showed more serious adverse events such as weight gain and prolactin than other predicted phenotype groups. The knowledge of pharmacogenomics of CYP2D6 in risperidone treatment is increasing, and it can be used for the development of personalized medication in term of genetic-based dose recommendation. Moreover, the effects of many factors in risperidone treatment are still being investigated. Both the CYP2D6 genotyping and therapeutic drug monitoring are the important steps to complement the genetic-based risperidone treatment. Keywords: CYP2D6, risperidone, polymorphisms, adverse drug reaction, pharmacogenetics, pharmacokinetics, pharmacodynamics

  15. The efficacy of Danhong injection for chronic heart failure:Meta-analysis%丹红注射液辅治慢性心力衰竭的Meta分析

    Institute of Scientific and Technical Information of China (English)

    李金; 唐其柱; 张宁; 张文斌

    2014-01-01

    目的:系统评价中药丹红注射液辅助治疗慢性心力衰竭的临床疗效。方法计算机检索Cochrane图书馆、PUBMED、EMBASE、Google学术搜索、中国知网、万方数据库、维普数据库和中国生物医学文献光盘数据库,搜集自建库至2014年3月国内外公开发表的丹红注射液治疗慢性心力衰竭的随机对照试验,按照Cochrane系统评价方法评价纳入研究文献的质量及资料提取后使用RevMan5.2软件进行Meta分析。结果共纳入10篇文献,总计886例慢性心力衰竭患者。 Meta分析结果显示:(1)联用丹红注射液的观察组临床疗效优于常规西药对照组( OR=3.97,95%CI 2.71~5.82, P <0.01);(2)观察组患者左室射血分数(LVEF)明显优于对照组(MD=8.44,95%CI 6.70~10.18, P <0.01)。10篇文献中均未报道明显不良反应。结论在常规治疗的基础上联用丹红注射液可明显提高心力衰竭治疗的有效率及改善心功能,且不良反应发生率较低。%Objective To evaluate the clinical curative effect of traditional Chinese medicine of Danhong injection in the treatment of chronic heart failure .Methods Searched on Cochrane library , PUBMED, EMBASE, Google academic search, CNKI, Wan fang database , VIP database and China biomedical literature database , a randomized controlled trial of Danhong injection in the treatment of chronic heart failure were collected from the beginning of these database to 2014 March of domestic and abroad , according to the Cochrane evaluation system , the quality of these data were evaluated and then extrac-ted data of these research, Meta-analysis was performed using RevMan5.2 software.Results 10 studies and a total of 886 ca-ses of chronic heart failure patients were included .Meta-analysis showed that: (1) Combined with Danhong injection, ob-serve clinical efficacy is superior to conventional western medicine group (OR=3.97, 95

  16. Study on the luminescence behavior of sulfobutylether-β-cyclodextrin with risperidone and its analytical application

    Science.gov (United States)

    Wu, Min; Chen, Donghua; Song, Zhenghua

    2012-10-01

    The interaction of sulfobutylether-β-cyclodextrin (SBE-β-CD) with risperidone (RISP) was first described with luminol-SBE-β-CD chemiluminescence (CL) system by flow injection analysis (FIA). In luminol-SBE-β-CD CL system, the 1:1 SBE-β-CD⋯luminol∗ complexation could enhance CL intensity of luminol and produce the effect of complexation enhancement of CL (CEC). It was found that RISP could quench the CL intensity of SBE-β-CD⋯luminol∗ and caused the effect of complexation enhancement of quenching (CEQ), the formation constant KR-CD 3.4 × 104 L mol-1 and the stoichiometric ratio 1:1 of RISP⋯SBE-β-CD complex were obtained by the proposed CL model. Association degree α 0.036 of RISP⋯SBE-β-CD complex was also given by CL method. Based on the linear relationship to the decrement of luminol-SBE-β-CD-RISP CL intensity and the logarithm of RISP concentration, RISP also can be quantified in the linear range of 3.0-500.0 nmol L-1 with a detection limit of 1.0 nmol L-1 (3σ). The proposed method was successfully applied to monitoring excreted RISP in human urine. It was found that RISP reached its maximum after oral administration for 1.5 h with the total excretion of 14.26% within 8.5 h; the elimination rate constant k and half-life time t1/2 were 0.474 and 1.5 h, respectively.

  17. Risperidone and NAP protect cognition and normalize gene expression in a schizophrenia mouse model.

    Science.gov (United States)

    Vaisburd, Sinaya; Shemer, Zeev; Yeheskel, Adva; Giladi, Eliezer; Gozes, Illana

    2015-11-10

    Mutated disrupted in schizophrenia 1 (DISC1), a microtubule regulating protein, leads to schizophrenia and other psychiatric illnesses. It is hypothesized that microtubule stabilization may provide neuroprotection in schizophrenia. The NAP (NAPVSIPQ) sequence of activity-dependent neuroprotective protein (ADNP) contains the SxIP motif, microtubule end binding (EB) protein target, which is critical for microtubule dynamics leading to synaptic plasticity and neuroprotection. Bioinformatics prediction for FDA approved drugs mimicking SxIP-like motif which displace NAP-EB binding identified Risperidone. Risperidone or NAP effectively ameliorated object recognition deficits in the mutated DISC1 mouse model. NAP but not Risperidone, reduced anxiety in the mutated mice. Doxycycline, which blocked the expression of the mutated DISC1, did not reverse the phenotype. Transcripts of Forkhead-BOX P2 (Foxp2), a gene regulating DISC1 and associated with human ability to acquire a spoken language, were increased in the hippocampus of the DISC1 mutated mice and were significantly lowered after treatment with NAP, Risperidone, or the combination of both. Thus, the combination of NAP and standard of care Risperidone in humans may protect against language disturbances associated with negative and cognitive impairments in schizophrenia.

  18. Risperidone – Solid-state characterization and pharmaceutical compatibility using thermal and non-thermal techniques

    Energy Technology Data Exchange (ETDEWEB)

    Daniel, Josiane Souza Pereira; Veronez, Isabela Pianna; Rodrigues, Larissa Lopes [Laboratório de Análise e Caracterização de Fármacos – LACFar, Instituto de Química, Universidade Federal de Alfenas, Alfenas, Minas Gerais (Brazil); Trevisan, Marcello G. [Laboratório de Análise e Caracterização de Fármacos – LACFar, Instituto de Química, Universidade Federal de Alfenas, Alfenas, Minas Gerais (Brazil); National Institute of Bioanalytics Science and Technology – INCTBio, Institute of Chemistry – UNICAMP, 13084-653, Campinas, São Paulo (Brazil); Garcia, Jerusa Simone, E-mail: jerusa.garcia@unifal-mg.edu.br [Laboratório de Análise e Caracterização de Fármacos – LACFar, Instituto de Química, Universidade Federal de Alfenas, Alfenas, Minas Gerais (Brazil)

    2013-09-20

    Highlights: • DSC was used to characterize Risperidone and study its compatibility with excipients. • FT-IR associated with PCA was used to complement DSC data. • LC analyzes confirmed the DSC and FT-IR/PCA results. • Risperidone was incompatible with three among five excipients evaluated. - Abstract: A full solid-state characterization of risperidone was conducted using differential scanning calorimetry (DSC), thermogravimetry (TG), powder X-ray diffraction (PXRD), Fourier transform infrared spectroscopy (FT-IR) and scanning electron microscopy (SEM) to examine its physicochemical properties and polymorphism. The primary aim of this work was to study the compatibility of risperidone with pharmaceutical excipients using DSC to obtain and compare the curves of the active pharmaceutical ingredient (API) and the excipients with their 1:1 (w/w) binary mixtures. These same binary mixtures were turned to room temperature and analyzed by FT-IR combined with principal component analysis (PCA) to evaluate solid-state incompatibilities. The chemical incompatibilities of these samples were verified using a stability-indicating liquid chromatography (LC) method to assay for the API and evaluate the formation of degradation products. All of these methods showed incompatibilities between risperidone and the excipients magnesium stearate, lactose and cellulose microcrystalline.

  19. Optimization and in vivo toxicity evaluation of G4.5 PAMAM dendrimer-risperidone complexes.

    Directory of Open Access Journals (Sweden)

    Maria Jimena Prieto

    Full Text Available Risperidone is an approved antipsychotic drug belonging to the chemical class of benzisoxazole. This drug has low solubility in aqueous medium and poor bioavailability due to extensive first-pass metabolism and high protein binding (>90%. Since new strategies to improve efficient treatments are needed, we studied the efficiency of anionic G4.5 PAMAM dendrimers as nanocarriers for this therapeutic drug. To this end, we explored dendrimer-risperidone complexation dependence on solvent concentration, pH and molar relationship. The best dendrimer-risperidone incorporation (46 risperidone molecules per dendrimer was achieved with a mixture of chloroform:methanol 50∶50 v/v solution pH 3. In addition, to explore the possible effects of this complex, in vivo studies were carried out in the zebrafish model. Changes in the development of dopaminergic neurons and motoneurons were studied using tyrosine hydroxylase and calretinin, respectively. Physiological changes were studied through histological sections stained with hematoxylin-eosin to observe possible morphological brain changes. The most significant changes were observed when larvae were treated with free risperidone, and no changes were observed when larvae were treated with the complex.

  20. Optimization and in vivo toxicity evaluation of G4.5 PAMAM dendrimer-risperidone complexes.

    Science.gov (United States)

    Prieto, Maria Jimena; del Rio Zabala, Nahuel Eduardo; Marotta, Cristian Hernán; Carreño Gutierrez, Hector; Arévalo Arévalo, Rosario; Chiaramoni, Nadia Silvia; del Valle Alonso, Silvia

    2014-01-01

    Risperidone is an approved antipsychotic drug belonging to the chemical class of benzisoxazole. This drug has low solubility in aqueous medium and poor bioavailability due to extensive first-pass metabolism and high protein binding (>90%). Since new strategies to improve efficient treatments are needed, we studied the efficiency of anionic G4.5 PAMAM dendrimers as nanocarriers for this therapeutic drug. To this end, we explored dendrimer-risperidone complexation dependence on solvent concentration, pH and molar relationship. The best dendrimer-risperidone incorporation (46 risperidone molecules per dendrimer) was achieved with a mixture of chloroform:methanol 50∶50 v/v solution pH 3. In addition, to explore the possible effects of this complex, in vivo studies were carried out in the zebrafish model. Changes in the development of dopaminergic neurons and motoneurons were studied using tyrosine hydroxylase and calretinin, respectively. Physiological changes were studied through histological sections stained with hematoxylin-eosin to observe possible morphological brain changes. The most significant changes were observed when larvae were treated with free risperidone, and no changes were observed when larvae were treated with the complex.

  1. Desipramine enhances the ability of risperidone to decrease alcohol intake in the Syrian golden hamster.

    Science.gov (United States)

    Gulick, Danielle; Chau, David T; Khokhar, Jibran Y; Dawson, Ree; Green, Alan I

    2014-08-30

    The atypical antipsychotic clozapine reduces alcohol drinking in patients with schizophrenia. We have proposed that clozapine׳s ability to decrease alcohol drinking relates to its weak blockade of the dopamine D2 receptor and potent blockade of the norepinephrine α-2 receptor, as well as its ability to elevate plasma and brain norepinephrine. Another atypical antipsychotic, risperidone, which is a potent blocker of both the dopamine D2 receptor and norepinephrine α-2 receptor, does not decrease alcohol drinking. In this study, we used the Syrian golden hamster to test whether the ability of risperidone to reduce alcohol drinking would be enhanced if it was used in combination with the norepinephrine reuptake inhibitor desipramine. Hamsters were given free access to water and alcohol (15% v/v) until they reached a steady drinking baseline. They were then treated daily with each drug or drug combination for 20 days. Risperidone (0.2mg/kg) only transiently decreased alcohol drinking. However, 5.0mg/kg, and possibly 1.0mg/kg, desipramine added to 0.2mg/kg risperidone appeared to produce a more substantial and relatively sustained effect than risperidone alone. Data from this study provide leads toward the development of new treatments for patients with schizophrenia and alcoholism, and also for those with alcoholism alone.

  2. Short- and long-term efficacy of intra-articular injections with betamethasone as part of a treat-to-target strategy in early rheumatoid arthritis

    DEFF Research Database (Denmark)

    Hetland, Merete Lund; Østergaard, Mikkel; Ejbjerg, Bo;

    2012-01-01

    by Kaplan-Meier plots of the joint injection survival (ie, the time between injection and renewed flare). Potential predictors of joint injection survival were tested.RESULTS: 1373 Unique joints (ankles, elbows, knees, metacarpophalangeal (MCP), metatarsophalangeal, proximal interphalangeal (PIP), shoulders...

  3. 利培酮合并氯氮平治疗难治性精神分裂症临床分析%Clinical Effect of Risperidone Combined with Clozapine in Treatment of Re-fractory Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    赵圣兰; 郭晓静

    2015-01-01

    Objective To investigate the clinical effect of risperidone combined with clozapine in the treatment of refractory schizophrenia. Methods The control group received conventional treatment with risperidone; study group received combined treat-ment of risperidone and clozapine. Outcomes and adverse reaction of the patients with refractory schizophrenia in the two groups were recorded and statistically analyzed. Results Clinical total efficiency of the study group, 88.37%, was significantly higher than that of the control group, 69.77% (P 0.05). Conclusion Risperidone combined with clozapine used in the treatment of patients with refractory schizophrenia can significantly improve the clinical effi-cacy and quality of life and protect the safety of patients.%目的:探讨利培酮合并氯氮平治疗难治性精神分裂症临床应用效果。方法对照组给予利培酮常规治疗;研究组实施利培酮联合氯氮平片疗法。将两组中难治性精神分裂症患者的疗效及不良反应发生状况记录,通过统计学分析得出结论。结果研究组临床治疗的总有效率为88.37%,明显优于对照组临床治疗总有效率69.77%(P0.05)。结论难治性精神分裂症患者经利培酮联合氯氮平治疗可显著提高其临床疗效,有效保障患者生活质量及生命安全。

  4. 利培酮、氯氮平治疗精神分裂症的药物经济学评估%Pharmacoeconomic Evaluation of Schizophrenia in Risperidon and Cloza-pine Treatment

    Institute of Scientific and Technical Information of China (English)

    郑冰

    2014-01-01

    目的:比较利培酮、氯氮平治疗住院精神分裂症的成本-效果。方法对82例住院精神分裂症患者应用利培酮或氯氮平进行治疗,根据PANSS量表减分率评定疗效,对住院花费运用药物经济学成本-效果分析法进行评价。结果利培酮、氯氮平治疗精神分裂症的显效率分别为77.8%、71.4%,二者比较无显著性差异( P>0.05);产生单位效果所需成本二者无显著差异。结论利培酮与氯氮平治疗住院精神分裂症的疗效及费用基本相当。%OBJECTIVE To compare the efficiency and economic cost between Risperidon and Clozapine in the treatment of schizophrenia.METHODS 82 in-patients with schizophrenia were treated with Risperidon or Clozap-ine.PANSS was used to assess the clinical efficacy and pharmacoeconomic cost-effectiveness analysis was used to e-valuate costs.RESULTS The effective rates of Risperidon and Clozapine were 77.8% and 71.4% respectively with no significant difference ( P>0.05 ).There was no significant difference in the costs for an identical effect be-tween two drugs.CONCLUSION The ef-ective and costs of Risperidon and Clozapine are almost equal in the treat-ment of schizophrenia.

  5. A clinical study on substitution of risperidone for clozapine in the treatment of schizophrenia%利培酮替换氯氮平治疗精神分裂症临床研究

    Institute of Scientific and Technical Information of China (English)

    梅其一; 王晓龙; 杨小男; 方建中

    2001-01-01

    Objective:To explore a clinical optimal regime of substitutingrisperidone for clozapine. Method:Subjects were randomly enrolled into three groups: risperidone group, combination of risperidone and benzhexol group and combination of risperdone and alprazolam group. The efficacy and side effects were accessed with the positive and negative symptom scale (PANSS), a rating scale for extramidal side-effects (ESRS) and the treatment emergent symptom scale (TESS) before and after treatment. Results:The efficacy of all regimes was significant, and no significant differences were found among them. The female patients had more severe side effects than the male patients. The side effects were slightest in the combination of risperidone and alprazolam group and most severe in the risperidone group. Conclusion:Substituting risperidone and alprazolam for clozapine is the optimal regime in the treatment of schizophrenia.%目的:探索以利培酮替换氯氮平的临床换药方案。 方法:受试患者随机进入3组:单用利培酮组,利培酮+安坦组,利培酮+阿普唑仑组。在治疗前、治疗后1、2、4、6周用阳性症状与阴性症状量表(PANSS)、锥体外系副反应量表(ESRS)、不良反应症状量表(TESS)比较其疗效和副反应。 结果:3组换药后疗效均显著(P0.05)。女性较男性副反应大一些;利培酮+阿普唑仑组副反应最轻,单用利培酮组副反应最大。 结论:利培酮+阿普唑仑替换氯氮平方案较佳。

  6. Comparison of neuropsychological effects of adjunctive risperidone or quetiapine in euthymic patients with bipolar I disorder.

    Science.gov (United States)

    Kozicky, Jan-Marie; Torres, Ivan J; Bond, David J; Lam, Raymond W; Yatham, Lakshmi N

    2012-03-01

    Although associations between antipsychotic use and neuropsychological impairment in bipolar I disorder have been observed, there is a lack of studies comparing the effects of specific agents used in this population. We compared performance between patients receiving maintenance treatment with mood stabilizer monotherapy (n=15), adjunctive risperidone (n=15) or quetiapine (n=17), and a group of demographically matched healthy controls (n=28) on tests of executive function (working memory, set shifting, and inhibition) and verbal learning. Despite having a similar clinical profile, patients being treated with risperidone showed significantly impaired working memory, set-shifting, and verbal learning (Pdisorder, preliminary results indicate that addition of risperidone to a mood stabilizer has a negative impact on executive function and verbal learning, an effect not shared with quetiapine.

  7. 利培酮口服液治疗首发精神分裂症急性期对照观察%A control study of risperidone oral solution in treating first-episode schizophrenia patients in acute phase

    Institute of Scientific and Technical Information of China (English)

    黄卓玮; 龚传鹏

    2011-01-01

    目的:探讨利培酮13服液治疗首发精神分裂症急性期的疗效和安全性.方法:96例精神分裂症的急性期患者随机分为两组,分别给予利培酮口服液(研究组,n=49)和氯氮平(对照组,n=47)单药治疗4周.采用阳性和阴性症状量表(PANSS)评定临床疗效,临床总体印象量表(CGI-SI)评定病情严重程度,治疗中出现的症状量表(TESS)评定不良反应,自编依从性量表评定依从性.结果:治疗后两组患者PANSS及CGI-SI评分显著下降(P0.05).治疗后第4天,研究组兴奋、敌对、不合作、冲动控制缺乏因子分下降较对照组显著(P<0.05);研究组不良反应发生率明显低于对照组(P<0.05);研究组治疗依从性在治疗14 d、28 d、3个月和6个月时均优于对照组(P<0.05).结论:利培酮口服液对首发精神分裂症急性期患者的疗效和氯氮平相当,但利培酮口服液改善兴奋、敌对性等因子分较迅速,耐受性和依从性较好.%Objective: To evaluate the efficacy and safety of risperidone oral solution in the treatment of patients on the acute phase with first-episode schizophrenia. Method:96 schizophrenia patients were randomly assigned to the group treated with risperidone oral solution group ( n = 49 ) and the other group treated with clozapine (n =47 ),respectively for 4 weeks. The positive and negative syndrome scale (PANSS) and clinical global impressions-severity of illness rating scale(CGI-SI) were used to rate the efficacy;the treatment emergent symptom scale (TESS) was used to measure side effects and the compliance scale was used to assess the subjects'compliance with the treatment. Results:Both risperidone and clozapine group significantly showed score decrease on PANSS and CGI-SI after 4 weeks (P <0.01 ), but no significant difference was found between two groups ( P > 0.05 ). Excitement, hostility, uncooperativeness and poor impulse control of PANSS significantly decreased more in risperidone oral solution group

  8. Comparison the effectiveness of aripiprazole and risperidone for the treatment of acute bipolar mania

    Directory of Open Access Journals (Sweden)

    Amir Akhavan Rezayat

    2014-01-01

    Full Text Available Background: Second-generation antipsychotics, approved for the treatment of mania, are associated with adverse effects such as weight gain and metabolic disorders. Aripiprazole, a recently introduced second-generation antipsychotic, are thought to account for its low propensity for weight gain, metabolic disturbances and sedation. The purpose of this study was to investigate the effect of risperidone versus aripiprazole in the treatment of acute mania. Materials and Methods: Fifty patients with acute episodes of mania were enrolled in this study, and they were randomly assigned into a risperidone group of 24 cases and an aripiprazole group of 26 cases. In group A, aripiprazole with a dose of 5-30 mg/day and in group B, risperidone with a dose of 2-8 mg/day was given to patients. The average dose of aripiprazole was 27 mg/day, and the average dose of risperidone was 6 mg/day. The effects of each drug for the treatment of acute mania were assessed on the 1 st day of admission and on days 2, 4, 6, 8 and at weeks 2, 4 and 6 after therapy using the young mania rating scale (YMRS and at the baseline and on weeks 3 and 6 after admission using the clinical global impression (CGI scale. Results: The mean age of the group of risperidone was 34 ± 8.6 years and in a group of aripiprazole it was 34 ± 9.1 years (P = 0.83. Comparison of YMRS scores over the period of 6 weeks revealed a statistically significant difference in both groups (P < 0.0001.There was also a statistically significant difference in YMRS scores between risperidone and aripiprazole at day 8 (P = 0.026 and weeks 2 (P = 0.035 and 4 (P = 0.042. There was also a statistically significant difference in CGI-Severity scale score at weeks 3 (P = 0.003 and 6 (P = 0.000 and in CGI-Improvement scale score at weeks 3 (P = 0.005 and 6 (P = 0.002. The most common side-effect observed in both groups was headache (0%15/4 in aripiprazole vs. %16/7 in risperidone Conclusion: Aripiprazole that is readily

  9. 银杏叶提取物合并利培酮口腔崩解片治疗精神分裂症的临床研究%A clinical study of combined utization of ginkgo biloba extract and risperidone orally disintegrating tablets in the treatment of schlzophrenia

    Institute of Scientific and Technical Information of China (English)

    龚飞中; 曾骥; 余瑞; 龚昌群; 刘均富

    2012-01-01

    Objective To compare clinical efficacy and the side effects between combined utilization of ginkgo biloba extract and risperidone orally disintegrating tablets and only the use of risperidone orally disintegrating tablets in the treatment of schizophrenia. Methods Seventy-five patients with schizophrenia were treated randomly with combined utilization of ginkgo biloba extract and risperidone orally disintegrating tablets or risperidone orally disintegrating tablets only for six weeks,and measured with the brief psychiatric rating scale (BPRS) and treatment emergent symptom scale(TESS) before treatment and 1,2,4,6 weeks after treatment. Results The both programes were different in efficacy, combined utilization of ginkgo biloba extract and risperidone o-rally disintegrating tablets is more effective than risperidone orally disintegrating tablets only in treating schizophrenia, and the side effects combined utilization of ginkgo biloba extract and risperidone orally disintegrating tablets is no more effective than risperidone orally disintegrating tablets only in treating schizophrenia. Conclusion The therapeutic effect of combined utilization of ginkgo biloba extract and risperidone orally disintegrating tablets take a active part earlier than only the use of risperidone orally disintegrating tablets in the treatment of schizophrenia, however, the reduced rate of BPRS was no significant difference after 2 weeks, itcould be necessary to continue the joint use of ginkgo biloba extract.%目的 比较银杏叶提取物合并利培酮口腔崩解片与单用利培酮口腔崩解片治疗精神分裂症的疗效及不良反应.方法 将符合标准的75例精神分裂症患者分为两组,一组给予银杏叶提取物合并利培酮口腔崩解片治疗(治疗组,n=40),另一组给予利培酮口腔崩解片治疗(对照组,n=35),疗程6周.用简明精神量表(BPRS)在治疗前及治疗1、2、4、6周末评定疗效,用副反应量表(TESS)评定不良反应.结果

  10. Risperidone-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure

    Directory of Open Access Journals (Sweden)

    Sarah M. Bahr

    2015-11-01

    Full Text Available Risperidone is a second-generation antipsychotic that causes weight gain. We hypothesized that risperidone-induced shifts in the gut microbiome are mechanistically involved in its metabolic consequences. Wild-type female C57BL/6J mice treated with risperidone (80 μg/day exhibited significant excess weight gain, due to reduced energy expenditure, which correlated with an altered gut microbiome. Fecal transplant from risperidone-treated mice caused a 16% reduction in total resting metabolic rate in naïve recipients, attributable to suppression of non-aerobic metabolism. Risperidone inhibited growth of cultured fecal bacteria grown anaerobically more than those grown aerobically. Finally, transplant of the fecal phage fraction from risperidone-treated mice was sufficient to cause excess weight gain in naïve recipients, again through reduced energy expenditure. Collectively, these data highlight a major role for the gut microbiome in weight gain following chronic use of risperidone, and specifically implicates the modulation of non-aerobic resting metabolism in this mechanism.

  11. Enhancement of the anti-immobility action of antidepressants by risperidone in the forced swimming test in mice.

    Science.gov (United States)

    Rogóż, Zofia; Kabziński, Marcin

    2011-01-01

    The aim of the present study was to examine the effect of antidepressants (ADs) belonging to different pharmacological groups and risperidone (an atypical antipsychotic drug), given separately or jointly, on immobility time in the forced swimming test in male C57BL/6J mice. The antidepressants: citalopram, fluvoxamine, sertraline, reboxetine, milnacipran (5 and 10 mg/kg), or risperidone in low doses (0.05 and 0.1 mg/kg) given alone did not change the immobility time of mice in the forced swimming test. Co-treatment with reboxetine or milnacipran (10 mg/kg) and risperidone in a lower dose of 0.05 mg/kg or with sertraline, reboxetine (5 and 10 mg/kg), citalopram, fluvoxamine, milnacipran (10 mg/kg) and risperidone in a higher dose of 0.1 mg/kg produced antidepressant-like effect in the forced swimming test. WAY100635 (a 5-HT(1A) receptor antagonist) inhibited the effects induced by co-administration of ADs and risperidone. Active behavior in the forced swimming test was not a consequence of an increased general activity, since the combined treatment with ADs and risperidone failed to enhance the locomotor activity of mice. The obtained results indicate that a low dose of risperidone enhances the activity of ADs in an animal model of depression, and that, among other mechanisms, 5-HT(1A) receptors may play a role in these effects.

  12. Effect of cyamemazine on the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: a preliminary retrospective study.

    Science.gov (United States)

    Lancelin, Frédérique; Bourcier, Elsa; Le Masson, Valérie; Lemeille, Yolande; Brovedani, Sophie; Paubel, Pascal; Piketty, Marie-Liesse

    2010-12-01

    Administration of cyamemazine, an antipsychotic drug with anxiolytic properties, together with other antipsychotic agents is common in patients with schizophrenia. This retrospective study investigated the effects of cyamemazine on the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in 47 patients treated with 1 to 12 mg/day of risperidone. Of these 47 patients, 24 were receiving cyamemazine comedication ("cyamemazine" group) and 23 patients were treated with risperidone alone ("control" group). Plasma concentrations were measured using a high-performance liquid chromatographic method with photodiode-array ultraviolet detection. The median plasma concentration of risperidone was significantly higher in the cyamemazine group (31.5 ng/mL) than in the control group (5.0 ng/mL), whereas the 9-hydroxyrisperidone median concentration was significantly lower in the cyamemazine group (16.5 ng/mL versus 39.0 ng/mL in the control group). However, the sum of risperidone plus 9-hydroxyrisperidone (active moiety) plasma concentration was not significantly affected by cyamemazine comedication. A combination with cyamemazine resulted in an inverted metabolic ratio (risperidone/9-hydroxyrisperidone). These findings suggest that cyamemazine inhibits the 9-hydroxylation of risperidone and is probably an inhibitor of cytochrome P450 2D6 as are many other phenothiazine drugs.

  13. 奥美拉唑对利培酮和9-羟利培酮血药浓度影响的研究%Influence study of omeprazole on blood drug concentration of risperidone and 9-hydroxy risperidone

    Institute of Scientific and Technical Information of China (English)

    巫艳芬; 王玉梅; 陈宝燕

    2014-01-01

    目的:观察奥美拉唑对利培酮和9-羟利培酮血药浓度的影响。方法20例精神分裂症合并胃溃疡患者,给予利培酮联合奥美拉唑治疗1周。检测奥美拉唑治疗后利培酮以及9-羟利培酮血药浓度。结果未使用奥美拉唑前,利培酮与9-羟利培酮血药浓度为(29.25±7.82)μg/L;使用奥美拉唑后,利培酮与9-羟利培酮血药浓度为(37.15±11.68)μg/L,差异有统计学意义(P<0.05)。结论奥美拉唑能够提高利培酮与9-羟利培酮血药浓度,因此,临床上治疗精神分裂症合并胃溃疡患者,给予奥美拉唑联合利培酮治疗时,应该监测患者利培酮与9-羟利培酮血药浓度,及时对药物剂量进行调整。%Objective To observe the influence of omeprazole on blood drug concentration of risperidone and 9-hydroxy risperidone. Methods A total of 20 schizophrenia with gastric ulcer cases were treated by risperidone combined with omeprazole for 1 week. Detections of blood drug concentration of risperidone and 9-hydroxy risperidone were made after the omeprazole treatment. Results Before application of omeprazole, blood drug concentration of risperidone and 9-hydroxy risperidone was (29.25±7.82)μg/L. After using omeprazole, blood drug concentration of risperidone and 9-hydroxy risperidone was (37.15±11.68) μg/L. The difference had statistical significance (P<0.05). Conclusion Omeprazole can increase the blood drug concentration of risperidone and 9-hydroxy risperidone, which should be monitored in the risperidone combined with omeprazole treatment of schizophrenia with gastric ulcer, and timely adjustment of drug dose is necessary.

  14. Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial

    Directory of Open Access Journals (Sweden)

    Ma Yi-Wen

    2011-04-01

    Full Text Available Abstract Background This post hoc analysis (trial registration: ClinicalTrials.gov NCT00590577 assessed onset of efficacy and tolerability of acute treatment with once-monthly paliperidone palmitate (PP, a long-acting atypical antipsychotic initiated by day 1 and day 8 injections, in a markedly to severely ill schizophrenia population. Methods Subjects entering the 13-week, double-blind trial were randomized to PP (39, 156, or 234 mg [25, 100, and 150 mg eq of paliperidone, respectively] or placebo. This subgroup analysis included those with a baseline Clinical Global Impressions-Severity (CGI-S score indicating marked to severe illness. PP subjects received a 234-mg day 1 injection (deltoid, followed by their assigned dose on day 8 and monthly thereafter (deltoid or gluteal. Thus, data for PP groups were pooled for days 4 and 8. Measures included Positive and Negative Syndrome Scale (PANSS, CGI-S, Personal and Social Performance (PSP, and adverse events (AEs. Analysis of covariance (ANCOVA and last-observation-carried-forward (LOCF methodologies, without multiplicity adjustments, were used to assess changes in continuous measures. Onset of efficacy was defined as the first time point a treatment group showed significant PANSS improvement (assessed days 4, 8, 22, 36, 64, and 92 versus placebo, which was maintained through end point. Results A total of 312 subjects met inclusion criterion for this subgroup analysis. After the day 1 injection, mean PANSS total scores improved significantly with PP (all received 234 mg versus placebo at day 4 (P = 0.012 and day 8 (P = 0.007. After the day 8 injection, a significant PANSS improvement persisted at all subsequent time points in the 234-mg group versus placebo (P P P P Conclusions In this markedly to severely ill population, acute treatment with 234 mg PP improved psychotic symptoms compared with placebo by day 4. After subsequent injections, observed improvements are suggestive of a dose

  15. 合用阿立哌唑及单用利培酮对精神分裂症体质量的影响%Effects of Aripiprazole Combined with Risperidone and Risperidone on the Body Mass of Patients with Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    史玲; 杨云龙; 韩笑; 于丽燕; 严保平; 韩彦超; 周玉娟; 高景娜

    2016-01-01

    Objective:To compare the effects of risperidone combined with aripiprazle with only use of risperidone on body weight and BMI in patients with schizophrenia .Methods:70 patients with schizophrenia who met the criteria were randomized to two groups receiving risperidone combined with aripiprazle(research group)and only risperidone (control group) .Each group consists of 35cases .Clinical efficacies and the indexes body weight and BMI in patients were assessed with PANSS at the base line and at the end of the 4th week ,and 8th week .Results:There were 65 cases finishing the experiment including 31 cases of research group and 34 of control group .After the treatment of the end of the 4th week and 8th week ,there were no significant differences in the scores of PANSS between two groups . There was obvious change in two groups after the treatment I.n comparison with the research group ,the change was higher in control group in body weight and BMI(P<0 0.5) I.n comparison with the control group ,the body BMI was lower in research group(t=2 6.1 ,P<0 0.5) .Conclusion:Risperidone combined with aripiprazole can obviously reduce the effect of risperidone on body quality .%目的:对比利培酮与阿立哌唑合用及单用利培酮对精神分裂症患者体重及体重指数(BM I)的影响。方法:将符合入组标准的70例精神分裂症患者随机分为阿立哌唑合并利培酮组(合用阿立哌唑组)及单用利培酮组(单一利培酮组)。两组各入组35例,在基线及4周末、8周末,用阳性和阴性症状量表(PANSS)评定疗效,并进行体重及体重指数(BM I)的测定。结果:共完成65例,合用阿立哌唑组31例,单一利培酮组34例。治疗4周末及8周末,两组PANSS评分差异均无统计学意义;治疗后两组间有明显的变化,单一利培酮组体重及BMI值均增加明显(P<00.5);组间变化值的比较,合用阿立哌唑组BMI值均较单一利培酮组低(t=26

  16. 喹硫平与利培酮对女性精神分裂症患者血清泌乳素水平的影响%Effects of quetiapine and risperidone on serum prolactin levels of female schizophrenia

    Institute of Scientific and Technical Information of China (English)

    孙海华; 杨焕

    2013-01-01

    Objective To explore the effects of quetiapine and risperidone in the treatmemt of female schizophrenic patients and the effect of levels on serum prolactin. Methods 76 female schizophrenic patients were treated with quetiapine and risperidone randomly. The serum prolactin were measured and the scores of PANSS were evaluated before treatment and at the 1st、2nd、4th、8th week respectively. TESS was used to evaluate side effect. Results There were no significant differences in PANSS basal scores and the decreased scores after the treatment in two groups. The level of serum prolactin in risperidone group increased markedly than quetiapine group, and the serum prolactin level in quetiapine group were not increase significantly. Conclusion Quetiapine and risperidone have similar efficacy in the treatment of femal patients with schizophrenia. Risperidone produced increases in plasma prolactin levels in femal patients.%目的:评价喹硫平与利培酮对女性精神分裂症患者疗效和血清泌乳素水平的影响。方法选择女性精神分裂症患者76例,随机分为喹硫平与利培酮组治疗8周。采用阳性和阴性症状量表(PANSS)在治疗前及治疗第1周、2周、4周、8周末分别评定疗效,检测血清泌乳素水平,同时精神药物副反应量表(TESS)评定药物副反应。结果治疗前和治疗8周,两组在PANSS总分无显著差异。利培酮组血清泌乳素水平显著升高,并显著高于喹硫平组。喹硫平组血清泌乳素水平治疗前后无显著变化。结论喹硫平与利培酮对女性精神分裂症的疗效相似,利培酮对女性精神病患者的血清泌乳素水平有较大影响。

  17. Sustained release of risperidone from biodegradable microspheres prepared by in-situ suspension-evaporation process.

    Science.gov (United States)

    An, Taekun; Choi, Juhyuen; Kim, Aram; Lee, Jin Ho; Nam, Yoonjin; Park, Junsung; Sun, Bo kyung; Suh, Hearan; Kim, Cherng-ju; Hwang, Sung-Joo

    2016-04-30

    Risperidone-loaded poly (D,L-lactide-co-glycolide) (PLGA) microspheres were prepared with a suspension-evaporation process with an aqueous suspension containing an in situ-formed aluminum hydroxide inorganic gel (SEP-AL process) and evaluated for encapsulation efficiency, particle size, surface morphology, glass transition temperature, in vitro drug release profile, and in vivo behavior. The SEP-AL microspheres were compared with conventional oil-in-water (O/W) emulsion solvent evaporation method using polyvinylalcohol (PVA) as an emulsifier (CP-PVA process). The microspheres were spherical in shape. DSC measurements showed that risperidone crystallinity was greatly reduced due to the homogeneous distribution of risperidone in PLGA microspheres. In vitro drug release profile from the microspheres showed a sigmoidal pattern of negligible initial burst up to 24h and minimal release (time-lag) for 7 days. After the lag phase, slow release took a place up to 25 days and then rapid release occurred sharply for 1 week. In vivo rat pharmacokinetic profile from the microspheres showed very low blood concentration level at the initial phase (up to 24h) followed by the latent phase up to 21 days. At the 3rd week, main phase started and the blood concentration of the drug increased up to the 5th week, and then gradually decreased. The risperidone-loaded PLGA microspheres produced by SEP-AL process showed excellent controlled release characteristics for the effective treatment of schizophrenia patients.

  18. Potentiating effect of fluphenazine decanoate and risperidone on development of neuroleptic malignant syndrome.

    Science.gov (United States)

    Liu, Pang-Yen; Wu, Pei-Chuan; Chen, Chun-Yen; Chen, Yi-Chyan

    2011-01-01

    We present the case of a woman with paranoid schizophrenia who was receiving oral risperidone. She developed neuroleptic malignant syndrome (NMS) following the addition of depot fluphenazine for the treatment of refractory delusions. NMS subsided and psychotic features were controlled after both antipsychotics were discontinued and the patient was treated instead with olanzapine.

  19. Spontaneous seizures after ECT in a patient medicated with bupropion, sertraline and risperidone

    Directory of Open Access Journals (Sweden)

    Orlando von Doellinger

    Full Text Available Abstract Objective: To report a case of post-electroconvulsive therapy spontaneous seizures in a patient medicated with sertraline, bupropion and risperidone. Case description: A 53-year-old woman with recurrent major depression was admitted to our psychiatry department for a major depressive episode of 6 weeks' duration, with psychotic symptoms. She was already on 200 mg/day of sertraline and 2 mg/day of risperidone. After 8 weeks on 200 mg/day of sertraline, 4 mg/day of risperidone and slow release bupropion (titrated to 300 mg/day, with no objective improvements, the decision was taken to initiate a course of 8-10 electroconvulsive therapy (ECT sessions. Two days after the first treatment, three generalized tonic-clonic seizures occurred within 6 hours. Phenytoin and sodium valproate were added to the patient's daily medication and no further spontaneous seizures were observed. After neurologic assessment and discussion of the case, phenytoin and bupropion were withdrawn at once (two days after the spontaneous seizures and the decision was taken to resume the ECT treatment. No further spontaneous seizures occurred and, at discharge, the patient exhibited significant improvements and was free from major depressive symptoms. Comments: This report illustrates a case of post-ECT spontaneous seizures that might have been due to a specific pharmacological etiological pathway, namely, bupropion's proconvulsive properties, although both sertraline and risperidone also lower the convulsive threshold.

  20. Switching to quetiapine for risperidone-induced amenorrhea: Report of two cases

    Directory of Open Access Journals (Sweden)

    P K Pardal

    2010-01-01

    Full Text Available Almost all the antipsychotics can cause hyperprolactinemia-related side-effects like amenorrhea. Quetiapine has been reported to have minimal propensity to cause hyperprolactinemia. We report here two cases of risperidone-induced amenorrhea, who resumed their normal cycle on switching over the medication to quetiapine.

  1. Stability Indicating HPLC Determination of Risperidone in Bulk Drug and Pharmaceutical Formulations

    Directory of Open Access Journals (Sweden)

    Zarna R. Dedania

    2011-01-01

    Full Text Available The objective of the current study was to develop a validated stability-indicating assay method (SIAM for risperidone after subjecting it to forced decomposition under hydrolysis, oxidation, photolysis, and thermal stress conditions. The liquid chromatographic separation was achieved isocratically on a symmetry C18 column (5 μm size, 250 mm × 4.6 mm i.d. using a mobile phase containing methanol: acetonitrile (80 : 20, v/v at a flow rate of 1 mL/min and UV detection at 280 nm. Retention time of risperidone was found to be 3.35±0.01. The method was linear over the concentration range of 10–60 μg/mL(2=0.998 with a limit of detection and quantitation of 1.79 and 5.44 μg/mL, respectively. The method has the requisite accuracy, specificity, sensitivity, and precision to assay risperidone in bulk form and pharmaceutical dosage forms. Degradation products resulting from the stress studies did not interfere with the detection of Risperidone, and the assay is thus stability indicating.

  2. Clinical and pharmacokinetic evaluation of risperidone for the management of autism spectrum disorder

    NARCIS (Netherlands)

    Dinnissen, Mariken; Dietrich, Andrea; van den Hoofdakker, Barbara J.; Hoekstra, Pieter J.

    2015-01-01

    Introduction: Autism spectrum disorder (ASD) is a neurodevelopmental disorder that is often accompanied by psychiatric comorbidity. Although there is no medication currently available to treat the core symptoms of ASD, risperidone was the first drug to be approved for use in ASD and is still the bes

  3. Antipsychotic-induced extrapyramidal syndromes - Risperidone compared with low- and high-potency conventional antipsychotic drugs

    NARCIS (Netherlands)

    Schillevoort, [No Value; de Boer, A; Herings, RMC; Roos, RAC; Jansen, PAF; Leufkens, HGM

    2001-01-01

    Aim: To compare the risk of extrapyramidal syndromes (EPS) between patients using risperidone and those using low-potency conventional antipsychotic drugs (APDs) in outpatient clinical practice, as measured by the use of anticholinergic medication. We tried to replicate results from previous clinica

  4. Pregnancy exposure to olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations. A systematic review

    DEFF Research Database (Denmark)

    Ennis, Zandra Nymand; Damkier, Per

    2015-01-01

    To review available data on first-trimester exposure to olanzapine, quetiapine, risperidone and aripiprazole and risk of congenital malformations. We performed a systematic literature search in accordance with PRISMA guidelines identifying studies containing original data on first-trimester expos......To review available data on first-trimester exposure to olanzapine, quetiapine, risperidone and aripiprazole and risk of congenital malformations. We performed a systematic literature search in accordance with PRISMA guidelines identifying studies containing original data on first......-trimester exposure and pregnancy outcome with respect to congenital malformations. Cumulated data for olanzapine were 1090 first-trimester-exposed pregnancies with 38 malformations resulting in a malformation rate of 3.5%. The corresponding numbers for quetiapine, risperidone and aripiprazole were 443/16 (3.6%), 432....../22 (5.1%) and 100/5 (5.0%), respectively. Relative risk estimates and 95% confidence intervals were 1.0 (0.7-1.4) (olanzapine), 1.0 (0.6-1.7) (quetiapine), 1.5 (0.9-2.2) (risperidone) and 1.4 (0.5-3.1) (aripiprazole). First-trimester exposure to olanzapine is not associated with an increased risk...

  5. Risperidone treatment for ADHD in children and adolescents with bipolar disorder

    Directory of Open Access Journals (Sweden)

    Joseph Biederman

    2008-03-01

    Full Text Available Joseph Biederman, Paul Hammerness, Robert Doyle, Gagan Joshi, Megan Aleardi, Eric MickPediatric Psychopharmacology Research Department, Massachusetts General Hospital, Boston, MA, USAObjective: Children and adolescents with bipolar disorder are also at high risk of having comorbid attention-deficit hyperactivity disorder (ADHD. The objective of this study was to estimate improvement in ADHD symptoms in children with bipolar disorder.Methods: This was an open-label, study of risperidone monotherapy for the treatment of pediatric bipolar disorder. Thirty-one children and adolescents 4–15 years of age (7.2 ± 2.8 years of both sexes (71%, N = 22 male with pediatric bipolar disorder (YMRS score = 32.9 ± 8.8 and ADHD (ADHD-RS score = 37.9 ± 8.9 were included in these analyses.Results: Improvement in ADHD symptoms was contingent on improvement in manic symptoms. Although both hyperactive/impulsive (−7.5 ± 5.5.6, p < 0.05 and inattentive (−6.8 ± 5.0, p < 0.05 ADHD symptoms were significantly improved with risperidone, improvement was modest, and only 29% of subjects (N = 6 showed a 30% reduction in ADHD rating scale scores and had a CGI-I ≤ 2.Conclusions: These results suggest that that treatment with risperidone is associated with tangible but generally modest improvement of symptoms of ADHD in children with bipolar disorder.Keywords: ADHD, bipolar disorder, children, risperidone

  6. Neuropsychological effects of risperidone in children with pervasive developmental disorders: a blinded discontinuation study.

    NARCIS (Netherlands)

    Troost, P.W.; Althaus, M.; Lahuis, B.E.; Buitelaar, J.K.; Minderaa, R.B.; Hoekstra, P.J.

    2006-01-01

    OBJECTIVE: Little is known about the neuropsychological effects of risperidone in children with pervasive developmental disorders. METHOD: Twenty-four children (aged 5-17 years) with pervasive developmental disorders and co-morbid disruptive behavior who responded favorably to open-label treatment w

  7. Dietary Status and Impact of Risperidone on Nutritional Balance in Children with Autism: A Pilot Study

    Science.gov (United States)

    Lindsay, Ronald L.; Arnold, L. Eugene; Aman, Michael G.; Vitiello, Benedetto; Posey, David J.; McDougle, Christopher J.; Scahill, Lawrence; Pachler, Maryellen; McCracken, James T.; Tierney, Elaine; Bozzolo, Dawn

    2006-01-01

    Background: Risperidone may be effective in improving tantrums, aggression, or self-injurious behaviour in children with autism, but often leads to weight gain. Method: Using a quantitative Food Frequency Questionnaire (FFQ), we prospectively examined the nutritional intake of 20 children with autism participating in a randomised…

  8. Tic Reduction with Risperidone Versus Pimozide in a Randomized, Double-Blind, Crossover Trial

    Science.gov (United States)

    Gilbert, Donald L.; Batterson, J. Robert; Sethuraman, Gopalan; Sallee, Floyd R.

    2004-01-01

    Objective: To compare the tic suppression, electrocardiogram (ECG) changes, weight gain, and side effect profiles of pimozide versus risperidone in children and adolescents with tic disorders. Method: This was a randomized, double-blind, crossover (evaluable patient analysis) study. Nineteen children aged 7 to 17 years with Tourette's or chronic…

  9. 利培酮联合帕罗西汀治疗慢性精神分裂症阴性症状%Paroxetine combined risperidone in the treatment of negative symptoms of chronic schizophrenia patients

    Institute of Scientific and Technical Information of China (English)

    王永萍; 尤加永; 赵长银

    2012-01-01

    目的:探讨利培酮联合帕罗西汀治疗慢性精神分裂症阴性症状的临床疗效以及安全性.方法:将126例以阴性症状为主的慢性精神分裂症住院患者随机分为研究组(利培酮联合帕罗西汀治疗)和对照组(单用利培酮治疗),疗程12周,采用阳性和阴性症状量表(PANSS)和治疗中出现的症状量表(TESS)评定疗效和安全性. 结果:治疗后两组PANSS评分均较治疗前有显著降低(P<0.05).治疗后4、8、12周末,研究组阴性因子分及情感迟钝、情感退缩、情感交流障碍及社会退缩因子分均显著低于对照组,差异具有统计学意义(P<0.05或P<0.01).两组不良反应均为轻至中度. 结论:利培酮联合帕罗西汀较单用利培酮治疗慢性精神分裂症阴性症状具有起效更快、疗效更好、依从性好的特点.%Objective:To evaluate clinical efficacy and safety of paroxetine combined risperidone in the treatment of negative symptoms of chronic schizophrenia patients. Method; 126 patients with predominantly negative symptoms of chronic schizophrenia were randomly divided into study group (paroxetine combined risperidone) and the control group (risperidone alone) with 12 weeks'treatment. PANSS and TESS were used to assess the efficacy and safety respectively. Results: compared with before treatment, PANSS scores decreased significantly after treatment (P < 0.05). The scores on blunted affect,emotional withdrawal, poor rapport and passive/apathetic social withdrawal were lower in the study group than in the control group at week 4,8 and 12, the score difference was statistically significant (P < 0.05 or P < 0.01). The adverse events of two groups were mild or moderate. Conclusion; Paroxetine combined risperidone in the treatment of chronic schizophrenia with negative symptoms showed rapid response, better efficacy and good patient compliance.

  10. Anesthetic efficacy of X-tip intraosseous injection using 2% lidocaine with 1:80,000 epinephrine in patients with irreversible pulpitis after inferior alveolar nerve block: A clinical study

    Directory of Open Access Journals (Sweden)

    Pushpendra Kumar Verma

    2013-01-01

    Full Text Available Introduction: The inferior alveolar nerve block (IAN is the most frequently used mandibular injection technique for achieving local anesthesia in endodontics. Supplemental injections are essential to overcome failure of IAN block in patients with irreversible pulpitis. Aim: To evaluate the anesthetic efficacy of X-tip intraosseous injection (2% lidocaine with 1:80,000 epinephrine in patients with irreversible pulpitis in mandibular posterior teeth when conventional IAN block failed. Materials and Methods: Thirty emergency patients diagnosed with irreversible pulpitis in a mandibular posterior tooth received an IAN block and experienced moderate to severe pain on endodontic access or initial instrumentation. The X-tip system was used to administer 1.8 ml of 2% lidocaine with 1:80,000 epinephrine. The success of X-tip intraosseous injection was defined as none or mild pain (Heft-Parker visual analogue scale ratings < 54 mm on endodontic access or initial instrumentation. Results: Ninety-three percent of X-tip injections were successful and 7% were unsuccessful. Discomfort rating for X-tip perforation: 96.66% patients reported none or mild pain, whereas 3.34% reported moderate to severe pain. For discomfort rating during solution deposition, 74.99% patients reported none or mild pain and 24.92% reported moderate to severe pain. Ninety-six percent of the patients had subjective/objective increase in heart rate. Conclusions: Supplemental X-tip intraosseous injection using 2% lignocaine with 1:80,000 epinephrine has a statistically significant influence in achieving pulpal anesthesia in patients with irreversible pulpitis.

  11. Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro.

    Science.gov (United States)

    Kato, Takahiro; Monji, Akira; Hashioka, Sadayuki; Kanba, Shigenobu

    2007-05-01

    Microglia has recently been regarded to be a mediator of neuroinflammation via the release of proinflammatory cytokines, nitric oxide (NO) and reactive oxygen species (ROS) in the central nervous system (CNS). Microglia has thus been reported to play an important role in the pathology of neurodegenerative disease, such as Alzheimer's disease (AD) and Parkinson's disease (PD). The pathological mechanisms of schizophrenia remain unclear while some recent neuroimaging studies suggest even schizophrenia may be a kind of neurodegenerative disease. Risperidone has been reported to decrease the reduction of MRI volume during the clinical course of schizophrenia. Many recent studies have demonstrated that immunological mechanisms via such as interferon (IFN)-gamma and cytokines might be relevant to the pathophysiology of schizophrenia. In the present study, we thus investigated the effects of risperidone on the generation of nitric oxide, inducible NO synthase (iNOS) expression and inflammatory cytokines: interleukin (IL)-1beta, IL-6 and tumor necrosis factor (TNF)-alpha by IFN-gamma-activated microglia by using Griess assay, Western blotting and ELISA, respectively. In comparison with haloperidol, risperidone significantly inhibited the production of NO and proinflammatory cytokines by activated microglia. The iNOS levels of risperidone-treated cells were much lower than those of the haloperidol-treated cells. Antipsychotics, especially risperidone may have an anti-inflammatory effect via the inhibition of microglial activation, which is not only directly toxic to neurons but also has an inhibitory effect on neurogenesis and oligodendrogenesis, both of which have been reported to play a crucial role in the pathology of schizophrenia.

  12. A comparison of the oral application and injection routes using the Onderstepoort Biological Products Fowl Typhoid vaccine, its safety, efficacy and duration of protection in commercial laying hens : article

    Directory of Open Access Journals (Sweden)

    C. Purchase

    2008-05-01

    Full Text Available This study was undertaken to establish whether the Onderstepoort Biological Products Fowl Typhoid (OBPft vaccine registered as an injectable vaccine was effective and safe when administered orally to commercial layers. Its efficacy and duration of protection were compared with application by intramuscular injection. Commercial brown layer hens were used as they were found to be highly susceptible to Salmonella gallinarum infections. In the vaccine safety trial birds were euthanased at timed intervals spanning 4 weeks post-vaccination. Necropsies were performed and samples were taken and tested. No clinical signs or mortalities could be attributed to the OBPft vaccine nor could active shedding of the vaccine strain be detected. Slight pathological changes were noted with both routes of vaccination; however, these changes were transient, returning to normal within the observation period. The injected groups showed a better serological response with the rapid serum plate agglutination (RSPA test than the orally vaccinated groups. In the duration of protection trial, birds were challenged at 3-8-week intervals post-vaccination. All unvaccinated birds died. Protection 8 and 16 weeks after vaccination was above 60 %, by 24 weeks after challenge, the vaccine protection was below 30 %. It was found that there was no significant difference (P < 0.05 in the protection offered by either the oral or injected route of vaccination with the OBPft vaccine.

  13. Botulinum toxin A injection for facial analysis the clinical efficacy and safety of facial wrinkles%A型肉毒毒素面部除皱的临床观察

    Institute of Scientific and Technical Information of China (English)

    王忠志; 刘茜

    2014-01-01

    目的:了解A型肉毒毒素面部注射进行面部除皱的临床疗效及安全性。方法回顾性分析我院2012年3月至2014年3月收治的64例行面部除皱的患者的临床资料,均应用A型肉毒毒素进行面部注射治疗,分析其临床疗效与安全性。结果64例患者经由A型肉毒毒素面部注射治疗后,所取得的效果较为理想,仅1例鼻部除皱术疗效欠佳。结论 A型肉毒毒素面部注射进行面部除皱临床疗效确切,不良反应少,值得临床大力推广与应用。%Objective: To investigate the botulinum toxin type A injection for facial clinical efficacy and safety of facial wrinkles. Methods: retrospective analysis of clinical data in our hospital from 2012 March to 2014 March treated 64 cases of facial wrinkles patients, both the application of botulinum toxin type A injection in the treatment of facial, analyze its clinical efficacy and safety. Results: 64 patients with botulinum toxin A injection for facial treatment, the effect is more ideal, only 1 cases of nasal rhytidectomy curative effect. Conclusion: botulinum toxin A injection for facial facial rhytidectomy clinical curative effect, less adverse reaction, it is worthy of clinical popularization and application.

  14. Xuesaitong injection point injection of spastic limb spasticity after stroke improved clinical efficacy%血塞通注射液痉挛点注射治疗脑卒中后肢体痉挛22例临床观察

    Institute of Scientific and Technical Information of China (English)

    蒋再轶; 韩国栋; 冯建宏

    2011-01-01

    Objective Xuesaitong injection point injection for spasticity after stroke improved clinical efficacy of limb spasticity. Methods 51 patients were randomly divided into A, B group and C group, A group given Xuesaitong injection injection combined hemiplegic limb rehabilitation, B group was given acupuncture treatment acupuncture and rehabilitation of hemiplegic limb, C group only to be hemiplegic limb rehabilitation treatment, 4 weeks for a course of treatment, were treated with a course of treatment, in the treatment of 2 weeks, 4 weeks to Ashworth spasticity scale for efficacy evaluation. Results Three groups of patients with limb spasticity were improved, A group and the other two groups, the difference was statistically significant (P <0.05), for improving the physical state of spasm, spasm Xuesaitong injection point injection group was better than the other two group. Conclusion Xuesaitong injection point injection combined spastic hemiplegic limb rehabilitation after stroke can improve limb spasticity.%目的:观察血塞通注射液痉挛点注射对改善脑卒中后肢体痉挛状态的临床疗效.方法:将51例患者随机分为A组、B组与C组,A组给予血塞通注射液痉挛点注射联合偏瘫肢体康复治疗,B组给予穴位针刺联合偏瘫肢体康复治疗,C组只予以偏瘫肢体康复治疗.3组均以4周为1个疗程,共治疗1个疗程,在治疗2周、4周末以Ashworth痉挛量表进行疗效评价.结果:3组患者患肢痉挛状态均有改善,A组与其他两组疗效比较,差异有统计学意义(P<0.05),优于B、C组.结论:血塞通注射液痉挛点注射,联合偏瘫肢体康复治疗能够改善脑卒中后肢体痉挛状态.

  15. Efficacy of a Multi-level Intervention to Reduce Injecting and Sexual Risk Behaviors among HIV-Infected People Who Inject Drugs in Vietnam: A Four-Arm Randomized Controlled Trial.

    Directory of Open Access Journals (Sweden)

    Vivian F Go

    Full Text Available Injecting drug use is a primary driver of HIV epidemics in many countries. People who inject drugs (PWID and are HIV infected are often doubly stigmatized and many encounter difficulties reducing risk behaviors. Prevention interventions for HIV-infected PWID that provide enhanced support at the individual, family, and community level to facilitate risk-reduction are needed.455 HIV-infected PWID and 355 of their HIV negative injecting network members living in 32 sub-districts in Thai Nguyen Province were enrolled. We conducted a two-stage randomization: First, sub-districts were randomized to either a community video screening and house-to-house visits or standard of care educational pamphlets. Second, within each sub-district, participants were randomized to receive either enhanced individual level post-test counseling and group support sessions or standard of care HIV testing and counseling. This resulted in four arms: 1 standard of care; 2 community level intervention; 3 individual level intervention; and 4 community plus individual intervention. Follow-up was conducted at 6, 12, 18, and 24 months. Primary outcomes were self-reported HIV injecting and sexual risk behaviors. Secondary outcomes included HIV incidence among HIV negative network members.Fewer participants reported sharing injecting equipment and unprotected sex from baseline to 24 months in all arms (77% to 4% and 24% to 5% respectively. There were no significant differences at the 24-month visit among the 4 arms (Wald = 3.40 (3 df; p = 0.33; Wald = 6.73 (3 df; p = 0.08. There were a total of 4 HIV seroconversions over 24 months with no significant difference between intervention and control arms.Understanding the mechanisms through which all arms, particularly the control arm, demonstrated both low risk behaviors and low HIV incidence has important implications for policy and prevention programming.ClinicalTrials.gov NCT01689545.

  16. Atypical antipsychotics olanzapine, quetiapine, and risperidone and risk of acute major cardiovascular events in young and middle-aged adults

    DEFF Research Database (Denmark)

    Pasternak, Björn; Svanström, Henrik; Ranthe, Mattis F

    2014-01-01

    risperidone (n = 14,134). The primary outcome was any major cardiovascular event (composite of cardiovascular mortality, acute coronary syndrome, or ischemic stroke) within 1 year following treatment initiation. Cox regression was used to estimate hazard ratios (HRs) while on current antipsychotic monotherapy...... in the outpatient setting, adjusting for an outcome-specific disease risk score. RESULTS: The crude rate of any major cardiovascular event was 5.3 per 1,000 person-years among olanzapine users, 3.4 in quetiapine users, and 5.2 in risperidone users. Compared with risperidone, the risk of any major cardiovascular.......9 to 2.0) events for quetiapine. CONCLUSIONS: Among young and middle-aged outpatients, the risk of acute major cardiovascular events was similar with use of olanzapine, quetiapine, and risperidone. Although moderate relative differences cannot be ruled out, any differences are small in absolute terms....

  17. 齐拉西酮与利培酮治疗女性精神分裂症的对照研究%A comparative study of Ziprasidone and Risperidone in the treatment of female patients with schizophrenia

    Institute of Scientific and Technical Information of China (English)

    张桂华; 赵祖安; 李淑香; 丁琳; 白玉红

    2011-01-01

    目的:比较齐拉西酮与利培酮治疗女性精神分裂症的疗效及安全性.方法:将72例女性精神分裂症患者随机分为齐拉两酮组[(131.6±10.3)mg/d]36例,利培酮组[(5.9±1.3)mg/d]36例,疗程均为12周,采用阳性及阴性症状量表(PANSS),治疗中需处理的不良反应症状量表(TESS),在治疗前及治疗第2、4、8、12周末分别评定疗效和不良反应.结果:治疗第2周末开始,两组PANSS评分较入组时均显著降低,差异有统计学意义(P0.05).不良反应的发生率齐拉西酮组为47.2%(17/36)、利培酮组为52.8%(19/36),两组比较,差异无统计学意义(P>0.05).但齐拉西酮组锥体外系反应、体重增加、血脂增高、高泌乳素的发生率明显低于利培酮组,差异有统计学意义(P<0.05).结论:齐拉西酮治疗女性精神分裂症疗效好,不良反应轻微.%Objective: To compare the efficacy and safety of Ziprasidone and Risperidone in the treatment of female patients with schizophrenia.Methods: A total of 72 female patients were randomly assigned to Ziprasidone group (n=36) and Risperidone group (n=36), and received Ziprasidone (131.6±10.3) mg/d and Risperidone (5.9±1.3) mg/d treatment for 12 weeks respectively.The efficacy and adverse reaction were assessed with the Positive and Negative Syndrome Sale (PANSS), the Treatment Emergency Syndrome Scale (TESS) after the tveatment of 2,4, 8, 12 week.Results: The PANSS scores significantly decreased compared with the baseline sores in both groups since the second week (P<0.05); the marked improvement rate was 50.0% and the total clinical effective rate was 77.8% in Ziprasidone group while 47.3% and 75.0% in Risperidone group, there were not significant differences between two groups (P>0.05).There were similar rates of side effects between both groups (P>0.05), Ziprasidone group was 47.2% (17/36) and Risperidone group was 52.8% (19/36) (P>0.05).But the incidence of extrapyramidal symptoms, weight

  18. Cost-effectiveness analysis of Risperidone and Aripiprazole in the treat-ment of outpatients with schizophrenia%利培酮、阿立哌唑治疗门诊精神分裂症患者成本-效果分析

    Institute of Scientific and Technical Information of China (English)

    吴宇杰; 李君; 杜鹏; 饶顺曾; 吴彦

    2015-01-01

    Objective To compare therapeutic cost-effects and safety between Risperidone and Aripiprazole in treatment of outpatients with schizophrenia. Methods The schizophrenia patients, who were going on treating with Risperidone or Aripiprazole at discharge, were followed-up 1 year in outpatient. While economic cost-effectiveness and adverse reaction were observed and analyzed. Results Comparing the efficacy between the two groups, it was better in Risperidone group than Aripiprazole group, but there was no statistically significant difference (字2= 0.804, P= 0.84). Drug costs in the Risperidone group was slightly lower than the Aripiprazole group, but there was no statistically significant difference (t = 0.39, P=0.69). The cost-effectiveness of Risperidone was better than Aripiprazole (62.41 v s 64.40). The incidence of high prolactin was up to 26.19% (11/42) in Risperidone group, while in Aripiprazole group had no high prolactin occurring. Conclusion The expenses and efficacy are considerably between Risperidone and Aripiprazole, but the adverse reaction of high prolactin often appears in Risperidone treatment, must be cause caution, for young female patients chosen Risperidone is better.%目的:比较单用利培酮或阿立哌唑治疗门诊精神分裂症患者的经济效果及安全性。方法对出院时使用利培酮治疗方案或阿立哌唑治疗方案的精神分裂症患者门诊随访1年,运用经济学成本-效果分析比较两组优劣,观察治疗不良反应。结果两组在疗效方面比较,利培酮组较阿立哌唑组差,但差异无统计学意义(字2=0.804,P=0.84);利培酮组药物费用略低于阿立哌唑组,但差异无统计学意义(t=0.39,P=0.69);成本-效果方面利培酮组优于阿立哌唑组(62.41比64.40);利培酮组高泌乳素发生率高达26.19%(11/42),而阿立哌唑无高泌乳素发生。结论使用利培酮及阿立哌唑费用及疗效相当,而利培酮引起的高泌乳素副作用发生率较高,

  19. A case of resistant schizophrenia responding at a higher than recommended dose of risperidone without significant side effects

    Directory of Open Access Journals (Sweden)

    Anirban Ray

    2013-01-01

    Full Text Available A patient, diagnosed with schizophrenia, non-responsive to two atypical antipsychotics and partially responsive to the third (risperidone in therapeutic dose, ultimately showed complete response without any unacceptable side-effect in a dose (20mg that was untried previously. This case makes an important observation that high dose of risperidone can be tried in a patient with good results if his clinical condition permits.

  20. Efficacy of risperidone, olanzapine and clozapine in the treatment of therapy resistant schizophrenia

    NARCIS (Netherlands)

    Wardenier, M; Slooff, CJ; Arends, J

    2000-01-01

    Therapy-resistance for positive symptoms is one of the most important problems that occurs with the medical treatment of schizophrenia. In the past years, clozapine has proven its effectiveness in this area and has been included in the treatment protocols and guidelines, Because of the risk of agran

  1. Efficacy of risperidone treatment in Smith-Magenis syndrome (del 17 pll. 2).

    Science.gov (United States)

    Niederhofer, Helmut

    2007-09-01

    Smith-Magenis syndrome (SMS) is a clinically recognizable multiple congenital anomaly and mental retardation syndrome caused by an interstitial deletion of chromosome 17 pll.2. Although the physical and molecular genetic features of SMS are increasingly well understood, work is more limited on SMS's behavioral phenotype, which includes self-injury, tantrums, aggression, attention deficit, and sleep disturbance. This case-report describes the lowering of the aggression level of a 13 year old individual with SMS.

  2. 东菱克栓酶联合银杏达莫注射液治疗突发性耳聋疗效观察%Batroxobin injection combined Ginkgo biloba extract and dipyridamole injection efficacy of treatment of sudden deafness

    Institute of Scientific and Technical Information of China (English)

    朱韵

    2012-01-01

    Objective Summary Batroxobin injection combined Cinkgo biloba extract and dipyridamole injection efficacy of treatment of sudden deafness,Treatment of sudden deafness of effective drug. Method Selected 108 cases (120 ears) in patients with sudden deafness diagnosis, Randomly divided into treatment and control groups, The treatment for 2 weeks. Result Treatment group was 85% .Control group was 66% ,Two groups was highly significant difference ( P <0.05) ,No serious adverse reactions and complications. Conclusion Batroxobin injection combined Ginkgo biloba extract and dipyridamole injection assisted treatment of sudden deafness results were satisfactory.%目的 总结东菱克栓酶联合银杏达莫注射液治疗突发性耳聋的疗效,探讨治疗突发性耳聋的有效药物.方法 选择108例(120耳)突发性耳聋明确诊断患者,随机分成治疗组和对照组,两组疗程均为2周.结果 治疗组有效率85%,对照组有效率66%,两组比较有极显著性差异(P<0.05),未见严重的不良反应和并发症.结论 银杏达莫辅助治疗突发性耳聋疗效满意.

  3. Evaluations of therapeutic efficacy of intravitreal injected polylactic-glycolic acid microspheres loaded with triamcinolone acetonide on a rabbit model of uveitis.

    Science.gov (United States)

    Li, Wenchang; He, Bing; Dai, Wenbing; Zhang, Qiang; Liu, Yuling

    2014-06-01

    Conventional treatments of uveitis are not ideal because of the short period of therapeutic efficacy. In the present study, biodegradable polylactic-glycolic acid microspheres loaded with triamcinolone acetonide (TA) were prepared to achieve sustained drug release and their therapeutic efficacy was investigated on a rabbit model of uveitis. TA-loaded microspheres (TA-MS) were prepared by the solvent evaporation method and characterized for encapsulation efficiency, particle size, morphology and in vitro release. The therapeutic efficacy was studied on the rabbit experimental uveitis model based on scoring of the inflammation, aqueous leukocyte counting, aqueous protein determination and histological examination. The TA-MS exhibited smooth and intact surfaces with an average diameter of 50.87 μm. The drug-loading coefficient and encapsulation efficiency were 15.2 ± 0.6 % and 91.24 ± 3.77 %, respectively. The drug release from TA-MS lasted up to 87 days, but only 46 days for TA suspension. The change in surface morphology also showed sustained drug release from TA-MS. TA-MS exhibited improved therapeutic efficacy in lipopolysaccharide -induced uveitis compared to TA suspension, especially in regard to the inhibition of inflammation. The TA-MS had a longer-term therapeutic effect on intraocular inflammation in LPS-induced uveitis in rabbits compared to TA suspension. The results suggested that TA-MS can be developed as a potential sustained-release system for the treatment of uveitis.

  4. Motherwort Injection Associate with Oxytocin Prevention and Treatment of Postpartum Hemorrhage Efficacy%益母草注射液与催产素联用防治产后出血的疗效观察

    Institute of Scientific and Technical Information of China (English)

    刘淑芳

    2013-01-01

    Objective:The contrast observed motherwort injection and oxytocin in combination in the prevention of postpartum hemorrhage clinical efficacy. Method:We randomly selected 180 cases of pregnant women giving birth in our hospital September 2009 to September 2012 conducted a case-control study,all patients randomized divided into the control group and the test group.control group after delivery of the fetus 20 U injection oxytocin Suji;joint injection motherwort injection 2 ml of test group on the basis of the control group;compare the number of record the two groups of patients 2 and 24 hours post-partum bleeding,to assess of motherwort injection of oxytocin joint applications clinical efficacy. Result:motherwort injection combined with oxytocin treatment group 2 hours postpartum hemorrhage(164.3 ± 30.2)ml significantly less than a single injection of oxytocin group( 254.1±29.3) ml;cases of postpartum hemorrhage(3/3.3%)was significantly less than the control group(9/10);significant difference between the two sets of data,a statistically significant(P0.05). Conclusion:Postpartum joint the intramuscular injection Motherwort injection and oxytocin to effective prevention of maternal postpartum hemorrhage.%  目的:对比观察益母草注射液与催产素联合应用在预防产后出血中的临床疗效.方法:随机选取于本院分娩的孕妇的180例2009年9月-2012年9月进行病例对照研究,将所有患者随机分为对照组和试验组.对照组在胎儿分娩后给予20 U 催产素肌内注射;试验组在对照组的基础上联合注射益母草注射液2 ml;记录两组患者产后2 h 和24 h 的出血数量,进行比较,评定益母草注射液与催产素联合应用的临床疗效.结果:益母草注射液联合催产素治疗组2 h 的产后出血量(164.3±30.2)ml 明显少于单独注射催产素组(254.1±29.3)ml;产后出血的例数(3/3.3%)明显少于对照组(9/10%),差异均有统计学意义(P0.05).结论:产后联

  5. Pentamidine Injection

    Science.gov (United States)

    Pentamidine injection is used to treat pneumonia caused by a fungus called Pneumocystis carinii. It is in ... Pentamidine injection comes as powder to be mixed with liquid to be injected intramuscularly (into a muscle) ...

  6. 利培酮联合舍曲林治疗精神分裂症阴性症状临床研究%Combination of Risperidone and Sertraline in Negative Symptoms of Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    江永

    2013-01-01

    Objective:To explore the efficacies and safety of combination of risperidone and sertraline in negative symptoms of schizo -phrenia.Methods:60 schizophrenics were randomly divided into treatment (n=30,took risperidone combined with sertraline ) and control group (n=30,took risperidone ) dose of risperidone was 2~6mg/d and that of sertraline 100~200mg/d for 8 weeks.Before and after treatment , efficacies and side effects were assessed using the Negative Syndrome Scale ( NSS) and the Treatment Emergent Symptom Scale ( TESS) .Results:After treatment total score and factors , score of the NSS of both 2 groups obviously reduced and differences were signifi-cant (P<0.05).compared with the control group the total score of the NSS and factors',score of apathy poverty of thought abulia and in-terest blank obviously reduced in the treatment group and differences were significant (P<0.05).there was no difference in side effects between the 2 groups.Conclusion:combination of risperidone and sertraline is better than single risperidone in the treatment of negative symptoms of schizophrenia .%目的:探讨利培酮联合舍曲林治疗精神分裂症阴性症状的临床疗效和安全性。方法:将60例精神分裂症患者随机分为治疗组(利培酮+舍曲林)和对照组(利培酮)各30例,利培酮治疗剂量2~6mg/d,舍曲林50mg~200mg/d,疗程8周,治疗后采用阴性症状量表和副反应量表[1]评定临床疗效与不良反应。结果:2组治疗后阴性症状量表总分和因子分均显著下降,差异有统计学意义(P<0.05),治疗组阴性症状量表总分、情感平淡、思维贫乏、意志缺乏、兴趣缺乏等因子分较对照组下降明显,差异有统计学意义(P<0.05)。不良反应2组无显著性差异(P>0.05)。结论:利培酮联合舍曲林治疗精神分裂症阴性症状疗效优于单用利培酮治疗。

  7. 哌罗匹隆与利培酮治疗首发精神分裂症对照研究%A control study of perospi rone vs .risperidone in the treatment of first-episode schizophrenia

    Institute of Scientific and Technical Information of China (English)

    杨冬冰; 马元业; 王军

    2014-01-01

    目的:探讨哌罗匹隆与利培酮治疗首发精神分裂症患者的临床疗效和安全性。方法将70例首发精神分裂症患者随机分为两组,分别口服哌罗匹隆和利培酮治疗,观察8周。采用阳性与阴性症状量表评定临床疗效,副反应量表评定不良反应。结果治疗8周末,哌罗匹隆组总有效率87.9%,利培酮组为85.3%,两组比较差异无显著性(χ2=0.10,P>0.05)。哌罗匹隆组不良反应发生率为60.0%,利培酮组为62.9%,两组比较差异无显著性(χ2=0.06,P>0.05),但哌罗匹隆组内分泌改变及体质量增加发生率显著低于利培酮组(χ2=5.08、5.08,P<0.05)。结论哌罗匹隆与利培酮治疗首发精神分裂症疗效显著,安全性高,依从性好,但哌罗匹隆较少引起内分泌改变和体质量增加,尤其适用于女性首发精神分裂症患者。%Objective To explore the efficacy and safety of perospirone and risperidone in first-episode schizophrenia (FES) .Methods Seventy FES patients were randomly divided into two groups ,they took orally perospirone and risperidone respectively for 8 weeks .Clinical efficacies were assessed with the Posi-tive and Negative Syndrome Scale (PANSS) and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results At the end of the 8th week total effective rate was respectively 87 .9% in perospi-rone and 85 .3% in risperidone group ,which showed no significant difference (χ2 =0 .10 ,P>0 .05) .Inci-dences of adverse reactions were 60 .0% in perospirone and 62 .9% in risperidone group ,which showed no significant difference (χ2 =0 .06 ,P>0 .05) ,but those of endocrine alteration and weight gain were signifi-cantly lower in perospirone than risperidone group (χ2 =5 .08 ,5 .08 ;P<0 .05) .Conclusion Perospirone has an evident effect equivalent to risperidone ,higher safety and better compliance in FES ,but the former causes

  8. Treatment of radiculopathies: a study of efficacy and tollerability of paravertebral oxygen-ozone injections compared with pharmacological anti-inflammatory treatment.

    Science.gov (United States)

    Melchionda, D; Milillo, P; Manente, G; Stoppino, L; Macarini, L

    2012-01-01

    The study was performed to evaluate the effectiveness of lumbar paravertebral injections of a gas mixture of Oxygen and Ozone in patients with lumbar radiculopathies caused by L4-L5 or L5-S1 disk herniations compared to a pharmacological therapy based on non-steroidal anti-inflammatory drugs. Lumbar radiculopathy caused by disc herniation is widely spread. Many therapeutic options are available before steering patients to the surgery. Low back pain and sciatica represent some of the most frequent causes of antinflammatory-analgesic drugs overuse. Recent findings have shown that medical Ozone can be used in the treatment of radicular syndrome caused by herniated intervertebral discs. Although widely spread, there are insufficient published data supporting the effectiveness of this approach in clinical practice. We studied 38 affected patients with acute L5 or S1 radicolopathy. The patients were randomly divided in two groups: A) 20 patients treated with lumbar paravertebral injections of Oxygen and Ozone; B) 18 patients treated pharmacologically with antinflammatory-analgesic drugs. All patients underwent a clinical and neurological examination at baseline (T1) and after 1 (T2), 2 (T3), 4 weeks (T4) and after 3 (T5) and 6 months (T6). An MRI and EMG examination were performed at baseline and after 6 months. The intensity of pain and the outcome of treatments were evaluated in all patients with the Visual Analogue Scale and with the Oswestry Disability Index. We found a reduction of pain and discomfort soon after one week with oxygen-ozone injections compared with pharmacological treatment, but this difference of response became statistically significant after two weeks (50 percent vs 16.6 percent) and is confirmed after 3 and 6 months, when 80 percent of patients treated with injections turned out pain free compared with half of the patients treated pharmacologically. No statistical difference were found in MRI and EMG examinations. No adverse effects were found in

  9. 氨磺必利与利培酮治疗首发精神分裂症的疗效对照研究%Amisulpride and Risperidone Treatment First-episode Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    李婕

    2014-01-01

    Objective To analysis efficacy of amisulpride and risperidone treatment first -episode schizophrenia.Methods 74 patients with first -episode schizo-phrenia were given Amisulpride and risperidone therapy,BPRS score,adverse reaction were compared.Result BPRS rating scale values were significantly reduced,be-tween groups was no significant difference;observation group adverse reactions(18.92%) was obviously lower than the control group.Conclusion Amisulpride and risper-idone can be effective in the treatment of first-episode schizophrenia,Amisulpride low adverse reaction,good safety.%目的:分析氨磺必利与利培酮治疗首发精神分裂症的疗效差异。方法选择74例首发精神分裂症患者为研究对象,分别给予氨磺必利及利培酮治疗,比较BPRS量表评分、不良反应发生率。结果观察组与对照组BPRS量表评分值均明显降低,组间比较无明显差异(P>0.05);观察组不良反应发生率(18.92%)明显低于对照组(P<0.05)。结论氨磺必利与利培酮均可有效治疗首发精神分裂症,氨磺必利不良反应较少,具有优良的治疗安全性。

  10. Risperidone-induced priapism in an autistic child: a case report

    OpenAIRE

    Aabbassi, Bouchra; Benali, Abdeslam; Asri, Fatima

    2016-01-01

    Background Priapism is a prolonged stimulation with painful, persistent penile erection unaccompanied by sexual desire. It is a rare but serious urological emergency. Risperidone is an atypical antipsychotic widely prescribed for the treatment of behavior problems in children with autism spectrum disorder. It seems associated with priapism in children. Case presentation We present a case of a 12-year-old Moroccan boy diagnosed with autism spectrum disorder who developed priapism while on an e...

  11. Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients.

    Science.gov (United States)

    Ruaño, G; Goethe, J W; Caley, C; Woolley, S; Holford, T R; Kocherla, M; Windemuth, A; de Leon, J

    2007-05-01

    Atypical antipsychotics induce pre-diabetic symptoms in some but not all patients, characterized most notably by elevated weight. The side effect profiles of the various drugs in the class differ, however, raising the possibility of drug-specific mechanisms for similar side effects. We used physiogenomic analysis, an approach previously employed to study the genetics of drug and diet response, to discover and compare genetic associations with weight profiles observed in patients treated with olanzapine and risperidone as an approach to unraveling contrasting mechanistic features of both drugs. A total of 29 single nucleotide polymorphisms (SNPs) were selected from 13 candidate genes relevant to two potential pharmacological axes of psychotropic-related weight profiles, appetite peptides and peripheral lipid homeostasis. We applied physiogenomic analysis to a cross-section of 67 and 101 patients being treated with olanzapine and risperidone, respectively, and assessed genetic associations with the weight profiles. Weight profiles in patients treated with olanzapine were significantly associated with SNPs in the genes for apolipoprotein E, apolipoprotein A4 and scavenger receptor class B, member 1. Weight profiles in patients treated with risperidone were significantly associated with SNPs in the genes for leptin receptor, neuropeptide Y receptor Y5 and paraoxonase 1. These results are consistent with contrasting mechanisms for the weight profile of patients treated with these drugs. Genes associated with olanzapine weight profiles may be related to peripheral lipid homeostatic axes, whereas those associated with risperidone's may be related to brain appetite peptide regulation. Future physiogenomic studies will include neurotransmitter receptor SNPs and validation in independent samples.

  12. Development of novel risperidone implants using blends of polycaprolactones and in vitro in vivo correlation studies.

    Science.gov (United States)

    Navitha, Aerrolla; Jogala, Satheesh; Krishnamohan, Chinnala; Aukunuru, Jithan

    2014-04-01

    The objective of this study was to develop a novel implant containing risperidone intended for long-term treatment in Schizophrenia utilizing in vitro in vivo correlation (IVIVC) studies. Different implants (F1-F8) containing an antipsychotic drug, risperidone, were prepared using a hot melt extrusion technique by taking polycaprolactones of different molecular weights (Mwt. 15000, 45000, 80000) either alone or as their blends, and PLGA (75:25). The implants contained 40% of the drug. After fabrication, the implants were characterized for various in vitro properties such as drug release and physical strength. Prior to conducting drug release studies, optimum drug release method was developed based on IVIVC studies. An optimized formulation based on drug release and physical strength at the end of fabrication was selected from the various implants fabricated. The bioactivity, reversibility, and IVIVC of optimized formulation were determined using pharmacokinetic studies in rats. Short-term stability studies were conducted with optimized formulation. Drug release depended on polymer molecular weight. Implant fabricated using 50:50 polycaprolactone 45,000 and polycaprolactone 80,000 was considered optimized implant. Optimized formulation selected released the drug for 3-months in vitro and was physically rigid. The optimized implant was able to release the drug in vivo for a period of 3 months, the implants are reversible throughout the delivery interval and, a 100% IVIVC was achieved with optimized implant, suggesting the development of 3-month drug-releasing implant for risperidone. The optimized implant was stable for 6 months at room temperature (25°C) and 45°C. A novel implant for risperidone was successfully prepared and evaluated.

  13. Development of novel risperidone implants using blends of polycaprolactones and in vitro in vivo correlation studies

    Directory of Open Access Journals (Sweden)

    Aerrolla Navitha

    2014-01-01

    Full Text Available The objective of this study was to develop a novel implant containing risperidone intended for long-term treatment in Schizophrenia utilizing in vitro in vivo correlation (IVIVC studies. Different implants (F1-F8 containing an antipsychotic drug, risperidone, were prepared using a hot melt extrusion technique by taking polycaprolactones of different molecular weights (Mwt. 15000, 45000, 80000 either alone or as their blends, and PLGA (75:25. The implants contained 40% of the drug. After fabrication, the implants were characterized for various in vitro properties such as drug release and physical strength. Prior to conducting drug release studies, optimum drug release method was developed based on IVIVC studies. An optimized formulation based on drug release and physical strength at the end of fabrication was selected from the various implants fabricated. The bioactivity, reversibility, and IVIVC of optimized formulation were determined using pharmacokinetic studies in rats. Short-term stability studies were conducted with optimized formulation. Drug release depended on polymer molecular weight. Implant fabricated using 50:50 polycaprolactone 45,000 and polycaprolactone 80,000 was considered optimized implant. Optimized formulation selected released the drug for 3-months in vitro and was physically rigid. The optimized implant was able to release the drug in vivo for a period of 3 months, the implants are reversible throughout the delivery interval and, a 100% IVIVC was achieved with optimized implant, suggesting the development of 3-month drug-releasing implant for risperidone. The optimized implant was stable for 6 months at room temperature (25°C and 45°C. A novel implant for risperidone was successfully prepared and evaluated.

  14. Safety and efficacy findings from a non-interventional study of a new hyaluronic acid/sorbitol formulation (GO-ON® matrix) for intra-articular injection to relieve pain and disability in osteoarthritis patients.

    Science.gov (United States)

    Heisel, J; Kipshoven, C

    2013-09-01

    This non-interventional study was intended to examine the efficacy and tolerability of intra-articular injections with the GO-ON® matrix, a new viscosupplement product made of non-animal sodium hyaluronate combined with the oxygen free radical scavenger sorbitol, when used in routine clinical practice. A total of 1 147 patients (43.5% male, 53,5% female, 3% missing) aged on average 63.3 years with osteoarthritis were enrolled in 398 centers and treated with the product. The most commonly treated joint was the knee (92.9%) with a Kellgren-Lawrence classification of Grade I (6.7%), Grade II (31.4%), Grade III (48.0%), and Grade IV (13.9%).Most patients (58-66%, imputing for missing data) received 1 injection, 29-40% received 3 injections. Using a Likert scale to asses pain, the mean change in pain due to osteoarthritis was a reduction of 56.5% from baseline (2.61±0.80) to 6 months (1.07±0.86). At baseline, 56.2% of patients reported severe/very severe pain versus 5.9% after 6 months. Accordingly, 6.8% of patients reported no pain/mild pain at baseline vs. 67.1% after 6 months. At baseline, 28.9% reported no pain/mild pain vs. to 66.4% after 6 months. At baseline, 29.1% of patients reported severe/very severe functional impairment vs. 3.9% 6 months after the first injection. The 3 and 6 month results were comparable.Adverse reactions were rare and confined to musculoskeletal and connective tissue disorders. No infections were reported in any treated joints. The results confirm that the GO-ON matrix® treatment is effective and well tolerated in the treatment of symptoms due to osteoarthritis.

  15. Amenorrhoea - consequence of combined treatment with sulpiride and risperidone in a patient suffering from schizophrenia.

    Science.gov (United States)

    Peitl, Marija Vucić; Pavlović, Eudard; Peitl, Antun; Peitl, Vjekoslav

    2010-03-01

    It is well documented that sulpiride causes hormonal adverse events, like amenorrhoea and galactorrhea, due to its mechanism of action. Furthermore, risperidone can produce amenorrhoea and galactorrhea also, due to its mechanism of action, which differs from that of sulpiride. This case report is of a patient that was treated with large doses of sulpiride, but did not develop an adverse event like amenorrhoea. However, when risperidone was introduced into therapy it leads to the onset of amenorrhoea. Gynecologist saw it as the beginning of menopause. General practitioner questioned the existence of an intra-cerebral process that could produce amenorrhoea as well. Therefore, the patient was sent to perform an MRI of the brain, under work diagnosis of pituitary adenoma, which was later ruled out as a cause of the illness. Well experienced psychiatrist linked the loss of menstruation with the adverse event profile of sulpiride and therefore gradually discontinued sulpiride from therapy, while risperidone was left and subsequently menstrual cycle was restored. Good knowledge of adverse events profile of antipsychotic medication used, especially when used in a combination, allows us to correctly question appearance of adverse events, to adequately treat them and lowers the cost of unneeded medical procedures.

  16. Risperidone oral disintegrating mini-tablets: A robust-product for pediatrics

    Directory of Open Access Journals (Sweden)

    El-Say Khalid M.

    2015-12-01

    Full Text Available This study was aimed at developing risperidone oral disintegrating mini-tablets (OD-mini-tablets as age-appropriate formulations and to assess their suitability for infants and pediatric use. An experimental Box-Behnken design was applied to assure high quality of the OD-mini-tablets and reduce product variability. The design was employed to understand the influence of the critical excipient combinations on the production of OD-mini-tablets and thus guarantee the feasibility of obtaining products with dosage form uniformity. The variables selected were mannitol percent in Avicel (X1, swelling pressure of the superdisintegrant (X2, and the surface area of Aerosil as a glidant (X3. Risperidone-excipient compatibilities were investigated using FTIR and the spectra did not display any interaction. Fifteen formulations were prepared and evaluated for preand post-compression characteristics. The prepared ODmini- tablet batches were also assessed for disintegration in simulated salivary fluid (SSF, pH 6.2 and in reconstituted skimmed milk. The optimized formula fulfilled the requirements for crushing strength of 5 kN with minimal friability, disintegration times of 8.4 and 53.7 s in SSF and skimmed milk, respectively. This study therefore proposes the risperidone OD-mini-tablet formula having robust mechanical properties, uniform and precise dosing of medication with short disintegration time suitable for pediatric use.

  17. The clinical efficacy of Tanreqing injections combined with antibiotics for bacterial pneumonia%痰热清注射液联合抗生素治疗细菌性肺炎临床疗效分析

    Institute of Scientific and Technical Information of China (English)

    宋军平; 谢丽华; 傅冬莲; 李建华

    2012-01-01

    Objective To explore the clinical efficacy and safety of Tanreqing injections combined with antibiotics in the treatment of bacterial pneumonia.Methods 96 patients with bacterial pneumonia were divided into study group ( 57 patients ) and control group ( 39 patients ).The study group received combination therapy with Tanreqing injections and antibiotics,while the control group received antibiotics alone.The clinical efficacy and adverse reactions were observed in the two groups.Results Time to disappearance or improvement of symptoms including fever,cough,and expectoration was significantly shorter in the study than in the control group ( P< 0.01 ).The total effectiveness rate was obviously higher in the study group than in the control group ( 100% vs.94.87%,P < 0.05 ).No marked adverse reactions were found both groups.Conclusions Combination therapy with Tanreqing injections and antibiotics bacterial pneumonia is efficacious and has quick onset of action effect,thus making it a better therapeutic regimen.%目的 探讨痰热清注射液联合抗生素治疗细菌性肺炎的临床疗效及安全性.方法 将96例细菌性肺炎患者分为观察组(57例)和对照组(39例),观察组给予痰热清注射液联合抗生素治疗,对照组给予单一抗生素治疗,观察两组患者临床疗效及不良反应.结果 观察组发热、咳嗽、咳痰等症状消退或改善时间明显低于对照组(P<0.01);观察组总有效率为100%,明显高于对照组的94.87%,(P<0.05);两组患者均未见明显不良反应.结论 痰热清注射液联合抗生素治疗细菌性肺炎疗效好、见效快,是一种较佳的治疗方案.

  18. Injectable hydrogel delivery plus preconditioning of mesenchymal stem cells: exploitation of SDF-1/CXCR4 axis toward enhancing the efficacy of stem cells' homing.

    Science.gov (United States)

    Naderi-Meshkin, Hojjat; Matin, Maryam M; Heirani-Tabasi, Asieh; Mirahmadi, Mahdi; Irfan-Maqsood, Muhammad; Edalatmanesh, Mohmmad Amin; Shahriyari, Mina; Ahmadiankia, Naghmeh; Moussavi, Nasser Sanjar; Bidkhori, Hamid Reza; Bahrami, Ahmad Reza

    2016-07-01

    Clinical applications of mesenchymal stem cells (MSCs) rely on their capacity to home and engraft in the appropriate target injury tissues for the long term. However, their homing efficiency has been observed to be very poor because of the lack or modifications of homing factors SDF-1α and CXCR4 receptors. Hence, this study was designed to investigate the homing and retention of pretreated human adipose tissue-derived MSCs (hASCs) from three different delivery routes in response to SDF-1α, released from chitosan-based injectable hydrogels. After stimulation of ASCs with a hypoxia mimicking agent, the expression level and functionality of CXCR4 were analyzed by flowcytometric analysis (FACS), transwell migration assay and qPCR. Then, the homing/retention of pretreated DiI-labeled hASCs were compared through three different in vivo delivery routes, 2 weeks after transplantation in Wistar rats. The cells were tracked histologically by fluorescent microscope and by PCR for human-specific CXCR4 gene. Results showed CXCR4 has dynamic expression pattern and pretreatment of hASCs significantly up-regulates CXCR4, leading to an increase in migration capacity toward 100 ng/mL SDF-1α in vitro and homing into the subcutaneously implanted hydrogel releasing SDF-1α in vivo. Furthermore, it seems that SDF-1α is particularly important in the retention of ASCs, in addition to its chemoattraction role. In summary, the delivery route in which the ASCs were mixed with the hydrogel rather than systemic delivery and local injection and preconditioning undertaken to increase CXCR4 expression concomitant with SDF-1α delivery by the injectable hydrogel, allowed for further homing/retention of ASCs. This might be a promising way to get better therapeutic outcomes in stem cell therapy.

  19. Safe and Efficacious Use of Automated Bolus Advisors in Individuals Treated With Multiple Daily Insulin Injection (MDI) Therapy: Lessons Learned From the Automated Bolus Advisor Control and Usability Study (ABACUS).

    Science.gov (United States)

    Parkin, Christopher G; Barnard, Katharine; Hinnen, Deborah A

    2015-03-20

    Numerous studies have shown that use of integrated automated bolus advisors (BAs) provides significant benefits to individuals using insulin pump devices, including improved glycemic control and greater treatment satisfaction. Within the past few years, BA devices have been developed specifically for individuals treated with multiple daily insulin injection (MDI) therapy; however, many clinicians who treat these individuals may be unfamiliar with insulin pump therapy and, thus, BA use. Findings from the Automated Bolus Advisor Control and Usability Study (ABACUS) revealed that BA use can be efficacious and clinically meaningful in MDI therapy, and that most patients are willing and able to use this technology appropriately when adequate clinical support is provided. The purpose of this article is to review key learnings from ABACUS and provide practical advice for initiating BA use and monitoring therapy.

  20. The antidepressant- and anxiolytic-like effects following co-treatment with escitalopram and risperidone in rats.

    Science.gov (United States)

    Kaminska, K; Rogoz, Z

    2016-06-01

    Several clinical reports have documented a beneficial effect of the addition of a low dose of risperidone to the ongoing treatment with antidepressants, in particular selective serotonin reuptake inhibitors (SSRI), in the treatment of drug-resistant depression and treatment-resistant anxiety disorders. In the present study, we investigated the effect of treatment with the antidepressant escitalopram (SSRI) given separately or jointly with a low dose of risperidone (an atypical antipsychotic) in the forced swim test and in the elevated plus-maze test in rats. The obtained results showed that escitalopram at doses of 2.5 or 5 mg/kg evoked antidepressant-like effect in the forced swim test. Moreover, risperidone at low doses (0.05 or 0.1 mg/kg) enhanced the antidepressant-like activity of escitalopram (1 mg/kg) in this test by increasing the swimming time and decreasing the immobility time in those animals. WAY 100635 (a serotonin 5-HT1A receptor antagonist) at a dose of 0.1 mg/kg abolished the antidepressant-like effect induced by co-administration of escitalopram and risperidone. The active behavior in that test did not reflect an increase in general activity, since the combined treatment with escitalopram and risperidone failed to enhance the exploratory activity of rats. In the following experiment, we showed that escitalopram (5 mg/kg) and mirtazapine (5 or 10 mg/kg) or risperidone (0.1 mg/kg) induced an anxiolytic-like effect in the elevated plus-maze test, and the combined treatment with an ineffective dose of risperidone (0.05 mg/kg) enhanced the anxiolytic-like effects of escitalopram (2.5 mg/kg) or mirtazapine (1 and 2.5 mg/kg) in this test. The obtained results suggest that risperidone applied at a low dose enhances the antidepressant-like activity of escitalopram in the forced swim test, and that 5-HT1A receptors may play some role in these effects. Moreover, a low dose of risperidone may also enhance the anxiolytic-like action of the studied

  1. Hard to heal pressure ulcers (stage III-IV): efficacy of injected activated macrophage suspension (AMS) as compared with standard of care (SOC) treatment controlled trial.

    Science.gov (United States)

    Zuloff-Shani, Adi; Adunsky, Abraham; Even-Zahav, Aviva; Semo, Haim; Orenstein, Arie; Tamir, Jeremy; Regev, Eli; Shinar, Eilat; Danon, David

    2010-01-01

    The objective of this study was to compare local injections of AMS with SOC treatments for stage III and IV pressure ulcers in elderly patients. It was designed as historically prospective 2-arms non-parallel open controlled trial, and conducted in a department of geriatric medicine and rehabilitation of a university affiliated tertiary hospital. We studied 100 consecutive elderly patients with a total of 216 stage III or IV pressure ulcers, 66 patients were assigned to the AMS group and had their wounds injected, while 38 patients were assigned to the SOC group. Primary outcome was rate of complete wound closure. Time to complete wound closure and 1-year mortality served as secondary outcomes. Statistical analyses were performed at both patient and wound levels. Percentage of completely closed wounds (wound level and patient level) were significantly better (pAMS, as well as in the subset of diabetic patients (pAMS proved significantly better for the subset of those with leg ulcers and with baseline wounds ≤15 cm(2), compared with SOC. There were no statistically significant differences with regard to time to complete closure or 1-year mortality rates in the two groups. It is concluded that there is a significant difference in favor of stage III and IV wound closure rates by AMS, as compared with SOC treatments.

  2. Risperidone and Clozapine on Blood Glucose and Lipid Metabolism in Patients With Schizophrenia%利培酮和氯氮平对精神分裂症患者血糖和脂代谢的影响

    Institute of Scientific and Technical Information of China (English)

    刘召英

    2016-01-01

    目的:研究利培酮和氯氮平对精神分裂症患者血糖和脂代谢的影响。方法选择2014年1月~2015年1月来我院精神科治疗精神分裂症的患者62例,随机分成利培酮组和氯氮平组,各31例,观察两组患者治疗效果。结果治疗后,利培酮组 TC 水平为(4.81±0.15) mmol/L 低于氯氮平组 TC 水平(5.25±0.24)mmol/L,两组血糖及血脂指标相比,差异均有统计学意义(P <0.05)。结论采用利培酮和氯氮平治疗精神分裂症对患者的血糖和脂代谢水平均有影响,相对而言氯氮平影响较大,临床医生在治疗精神分裂症时应该慎重使用药物。%Objective To observe the efficacy of risperidone and clozapine on blood glucose and lipid metabolism in patients with schizophrenia. Methods Selected 62 patients with schizophrenia from January 2014 to January 2015 in our hospital were randomly divided into risperidone group and clozapine group,31 cases,the treatment groups were observed. Results After treatment,the levels of TC risperidone group(4.81±0.15)mmol/L group was significantly lower than clozapine TC levels(5.25±0.24)mmol/L,glucose and lipid levels compared to the two groups,the differences were statistical y significance(P< 0.05). Conclusion Use wil significantly affect the treatment of schizophrenia with risperidone and clozapine on blood glucose and lipid metabolism in patients with relatively greater impact in terms of clozapine,clinicians in the treatment of schizophrenia drugs should be used with caution.

  3. Risperidone and Divalproex Differentially Engage the Fronto-Striato-Temporal Circuitry in Pediatric Mania: A Pharmacological Functional Magnetic Resonance Imaging Study

    Science.gov (United States)

    Pavuluri, Mani N.; Passarotti, Alessandra M.; Fitzgerald, Jacklynn M.; Wegbreit, Ezra; Sweeney, John A.

    2012-01-01

    Objective: The current study examined the impact of risperidone and divalproex on affective and working memory circuitry in patients with pediatric bipolar disorder (PBD). Method: This was a six-week, double-blind, randomized trial of risperidone plus placebo versus divalproex plus placebo for patients with mania (n = 21; 13.6 [plus or minus] 2.5…

  4. Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study

    Directory of Open Access Journals (Sweden)

    Sacristán Jose A

    2001-12-01

    Full Text Available Abstract Background In order to compare the effectiveness of different antipsychotic drugs in the treatment of schizophrenia it is very important to evaluate subjective response and compliance in patient cohorts treated according to routine clinical practice. Method Outpatients with schizophrenia entered this prospective, naturalistic study when they received a new prescription for an antipsychotic drug. Treatment assignment was based on purely clinical criteria, as the study did not include any experimental intervention. Patients treated with olanzapine, risperidone or haloperidol were included in the analysis. Subjective response was measured using the 10-item version of the Drug Attitude Inventory (DAI-10, and treatment compliance was measured using a physician-rated 4 point categorical scale. Results A total of 2128 patients initiated treatment (as monotherapy with olanzapine, 417 with risperidone, and 112 with haloperidol. Olanzapine-treated patients had significantly higher DAI-10 scores and significantly better treatment compliance compared to both risperidone- and haloperidol-treated patients. Risperidone-treated patients had a significantly higher DAI-10 score compared to haloperidol-treated patients. Conclusion Subjective response and compliance were superior in olanzapine-treated patients, compared to patients treated with risperidone and haloperidol, in routine clinical practice. Differences in subjective response were explained largely, but not completely, by differences in incidence of EPS.

  5. Adverse Effects of Risperidone in Children with Autism Spectrum Disorders in a Naturalistic Clinical Setting at Siriraj Hospital, Thailand

    Directory of Open Access Journals (Sweden)

    Vitharon Boon-yasidhi

    2014-01-01

    Full Text Available A cross-sectional study was conducted to evaluate adverse effects associated with risperidone in 45 children with autism spectrum disorders (ASD, aged 2–15 years, who were treated at Siriraj Hospital, Thailand, between the years 2006 and 2007. Adverse effects were assessed by parent interview, using a semistructure questionnaire, and medical records review. The mean ± SD age of the children at starting risperidone was 8.15±2.98 years. The mean ± SD of risperidone dose was 0.94±0.74 mg/day and the mean ± SD duration of treatment was 36.8±27.8 months. Adverse effects were reported in 39 children (86.7%. Common adverse effects included increased appetite, somnolence, and rhinorrhea and most of the adverse effects were tolerable. Tardive dyskinesia or other serious adverse events were not found in this study. The child’s mean ± SD weight gain was 4.18±2.82 kg/year, which exceeded developmentally expected norms. The results from this study suggest that risperidone treatment in children with ASD is associated with frequent mild and tolerable adverse effects. However, excessive weight gain could be found to be a concerning adverse effect and weight monitoring is warranted when risperidone is being prescribed.

  6. Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study

    Directory of Open Access Journals (Sweden)

    Li HF

    2015-12-01

    Full Text Available HuaFang Li,1 Ibrahim Turkoz,2 Fan Zhang3 1Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China; 2Janssen Research & Development, LLC, Titusville, NJ, USA; 3Xi’an Janssen Pharmaceutical Ltd., Beijing, People’s Republic of China Introduction: This single-group, open-label, prospective, noncomparative, multicenter, Phase IV study explored the efficacy and tolerability of paliperidone palmitate (PP in hospitalized patients with acute exacerbation of schizophrenia.Methods: Asian patients of either sex, between 18 and 65 years of age, diagnosed with schizophrenia (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition with acute exacerbations within the previous 4 weeks, were enrolled. Intramuscular PP was initiated at doses of 150 milligram equivalent (mg eq (day 1 and 100 mg eq (day 8, followed by a monthly maintenance dose between 75 mg eq and 150 mg eq (days 36 and 64. Primary efficacy endpoint was the change from baseline in the Positive and Negative Syndrome Scale (PANSS total score (last-observation-carried-forward at week 13.Results: Of the 212 enrolled patients, 152 (71.7% completed the 13-week treatment; withdrawal of consent (24 [11.3%] patients was the most common reason for study discontinuation. Mean (standard deviation PANSS total score from baseline (90.0 [17.41] improved significantly at day 4 (-6.1 [9.27]; 95% confidence interval: -7.38, -4.85; P<0.001 and week 13 endpoint (-23.9 [23.24]; 95% confidence interval: -27.10, -20.78; P<0.001. Similarly, the secondary endpoints (Clinical Global Impression-Severity, Physical and Social Performance, each PANSS subscale, and Marder factor scores improved significantly from baseline to week 13 endpoint (P<0.001 for all. At week 13, 112/210 (53.3% patients had a 40% improvement in the PANSS total score (responder rate, and 133/212 (62.7% patients were ready for hospital discharge. Overall, 139 (65

  7. Efficacy of 3,4,3-LI(1,2-HOPO) for decorporation of Pu, Am and U from rats injected intramuscularly with high-fired particles of MOX.

    Science.gov (United States)

    Paquet, F; Chazel, V; Houpert, P; Guilmette, R; Muggenburg, B

    2003-01-01

    This study aimed to assess the efficacy of 3,4,3-LI(1,2-HOPO) for reducing uranium, plutonium and americium in rats after intramuscular injection of (U-Pu)O2 particles (MOX). Sixteen rats were contaminated by intramuscular injection of a 1 mg MOX suspension and then treated daily for 7 d with LIHOPO (30 or 200 micromol kg(-1)) or DTPA (30 micromol kg(-1)). LIHOPO was inefficient for removing Pu, Am and U from the wound site. However, it reduced Pu retention in carcass and liver by factors of 2 and 6 respectively, and Am retention in carcass and liver by factors of 10 and 30. In contrast, the effect of LIHOPO on U was to decrease the retention in kidneys by a factor of 75. These results confirm that LIHOPO is a good candidate for use after contamination with MOX, in combination with localised wound lavage or surgical treatment aimed at removing most of the contaminant at the wound site.

  8. Efficacy of Potassium Sodium Dehydroandroan Drographolide Succinate Injection for Treatment of Infantile Rotavirus Diarrhea%炎琥宁注射液治疗小儿轮状病毒腹泻的临床效果

    Institute of Scientific and Technical Information of China (English)

    孙晓亮; 张苗

    2016-01-01

    目的:分析炎琥宁注射液治疗小儿轮状病毒腹泻的临床效果。方法选取我院2013年2月~2015年2月收治的小儿轮状病毒腹泻患儿100例为研究对象,随机分为2组。对照组给予常规治疗,观察组在对照组的基础上采用炎琥宁注射液进行治疗,比较2组治疗效果。结果观察组的治疗有效率高于对照组。结论炎琥宁注射液治疗小儿轮状病毒腹泻的临床效果显著。%ObjectiveTo analyze the efficacy of potassium sodium dehydroandroan drographolide succinate injection for treatment of infantile rotavirus diarrhea. Methods From February 2013 to February 2015 were children with infantile rotavirus diarrhea 100 cases as the research object,were randomly divided into 2 groups. Control group given conventional treatment,the observation group in the control group on the basis of using potassium sodium dehydroandroan drographolide succinate injection treatment,compared two groups treatment effect.ResultsThe treatment group effectiveness was higher than the control group.Conclusion Potassium sodium dehydroandroan drographolide succinate injection in the treatment of infantile rotavirus diarrhea effect is remarkable.

  9. Clinical observations on the efficacy of point-injection with NGF in treatment of infantile cerebral palsy%神经生长因子穴位注射治疗小儿脑性瘫痪疗效观察

    Institute of Scientific and Technical Information of China (English)

    陈维华; 黄嫚; 周江

    2013-01-01

    目的 探讨神经生长因子穴位注射治疗小儿脑性瘫痪的临床疗效.方法 50例脑瘫患儿按就诊时间顺序随机分为治疗组30例,对照组20例,两组均采用Bobath法为主的运动疗法、作业疗法及语言治疗等常规治疗,治疗组在此治疗基础上加用神经生长因子穴位注射.所有患儿在训练前及训练后采用Gesell量表进行评估.结果 两组治疗前Gesell量表评分差异均无统计学意义(均P>0.05),两组治疗后Gesell量表评分差异均有统计学意义(t=-2.096、-2.187、-2.048、-2.053、-2.225,均P<0.05).结论 在康复训练的基础上应用神经生长因子穴位注射对改善小儿脑性瘫痪智能、运动等有较好的效果.%Objective To discuss the clinical efficacy of point-injection with nerve growth factor (NGF) in treatment of infantile cerebral palsy.Methods According to the time order,50 cases with cerebral palsy were randomly divided into the treatment group(30 cases) and the control group (20 cases).Both groups were given the conventional treatment of Bobath mainly exercise therapy,homework therapy and the language therapy.In addition,the treatment group was given the treatment of point-injection with NGF.Gesell scale was used to evaluate all the patients before and after treatment.Results After treatment,the Gesell evaluation of the treatment group was higher than control group,and the difference was statistically significant (t =-2.096,-2.187,-2.048,-2.053,-2.225,all P <0.05).Conclusion On the basis of rehabilitation training,point-injection with NGF could improve intelligence,motor function and language in children with cerebral palsy,and the efficacy was obvious.

  10. 电针配合穴位注射治疗腕管综合征疗效观察%Observations on the Efficacy of Electroacupuncture plus Acupuncture Point Injection in Treating Carpal Tunnel Syndrome

    Institute of Scientific and Technical Information of China (English)

    叶爱萍; 邹燃

    2014-01-01

    Objective To assess the clinical efficacy of electroacupuncture plus acupuncture point injection in treating carpal tunnel syndrome. Method Sixty-three patients with carpal tunnel syndrome were allocated, using a random number table, to a treatment group (32 cases) and a control group (31 cases). The treatment group received electroacupuncture plus acupuncture point injection and the control group, conventional acupuncture. One course of treatment was given. After treatment, the clinical therapeutic effects and the recurrence rates based on the symptoms and signs were compared between the two groups. Result The total efficacy rates in the treatment and control groups were 93.8% and 77.4%, respectively. There was a statistically significant difference in clinical therapeutic effect between the two groups (P<0.05). There was a statistically significant posttreatment difference in the recurrence rate between the two groups of patients (P<0.05). Conclusion Electroacupuncture plus acupuncture point injection is easy to perform and has a good effect in treating carpal tunnel syndrome.%目的:评价电针配合穴位注射治疗腕管综合征的临床疗效。方法将63例腕管综合征患者按入组先后根据随机数字表法分为治疗组(32例)和对照组(31例)。治疗组予电针配合穴位注射治疗,对照组予普通针刺治疗,共治疗1个疗程。经治疗后,从症状和体征上比较两组临床疗效及复发率。结果治疗组、对照组总有效率分别为93.8%和77.4%,两组总有效率比较差异有统计学意义(P<0.05);两组患者治疗后复发率比较差异有统计学意义(P<0.05)。结论电针配合穴位注射治疗腕管综合征操作简单、疗效好。

  11. Doxycycline Injection

    Science.gov (United States)

    Doxycycline injection is used to treat or prevent bacterial infections, including pneumonia and other respiratory tract infections. ... certain skin, genital, intestine, and urinary system infections. Doxycycline injection may be used to treat or prevent ...

  12. Pembrolizumab Injection

    Science.gov (United States)

    Pembrolizumab injection is used to treat melanoma (a type of skin cancer) that cannot be treated with ... who have a specific type of melanoma tumor. Pembrolizumab injection is also used to treat a certain ...

  13. Lacosamide Injection

    Science.gov (United States)

    ... injection is in a class of medications called anticonvulsants. It works by decreasing abnormal electrical activity in ... older (about 1 in 500 people) who took anticonvulsants like lacosamide injection to treat various conditions during ...

  14. Paclitaxel Injection

    Science.gov (United States)

    ... with other medications. Paclitaxel injection manufactured with polyoxyethylated castor oil is used to treat ovarian cancer (cancer that ... cancer, and lung cancer. Paclitaxel injection with polyoxyethylated castor oil is also used to treat Kaposi's sarcoma (a ...

  15. Obinutuzumab Injection

    Science.gov (United States)

    Obinutuzumab injection is used with chlorambucil (Leukeran) to treat chronic lymphocytic leukemia (CLL; a type of cancer of the white blood cells). Obinutuzumab injection is in a class of medications called ...

  16. Moxifloxacin Injection

    Science.gov (United States)

    ... Moxifloxacin injection may also be used to treat bronchitis or sinus infections but should not be used for these conditions if there are other treatment options available.Moxifloxacin injection is in a class ...

  17. Temozolomide Injection

    Science.gov (United States)

    Temozolomide is used to treat certain types of brain tumors. Temozolomide is in a class of medications called alkylating ... Temozolomide injection comes as a powder to be added to fluid and injected over 90 minutes intravenously ( ...

  18. Midazolam Injection

    Science.gov (United States)

    ... injection is in a class of medications called benzodiazepines. It works by slowing activity in the brain ... breast-feeding.talk to your doctor about the risks and benefits of receiving midazolam injection if you ...

  19. Methotrexate Injection

    Science.gov (United States)

    Methotrexate injection is used alone or in combination with other medications to treat gestational trophoblastic tumors (a ... in bones) after surgery to remove the tumor. Methotrexate injection is also used to treat severe psoriasis ( ...

  20. Doripenem Injection

    Science.gov (United States)

    ... injection is in a class of medications called carbapenem antibiotics. It works by killing bacteria.Antibiotics such ... if you are allergic to doripenem injection; other carbapenem antibiotics such as imipenem/cilastatin (Primaxin) or meropenem ( ...

  1. Cefotaxime Injection

    Science.gov (United States)

    Cefotaxime injection is used to treat certain infections caused by bacteria including pneumonia and other lower respiratory ... skin, blood, bone, joint, and urinary tract infections. Cefotaxime injection may also be used before surgery, and ...

  2. Bendamustine Injection

    Science.gov (United States)

    Bendamustine injection is used to treat chronic lymphocytic leukemia (CLL; a type of cancer of the white ... injection. You should use birth control to prevent pregnancy in yourself or your partner during your treatment ...

  3. Caspofungin Injection

    Science.gov (United States)

    Caspofungin injection is used in adults and children 3 months of age and older to treat yeast ... people with a weakened ability to fight infection. Caspofungin injection is in a class of antifungal medications ...

  4. Estrogen Injection

    Science.gov (United States)

    The estradiol cypionate and estradiol valerate forms of estrogen injection are used to treat hot flushes (hot ... should consider a different treatment. These forms of estrogen injection are also sometimes used to treat the ...

  5. Use of a Direct Observational Measure in a Trial of Risperidone and Parent Training in Children with Pervasive Developmental Disorders.

    Science.gov (United States)

    Handen, Benjamin L; Johnson, Cynthia R; Butter, Eric M; Lecavalier, Luc; Scahill, Lawrence; Aman, Michael G; McDougle, Christopher J; Arnold, L Eugene; Swiezy, Naomi B; Sukhodolsky, Denis G; Mulick, James A; White, Susan W; Bearss, Karen; Hollway, Jill A; Stigler, Kimberly A; Dziura, James; Yu, Sunkyung; Sacco, Kelley; Vitiello, Benedetto

    2013-06-01

    A Structured Observational Analog Procedure (SOAP), an analogue measure of parent-child interactions, was used to assess treatment outcome in children with Autism Spectrum Disorder and serious behavior problems. It served as a secondary outcome measure in a 24-week, randomized trial of risperidone (MED; N=49) versus risperidone plus parent training (COMB; n=75) (ages 4-13 years). At 24-weeks, there was 28 % reduction in child inappropriate behavior during a Demand Condition (p=.0002) and 12 % increase in compliance to parental requests (p=.004) for the two treatment conditions combined. Parents displayed 64 % greater use of positive reinforcement (p=.001) and fewer repeated requests for compliance (ppositive reinforcement (p=.01) and fewer restrictive statements (p<.05) than MED parents. The SOAP is sensitive to change in child and parent behavior as a function of risperidone alone and in combination with PMT and can serve as a valuable complement to parent and clinician-based measures.

  6. Efficacy Observation of Lipo-alprostadil Injection in the Treatment of Progressive Cerebral Infarction%前列地尔脂微球注射液治疗进展性脑梗死的疗效观察

    Institute of Scientific and Technical Information of China (English)

    梁涛; 张建文

    2012-01-01

    OBJECTIVE: To investigate the application of Lipo-alprostadil injection in the treatment of progressive cerebral infarction. METHODS: 120 patients with progressive cerebral infarction in our hospital during Jan. 2010 -Jan. 2011 were randomly divided into experiment group and control group. Control group was given Danshen injection(20 mL·d-1), and experiment group was additionally given Lipo-alprostadil injection(10 ug·d-1) on the basis of the treatment for control group. The efficacy and ADRs were observed in 2 groups. RESULTS: Total effective rate of experiment group was 85.00% and that of control group was only 66.67% , which indicated clinical efficacy of experiment group was better than that of control group (P0.05). CONCLUSION: Lipo-alprostadil injection is safe and reliable in the treatment of progressive cerebral infarction with sound efficacy and little ADR.%目的:观察前列地尔脂微球注射液治疗进展性脑梗死的临床效果.方法:将2010年1月-2011年1月我院收治的进展性脑梗死患者120例,随机均分为试验组与对照组:对照组采用丹参注射液20 mL·d-1治疗,试验组在对照组基础上加用前列地尔脂微球注射液10 μg·d-1治疗.观察2组疗效及不良反应.结果:试验组患者临床疗效总有效率为85.00%,对照组为66.67%,2组比较差异有统计学意义(P<0.05);治疗前、后2组患者的NIHSS评分及Barthel评分组内比较差异均具有统计学意义(P<0.05),且治疗30 d后试验组患者的NIHSS评分显著低于对照组(P<0.05),Barthel评分显著高于对照组(P<0.05);2组患者的不良反应发生率比较差异无统计学意义(P>0.05).结论:前列地尔脂微球注射液治疗进展性脑梗死疗效较好、不良反应较小.

  7. Ranitidine Injection

    Science.gov (United States)

    Ranitidine injection comes as a solution (liquid) to be mixed with another fluid and injected intravenously (into a vein) over 5 to 20 minutes. Ranitidine may also be injected into a muscle. It is usually given every 6 to 8 hours, but may also be given ...

  8. Ustekinumab Injection

    Science.gov (United States)

    ... Do not inject into an area where the skin is tender, bruised, red, or hard or where you have scars or stretch marks.Your doctor or pharmacist will ... injection.you should know that ustekinumab injection may decrease your ability ... new or changing skin lesions, minor infections (such as open cuts or ...

  9. Effects of lactational exposure of olanzapine and risperidone on hematology and lymphoid organs histopathology: a comparative study in mice neonates.

    Science.gov (United States)

    Mishra, Akash C; Mohanty, Banalata

    2010-05-25

    Body weight gain, sexual/reproductive dysfunction and hematological abnormalities are serious consequences of atypical antipsychotics treatment. No attempts however have been made preclinically to elucidate the adverse hematological impacts. Presently, effects of lactational exposure of olanzapine (4, 8 and 10 mg/kg) and risperidone (1 and 2 mg/kg) on hematology as well as lymphoid organ histopathology of mice neonates were investigated. Both olanzapine and risperidone transfers through milk and make the neonates susceptible to their adverse side effects. Corticosterone elevation tendency of both the drugs further enhance the susceptibility for immune dysfunction. Analysis of total and differential leukocytes counts revealed neutropenia with all the doses of olanzapine but only with risperidone 2mg/kg. Weight analysis and histopathology of thymus and spleen indicated a state of suppression; less in the risperidone-exposed groups. Significant plasma corticosterone elevation occurred on 4 and 8 mg/kg olanzapine exposures but not with 10 mg/kg as well as with both the risperidone doses. Elevation of plasma prolactin levels occurred dose-dependently for both the drugs. Hematological toxicity (neutropenia) might be the direct toxic effects of the drugs/unstable metabolites on circulating neutrophils and/or on the bone marrow hemopoietic cells. Direct toxicity of the drugs might also have suppressed the lymphoid organs thymus and spleen. Further, it could be associated to hormonal imbalance induced by adverse pharmacological effects of the drugs on the endocrine system. Suppression of lymphoid organs in olanzapine groups might have resulted because of corticosteronemia and hyperprolactinemia, while in risperidone it could be mediated by pronounced hyperprolactinemic effect alone.

  10. Risperidone regulates Dopamine D2-like receptors expression in rat brain in a time-dependent manner

    Directory of Open Access Journals (Sweden)

    Ni Peiyan

    2015-03-01

    Full Text Available Background and Objectives: Antipsychotics can elicit dopamine super-sensitivity by up-regulation of D2-like receptors (DRD2, DRD3, and DRD4 expression. Nevertheless, the expression profile of dopamine D2-like receptors in different brain regions and peripheral blood mononuclear cells (PBMCs, and changes following risperidone administration were still unclear. In this study, we would investigate the expression of D2-like receptors mRNA in different brain regions and the peripheral blood mononuclear cells (PBMCs in rats after 2, 6 weeks risperidone administration. Methods: The experimental rats were given risperidone (0.25mg/kg/day, i.p., and the control rats were given 0.9% NaCl. The rats were sacrificed at 0 week, 2 weeks and 6 weeks after the drug administration. Expression of the dopamine D2-like receptors was quantified by Real-time PCR method. Results: Dopamine D2-like receptors expressed in all the examined regions of rat brain. Their expression significantly increased 2weeks after risperidone administration in different brain regions. However, the changed expression of DRD2 and DRD3 turned back to the basal level 6weeks later, while the increased DRD4 expression remained in left parietal cortex. Meanwhile, DRD2 and DRD3 but not DRD4 expressed in PBMCs, however, the risperidone could not affect their expression. Conclusions: The risperidone could change the dopamine D2-like receptors expression in a time-dependent manner in different brain regions, which might guide the clinical use in the near future.

  11. Review of the safety, efficacy, costs and patient acceptability of recombinant follicle-stimulating hormone for injection in assisting ovulation induction in infertile women

    Directory of Open Access Journals (Sweden)

    Marleen Nahuis

    2009-11-01

    Full Text Available Marleen Nahuis1,2,3, Fulco van der Veen1, Jur Oosterhuis2, Ben Willem Mol1, Peter Hompes3, Madelon van Wely11Center for Reproductive Medicine, Department of Obstetrics and Gynaecology (H4-205, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; 2Department of Obstetrics and Gynaecology, Medisch Spectrum Twente, Enschede, The Netherlands; 3Department of Obstetrics and Gynaecology, Free Medical University, Amsterdam, The NetherlandsAbstract: Anovulation is a common cause of female subfertility. Treatment of anovulation is aimed at induction of ovulation. In women with clomiphene-citrate resistant WHO group II anovulation, one of the treatment options is ovulation induction with exogenous follicle-stimulating hormone (FSH or follitropin. FSH is derived from urine or is produced as recombinant FSH. Two forms of recombinant FSH are available – follitropin alpha and follitropin beta. To evaluate the efficacy, safety, costs and acceptability of recombinant FSH, we performed a review to compare recombinant FSH with urinary-derived FSH products. Follitropin alpha, beta and urinary FSH products appeared to be equally effective in terms of pregnancy rates. Patient safety was also found to be comparable, as the incidence of side effects including multiple pregnancies was similar for all FSH products. In practice follitropin alpha and beta may be more convenient to use due to the ease of self-administration, but they are also more expensive than the urinary products.Keywords: follitropin apha, follitropin beta, urinary gonadotropins, polycystic ovary syndrome

  12. Clinical efficacy of medical ozone injection in the treatment of patients with supraspinatus tendinitis%医用三氧注射治疗冈上肌肌腱炎的临床疗效

    Institute of Scientific and Technical Information of China (English)

    卓锦钊; 陈琳

    2015-01-01

    目的 探讨医用三氧注射治疗冈上肌肌腱炎的疗效.方法 冈上肌肌腱炎患者60例,随机分为两组,每组30例.三氧组注入浓度为40μg/ml的医用三氧6 ml,每周1次,3次为1疗程;针刺组采用穴位针刺治疗,隔日1次,3次为1疗程,共3疗程.结果 随访3个月时三氧组有效率(90%,27/30例)高于针刺组(60%,18/30例)(P<0.05);两组复发率比较差异无统计学意义(P>0.05).结论 两种方法均有效,但医用三氧注射治疗疗效更佳.%Objective To evaluate the clinical efficacy of medical ozone injection in the treatment of patients with supraspinatus tendinitis.Methods Sixty patients with supraspinatus tendinitis were randomly divided into two groups, 30 cases in each group.Patients in the injection group were treated with 40 μg/ml medical ozone 6 ml, once a week, for three weeks.Patients were received acupuncture in the acupuncture group, once two days, 3 times in one course, three courses in total.Results The effective rate in medical ozone injection group (90%, 27/30 cases) was higher than that in acupuncture group (60%, 18/30 cases) after three months (P <0.05).There was no significant difference in the recurrent rate between the two groups (P > 0.05).Conclusion Both of the treatments are effective, but the effect of medical ozone injection is better.

  13. Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study

    Directory of Open Access Journals (Sweden)

    Adel Gabriel

    2010-10-01

    Full Text Available Adel GabrielDepartments of Psychiatry and Community Health Sciences, University of Calgary, Alberta, CanadaBackground: There is a great need in the treatment of schizophrenia for a drug, or drug ­combinations, to improve clinical response with fewer serious side effects. The objective of this study was to explore the therapeutic effects and tolerability of the anticonvulsant gabapentin as an adjunctive in the treatment of patients with partially responsive schizophrenia.Methods: Ten consenting patients with a confirmed Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision diagnosis of schizophrenia were identified. All patients failed at least one 12-week treatment trial with risperidone or olanzapine. Gabapentin was added to ongoing antipsychotic treatment with olanzapine or risperidone for eight weeks. The primary outcome measure was the Positive and Negative Syndrome Scale (PANSS. Other scales included the Calgary Depression Scale (CDSS and the Abnormal Involuntary Movement Scale (AIMS. Repeated-measures multivariate analysis of variance was utilized to examine changes in outcome measures over time with adjunctive treatment with gabapentin.Results: There was a significant drop in the PANSS and CDSS scores at endpoint (week 8. There were no significant differences between the two treatment groups with regard to changes in all outcome measures or in AIMS score. The adjunctive treatments were well tolerated and side effects were transient.Conclusion: Gabapentin could be used successfully as an adjunct to novel antipsychotics in partially responsive schizophrenia. However, large controlled studies are needed to examine the effectiveness of gabapentin in psychotic disorders.Keywords: schizophrenia, refractory, adjunctive treatment, gabapentin, risperidone, olanzapine

  14. Report of a Rare Case of Olanzapine and Risperidone Induced Hypomania

    Directory of Open Access Journals (Sweden)

    AR Zahiroddin

    2006-07-01

    Full Text Available Introduction & Objective: Hypomania is a mood disorder with symptoms of constantly high expansive or irritable mood. After a 4-day period, the patient feels to be in need of less sleep, being talkative, or feeling pressure if not treated kindly, having flight of ideas, distractibility, and increase in goal oriented activities (including social, occupational, educational or sexual activities and being extravagant. Hypomania could be a mood episode of bipolar I and II mood disorder or cyclothymia and could be resulted from consumption of drugs, materials, Electro Convulsive Therapy (ECT or photo therapy. Case: The present report is the case of a 57-year old married woman, who has had a record of bipolar I mood disorder since 30 years ago. The patient was hospitalized once in psychiatry hospital and referred to psychiatry office 2 years ago. She has been under medication therapy by lithium 600 mg, nortriptyline 75 mg, and colonazpam 1 mg. She has taken risperidone 2 mg, the symptoms of hypomania have revealed. After stopping the consumption of risperidone, the treatment continued by lithium tablet 900 mg, eskazina tablet 4 mg, nortriptyline 75 mg for one day. She was under care for 15 months and then due to muscle complications of lithium, pessimism, auditory and visual hallucination, she was recommended to take olanzapine tablet 5 mg once every night. Two days after taking olanzapine the symptoms of hypomania revealed. Consumption of olanzapine was then stopped and the symptoms disappeared and she was brought under control after taking sodiumvalproate tablet. Conclusion: Rarely could Hypomania be a mood episode induced by consuming atypical antipsychotics such as risperidone and olanzapine.

  15. Safety and efficacy of botox injection in alleviating post-operative pain and improving quality of life in lower extremity limb lengthening and deformity correction

    Directory of Open Access Journals (Sweden)

    Finley Allen

    2007-09-01

    Full Text Available Abstract Background Distraction osteogenesis is the standard treatment for the management of lower limb length discrepancy of more than 3 cm and bone loss secondary to congenital anomalies, trauma or infection. This technique consists of an osteotomy of the bone to be lengthened, application of an external fixator, followed by gradual and controlled distraction of the bone ends. Although limb lengthening using the Ilizarov distraction osteogenesis principle yields excellent results in most cases, the technique has numerous problems and is not well tolerated by many children. The objective of the current study is to determine if Botulinum Toxin A (BTX-A, which is known to possess both analgesic and paralytic actions, can be used to alleviate post-operative pain and improve the functional outcome of children undergoing distraction osteogenesis. Methods/Design The study design consists of a multi centre, randomized, double-blinded, placebo-controlled trial. Patients between ages 5–21 years requiring limb lengthening or deformity correction using distraction will be recruited from 6 different sites (Shriners Hospital for Children in Montreal, Honolulu, Philadelphia and Portland as well as DuPont Hospital for Children in Wilmington, Delaware and Hospital for Sick Children in Toronto, Ont. Approximately 150 subjects will be recruited over 2 years and will be randomized to either receive 10 units per Kg of BTX-A or normal saline (control group intraoperatively following the surgery. Functional outcome effects will be assessed using pain scores, medication dosages, range of motion, flexibility, strength, mobility function and quality of life of the patient. IRB approval was obtained from all sites and adverse reactions will be monitored vigorously and reported to IRB, FDA and Health Canada. Discussion BTX-A injection has been widely used world wide with no major side effects reported. However, to the best of our knowledge, this is the first time BTX

  16. The efficacy and safety of systemic injection of Ginkgo biloba extract, EGb761, in idiopathic sudden sensorineural hearing loss: a randomized placebo-controlled clinical trial.

    Science.gov (United States)

    Koo, Ja-Won; Chang, Mun Young; Yun, Sung-Cheol; Kim, Tae Su; Kong, Soo-Keun; Chung, Jong Woo; Goh, Eui-Kyung

    2016-09-01

    Steroids are currently the most frequently accepted agents for idiopathic sudden sensorineural hearing loss (ISSNHL). However, the therapeutic effect of steroids is not always satisfactory. In this pilot study, we evaluated whether systemic treatment with Ginkgo biloba extract (EGb761) has an additive therapeutic effect in patients receiving a systemic steroid due to ISSNHL. A multicenter, randomized, double-blind clinical trial was performed. Fifty-six patients with ISSNHL were allocated to either EGb761 or placebo. In both groups, methylprednisolone was administered for 14 days. EGb761 was infused intravenously for 5 days in the EGb761 group, while the same amount of normal saline was infused in the placebo group. For the efficacy evaluation, pure-tone audiometry, speech audiometry, tinnitus handicap inventory (THI) and short form-36 health (SF-36) survey outcomes were obtained before administration and on days 3, 5, 14 and 28 of administration. Twenty-four patients in each group completed the study protocol. There was no difference in hearing loss between the two groups before treatment. At day 28, air conduction threshold values in the placebo and EGb761 groups were 34.63 ± 28.90 and 23.84 ± 25.42 dB, respectively (p = 0.082). Speech discrimination scores in the placebo and EGb761 groups were 69.17 ± 40.89 and 87.48 ± 28.65 %, respectively (p = 0.050). THI and SF-36 scores in the placebo and EGb761 groups were similar. Although a combination of steroid and EGb761 for initial treatment did not show better pure tone threshold, compared with steroid alone, speech discrimination was significantly improved in combination therapy. Further studies will be needed to know if addition of EGb761 actually improves the outcome of ISSNHL treatment.

  17. 臭氧联合胶原酶注射与单纯臭氧治疗腰椎间盘突出症的疗效观察%Combined use of ozone and collagenase injection for the treatment of lumbar disc herniation: comparison of therapeutic efficacy with simple ozone injection

    Institute of Scientific and Technical Information of China (English)

    高宗根; 殷世武; 项廷淼; 张惠林; 王菊; 黄守珍; 张武芝

    2011-01-01

    目的 观察臭氧联合胶原酶注射治疗腰椎间盘突出症(LDH)与单纯臭氧治疗椎间盘突出症的不同疗效.方法 在DSA导向下,正侧位透视后准确定位,采用9号穿刺针经皮穿刺向椎间盘内单纯注射臭氧或先后注射臭氧及胶原酶治疗76例腰椎间盘突出患者.结果 治疗后1、3和6个月进行随访.1个月后随访,臭氧联合胶原晦注射治疗组(A组,38例)有效率为89.5%,单纯臭氧注射治疗组(B组,38例)有效率为86.8%;3个月后随访,A组有效率为92.1%,B组有效率为84.2%;6个月后随访,A组有效率为94.7%,B组有妓率为81.6%.结论 臭氧联合胶原酶注射治疗椎间盘突出症较单纯臭氧注射治疗椎间盘突出症,疗效更加显著,且中远期疗效更稳定.%Objective To observe the therapeutic effects of combined use of ozone and collagenase injection in treating lumbar disc herniation and to make a comparison of therapeutic efficacy with simple ozone injection. Methods Under DSA guidance, percutaneous puncturing of diseased lumbar disk with a gauge 9 needle was performed in 76 patient with lumbar disc herniation. After the needle position was confirmed in the right site simple ozone injection (control group, n = 38) or combined use of ozone and collagenase injection (study group, n = 38) was carried outs. The clinical results were evaluated and compared between two groups. Results After the treatment, all 76 patients were followed up regularly at 1,3 and 6 months. At 1. 3 and 6 months after the therapy, the effective rate of study group was 89.5%, 92.1% and 94.7% respectively, while the effective rate of control group was 86.8%, 84.2% and 81.6% respectively.Conclusion For the treatment of lumbar disc herniation, the therapeutic effect of combined use of ozone and collagenase injection is much better than that by using simple ozone injection, moreover. it carries a quite stable long-term efficacy. (J Intervent Radiol. 2011 . 20 : 42-44)

  18. Bioequivalence study of a generic Risperidone (Iperdal® in healthy Thai male volunteers

    Directory of Open Access Journals (Sweden)

    Werawath Mahatthanatrakul

    2008-05-01

    Full Text Available The objective of this study was to compare the rate and extent of absorption of a generic risperidone (Iperdal® with a reference formulation (Risperdal® when given orally. The study was an open label, randomized, two-period, two-sequence,single dose cross-over design with a 2 weeks washout period in 16 healthy Thai male volunteers. Single oral dose of two 2-mg tablets of risperidone were administered and serial blood samples were collected from the antecubital vein before and at0.17, 0.33, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 12, 24 and 48 hours post dose. Risperidone plasma concentrations were assayed using a validated High Performance Liquid Chromatographic (HPLC-UV method modified from Avenosoet al. (2000. Pharamcokinetic parameters i.e. Cmax, AUC0à48 and Tmax were analyzed by noncompartment analysis. Variations of the data were analyzed by “Two Way Analysis of Variance” (ANOVA. Statistics were tested as stated in USP 28 guidelinefor bioequivalence study. The maximum concentration (Cmax, ng/ml of risperidone for the innovator and the generic product were 31.11±17.24 (range 5.64-56.78 and 32.58±19.77 (range 5.29-84.56 ng/ml, respectively. The area under theplasma concentration-time curve (AUC0®48 of the innovator and the generic product were 160.64±152.89 (range 18.57- 550.32 and 144.03±127.37 (range 16.27-456.0 ng.hr/ml, respectively. The time to maximum concentration (Tmax of theinnovator and the generic product were 0.97±0.41(range 0.5-2 and 1.02±0.32 (range 0.5-1.5 hr, respectively. The 90% confidence interval of the ratio of the ln-transformed of Cmax and AUC0à48 of both preparations were 89.39-112.99% and80.02-107.28% respectively which were within the acceptance range of 80.00-125.00%. Therefore, it can be concluded that both preparations used in this study are bioequivalent in terms of both the rate and extent of absorption.

  19. Evaluation of teratogenic effects of risperidone following simultaneous administration with antihypertensive and antiemetic drugs.

    Science.gov (United States)

    Tauqeer, Shaista; Khan, Rafeeq Alam; Siddiqui, Afaq Ahmed

    2012-01-01

    Multiple drug administration is an important aspect of clinical practice particularly in specific physiological situation such as in neonates, elderly or pregnancy, since in all such situations, possibility of unwanted effects increases due to altered body physiology. In present study, the teratogenic effects of multiple drug administration risperidone, meclizine/pyridoxine and hydralazine have been compared with the teratogenic effects of individual drugs in pregnant mice. Moreover the role of folic acid and α-tocopherol if any had also been investigated in reducing the teratogenic effects of these drugs in combinations.

  20. 静脉注射维生素C对透析后肾性贫血的治疗效果%Clinical efficacy of Vitamin C injection in the treatment of renal anemia after dialysis

    Institute of Scientific and Technical Information of China (English)

    李敏芝; 熊燕移; 张莞灵; 卓华钦

    2015-01-01

    目的:探讨静脉注射维生素 C 对透析后肾性贫血的治疗效果。方法将80例接受透析治疗的肾性贫血患者依据数字表法随机分为研究组和对照组,每组40例。两组患者均给予皮下注射重组人红细胞生成素(EPO)和蔗糖铁静脉滴注,研究组在此基础上加用维生素 C 静脉推注治疗。对比两组患者血红蛋白(Hb)、血红细胞指标、铁代谢相关指标及不良反应。结果研究组患者治疗后各时段 Hb、红细胞比容(Hct)、红细胞数量(RBC)和未溶解红细胞比例(RBC%)均显著高于对照组和治疗前,且差异有统计学意义(P ﹤0.05)。同时研究组患者治疗后各时段的血清铁(SI)、血清铁蛋白(SF)、转铁蛋白饱和度(TSAT)均显著高于治疗前和对照组,且差异有统计学意义(P ﹤0.05)。两组患者不良反应的差异无统计学意义(P ﹥0.05)。结论透析时静脉推注维生素 C 可以有效改善肾性贫血患者的贫血症状和铁代谢。%Objective To study the clinical efficacy of vitamin C injection in the treatment of renal anemia after dialysis. Methods A total of 80 patients with renal anemia were randomly divided into study group and control group according to random number tables,with 40 patients in each group. All the patients were treated with EPO subcutaneous injection,iron sucrose intravenous drip and dialysis. Addi-tionally,patients in the study group were treated with vitamin C injection. The hemoglobin level,red blood cell indexes,iron metabolism in-dexes and adverse reaction between the two groups were compared. Results After treatment,the hemoglobin level,RBC count and hemato-crit in the study group were significantly higher than those in the control group and before treatment(P ﹤ 0. 05),the blood SI,SF,TSAT in the study group were also significantly higher than those in the control group and before treatment(P ﹤ 0. 05). There was no

  1. A double-blind, placebo-controlled study of traditional Chinese medicine sarsasapogenin added to risperidone in patients with negative symptoms dominated schizophrenia%利培酮合并知母皂甙元治疗阴性症状为主的精神分裂症的双盲随机对照研究

    Institute of Scientific and Technical Information of China (English)

    肖世富; 薛海波; 李霞; 陈超; 李冠军; 苑成梅; 张明园

    2011-01-01

    Objective To identify whether sarsasapogenin,a sapogenin from the Chinese medicinal herb Anemarrhena Asphodeloides Bunge,would augment the efficacy of risperidone and significantly improve cognitive functions in patients with negative symptoms dominated schizophrenia.Methods The trial was a double-blind,placebo-controlled,parallelgroup design.The eligible patients were randomized into 2 treatment groups:sarsasapogenin group (sarsasapogenin plus risperidone for 8 weeks,n = 41) and placebo group (risperidone only for 8 weeks,n = 39).At the baseline,as well as at weeks 2,4 and 8 of treatment,the therapeutic response was measured by using scales including Positive and Negative Symptoms Scale (PANSS),Wechsler Memory Scale (WMS),modified Chinese Wechsler Adult Intelligence Scale (mWAIS),Clinical Global Impression (CGI) and Brief Psychiatry Rating Scale (BPRS).The study period for each subject was 8 weeks and duration of overall trial was 2 years.Results Patients treated with sarsasapogenin plus risperidone demonstrated no statistically significant differences in changes in PANSS,WMS or mWAIS score at the end-point of the trial compared with patients treated with placebo plus risperidone.The incidence of treatment-emergent adverse events in patients treated with sarsasapogenin was not different from that observed in placebo group.Conclusion Sarsasapogenin did not augment the efficacy of risperidone in treating negative symptoms dominated schizophrenia.Sarsasapogenin at a dosage of 200 mg per day added to a flexible dosage of risperidone at 2-4 mg per day is safe and well tolerated by patients with negative symptoms dominated schizophrenia.%目的 探讨知母皂甙元是否能增强利培酮的治疗作用,以及两者联用是否能显著提高阴性症状为主的精神分裂症病人的认知功能.方法 本研究采用双盲、安慰剂对照的平行设计方案.研究对象随机分为知利培酮合并母皂甙组(n= 41)和利培酮合并安慰剂组(n=39

  2. Efficacy of intravenous injection of urapidil by micro-pump in treatment of hypertensive emergency patients%经微量泵静脉注射乌拉地尔治疗高血压急症疗效观察

    Institute of Scientific and Technical Information of China (English)

    庄小静; 周朝虹

    2009-01-01

    目的 探讨乌拉地尔微量泵静脉注射治疗高血压急症的疗效和安全性.方法 对78例高血压急症患者用乌拉地尔50mg加入40ml液体中静脉微泵输注,监测并记录用药前及用药后5、10、30、60、120min血压(BP)、心率(HR)、伴随症状及不良反应.结果 应用乌拉地尔后各时段BP较用药前均明显下降,差异有统计学意义(P<0.05),而HR则无明显变化.结论 乌拉地尔微量泵静脉注射治疗高血压急症,疗效确切,不良反应少.%Objective To investigate the efficacy and safety of urapidil intravenous injected by micro-pump in treatment of hypertensive emergency patients. Methods There 78 cases with hypertensive, emergency werereated wih 50rag urapidil by intravenous micro-pump. The blood pressure (BP),heart rate (HR),adverse reactions were monitored and recorded before administration and 5min,10min,30min,60min,120min after administration. Results Compared to that before administration,blood pressure were significantly decreased after administration, showing a significant difference. While there was no significant difference in the heart rate. Conclusion Urapidil intravenous injected by micro-pump is effective for treatment of hypertensive emergency with fewer adverse reactions.

  3. 溴隐亭治疗利培酮致女性中度高催乳素血症的临床研究%Clinical study of Bromocriptine in treatment of moderate hyperprolactinemia caused by Risperidone

    Institute of Scientific and Technical Information of China (English)

    秦卫红; 魏时懿; 张军勐

    2014-01-01

    Objective:To discuss the efficacy of Bromocriptine in treatment of hyperprolactinemia cause by Risperidone and an-alyze the possibility of psychiatric symptom fluctuation for female patients with schizophrenia. Methods:According to the ICD-10, 59 female inpatients diagnosed as schizophrenia and got the mild hyperprolactinemia (100ug/ Lt0. 001(59), Pt0.001(59),P<0.001〕,BPRS 量表前后3次评定结果进行比较无显著差异。结论:本研究证实溴隐亭治疗利培酮所致女性中度高催乳素血症有实际临床应用价值,其有效性和安全性均非常可靠。

  4. Subcutaneous Injections

    DEFF Research Database (Denmark)

    Thomsen, Maria

    This thesis is about visualization and characterization of the tissue-device interaction during subcutaneous injection. The tissue pressure build-up during subcutaneous injections was measured in humans. The insulin pen FlexTouchr (Novo Nordisk A/S) was used for the measurements and the pressure...... build-up was evaluated indirectly from the changes in the flow rate between subcutaneous injections and air injections. This method enabled the tissue counter pressure to be evaluated without a formal clinical study approval. The measurements were coupled to a model for the pressure evolution...

  5. 氨磺必利与利培酮治疗精神分裂症对照研究%A control study of amisulpride vs .risperidone in the treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    张华江; 徐清

    2014-01-01

    Objective To explore the efficacy and safety of amisulpride vs .risper-idone in the treatment of schizophrenia .Methods Sixty schizophrenics were randomly divided into two groups of 30 ones each ,research group took orally amisulpride and control group did risperidone for 8 weeks .Efficacies were assessed with the Positive and Negative Syndrome Scale (PANSS) and adverse re-actions with the Treatment Emergent Symptom Scale (TESS) .Results At the end of the 8th week obvious effective and effective rate were respectively 70 .0% and 93 .3% in research and 66 .7% and 93 .3% in con-trol group ,which showed no significant differences (P> 0 .05) .Incidences of extrapyramidal reactions , dysfunction of liver and weight gain were significantly lower in research than in control group (P<0 .05) . Conclusion Amisulpride has an evident effect equivalent to risperidone ,higher safety and better compli-ance in the treatment of schizophrenia .%目的:探讨氨磺必利与利培酮治疗精神分裂症的临床疗效和安全性。方法将60例精神分裂症患者随机分为两组,每组30例,研究组口服氨磺必利治疗,对照组口服利培酮治疗。观察8周。采用阳性与阴性症状量表评定临床疗效,副反应量表评定不良反应。结果治疗8周末,研究组显效率为70.0%、有效率为93.3%,对照组分别为66.7%、93.3%,两组比较差异无显著性(P>0.05)。研究组锥体外系反应、肝功能异常及体质量增加发生率均显著低于对照组(P<0.05)。结论氨磺必利治疗精神分裂症疗效显著且与利培酮相当,安全性高,依从性好。

  6. 利培酮治疗难治性分裂情感性精神病临床研究%Clinical research on risperidone in the treatment of refractory schizoaffective psychosis

    Institute of Scientific and Technical Information of China (English)

    刘元华

    2014-01-01

    Objective To evaluate the clinical efficacy of risperidone for the treatment of refractory schizoaffective psychosis. Methods 84 patients with refractory schizoaffective psychosis were randomly divided into observation group and control group, and 42 cases were in each group.The two groups were received lithium treatment, and risperidone was added in observation group, while the control group added clozapine. The clinical efficacy of two groups were compared. Results After treatment, the HAMD, BRMS and the PANSS factor scores were significantly lower, but the observation group was significantly lower than the control group(P<0.05);the total effective rate of HAMD,BRMS and PANSS in observation group were significantly higher than the control group (P<0.05);the TESS score of observation group was significantly lower than the control group(P<0.05). Conclusion Risperidone for the treatment of refractory schizoaffective psychosis has a significant effect and less adverse reactions, it should be widely applied.%目的:探讨利培酮用于治疗难治性分裂情感性精神病的临床疗效。方法84例分裂情感性精神病患者随机分为观察组与对照组,各42例,两组均予以碳酸锂治疗,观察组加用利培酮,对照组加用氯氮平,比较两组的临床疗效。结果两组治疗后HAMD、BRMS以及PANSS各项因子评分均降低,且观察组各因子评分低于对照组,差异具统计学意义(P<0.05);观察组的临床总有效率均高于对照组,差异具统计学意义(P<0.05);观察组的TESS评分显著低于对照组,差异具统计学意义(P<0.05)。结论利培酮用于治疗难治性分裂情感性精神病疗效显著,不良反应少。

  7. 鼓室注射泼尼松龙与左氧氟沙星注射液对分泌性中耳炎的疗效观察%Clinical efficacy of prednisone and levofloxacin injection injected in tympanic in the treatment of secretory otitis media

    Institute of Scientific and Technical Information of China (English)

    曹雄卫

    2013-01-01

    Objective To study the clinical therapeutic efficacy of inject prednisone and levofloxacin injection into intratympanic in the treatment of secretory otitis media. Methods 62 patients (78 ears) come to our hospital for treatment from February 2009 to February 2012, diagnosed and classified with secretory otitis media were divided into two groups, the treatment group received prednisone in combination with levofloxacin injection while control group received prednisone only and study the clinical therapeutic efficacy of two groups. Results In the three months of follow-up, the total cure rate in treatment group was 97.44% (38/39), significantly higher than the control group was 89.74% (35/39), the difference in cure rate between the two groups were statistically significant (x2= 7.59,P<0.05), in terms of the treatment times, the treatment group is lower than the control group (x2= 105.178, P < 0.05), the two groups with no adverse events such as ear infections. Conclusion Prednisone in combination with levofloxacin injection is effective in the treatment of secretory otitis media, its clinical effect is significantly better than inject prednisone alone, and worthy of promotion.%  目的分析研究鼓室内注入泼尼松龙与左氧氟沙星注射液对分泌性中耳炎的治疗效果。方法选取了2009年2月~2012年2月期间来我院治疗的62例(78耳)分泌性中耳炎患者作为研究对象,将全部患者分成治疗组和对照组,其中治疗组采用泼尼松龙及左氧氟沙星注射液进行治疗,对照组采用泼尼松龙进行治疗,对两组患者的临床疗效进行分析。结果经过为期3个月的随访发现治疗组的总有效率达到了97.44%(38/39),明显高于对照组的89.74%(35/39),两组患者在治疗效果比较差异有统计学意义(x2=7.59,P<0.05),在治疗次数方面,治疗组低于对照组(x2=105.178,P<0.05),治疗组患者和对照组患者均未出现中耳感

  8. Analy sis of the Efficacy of Iron Sucrose Injection in the Treatment of Hemodialysis Renal Anemia%蔗糖铁注射液治疗维持性血液透析肾性贫血疗效分析

    Institute of Scientific and Technical Information of China (English)

    吕青; 古兰

    2014-01-01

    目的:分析蔗糖铁注射液治疗维持性血液透析肾性贫血的临床疗效。方法将收治的维持性血液透析后发生肾性贫血的120例患者纳入研究,随机分组。在促红细胞生成素基础上对照组口服铁剂治疗,试验组静脉注射蔗糖铁治疗。连续治疗8w,对比两组患者Hb、Hct、SF、TSAT等指标的变化和不良反应的差异。结果与治疗前对比,治疗后患者Hb、Hct、SF、TSAT等指标均有所上升,其中试验组各指标上升幅度明显大于对照组,组间差异有统计学意义(P<0.05)。与对照组对比,试验组患者治疗期间不良反应发生率较低,组间差异有统计学意义(P<0.05)。结论采用蔗糖铁注射液治疗维持性血液透析肾性贫血,可明显改善贫血症状,且不良反应轻微,可在临床推广应用。%Objective To analyze efficacy of iron sucrose injection in the treatment of hemodialysis renal anemia. Methods 120 patients with renal anemia after hemodialysis were chosen in our hospital, grouped randomized. On the basis of erythropoietin, control group was received oral iron, experimental group was received iron sucrose injection. 8 weeks later, compared difference of Hb, Hct, SF, TSAT and adverse reaction. Results Compared with before treatment, Hb, Hct, SF, TSAT were on the rise, ex-periment group had a greater indexes than control group, the differences had statistically significant (P<0.05). Compared with control group, adverse reactions in experimental group was lower, the differences had statistically significant (P<0.05). Conclusion Iron sucrose injection in maintenance hemodialysis patients with renal anemia, can improve the symptoms of anemia, the adverse reactions are mild, it can be widely applied in clinical practice in the future.

  9. 热毒宁注射液治疗手足口病35例疗效观察%The Efficacy Observation on Reduning Injection Treats 35 Cases of Hand-foot-mouth Disease

    Institute of Scientific and Technical Information of China (English)

    刘云芳; 陈华

    2013-01-01

      目的:观察热毒宁注射液治疗婴幼儿手足口病的临床疗效.方法:将70例手足口病患者随机分成两组,治疗组(35例)给予热毒宁合并病毒唑,对照组(35例)给予病毒唑治疗.两组均予维生素C、维生素B族,如合并感染者给予头孢曲松治疗,其他对症治疗相同.结果:治疗组总有效率为100.00%,明显高于对照组91.43%(P<0.05),治疗组在症状、体征消失时间及治愈时间明显少于对照组(P<0.05).结论:热毒宁注射液联合利巴韦林注射液治疗手足口病疗效显著,无明显毒副作用.%Objective: To observe the efficacy of reduning injection treats infant Hand-foot-mouth disease (HFMD). Methods:70 patients with HFMD were randomly divided into two groups. The treatment group (35 cases) afforded reduning combine virazole, while the control group (35 cases) afforded virazole. These two groups were afforded vitamin C and vitamin B fami-ly. If someone complicated infection, he would be given ceftriaxone to treat. Other symptomatic treatment was the same. Results:The total effective rate of treatment group was 100.00%, it was ob-viousely higher than control group (91.43%)(P<0.05). The treatment group disappear time of symp-tom and sign was obviously less than control group (P<0.05). Conclusion:Reduning injection com-bine ribavirin injection treating HFMD is effective, and it has no obvious toxic and side effects.

  10. Efficacy of medical ozone intra-articular injection for the treatment of patients with knee joint meniscus injury%医用三氧膝关节腔内注射治疗半月板损伤的疗效

    Institute of Scientific and Technical Information of China (English)

    董俊球; 黎小雅

    2015-01-01

    目的 探讨膝关节腔内注射医用三氧治疗半月板损伤的疗效.方法 半月板损伤患者64例,以随机法分为三氧组和理疗组,每组32例.三氧组采用膝关节腔内医用三氧注射治疗;理疗组采用中西结合物理治疗,两组均配合股四头肌功能训练.于治疗后1个月时行AKS评分及临床疗效评定.结果 治疗后三氧组患者AKS各分项及总评分均高于理疗组,优良率三氧组94%(30/32例)高于理疗组56%(18/32例),差异均有统计学意义(P<0.05).结论 膝关节腔内医用三氧注射治疗半月板损伤疗效良好.%Objective To observe the efficacy of medical ozone intra-articular injection in the treatment of patients with knee joint meniscus injury.Methods Sixty-four patients with knee joint meniscus injury were randomly divided into two groups,32 cases in each group.Patients in ozone group were received intraarticular injection of ozone,while physiotherapy group were received combination of traditional Chinese and Western physical therapy.All of the patients were combined with functional training of quadratus femoris muscle.AKS and clinical effects were evaluated at 1 month after the treatment.Results The total score of AKS and its each item were significantly higher in ozone group than those in physiotherapy group (P < 0.05).The excellent and good rate in ozone group (94%,30/32 cases) was significantly higher than that in physiotherapy group (56%,18/32 cases) (P < 0.05).Conclusion Medical ozone intra-articular injection is effective in the treatment of knee joint meniscus injury.

  11. A Double-Blind Placebo Controlled Trial of "Ginkgo Biloba" Added to Risperidone in Patients with Autistic Disorders

    Science.gov (United States)

    Hasanzadeh, Elmira; Mohammadi, Mohammad-Reza; Ghanizadeh, Ahmad; Rezazadeh, Shams-Ali; Tabrizi, Mina; Rezaei, Farzin; Akhondzadeh, Shahin

    2012-01-01

    "Ginkgo biloba" has been reported to affect the neurotransmitter system and to have antioxidant properties that could impact the pathogenesis of Autism Spectrum Disorder. Based on these studies, we decided to assess the effectiveness of "Ginkgo biloba" extract (Ginko T.D., Tolidaru, Iran) as an adjunctive agent to risperidone in the treatment of…

  12. Add-on effects of a low-dose aripiprazole in resolving hyperprolactinemia induced by risperidone or paliperidone.

    Science.gov (United States)

    Qiao, Ying; Yang, Fuzhong; Li, Chunbo; Guo, Qian; Wen, Hui; Zhu, Suoyu; Ouyang, Qiong; Shen, Weidi; Sheng, Jianhua

    2016-03-30

    This study investigated the effects of a low-dose aripiprazole adjunctive treatment for risperidone- or paliperidone-induced hyperprolactinemia in Han Chinese women with schizophrenia. After 4 weeks of risperidone or paliperidone treatment, 60 out of 66 patients improved significantly and experienced hyperprolactinemia. They were randomly assigned to the treatment group (aripiprazole adjunctive treatment) (n=30) or control group (non-adjunctive treatment) (n=30). The dosage of risperidone and paliperidone were maintained; and aripiprazole was maintained at 5mg/day during the 8-week study period. The prolactin levels at the end of the 8th week were significantly lower in the treatment group than in the control group. The estradiol level correlated negatively with serum prolactin level both in the treatment group and the control group at the end of the 8th week and the 4th week respectively. The Positive and Negative Syndrome Scale score improved significantly during the 8-week study period in both groups. The incidence of treatment-emergent adverse event was similar in two groups. Low-dose aripiprazole adjunctive treatment is effective in relieving risperidone- and paliperidone-induced hyperprolactinemia in female schizophrenic patients without increasing adverse event.

  13. Effects of risperidone on core symptoms of autistic disorder based on childhood autism rating scale: An open label study

    Directory of Open Access Journals (Sweden)

    Padideh Ghaeli

    2014-01-01

    Full Text Available Background: The aim of the present study was to evaluate the effect of risperidone in patients afflicted by autistic disorder especially with regards to its three core symptoms, including "relating to others", "communication skills", and "stereotyped behaviors" based on Childhood Autism Rating Scale (CARS. Materials and Methods: An 8-week open-label study of risperidone for treatment of autistic disorder in children 4-17 years old was designed. Risperidone dose titration was as follow: 0.02 mg/kg/day at the first week, 0.04 mg/kg/day at the second week, and 0.06 mg/kg/day at the third week and thereafter. The outcome measures were scores obtained by CARS, Aberrant Behavior Checklist (ABC, and Clinical Global Impression-Improvement (CGI-I scale. Results: Fifteen patients completed this study. After 8 weeks, CARS total score decreased significantly, (P=0.001. At the end of the study, social interactions and verbal communication skills of the patients were significantly improved (P<0.001, P=0.03, respectively. However, stereotypic behaviors did not show any significant change in this study. Increase in appetite and somnolence were the most reported side effects. Conclusion: This study suggests that risperidone may be an effective treatment for the management of core symptoms of autistic disorder.

  14. Selective acquired long QT syndrome (saLQTS upon risperidone treatment

    Directory of Open Access Journals (Sweden)

    Lazarczyk Maciej

    2012-12-01

    Full Text Available Abstract Background Numerous structurally unrelated drugs, including antipsychotics, can prolong QT interval and trigger the acquired long QT syndrome (aLQTS. All of them are thought to act at the level of KCNH2, a subunit of the potassium channel. Although the QT-prolonging drugs are proscribed in the subjects with aLQTS, the individual response to diverse QT-prolonging drugs may vary substantially. Case presentation We report here a case of aLQTS in response to small doses of risperidone that was confirmed at three independent drug challenges in the absence of other QT-prolonging drugs. On the other hand, the patient did not respond with QT prolongation to some other antipsychotics. In particular, the administration of clozapine, known to be associated with higher QT-prolongation risk than risperidone, had no effect on QT-length. A detailed genetic analysis revealed no mutations or polymorphisms in KCNH2, KCNE1, KCNE2, SCN5A and KCNQ1 genes. Conclusions Our observation suggests that some patients may display a selective aLQTS to a single antipsychotic, without a potassium channel-related genetic substrate. Contrasting with the idea of a common target of the aLQTS-triggerring drugs, our data suggests existence of an alternative target protein, which unlike the KCNH2 would be drug-selective.

  15. Delayed drug interactions in psychiatry: armodafinil and risperidone as a potential case in point.

    Science.gov (United States)

    Andrade, Chittaranjan

    2015-12-01

    Modafinil or armodafinil (ar/mod) augmentation of antipsychotic medication in schizophrenia patients may be considered with a view to reduce negative symptoms associated with the illness or excessive daytime drowsiness due to any cause. The available data suggest that there is no role for ar/mod in reducing negative symptom burden. A recent pharmacokinetic (PK) study suggested that armodafinil (250 mg/d) reduces key PK parameters of risperidone by about 50%, and key PK parameters of 9-hydroxyrisperidone (paliperidone) by about 20%-30%, probably through induction of CYP3A4. Ar/mod augmentation is therefore best avoided in patients receiving risperidone or paliperidone (and most other atypical antipsychotic drugs, as well, because most atypical antipsychotics are metabolized by enzymes that ar/mod induce). If the ar/mod-antipsychotic drug combination is necessary, for whatever reason, then the dose of the atypical antipsychotic drug may need to be appropriately raised. If this is not done, relapse may occur; because the relapse may postdate the introduction of ar/mod by many months, the causal role of a metabolic drug interaction may not be suspected, and physicians may attribute the relapse to the natural course of the illness. Physicians need to be aware that any agent that induces the metabolism of psychotropic drugs that are used in maintenance therapy may, through lowered psychotropic drug levels, result in a delayed drug interaction that is characterized by illness relapse.

  16. An open-label trial of risperidone and fluoxetine in children with autistic disorder

    Directory of Open Access Journals (Sweden)

    Desousa Avinash

    2010-01-01

    Full Text Available Objective: Various studies have shown the effectiveness of risperidone and fluoxetine in the management of behavioral problems in autism. Aim: The purpose of this study was to compare these two drugs in the management of behavioral problems in autism. Materials and Methods: Forty children with autism were divided into 2 groups in a 16-week open trial that compared these two drugs. Parents rated the children using the Aberrant Behavior Checklist (ABC and the Conners′ Parent Rating Scale - Revised (CPRS-R. The author rated the children using the Children′s Psychiatric Rating Scale and Clinical Global Impression (CGI Scale. Results: The risperidone group showed significant improvement in areas like irritability and hyperactivity, while the fluoxetine group showed significant improvement in speech deviance, social withdrawal and stereotypy. When the two drugs were compared, fluoxetine showed greater improvement in stereotypy, while both drugs showed improvement on the general autism scale; and on anger, hyperactivity and irritability scales. Conclusions : In this open trial, both drugs were well tolerated and appeared to be beneficial in the treatment of common behavioral problems in children with autism. Further controlled and double-blind studies in larger samples are warranted.

  17. 参附注射液治疗心源性休克有效性和安全性系统评价%Systematic review on efficacy and safety of Shenfu Injection for cardiogenic shock

    Institute of Scientific and Technical Information of China (English)

    杨倩春; 毛炜; 刘旭生; 包坤; 邹川; 黎创; 刘帅帅

    2012-01-01

    Objective: To assess the efficacy and safety of Shenfu Injection for cardiogenic shock. Methods: Randomized controlled trials (RCTs) involving Shenfu Injection for cardiogenic shock were included. The quality and risk of bias were evaluated. The Cochrane Collaboration's RevMan 5.1.4 software was used for data analyses and 'GRADE profiler' software was used for the evidence classification of this system review's evaluation results. Results: A total of 6 trials involving 367 patients were included. Meta analyses showed that the mortality, the effective rate, after therapy 2h HR, after therapy 2h SBP, after therapy 2h DBP and EF were higher when Shenfu injection plus basic therapy group compared with basic therapy group. However, in improving ESV and EDV have no significant difference. GRADE evidence classification was very low. Conclusion: Shenfu Injection for cardiogenic shock with few adverse reactions was a relative safe. More high quality and large-scaled randomized controlled trials were required in the future in order to define the role of Shenfu Injection for cardiogenic shock.%目的:评价参附注射液治疗心源性休克有效性和安全性.方法:纳入参附注射液治疗心源性休克为研究对象的随机对照试验,对每个纳入研究进行偏倚风险和质量评估,统计学分析采用RevMan 5.1.4软件.用GRADE profiler软件和标准评估证据质量.结果:本系统评价纳入6个随机对照试验,共367例患者,Meta分析得出参附注射液合基础治疗在治疗病死率、有效率、2h后心率、2h后及2周后收缩压、舒张压及射血分数都优于基础治疗组,但改善收缩末期容积(ESV)和舒张末期容积(EDV)与基础治疗组比较,无统计学差异.GRADE证据质量评估为很低级别证据.参附注射液治疗心源性休克不良反应少,因此相对安全.结论:参附注射液治疗心源性休克安全、有效,但证据质量低,仍需高质量研究产生的证据支持.

  18. Injection MD

    CERN Document Server

    Bartmann, W; Bracco, C; Drosdal, L; Gianfelice, E; Goddard, B; Kain, V; Papaphilippou, Y; Vanbavinckhove, G

    2012-01-01

    This note summarizes the results obtained at injection during the 2nd MD block and the floating MD block in July. Highlights are presented for injection in the LHC with the Q20 SPS optics, influence of the supercycle and injection with 25 ns bunch spacing. Beams were successfully injected into the LHC using the Q20 optics [1, 3]. Small corrections were needed to steer the beam in the transfer lines. Dispersion measurements were conducted for both beams. The horizontal normalized dispersion in TI2 was a factor 2 smaller for Q20 with respect to Q26, for TI8 on the other hand the opposite was observed. The results for injection loss dependency on super cycle composition show only a small increase in losses for beam 2. The losses observed must therefore mainly come from other sources such as shot-by-shot stability or quality of scraping. For the injection with 25 ns bunch spacing bunches were injected for both beams. For B1 up to the maximum of 288 bunches. For B2 on the other only up to 144 bunches were injected...

  19. Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment: results of a 48-week open-label study

    Directory of Open Access Journals (Sweden)

    Esser S

    2011-10-01

    Full Text Available Abstract Objective To assess efficacy, adherence and tolerability of once daily antiretroviral therapy containing tenofovir disoproxil fumarate (DF 300 mg in HIV-1-infected former injecting drug users receiving opiate treatment (IVDU. Methods European, 48-week, open-label, single-arm, multicenter study. Patients were either antiretroviral therapy-naïve, restarting therapy after treatment discontinuation without prior virological failure or switching from existing stable treatment. Results Sixty-seven patients were enrolled in the study and 41 patients completed treatment. In the primary analysis (intent-to-treat missing = failure at week 48, 34% of patients (23/67; 95% CI: 23%-47% had plasma HIV-1 RNA 3. Although self-reported adherence appeared high, there were high levels of missing data and adherence results should be treated with caution. No new safety issues were identified. Conclusions Levels of missing data were high in this difficult-to-treat population, but potent antiretroviral suppression was achieved in a substantial proportion of HIV-infected IVDU-patients.

  20. A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: Effects on aberrant behavior in children with autism.

    Science.gov (United States)

    Ghaleiha, Ali; Rasa, Soudeh Mohebbi; Nikoo, Mohammadali; Farokhnia, Mehdi; Mohammadi, Mohammad-Reza; Akhondzadeh, Shahin

    2015-09-30

    To assess the safety and efficacy of pioglitazone added to risperidone in the treatment of irritability in autistic disorder (AD), we conducted this study. In a 10-week, randomized, double-blind, parallel-group, placebo-controlled clinical trial, 44 outpatients of both genders aged 4-12 years with a diagnosis of AD and a score of ≥12 on the Aberrant Behavior Checklist-Community (ABC-C) irritability subscale were included. Mean change of ABC-C irritability subscale score as primary outcome, change in other ABC-C subscale scores and partial and complete responses were compared between two groups. Twenty patients completed the trial in each group. Level of reduction and effect of time×treatment interaction in the treatment group were significant for irritability (P=0.03), lethargy/social withdrawal (P=0.04) and hyperactivity/non-compliance (P=0.03) but not for stereotypic behavior and inappropriate speech subscales compared with the placebo group. Vomiting and headache were the most frequent reported side-effects. Results of this preliminary study indicate positive effects of pioglitazone compared with placebo in improving the behavioral symptoms of AD.

  1. Study on Clozapine combined with Risperidone in replacement of single Clozapine in treatment of schizophrenia%氯氮平联合利培酮替代单用氯氮平治疗精神分裂症患者的研究

    Institute of Scientific and Technical Information of China (English)

    胡小平

    2014-01-01

    Objective:To observe clinical efficacy and safety of Clozapine combined with Risperidone and single Clozapine in treatment of schizophrenia. Methods:60 patients with schizophrenia were randomly divided into Clozapine combined with Risperidone group (30 cases) and Clozapine group (30 cases), and the treatments lasted for 12 weeks. Clinical global impression scale (CGI) was used to assess the efficacy, and treatment emergent symptom scale ( TESS) was selected to assess the adverse reactions and safety. Results:At the end of the treatment, there was no significant difference in the efficacy between the two groups; however, there were less adverse reactions in Clozapine combined with Risperidone group. Conclusions:Clozapine Combined with Risperidone can replace single Clozapine in the treatment of schizophrenia, their curative effects are similar, but the former has less adverse reactions.%目的::观察氯氮平联合利培酮与单用氯氮平治疗精神分裂症患者的临床疗效和安全性。方法:将60例精神分裂症患者随机分为观察组(氯氮平联合利培酮治疗)30例和对照组(氯氮平治疗)30例,疗程12周,采用临床总体疗效量表CGI评定疗效,用不良反应量表TESS评估患者出现的不良反应和安全性。结果:疗程结束时,两组患者疗效无显著性差异,观察组不良反应较少。结论:氯氮平联合利培酮可以替代单用氯氮平治疗精神分裂症,疗效与单用氯氮平相当,不良反应比单用氯氮平小。

  2. Movement disorders in elderly users of risperidone and first generation antipsychotic agents: a Canadian population-based study.

    Directory of Open Access Journals (Sweden)

    Irina Vasilyeva

    Full Text Available BACKGROUND: Despite concerns over the potential for severe adverse events, antipsychotic medications remain the mainstay of treatment of behaviour disorders and psychosis in elderly patients. Second-generation antipsychotic agents (SGAs; e.g., risperidone, olanzapine, quetiapine have generally shown a better safety profile compared to the first-generation agents (FGAs; e.g., haloperidol and phenothiazines, particularly in terms of a lower potential for involuntary movement disorders. Risperidone, the only SGA with an official indication for the management of inappropriate behaviour in dementia, has emerged as the antipsychotic most commonly prescribed to older patients. Most clinical trials evaluating the risk of movement disorders in elderly patients receiving antipsychotic therapy have been of limited sample size and/or of relatively short duration. A few observational studies have produced inconsistent results. METHODS: A population-based retrospective cohort study of all residents of the Canadian province of Manitoba aged 65 and over, who were dispensed antipsychotic medications for the first time during the time period from April 1, 2000 to March 31, 2007, was conducted using Manitoba's Department of Health's administrative databases. Cox proportional hazards models were used to determine the risk of extrapyramidal symptoms (EPS in new users of risperidone compared to new users of FGAs. RESULTS: After controlling for potential confounders (demographics, comorbidity and medication use, risperidone use was associated with a lower risk of EPS compared to FGAs at 30, 60, 90 and 180 days (adjusted hazard ratios [HR] 0.38, 95% CI: 0.22-0.67; 0.45, 95% CI: 0.28-0.73; 0.50, 95% CI: 0.33-0.77; 0.65, 95% CI: 0.45-0.94, respectively. At 360 days, the strength of the association weakened with an adjusted HR of 0.75, 95% CI: 0.54-1.05. CONCLUSIONS: In a large population of elderly patients the use of risperidone was associated with a lower risk of EPS

  3. 穴位注射联合中药颗料外洗治疗手部湿疹疗效观察%Efficacy observation of point injection combined Chinese medicine granule washing treatment of hand eczema

    Institute of Scientific and Technical Information of China (English)

    陈树钊

    2015-01-01

    目的:探讨观察穴位注射联合中药颗料外洗治疗手部湿疹的疗效。方法手部湿疹患者80例根据随机抽签方法分为治疗组与对照组各40例,对照组给予传统穴位注射治疗,治疗组在对照组治疗的基础上给予自拟中药颗粒洗剂治疗。结果治疗后治疗组的显效率分别为97.5%和85.0%,治疗组的显效率明显高于对照组(P<0.05)。两组治疗后的皮损与自觉症状评分明显低于治疗前(P<0.05),同时治疗后治疗组的皮损与自觉症状评分明显低于对照组(P<0.05)。经过观察,两组治疗后血清IL-15和IL-21值明显低于治疗前(P<0.05),同时治疗后治疗组的血清IL-15和IL-21值明显低于对照组(P<0.05)。结论穴位注射联合中药颗料外洗治疗手部湿疹能通过保护、润肤、收敛、抗过敏、止痒等综合作用改善临床症状,促进临床疗效的提高。%ObjectiveTo investigate the efficacy of point injection combined Chinese medicine granule washing treatment of hand eczema.Methods80 patients with hand eczema accorded a random draw method were equally divided into the treatment group and control group, the control group were received traditional acupuncture point injection therapy, the treatment group were added given self-made medicine particles lotion treatment on the basis of the control group.Results The effective rates of the treatment group and the control group were 97.5% and 85.0% respectively which the treatment group had significantly higher efficiency (P<0.05). After treatment, the skin lesions and symptoms scores were significantly lower than before treatment (P<0.05), while the lesions and symptoms scores in the treatment group were significantly lower than the control group (P<0.05). After treatment, the serum IL-15 and IL-21 were significantly lower than before treatment (P<0.05), while serum IL-15 and IL-21 value of the treatment group were significantly lower than

  4. Observation of clinical efficacy of amoxicillin and clavulanate potassium injection combined with compound danshen injection in treatment of community acquired pneumonia%注射用阿莫西林克拉维酸钾联合复方丹参注射液治疗社区获得性肺炎临床疗效观察

    Institute of Scientific and Technical Information of China (English)

    郁殿明

    2014-01-01

    目的:观察注射用阿莫西林克拉维酸钾联合丹参注射液治疗社区获得性肺炎的临床疗效。方法选取我院2013年1月~2014年5月期间收治的社区获得性肺炎患者80例,随机分成治疗组和对照组各40例,治疗组采用注射用阿莫西林克拉维酸钾联合复方丹参注射液静滴,对照组单独应用阿莫西林克拉维酸钾静滴,两组患者均连续静脉用药7d。于疗程结束后1周评价疗效,分别比较两组患者的临床表现,包括体温改变、咳嗽的变化及肺部体征的变化,并进行胸片及血常规检查,同时记录不良反应发生情况及症状消退的时间,对比分析两组的临床效果和用药安全性。结果治疗组总有效率92.50%,明显高于对照组的72.50%,两组患者退热时间方面无显著差异,但治疗组咳嗽消失时间、X线改变恢复正常平均时间及白细胞恢复正常时间均明显短于对照组,差异有统计学意义。结论使用注射用阿莫西林克拉维酸钾联合复方丹参注射液治疗社区获得性肺炎较单独应用阿莫西林克拉维酸钾可以明显缩短疗程,提高疗效,有一定的临床借鉴意义。%Objective To observe the clinical efficacy of amoxicillin and clavulanate potassium injection combined with compound danshen injection in treatment of community acquired pneumonia. Methods Eighty patients with community acquired pneumonia treated in our hospital from January 2013 to May 2014 were selected and randomly divided into the treatment group and the control group, with 40 patients in each group. The treatment group received amoxicillin and clavulanate potassium injection combined with compound danshen injection and the control group received the intra-venous infusion of single amoxicillin and clavulanate potassium. Both groups received intravenous medication for 7 continuous days. The efficacy was evaluated one week after the end of treatment. Clinical

  5. Efficacy comparison of atracurium through target control infusion and continuous close-loop muscle relaxant injection%靶控输注与闭环式肌松注射阿曲库铵效果比较

    Institute of Scientific and Technical Information of China (English)

    刘畅; 刘庆; 刘萍; 唐燕红

    2013-01-01

    Objective To compare the efficacy of atracurium administered through target control infusion and closed-loop muscle relaxant injection. Methods 75 patients undergoing laparotomy under total intravenous anesthesia were randomly divided into two groupsGroup T(n=39)received atracurium by target control infusion. The target concentration during induction was set at 5 mg/L,after trachea cannula at 1 mg/L, and during opera-tion according to the requirement. Group C (n=36),received atracurium by closed-loop muscle relaxant injection systemthe induction dose of atracurium was 0.5 mg/kg,the maintenance dose 2.5 μg/kg/min, increase to 10 μg/kg/min when T1/Tc > 10%. The onset time,recovery index, the time from stopping injection to extubation,dosages,frequence of dissatisfying muscle relaxation,mean arterial pressure,heart rate,respiratory rate,and SpO2 in the two groups were compared. No antagonist was used in both groups. It was the time for extubation when T1/Tc recovered to 90%. Results There were no statistical differences in onset time,mean arterial pressure, heart rate,respiratory rate,and SpO2 between the two groups (P> 0.05). Compared with group T, the recovery index,the time form stopping injection to extubation of group C was shorter,dosages larger and frequence of dissatisfy-ing muscle relaxation less (P10%,增药速度为10μg/kg/min,记录2组肌松起效时间、恢复指数、停药至拔管时间、用药量、术中肌松不足出现次数、各阶段平均动脉压、心率、呼吸频率、SpO2。2组均不使用拮抗剂,术毕待T1/Tc恢复至90%后拔管。结果:2组一般资料,各阶段平均动脉压、心率、SpO2比较无统计学意义(P>0.05),阿曲库铵起效时间、插管条件比较无统计学意义(P>0.05),与T组相比,C组恢复指数,拔管时间缩短,用药量增大,肌松不足出现次数减少(P<0.05);结论:靶控输注与闭环式肌松注射两种方式注射均能安全应用于临床,但闭环式肌松

  6. Oxytocin Injection

    Science.gov (United States)

    Oxytocin injection is used to begin or improve contractions during labor. Oxytocin also is used to reduce bleeding after childbirth. ... other medications or procedures to end a pregnancy. Oxytocin is in a class of medications called oxytocic ...

  7. Cidofovir Injection

    Science.gov (United States)

    Cidofovir injection is used along with another medication (probenecid) to treat cytomegaloviral retinitis (CMV retinitis) in people with acquired immunodeficiency syndrome (AIDS). Cidofovir is in a class of medications called antivirals. ...

  8. Brivaracetam Injection

    Science.gov (United States)

    ... older. Brivaracetam in a class of medications called anticonvulsants. It works by decreasing abnormal electrical activity in ... older (about 1 in 500 people) who took anticonvulsants like brivaracetam injection to treat various conditions during ...

  9. Fluconazole Injection

    Science.gov (United States)

    ... and fungal infections of the eye, prostate (a male reproductive organ), skin and nails. Fluconazole injection is ... Motrin, others) and naproxen (Aleve, Anaprox, Naprelan); oral contraceptives (birth control pills); oral medication for diabetes such ...

  10. Certolizumab Injection

    Science.gov (United States)

    ... and swelling and scales on the skin), active ankylosing spondylitis (a condition in which the body attacks the ... continues. When certolizumab injection is used to treat ankylosing spondylitis, it is usually given every 2 weeks for ...

  11. Butorphanol Injection

    Science.gov (United States)

    ... not understand the directions.Butorphanol injection may be habit-forming. Do not use a larger dose, use ... tiredness difficulty falling asleep or staying asleep unusual dreams headache constipation stomach pain feeling hot flushing pain, ...

  12. Dexamethasone Injection

    Science.gov (United States)

    ... body tissues,) gastrointestinal disease, and certain types of arthritis. Dexamethasone injection is also used for diagnostic testing. ... effects.tell your doctor if you have a fungal infection (other than on your skin or nails). ...

  13. Hydrocortisone Injection

    Science.gov (United States)

    ... own organs), gastrointestinal disease, and certain types of arthritis. Hydrocortisone injection is also used to treat certain ... effects.tell your doctor if you have a fungal infection (other than on your skin or nails). ...

  14. Methylprednisolone Injection

    Science.gov (United States)

    ... own organs), gastrointestinal disease, and certain types of arthritis. Methylprednisolone injection is also used to treat certain ... effects.tell your doctor if you have a fungal infection (other than on your skin or nails). ...

  15. Ciprofloxacin Injection

    Science.gov (United States)

    ... attack) . Ciprofloxacin may also be used to treat bronchitis and sinus infections, but should not be used for these conditions if there are other treatment options available. Ciprofloxacin injection is in a class ...

  16. Golimumab Injection

    Science.gov (United States)

    Golimumab injection is used alone or with other medications to relieve the symptoms of certain autoimmune disorders ( ... did not help or could not be tolerated. Golimumab is in a class of medications called tumor ...

  17. Evolocumab Injection

    Science.gov (United States)

    ... autoinjector in hot water, microwave, or place in sunlight.Before you use evolocumab injection, look at the ... chills pain or burning during urination muscle or back pain dizziness stomach pain Some side effects can be ...

  18. Glatiramer Injection

    Science.gov (United States)

    ... To inject glatiramer, follow these steps: Remove one blister pack from the carton of glatiramer syringes and place ... paper label and remove the syringe from the blister pack. Check your prefilled syringe to be sure it ...

  19. Insulin Injection

    Science.gov (United States)

    ... or buttocks. Do not inject insulin into muscles, scars, or moles. Use a different site for each ... you are using insulin.Alcohol may cause a decrease in blood sugar. Ask your doctor about the ...

  20. Tigecycline Injection

    Science.gov (United States)

    ... in a person who was not in the hospital), skin infections, and infections of the abdomen (area between the ... that developed in people who were in a hospital or foot infections in people who have diabetes. Tigecycline injection is ...

  1. Fludarabine Injection

    Science.gov (United States)

    Fludarabine injection is used to treat chronic lymphocytic leukemia (CLL; a type of cancer of the white ... a reliable method of birth control to prevent pregnancy during this time. Talk to your doctor for ...

  2. Ferumoxytol Injection

    Science.gov (United States)

    Ferumoxytol injection is used to treat iron-deficiency anemia (a lower than normal number of red blood ... pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or ...

  3. Alemtuzumab Injection

    Science.gov (United States)

    Alemtuzumab injection is used to treat B-cell chronic lymphocytic leukemia (a slowly developing cancer in which ... of white blood cell accumulate in the body). Alemtuzumab is in a class of medications called monoclonal ...

  4. Alirocumab Injection

    Science.gov (United States)

    ... further decrease the amount of low-density lipoprotein (LDL) cholesterol ('bad cholesterol') in the blood. Alirocumab injection is ... antibodies. It works by blocking the production of LDL cholesterol in the body to decrease the amount of ...

  5. Chloramphenicol Injection

    Science.gov (United States)

    ... an arm or leg sudden changes in vision pain with eye movement Chloramphenicol injection may cause a condition called gray syndrome in premature and newborn infants. There have also been reports of gray ...

  6. A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study: 12-month analysis

    Directory of Open Access Journals (Sweden)

    Singh RP

    2015-09-01

    Full Text Available Rishi P Singh, Sunil K Srivastava, Justis P Ehlers, Fabiana Q Silva, Rumneek Bedi, Andrew P Schachat, Peter K Kaiser Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA Summary statement: In subjects with active exudative age-related macular degeneration, treating with a fixed intravitreal aflibercept injection dosing regimen for 12 months demonstrated improved anatomic and vision endpoints from baseline.Purpose: Switching therapies in neovascular age-related macular degeneration (AMD may offer an advantage for some patients. This study evaluates the efficacy of intravitreal aflibercept injection (IAI in subjects previously treated with ranibizumab and/or bevacizumab.Methods: Subjects (n=26 were given monthly 2 mg of IAI for 3 months, followed by 2 mg once in every 2 months for up to 12 months. The mean absolute change from baseline in central subfield thickness (CST measured by optical coherence tomography and the mean change from baseline in best-corrected visual acuity (BCVA early treatment in diabetic retinopathy study (ETDRS letter score were obtained. Additionally, the percentage of subjects who gained or lost ≥15 letters of vision and the percentage of subjects who are 20/40 or better or 20/200 or worse were evaluated.Results: There was a mean decrease in CST of -50.3  µm (P<0.001 and a mean increase in ETDRS BCVA of +9.2 letters (P<0.001. Twenty-seven percent of subjects experienced a  ≥15-letter improvement in visual acuity, and no subject lost ≥3 lines of vision from baseline. Fifty percent of subjects were 20/40 or better, and 11.5% of subjects were 20/200 or worse at month 12.Conclusion: Fixed IAI dosing regimen for 12 months demonstrated improved anatomic and vision endpoints in subjects with active exudative AMD. Keywords: aflibercept, age-related macular degeneration, bevacizumab, ranibizumab, vascular endothelial growth factors

  7. A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation.

    Science.gov (United States)

    Hari, Parameswaran; Aljitawi, Omar S; Arce-Lara, Carlos; Nath, Rajneesh; Callander, Natalie; Bhat, Gajanan; Allen, Lee F; Stockerl-Goldstein, Keith

    2015-12-01

    Autologous stem cell transplantation (ASCT) after high-dose melphalan conditioning is considered a standard of care procedure for patients with multiple myeloma (MM). Current formulations of melphalan (eg, Alkeran for Injection [melphalan hydrochloride]; GlaxoSmithKline, Research Triangle Park, NC, USA) have marginal solubility and limited chemical stability upon reconstitution. Alkeran requires the use of propylene glycol as a co-solvent, which itself has been reported to cause such complications as metabolic/renal dysfunction and arrhythmias. EVOMELA (propylene glycol-free melphalan HCl; Spectrum Pharmaceuticals, Inc., Irvine, CA, USA) is a new i.v. melphalan formulation that incorporates Captisol (Ligand Pharmaceuticals, Inc., La Jolla, CA, USA), a specially modified cyclodextrin that improves the solubility and stability of melphalan and eliminates the need for propylene glycol. This new formulation has been shown to be bioequivalent to Alkeran. EVOMELA (200 mg/m(2)) was administered as 2 doses of 100 mg/m(2) each in a phase IIb, open-label, multicenter study to confirm its safety and efficacy as a high-dose conditioning regimen for patients with MM undergoing ASCT. At 5 centers, 61 patients (26 women) with a median age of 62 years (range, 32-73) were enrolled. All patients achieved myeloablation with a median time of 5 days post-ASCT, and all successfully achieved neutrophil and platelet engraftment with median times of 12 days post-ASCT and 13 days post-ASCT, respectively; treatment-related mortality on day 100 was 0%. Overall response rate (according to independent, blinded review) was high (100%), with an overall complete response rate of 21% (13% stringent complete response; 8% complete response) and overall partial response rate of 79% (61% very good partial response; 18% partial response). The incidence of grade 3 mucositis and stomatitis was low (10% and 5%, respectively) with no grade 4 mucositis or stomatitis reported (graded according to National

  8. Effects of co-treatment with mirtazapine and low doses of risperidone on immobility time in the forced swimming test in mice.

    Science.gov (United States)

    Rogóż, Zofia

    2010-01-01

    The aim of the present study was to examine the effect of mirtazapine (MIR) and risperidone (an atypical antipsychotic drug), given separately or jointly, on immobility time in the forced swimming test in male C57BL/6J mice. Fluoxetine (FLU) was used as a reference drug. MIR (2.5, 5 and 10 mg/kg) and FLU (5 and 10 mg/kg), or risperidone in low doses (0.05 and 0.1 mg/kg) given alone did not change the immobility time of mice in the forced swimming test. Joint administration of MIR (5 and 10 mg/kg) or FLU (10 mg/kg) and risperidone (0.1 mg/kg) produced antidepressant-like activity in the forced swimming test. WAY100636 (a 5-HT(1A) receptor antagonist) inhibited, while yohimbine (an α(2)-adrenergic receptor antagonist) potentiated the antidepressant-like effect induced by co-administration of MIR and risperidone. Active behavior in that test did not reflect an increase in general activity, since combined administration of antidepressants and risperidone failed to enhance the locomotor activity of mice. The obtained results indicate that risperidone applied in a low dose enhances the antidepressant-like activity of MIR and that, among other mechanisms, 5-HT(1A)-, and α(2)-adrenergic receptors may play a role in this effect.

  9. Comparison Of Effect Of Addition Of Fluvoxamine Or Risperidone To Clozapine In Chronic Partially Responsive Schizophrenic Patients On Clinical Response, QTc interval And Lipid profile

    Directory of Open Access Journals (Sweden)

    Sunil Mahakalkar

    2016-07-01

    Full Text Available Objective – To study & compare the augmentation effect of addition of fluvoxamine or risperidone in chronic partially responsive schizophrenic patients receiving clozapine on clinical and laboratory parameters.Methods - A prospective, randomized, parallel, open label 12 weeks study. The schizophrenic patients, aged 20-60 years, who followed the DSM-IV diagnostic criteria and receiving clozapine therapy, showing partial response to the treatment were recruited and the study was carried out from January 2007 to June 2008. Subjects were randomized into two groups: Group A (n=28: fluvoxamine (25-50mg/day was added to clozapine (25-200mg/day & Group B (n=27: risperidone (1-5mg/day was added to clozapine therapy. The effect of drugs was assessed by PANSS, BPRS scale and ECG and lipid profile were done at 6 and 12 weeks.Result - There was significant decrease in PANSS and BPRS score in both groups.Fluvoxamine + clozapine significantly reduced PANSS score as compared to risperidone + clozapine compared to baseline and between 6 and 12 weeks. Risperidone +clozapine prolonged QTc interval (at 12 weeks and elevated serum TG, VLDL, HDL significantly at 6 and 12 weeks.Conclusion – Although addition of fluvoxamine and risperidone to clozapine are effective in management of chronic partially responsive schizophrenia on clozapine, fluvoxamine is more effective as well as safer compared to Risperidone when compared for 6 and 12 weeks in these patients.

  10. CONTROL STUDY BETWEEN RISPERIDONE ORAL SOLUTION AND OLANZAPINE FOR ALCOHOL -INDUCED MENTAL DISORDER%利培酮口服液与奥氮平治疗酒精所致精神障碍对照研究

    Institute of Scientific and Technical Information of China (English)

    王丽莉; 吕浩; 杨建立

    2012-01-01

    目的:探讨利培酮口服液与奥氮平治疗酒精所致精神障碍的疗效和安全性.方法:将68例男性酒精所致精神障碍患者随机分为利培酮口服液治疗组和奥氮平治疗组.采用阳性与阴性症状量表( PANSS)评定临床疗效;采用治疗副反应量表( TESS)评定药物不良反应.结果:利培酮口服液与奥氮平两组疗效差异无显著性.利培酮口服液主要不良反应为锥外系反应,奥氮平为体重增加.结论:利培酮口服液与奥氮平治疗酒精所致精神障碍疗效及耐受性均好,可根据用药对象对不良反应的耐受等情况进行选择.%Objective: To compare the efficacy and safety of risperidone oral solution and olanzapine in the treatment of alcohol - induced mental disorder. Methods: Sixty - eight male patients with alcohol - induced mental disorder were randomly divided into risperidone oral solution group and olanzapine group. Clinical effect was evaluated by Positive and Negative Syndrome Scale (PANSS) ,and the adverse drug reactions were assessed with Treatment Emergent Symptom Scale ( TESS) . Results: No significant differences were observed in the clinical effect of the two groups. The main side effect experienced by the olanzapine group was body weight gain, while the resperidone oral solution group showed extrapyramidal responses. Conclusion: Both olanzapine and risperidone oral solution are safe and effective for the treatment of alcohol - induced mental disorder,and can be clinically selected according to patients' tolerance of the side effects.

  11. Observation Efficacy on Cerebral Hemorrhage Piracetam Sodium Chloride Injection Therapy%吡拉西坦氯化钠注射液治疗脑出血的疗效观察

    Institute of Scientific and Technical Information of China (English)

    王明达

    2016-01-01

    Objective Piracetam sodium chloride injection to be applied to the efficacy of the treatment of cerebral hemorrhage were observed and analyzed. Methods From March 2014 to September 2015 in our hospital, 238 cases of cerebral hemorrhage patients were divided into 2 groups and test groups of 119 cases of patients were to be mannitol treatment, and topiramate levetiracetam sodium chloride treatment. For the treatment groups were observed. Results Observed after treatment, the experimental group of patients with total efficiency than the conventional group, in addition to intracranial pressure and neuropeptide Y levels lower than conventional group. Conclusion Observed after treatment, the experimental group of patients with total efficiency than the conventional group, in addition to intracranial pressure and neuropeptide Y levels lower than conventional group.%目的:对吡拉西坦氯化钠注射液应用于治疗脑出血患者的疗效进行观察和分析。方法选取2014年3月~2015年9月来我院就诊并接受治疗的238例脑出血患者,分为常规组和试验组,每组119例,分别予以甘露醇治疗和吡拉西坦氯化钠进行治疗,对两组患者治疗效果进行观察。结果经治疗后观察比较,试验组患者的总有效率优于常规组,此外颅压和神经肽 Y 水平低于常规组。结论吡拉西坦氯化钠注射液治疗脑出血能够获得较好效果。

  12. 参麦注射液治疗冠心病疗效与安全性的Meta分析%Meta-analysis on efficacy and safety of Shenmai injection in treatment of coronary heart disease

    Institute of Scientific and Technical Information of China (English)

    李傅冬; 沈毅

    2012-01-01

    目的:评价参麦注射液治疗冠心病的疗效及安全性.方法:计算机检索CNKI(1979年-2011年12月)、维普期刊(1989年-2011年12月)、万方数据(1987年-2011年12月)等数据库,全面搜集有关参麦注射液治疗冠心病的随机对照试验(RCT)的文献,运用Jadad评分法进行质量评价,数据分析采用RevMan5.0及Stata12软件.结果:共纳入18项研究,Meta分析结果显示:参麦注射液联合常规疗法相对于单纯常规疗法治疗冠心病,可使临床症状疗效的总有效率提高22%[RD=0.22,95%CI (0.17,0.26),P<0.000 01],相对危险度[RR=1.31,95%CI (1.20,1.43),P<0.000 1];可使心电图疗效的总有效率提高25%[RD=0.25,95% CI(0.19,0.31),P<0.00001],相对危险度[RR=1.46,95%CI (1.32,1.62),P<0.000 1];可使心功能NYHA分级的改善率提高33%[RD=0.33,95% CI(0.16,0.49),P<0.000 01],相对危险度[RR =1.79,95%CI(1.28,2.51),P=0.000 6];增加左室射血分数[WMD=7.55,95% CI (2.28,12.83),P=0.005];此外分别各有1项研究显示参麦注射液有使冠心病患者提高左室每搏输出量,减小左室收缩末期内径,改善血液流变学指标,降低血NT-pro-BNP,ADMA,细胞因子,TNF-α,IL-6及血清酶,改善梗塞相关血管IRA再通指标,缩短症状改善时间及心电图恢复时间等作用.有3项研究报告了不良反应,主要为头昏、心悸、轻度腹胀、恶心、精神兴奋及面色潮红,无严重不良反应事件报道.结论:现有临床证据表明,参麦注射液治疗冠心病有一定效果,可提高治疗的总有效率.该文虽存在一些不足之处,但对临床仍具有一定的参考价值.有待于开展更多设计合理、执行严格、多中心大样本且随访时间足够的随机对照试验以进一步验证其疗效和安全性.%Objective: To evaluate the efficacy and safety of Shenmai injection in the treatment of coronary heart disease (CHD). Method: CNKI (1979 to December 2011) , VIP (1989 to December 2011

  13. Clinical efficacy and safety of urinary kallidinogenase injection in patients with acute cerebral infarction%尤瑞克林治疗急性脑梗死的疗效及安全性评价

    Institute of Scientific and Technical Information of China (English)

    谭少华; 林耀波; 刘聪; 李丽娟; 李少梅

    2013-01-01

    Objective To evaluate the clinical efficacy and safety of urinary kallidinogenase injection in patients with acute cerebral infarction.Methods One hundred patients with acute cerebral infarction were included in this trial,which were randomly divided into two groups.Patients in the control group (n=50) were treated with basic therapy,while those in the treatment group (n=50) were treated with urinary kal l idinogenase injection and basic therapy.NIHSS score were evaluated before treatment,7 days and 14 days after treatment,respectively.Hepatic function,renal function,coagulation function and hemorrhagic event were recorded before and after treatment.Results No significant difference was in NIHSS sore found 7 d after treatment (P>0.05),while 14 days after treatment,NIHSS score in the treatment group was significantly lower than that in the control group (P<0.05).No significant difference was found before and after treatment on hepatic,renal,coagulation impairment and hemorrhagic event (P<0.05).Conclusion Urinary kallidinogenase injection is effective and safe for patients with acute cerebral infarction,which is better than single use of basic therapy.%目的 评价注射用尤瑞克林对急性脑梗死的临床疗效及安全性.方法 根据1995年第四届全国脑血管病会议制订的诊断标准,选取急性脑梗死患者100例,入选病例随机分为两组各50例,对照组患者给予缺血性脑卒中基础治疗;治疗组患者除给予基础治疗外,予注射用尤瑞克林0.15 PNA,分别于治疗前、治疗7d及治疗14d行NIHSS评分,并对治疗前后肝肾功能、凝血功能及出血事件作比较.结果 治疗7d两组NIHSS评分差异无统计学意义(P>0.05);治疗14 d治疗组NIHSS评分较对照组明显下降,差异有统计学意义(P<0.05);两组肝肾功能损害、凝血功能及出血事件差异无统计学意义(P>0.05).结论 尤瑞克林治疗急性脑梗死患者安全有效,优于单纯使用缺血性脑卒中基础治疗.

  14. Efficacy of ribonucleic acid Ⅱ intrathoracic injection on malignant pleural effusion%注射用核糖核酸Ⅱ治疗恶性胸腔积液的疗效

    Institute of Scientific and Technical Information of China (English)

    鲁建军; 翁慧雯; 顾勇; 罗红鹤; 钟佛添

    2013-01-01

    目的 观察注射用核糖核酸Ⅱ胸内注入治疗恶性胸腔积液的疗效及其对机体免疫功能的影响.方法 收集2012年3月至2013年2月本院经病理和(或)细胞学确诊的晚期肺部肿瘤所至的恶性胸腔积液的患者63例,经胸腔穿刺抽液或胸腔闭式引流后即时注入注射用核糖核酸Ⅱ300 mg,治疗1周胸部X线显示如仍有胸腔积液再引流后重复给药1次.4周后按WHO规定的临床疗效评定标准,观察注射用核糖核酸Ⅱ的恶性胸腔积液控制疗效,并应用流式细胞仪对比治疗前后(注药前和注药后1周)患者外周血T淋巴细胞的变化情况.结果 注射用核糖核酸Ⅱ胸腔内注入疗法的总体有效率达90.48%,其中完全缓解(CR)30例(47.62%),部分缓解(PR)14例(22.22%),稳定(SR)13例(20.63%),无效6例.治疗后外周血T淋巴细胞亚群中的CD3+、CD4+水平和CD4+/CD8+值较治疗前升高(CD3+:67.49±6.41比64.21±4.87,CD4+:28.72±3.85比24.59±3.47,CD4+/CD8+:0.91±0.07比0.65±0.04,均P<0.05),CD8+水平明显下降(33.96±5.86比38.16±4.89,P<0.05).结论 注射用核糖核酸Ⅱ胸腔内注入疗法治疗恶性胸腔积液的疗效确切,能明显改善机体状况和增强免疫功能.%Objective To determine the efficacy of ribonucleic acid Ⅱ (RNA Ⅱ) intrathoracic injection on malignant pleural effusion and the host immunity.Methods Sixty-three patients with pathologyand (or) cytology-diagnosed malignant pleural effusion admitted to The First Affiliated Hospital,Sun Yatsen University between March 2012 and February 2013 were subjected to RNA Ⅱ (300 mg,once weekly) injection via thoracocentesis or thoracic cavity closed drainage.Repetitive administration was performed in case of pleural effusion as suggested by chest X-ray at week 1.The therapeutic outcomes were assessed based on the WHO criteria.The changes in peripheral blood T cells was assessed using flow cytometry prior to and following one week after the treatment

  15. 甲强龙鼓室注射对三种类型听力下降的疗效报告%Efficacies of intratympanic methylprednisolone injection in three types of hearing loss

    Institute of Scientific and Technical Information of China (English)

    李琦; 莫婷婷; 彭新宇; 刘钊; 刘友利; 梁勇

    2015-01-01

    limited efficacy for high-frequency loss. ALHL appears to respond best to intratympanic injection of methylprednisolone, although the treatment can also be used in SSHL-DM as the first choice treatment, which helps reduce potential systemic adverse effects of steroids. In SSHL-FOH, it may be used as a salvage therapy.%目的:探讨鼓室注射甲强龙在不同类型的听力下降中的疗效。方法收集2012.03至2014.06在我科门诊及住院治疗的不同类型听力下降病人48例。其中,急性低频感音神经性耳聋(acutc low-tone sensorineural hearing loss, ALHL)36例;伴有糖尿病的突发性耳聋7例;口服激素治疗失败的突发性耳聋5例。甲强龙单次注射剂量为0.5-0.7ml(20-28mg)。急性低频感音神经性耳聋患者均在门诊给予一次甲强龙鼓室注射,5天后复查听力,如听力改善不明显,再给予一次注射。伴有糖尿病及口服激素治疗失败的患者均住院治疗,隔天给予甲强龙鼓室注射一次,5次为一疗程。结果急性低频感音神经性耳聋患者治疗前0.25,0.5,1kHz平均听阈51.25±6.84dBHL,治疗后平均听阈19.36±4.85 dBHL,其中痊愈32例,有效4例(总有效率100%,36/36);伴有糖尿病的突发性耳聋患者治疗前0.5,1,2,4,8kHz平均听阈78.31±14.16dBHL,治疗后平均听阈49.36±12.69 dBHL,其中痊愈2例,显效2例,有效1例,无效2例(总有效率71.43%,5/7);其中听力改善主要发生在0.5,1,2kHz,4,8kHz听力均未见明显改善;口服激素治疗失败患者治疗前0.5,1,2,4,8kHz平均听阈79.25±16.28dBHL,治疗后平均听阈69.36±12.27 dBHL,其中显效1例,有效2例,无效2例(总有效率60.00%,3/5),其中听力改善亦主要发生在0.5,1,2kHz,4,8kHz听力亦未见明显改善。结论甲强龙鼓室注射可以有效地改善低频区域的听力下降;对于中、高频区域的听力下降则治疗效果有限。在不同类型的听力下降中

  16. Comparison of efficacy and safety of insulin aspart 30 injection and isophane protamine biosynthetic human insulin Injection for type 2 diabetes%双时相门冬胰岛素30与预混人胰岛素30R治疗2型糖尿病的疗效及安全性比较

    Institute of Scientific and Technical Information of China (English)

    谢树桂

    2011-01-01

    目的 比较双时相门冬胰岛素30和预混人胰岛素30R治疗2型糖尿病(T2DM)的疗效及安全性.方法 将本院2007年1月至2010年5月住院的80例T2DM患者采用简单随机方法分为两组,其中预混人胰岛素30R治疗40例(A组),双时相门冬胰岛素30治疗40例(B组),均采用每日早、晚餐前两次皮下注射方案,为期12周,比较两组患者空腹、早餐后2 h、午餐前、午餐后2 h、晚餐前、晚餐后2 h及睡前7个时点血糖的变化,糖化血红蛋白(HbA1c)及血糖控制达标所需要的胰岛素用量、低血糖事件、不良反应发生率.结果 B组三餐后血糖、HbA1c、低血糖事件发生率均低于A组,差异有统计学意义(P<0.05);两组胰岛素用量及其他不良事件发生率差异无统计学意义(P>0.05).结论 双时相门冬胰岛素30能有效降低餐后血糖,且低血糖事件发生率低,是一种简便、有效、安全的治疗方法.%Objective To compare the efficacy and safety between Insulin Aspart 30 Injection and Isophane Protamine Biosynthetic Human Insulin Injection (pre-mixed 30R) in the treatment of type 2 diabetes (T2DM).Methods Eighty patients with T2DM,which were hospitalized in the Chengdu Aerospace Hospital from January 2007 to May 2010,were randomly divided into two groups,group A (40 cases) and group B (40 cases).Patients in group A received pre-mixed 30R b.i.d,and those in group B received Insulin Aspart 30 Injection b.i.d.And a 12-week controlled trial was performed.Changes in blood glucose at 7 time points ( early morning/fasting,2h after breakfast,before lunch,2h after lunch,before dinner,2h after dinner and bedtime) ,glycosylated hemoglobin ( HbA1c ),insulin dosage,incidence of hypoglycemia and other adverse events were observed.Results Postprandial blood glucose levels, HbA1cand hypoglycemia incidence in group B were significantly lower than those in group A ( P < 0.05 ).There was no significant difference in insulin dosage between the two

  17. Risperidone-induced polydipsia and polyphagia associated with galactorrhea, abdominal pain, and rapid weight gain in an adolescent Hispanic female.

    Science.gov (United States)

    Afzal, Khalid I; Briones, David F; DeVargas, Cecilia

    2007-11-01

    A 15-year-old Hispanic female was started on risperidone for new-onset psychosis. The patient responded well to the gradual dose increase but developed rapid weight gain secondary to polydipsia and polyphagia. She also began complaining of nipple discharge and griping abdominal pain on the left lower quadrant by the third week of treatment. Her prolactin level escalated to three times normal with a weight gain of 12 pounds in 16 days. Risperidone was switched to another antipsychotic. Her prolactin level then dropped to a normal level within 7 days and she lost 7 pounds in the next 2 weeks. Her abdominal pain, galactorrhea, polydipsia, and polyphagia subsided within the first few days of the cessation of risperdione.

  18. 阿立哌唑与利培酮治疗女性精神分裂症的临床疗效分析%Effective analysis of aripiprazole and risperidone for patients with first-episode female Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    张加明

    2014-01-01

    目的:对阿立哌唑与利培酮对女性首发精神分裂症的临床疗效以及对患者认知功能的影响进行观察和分析。方法:将我院2010年4月~2013年11月收治的128例女性首发精神分裂患者随机分为阿立哌唑组和利培酮组,每组各64例。2组患者分别于治疗前后采用阳性与阴性症状量表(PANSS)、临床总体印象量表(CGI)以及副反应量表(TESS)对患者的临床疗效和副反应进行评定和比较。结果:2组患者治疗后其阳性症状、阴性症状、一般病理、PANSS总分以及CGI总分均较治疗前显著降低(P<0.01),但组间比较并无明显差异(P>0.05)。治疗后阿立哌唑组和利培酮组的临床显效率和有效率分别为73.44%、96.88%和70.31%、90.62%,差异均不具有统计学意义( P>0.05),而TESS评定结果显示,阿立哌唑组患者评分8.31±4.20分明显低于利培酮组患者评分9.29±4.16分。结论:阿立哌唑和利培酮治疗女性首发精神分裂症上均可有效改善患者的阳性症状、阴性症状、一般病理而起到良好的临床疗效,但相比而言阿立哌唑在治疗过程中副反应更小,因而更加安全有效。%Objective:To explore the efficacy of aripiprazole and risperidone in the treatment of first -episode female schizophrenia . Methods:To select 128 cases of patients with first-episode female schizophrenia who were treated in our hospital from April 2010 to No-vember 2013,and were randomly divided into the saripiprazole group and the risperidone group ,each group was 64 cases.Two groups of patients were take the positive and negative symptoms scale ( PANSS) , the clinical general impression scale (CGI) and the treatment e-mergent symptom scale ( TESS) respectively before and after treatment to evaluated the clinical efficacy and the adverse event .Results:The positive symptoms , negative symptoms , general pathology , PANSS

  19. Dexrazoxane Injection

    Science.gov (United States)

    ... are used to treat or prevent certain side effects that may be caused by chemotherapy medications. Dexrazoxane injection (Zinecard) is used to prevent ... this medication.If you experience a serious side effect, you or your doctor ... (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/ ...

  20. Fluorouracil Injection

    Science.gov (United States)

    ... of a doctor who is experienced in giving chemotherapy medications for cancer. Treatment with fluorouracil injection may cause serious side effects. ... this medication.If you experience a serious side effect, you or your doctor ... (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/ ...

  1. Cyanocobalamin Injection

    Science.gov (United States)

    ... used to treat inherited conditions that decrease the absorption of vitamin B12 from the intestine. Cyanocobalamin injection is also sometimes used to treat methylmalonic aciduria (an inherited disease in which the body cannot break down protein) and is sometimes given to unborn babies to ...

  2. Lanreotide Injection

    Science.gov (United States)

    Lanreotide injection is used to treat people with acromegaly (condition in which the body produces too much growth hormone, causing enlargement of the hands, feet, and facial features; joint pain; and other symptoms) who have not successfully, or cannot be treated ...

  3. Neurotoxic syndrome induced by clomipramine plus risperidone in a patient with autistic spectrum disorder: serotonin or neuroleptic malignant syndrome?

    Science.gov (United States)

    Nikolaou, Kalliopi N; Gournellis, Rossetos; Michopoulos, Ioannis; Dervenoulas, Georgios; Christodoulou, Christos; Douzenis, Athanasios

    2015-01-01

    To the best of our knowledge, there are no case studies of serotonin syndrome (SS) in patients with autism spectrum disorder. We report the case of a 33-year-old male who presented SS under the combined use of clomipramine and risperidone. More specifically, within 2 days after clomipramine (10 mg/BID-two times a day) was added to risperidone (4 mg/OD-once a day), mirtazapine 45 mg/OD and alprazolam (0,5 mg/TID-three times a day) he began to present mental, neurological and autonomic symptoms. All his psychopathological manifestations and laboratory findings normalized after the above-mentioned drugs' discontinuation, and the administration of supportive medical care and lorazepam 2,5 mg/TID. The diagnosis of serotonin syndrome was challenging due to the relatively low dose of clomipramine, an increase of risperidone which had taken place before clomipramine administration and clinical symptoms which could be attributed to both serotonin and neuroleptic malignant syndrome.

  4. Use of a Direct Observational Measure in a Trial of Risperidone and Parent Training in Children with Pervasive Developmental Disorders

    Science.gov (United States)

    Johnson, Cynthia R.; Butter, Eric M.; Lecavalier, Luc; Scahill, Lawrence; Aman, Michael G.; McDougle, Christopher J.; Arnold, L. Eugene; Swiezy, Naomi B.; Sukhodolsky, Denis G.; Mulick, James A.; White, Susan W.; Bearss, Karen; Hollway, Jill A.; Stigler, Kimberly A.; Dziura, James; Yu, Sunkyung; Sacco, Kelley; Vitiello, Benedetto

    2013-01-01

    A Structured Observational Analog Procedure (SOAP), an analogue measure of parent-child interactions, was used to assess treatment outcome in children with Autism Spectrum Disorder and serious behavior problems. It served as a secondary outcome measure in a 24-week, randomized trial of risperidone (MED; N=49) versus risperidone plus parent training (COMB; n=75) (ages 4–13 years). At 24-weeks, there was 28 % reduction in child inappropriate behavior during a Demand Condition (p=.0002) and 12 % increase in compliance to parental requests (p=.004) for the two treatment conditions combined. Parents displayed 64 % greater use of positive reinforcement (p=.001) and fewer repeated requests for compliance (p<.0001). In the analysis of covariance (ANCOVA), COMB parents used significantly more positive reinforcement (p=.01) and fewer restrictive statements (p<.05) than MED parents. The SOAP is sensitive to change in child and parent behavior as a function of risperidone alone and in combination with PMT and can serve as a valuable complement to parent and clinician-based measures. PMID:23730123

  5. Low-Dose Atypical Antipsychotic Risperidone Improves the 5-Year Outcome in Alzheimer's Disease Patients with Sleep Disturbances.

    Science.gov (United States)

    Yin, You; Liu, Yan; Zhuang, Jianhua; Pan, Xiao; Li, Peng; Yang, Yuechang; Li, Yan-Peng; Zhao, Zheng-Qing; Huang, Liu-Qing; Zhao, Zhong-Xin

    2015-01-01

    Sleep disturbances (SD) accelerate the progression of Alzheimer's disease (AD) and increase the stress of caregivers. However, the long-term outcome of disturbed nocturnal sleep/wake patterns in AD and on increased stress of spousal caregivers is unclear. This study assessed the 5-year effect of nocturnal SD on the long-term outcome in AD patients. A total of 156 donepezil-treated mild-moderate AD patients (93 AD + SD and 63 AD - SD as a control group) were recruited. The AD + SD patients were formed into 4 subgroups according to the preferences of spousal caregivers for treatment with atypical antipsychotics (0.5-1 mg risperidone, n = 22), non-benzodiazepine hypnotic (5-10 mg zolpidem tartrate, n = 33), melatonin (2.55 mg, n = 9), or no-drug treatment (n = 29). SD were evaluated by polysomnography, sleep scale, and cognitive scale examinations. Moreover, all spousal caregivers of AD patients were assessed using a series of scales, including sleep, anxiety, mood, and treatment attitude scales. Our data showed that nocturnal sleep/wake disturbances were significantly associated with lower 5-year outcomes for AD patients, earlier nursing home placement, and more negative emotions of spousal caregivers. Treatment with low-dose atypical antipsychotic risperidone improved the 5-year outcome in AD + SD patients. In conclusion, low-dose atypical antipsychotic risperidone improves the 5-year outcome in AD patients with SD. Moreover, improvement of nocturnal sleep problems in AD patients will also bring better emotional stability for AD caregivers.

  6. 复方苦参注射液腹腔内注射联合体外高频热疗对晚期肝癌腹水患者的疗效%Efficacy of Intraperitoneal Injection of Compound Matrine Injection Combined with External High Frequency Thermotherapy for the Treatment of Ascites in Advanced Liver Cancer

    Institute of Scientific and Technical Information of China (English)

    杨柳; 李小妹

    2015-01-01

    目的:探讨复方苦参腹注射液腔内注射联合体外高频热疗对晚期肝癌腹水患者的疗效。方法:选取我院2012年7月~2014年3月收治的确诊为晚期肝癌腹水患者29例的临床资料,按照随机分组的方法分为对照组和观察组。对照组给予复方苦参注射液腔内注射治疗,观察组在对照组的基础上联合体外高频热疗治疗。比较两组治疗总有效率、细胞免疫学指标、生活质量改善率为及不良反应发生情况。结果:治疗后,观察组治疗总有效率高于对照组(73.33% vs 50.00%,χ2=9.003,P<0.05);观察组治疗CD4+/CD8+及NK细胞数均高于对照组(P<0.05);观察组生活质量改善率高于对照组(73.33% vs 35.71%,χ2=10.324,P<0.05)。两组治疗中均未见明显不良反应发生。结论:复方苦参注射液腹腔内注射联合体外高频热疗可提高晚期肝癌腹水患者的治疗总有效率,改善患者的生活质量和免疫力,且不良反应发生率较低。%Objective: To investigate efficacy of intraperitoneal injection of compound matrine injection combined with external high frequency thermotherapy for the treatment of patients with ascites in advanced liver cancer.Methods:29 cases of patients with ascites in advanced liver cancer in the department of oncology in the Huainan east general hospital from July 2012 to March 2014 were randomly divided into the control group and observation group.The control group were treated by compound matrine injection via intraperitoneal injection,the observation group were treated by external high frequency thermotherapy on the base of the control group.The total efifciency rate,the cell immunological parameters,quality of life and adverse events of the two groups were compared.Results:After treatment,the total efifciency rate of observation group was higher than that of the control group(73.33% vs 50.00%,χ2=9.003,P<0.05).The CD4+/CD8+and NK cells of the

  7. Comparison of efficacy and safety among three injections of fat soluble drugs on fat dissolution%三种注射溶脂药物对脂肪溶解效果及安全性比较

    Institute of Scientific and Technical Information of China (English)

    许柯; 黄曹; 张好云; 刘少雄

    2015-01-01

    Objective To investigate the efficacy and safety of three injections fat soluble drugs to dissolve fat.Methods 3T3-L1 preadipocytes were treated with 5% phosphatidyl choline (PC),4.5% deoxycholate salts (DC) and lipostabil,respectively; thiazolyl tetrazolium (MTT) method was used to measure the different fat cell proliferation activity,the enzyme assay to measure liquid triglyceride (TG) content in culture media and to evaluate the degree of dissolution of the fat cells.16 Hartley white guinea pigs were randomly divided into four groups:shoulder (group a),scapular region (group b),hips (group c),and back (control group) were injected with fat soluble drug 0.5 ml in different parts of the guinea pig fat layer,and at different time points tissues were cut for pathological analysis.Results The proliferative activity of 3T3-L1 preadipocytes were significantly decreased after treatment with three types of fat soluble drugs compared with control group (P<0.05),and their effects on dissolution of fat cells were also significant:the contents were 5% PC (4.14±0.92)mmol/L,4.5% DC (3.91 ±0.67) mmol/L,and lipostabil (4.23± 0.76) mmol/L,respectively,which were significantly higher than that of the control (1.91±0.12) mmol/L (P<0.05); guinea pigs in vivo showed that the three types of fat soluble drugs on dissolving adipose tissue at the injection site had varying degrees of swelling,lymphocytic infiltration,and fat cell degeneration,fusion and decrease in number.Conclusions Three fat soluble injections could dissolve the fat cells in some degree,in whichi lipostabil is stronger than other fat soluble drugs,but their effect on adipose tissue is nonspecific,and therefore clinical application of those fat soluble drugs should be in high caution.%目的 探讨3种注射溶脂药物对脂肪溶解效果及安全性.方法 用5%磷脂酰胆碱(PC)、4.5%脱氧胆酸盐(DC)及Lipostabil,分别作用于3T3-L1前体脂肪细胞,采用四甲基偶氮噻唑蓝(MTT)

  8. 吡拉西坦氯化钠注射液治疗脑出血的临床疗效分析%Analysis of Clinical Efficacy of Piracetam Sodium Chloride Injection in the Treatment of Cerebral Hemor-rhage

    Institute of Scientific and Technical Information of China (English)

    程蓓

    2014-01-01

    [Objective] To explore the clinical efficacy of piracetam sodium chloride injection in the treatment of pa-tients with cerebral hemorrhage .[Methods] Totally 120 patients with cerebral hemorrhage in our hospital from Aug . 2010 to Aug .2012 were chosen and randomly divided into two groups .The experiment group( n=60) was treated with 20% piracetam sodium chloride injection 100ml by fast infusion every 6~8h for continuous 7d ,and then instilled by rou-tine velocity for 7d after 7d .The control group( n=60) was treated with intravenous injection of 20% mannitol 125ml every 6~8h for continuous 7d .All patients received consecutive monitoring of intracranial pressure .The changes of in-tracranial pressure ,plasma neuropeptide Y and neural function deficit score before ,7d and 14d after treatment were ob-served .[Results] There was no significant difference in intracranial pressure before treatment between experiment group and control group( P>0 .05) .Compared with before treatment ,intracranial pressure in two groups after drug therapy were obviously decreased ,and there was significant difference between before and after treatment ( P0 .05) .Compared with before treatment ,neural function deficit score and neuropeptide in two group were obviously decreased ,and there was significant difference between before and after treatment ( P<0 .05) .Neural function deficit score and neuropeptide in experiment group were decreased more obviously than that in control group ,and there was significant difference ( P<0 .05) .[Conclusion]Piracetam sodium chloride injection for the treatment of patients with cerebral hemorrhage can obviously reduce intracranial pressure ,improve the nerve function deficit score and markedly de-crease plasma level of neuropeptide .%【目的】探讨应用吡拉西坦氯化钠注射液治疗脑出血患者的临床效果。【方法】选择本院2010年8月至2012年8月间进行诊治的120例脑出血患者,将其随

  9. Risperidone combined with clozapine in the treatment of refractory schizophrenia research%利培酮联合氯氮平治疗难治性精神分裂症的临床研究

    Institute of Scientific and Technical Information of China (English)

    谢玲银; 张智勇

    2015-01-01

    目的:探讨使用利培酮联合氯氮平两种药物来治疗难治性精神分裂症的临床效果。方法选取我院收治的难治性精神分裂症患者100例为研究对象,随机将其分为观察组和对照组,其中观察组50例,采用利培酮联合氯氮平进行治疗,对照组50例则只服用氯氮平进行治疗,观察12周,分别于入组前、治疗6周末、12周末应用简明精神病评定量表(BPRS)评定治疗效果,同时应用副反应量表(TESS)评价不良反应发生情况。结果观察组在治疗6周末及12周末的BPRS 评定总分明显低于对照组,差异有统计学意义(P<0.05)。两组TESS总分比较差异无统计学意义(P>0.05)。结论临床上对于难治性精神分裂症这一疾病的治疗可采用利培酮联合氯氮平两种药物进行尝试,其临床效果显著,且安全性有较大程度的保障,值得临床推广应用。%Objective To discuss the clinical effect of risperidone combined with clozapine in the use of two kinds of drugs for the treatment of refractory schizophrenia.Methods 100 patients with refractory schizophrenia of our hospital was selected as the research object, randomly divided into observation group and control group,50 cases in each group,the cases in the observation group was treated by risperidone combined with clozapine,while the cases in the control group only received risperidone treatment,observation of 12 weeks,before entering the group,respectively treatment of 6 weeks and 12 weeks,the efficacy of treatment was assessed by the Brief Psychiatric Rating Scale (BPRS). And using the TESS to evaluate adverse reaction.ResultsIn the observation group,BPRS total score after 6 weeks and 12 weeks were significantly lower than the control group,the difference was statistically significant (P0.05).Conclusion For refractory schizophrenia,we may try to treat them with the combination of risperidone and clozapine,it is safety and

  10. Forum for injection techniques, India: The first Indian recommendations for best practice in insulin injection technique

    Directory of Open Access Journals (Sweden)

    Sanjay Kalra

    2012-01-01

    Full Text Available Advances in the treatment of diabetes have led to an increase in the number of injectable therapies, such as human insulin, insulin analogues, and glucagon-like peptide-1 analogues. The efficacy of injection therapy in diabetes depends on correct injection technique, among many other factors. Good injection technique is vital in achieving glycemic control and thus preventing complications of diabetes. From the patients′ and health-care providers′ perspective, it is essential to have guidelines to understand injections and injection techniques. The abridged version of the First Indian Insulin Injection technique guidelines developed by the Forum for Injection Technique (FIT India presented here acknowledge good insulin injection techniques and provide evidence-based recommendations to assist diabetes care providers in improving their clinical practice.

  11. A Study on the Changes of Prolaction Levels of Female Patients with Schizophrenia after the Treatment of Aripiprazone, Ziprasidone and Risperidone%阿立哌唑、齐拉西酮、利培酮治疗女性精神分裂症患者后催乳素的变化研究

    Institute of Scientific and Technical Information of China (English)

    李文学; 孔德荣; 殷晓; 李猛; 赵青霞; 赵中健

    2014-01-01

    Objective To study the changes of prolaction levels of female patients with schizophrenia after the treatment of arip-iprazone, ziprasidone and risperidone and the causes of amenorrhea. Methods A double-blind randomized-controlled study was adopted. 180 cases of first-episode female schizophrenic patients diagnosed in our hospital from July, 2012 to September, 2013, were selected and they were divided into aripiprazone group and risperidone group, ziprasidone group, 60 cases in each group. They were treated for 6 months. The prolaction level and the number of cases of amenorrhea before and 1, 3, 6 months after treat-ment were detected. Results The prolactin levels of risperidone group were elevated significantly after treatment ( P0.05), the cases of amenorrhea were less. Conclusion Prolactin elevation, amenorrhea and other symptoms easily occur in the patients who take risperidone, but seldom occur in the patients who take aripiprazole and ziprasidone, and the efficacy of aripiprazole and ziprasidone is better, so they are recommended to use.%目的:探讨女性精神分裂症患者在用阿立哌唑、齐拉西酮、利培酮治疗后催乳素水平变化及闭经原因分析。方法采用随机双盲对照研究,收集本院2012年7月—2013年9月首发确诊女性精神分裂症患者180例,分为阿立哌唑组、利培酮组,齐拉西酮组,每组各60例,疗程6个月,治疗前及治疗后1个月、3个月及3个月分别检测催乳素水平及闭经例数。结果利培酮组治疗后催乳素水平显著升高(P0.05),出现闭经例数比较少。结论利培酮用药的患者容易出现催乳素升高、闭经等现象,而阿立哌唑及齐拉西酮却很少出现这种情况,疗效也比较好,建议使用。

  12. A controlled study on effect of olanzapine and risperidone on quality of life in first-episode schizophrenia patients%奥氮平与利培酮治疗精神分裂症首次发病患者的疗效

    Institute of Scientific and Technical Information of China (English)

    徐彩; 李美银; 邓文

    2012-01-01

    目的:探讨奥氮平与利培酮治疗首发精神分裂症的疗效以及对生活质量的影响. 方法:68例首发精神分裂症患者随机分为奥氮平组和利培酮组各34例,分别给予奥氮平和利培酮治疗8周,随访6个月.于治疗前后采用阳性与阴性症状量表(PANSS)及治疗中出现的症状量表(TESS)评定疗效及不良反应;于治疗6个月前后,采用生活质量综合评定问卷(GQOLI)评定生活质量. 结果:两组PANSS评分治疗后均有显著下降(P<0.05或P<0.01).奥氮平组GQOLI总分及各维度与利培酮组GQOLI总分及躯体功能、心理功能维度治疗前后差异均有统计学意义(P均<0.01);两组间比较,治疗前两组GQOLI评分差异无统计学意义,6个月后随访,在躯体功能及社会功能差异有统计学意义(P均<0.01). 结论:奥氮平与利培酮治疗首发精神分裂症疗效相当,但奥氮平在提高生活质量方面略优于利培酮.%Objective: To study the curative powers and effect of olanzapine and risperidone on quality of life in the treatment of first onset schizophrenia patients. Method: 68 first onset schizophrenia patients were randomly divided into olanzapine group and risperidone group, each of which (n = 34 ) received the olanzapine or risperidone treatment respectively for 8 weeks and 6 months follow-up. The efficacy was assessed using positive and negative syndrome scales (PANSS) , and the adverse reaction using treatment emergent symptom scale (TESS). Generic quality of life inventory (GQOLI) was conducted before and 6 months after the treatment for assessmet of patients quality of life. Results: PANSS score of two groups decreased singnificanty after the treatment ( P < 0.05 or P < 0.01). The significant differences were found on GQOLI total score and each dimension score in olanzeoine group and GQOLI total score, physical function,psychological function in risperidone group between before and after treatment (all P<0.01). After 6

  13. Observation on Efficacy of Sodium Hyaluronate in Intra-articular Injection Treatment of Osteoarthrosis%玻璃酸钠膝关节腔内注射治疗骨关节病的疗效观察

    Institute of Scientific and Technical Information of China (English)

    王荣

    2016-01-01

    OBJECTIVE:To investigate the efficacy of sodium hyaluronate in treatment of rheumatoid arthritis ,and the nursing method in the treatment .METHODS:120 cases of patients with rheumatoid arthritis admitted into Hubei Shiyan Xunyang District Traditional Chinese Medicine Hospital from Feb .2013 to Mar.2015 were collected to be divided into control group and observation group via the random number table ,with 60 cases in each.The control group were given conventional treatment and care ,namely ,oral Meloxicam tablets ,ultrashort wave and joint function exercise . The observation group additionally received give sodium hyaluronate injection treatment and nursing measures based on the control group .By contrast ,the recovery of two groups were compared .RESULTS:After treatment of five weeks ,the curative effects of two group of patients showed obvious differences .The total effective rate of observation group was 91.67%( 55/60 ) , significantly higher than that of control group 80.00%( 48/60 ) , with statistically significant difference(P<0.05).As for the extent of osteoarthrosis score in observation group ,patients of zero increased 7 cases, patients of more than 11 points decreased 6 cases;while in control group ,patients of zero increased 1 case ,patients of more than 11 points decreased 3 cases.The control effects of observation group was significantly better than that of control group , with statistically significant difference ( P<0.05 ) .CONCLUSIONS:The efficacy of sodium hyaluronate in intra-articular injection treatment of osteoarthrosis in clinic is significant .It is worthy of clinical promotion and application .%目的:探讨应用玻璃酸钠治疗类风湿性关节炎的疗效及治疗中的护理方法。方法:选择湖北省十堰市郧阳区中医医院从2013年2月—2015年3月的类风湿性关节炎患者120例作为研究对象,按随机数字表法分为对照组和观察组,每组各60例。对照组患者给予常规综合治疗和护

  14. 奥氮平与利培酮治疗痴呆患者精神行为症状的对照研究%The comparative study of olanzapine and risperidone in the treatment of dementia patients with behavioral and psychological symptoms

    Institute of Scientific and Technical Information of China (English)

    黄文平; 赵祖安; 白玉红; 曾丽苹

    2012-01-01

    Objective To observe the efficacy and safety of Olanzapine and Risperidone in the treatment of dementia patients with behavioral and psychological symptoms. Methods 80 senile dementia patients were selected and divided into two groups randomly, Olanzapine group (40 cases) and Risperidone group (40 cases). Before the treatment and the treatment for two, four and eight weeks, the two groups were both given the BEHAVE-AD scale to evaluate the efficacy and TESS scale to evaluate the adverse reactions. Results In the treatment of the 8th week, the differences of all the BE-HAVE-AD scales compared with before the treatment in the two groups were statistically significant (P < 0.01). In the treatment of the 2nd week, the difference of total scales compared with before the treatment in the Olanzapine group was statistically significant (P < 0.01), the Risperidone group was not; but at the 8th week the difference of efficiency rate between the two groups was not statistically significant. In security, the difference of total adverse reactions rate was not statistically significant, but the incidence of extrapyramidal side effects (EPS) in the Risperidone group was higher than in the Olanzapine group(P < 0.05). Conclusion The efficacy of Olanzapine and Risperidone in the treatment of dementia patients with behavioral and psychological symptoms are equal, but Olanzapine works faster, side effects are less, so Olanzapine is more suitable to treat dementia patients with behavioral and psychological symptoms.%目的 观察奥氮平和利培酮治疗老年痴呆患者精神行为症状的疗效和安全性.方法 将80例老年痴呆患者随机分为奥氮平组和利培酮组,每组各40例,共观察8周.治疗前及治疗第2、4、8周末分别用BEHAVE-AD量表评定疗效,用TESS量表评定不良反应.结果 奥氮平组和利培酮组在治疗第8周末,BEHAVE-AD量所有项目评分与治疗前比较,差异均有高度统计学意义(均P < 0.01),

  15. 改良性电抽搐联合利培酮治疗甲基苯丙胺所致精神障碍的对照研究%Comparative study of modified electroconvulsive therapy combined with risperidone in the treatment of methamphetamine-induced psychiatric disorder

    Institute of Scientific and Technical Information of China (English)

    姚刚

    2012-01-01

    目的 探讨改良电抽搐治疗(MECT)联合药物治疗甲基苯丙胺所致精神障碍患者的临床疗效及安全性.方法 84例甲基苯丙胺所致精神障碍患者随机分为联合治疗组及单纯药物组各42例,单纯药物组给予利培酮治疗,联合治疗组给予MECT合并利培酮治疗.采用阳性与阴性症状量表(PANSS)及副反应量表(TESS)评定疗效和不良反应.结果 治疗一周后联合治疗组有效率为61.90%,单纯药物组有效率为38.10%,两组差异具有统计学意义(P<0.05).治疗3周后,联合治疗组有效率为88.10%,单纯药物组有效率为85.43%,两组差异无统计学意义(P>0.05).联合治疗组副反应较少,且消失较快.结论 MECT合并利培酮治疗甲基苯丙胺所致精神障碍起效更快,副作用小,且安全.%Objective To evaluate clinical efficacy and safety of modified electroconvulsive treatment (m-ECT) combined with risperidone in the treatment of methamphetamine-induced psychiatric disorder. Methods Eighty-four patients with methamphetamine-induced psychiatric disorder were consecutively divided into the study group and the control group, with 42 cases in each group. Patients in the study group were treated with m-ECT combined with risperidone, while those in the control group were treated with risperidone solely, Positive and Negative Syndromes Scale (PANSS) as well as Treatment Emergent Symptoms Scale (TESS) were used to evaluate the clinical efficacy and side effects. Results After one week of treatment, the effective rates of the study group and the control group were 61.90% and 38.10%, respectively, which showed difference between the two groups (P0.05). The study group was observed with few side effects, which disappeared quickly. Conclusion in For treating of methamphetamine-induced psychiatric disorder, modified electroconvulsive treatment combined with risperidone has better efficacy and less side effects than risperidone.

  16. 氨磺必利与利培酮治疗精神分裂症对照研究%A control study of amisulpride vs .risperidone in the treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    邵国艳; 常双海

    2014-01-01

    Objective To explore the efficacy and safety of amisulpride vs .risperidone in the treatment of schizophrenia .Methods Sixty schizophrenics were randomly assigned to two groups of 30 ones each ,re-search group took orally amisulpride and control group did risperidone for 8 weeks .Efficacies were as-sessed with the Positive and Negative Syndrome Scale (PANSS) and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results After treatment the total and each factor score of the PANSS of both groups lowered continuously compared with pretreatment (P0 .05);at the end of the 8th week obvious effec-tive and effective rate were respectively 60 .0% and 83 .3% in research and 66 .7% and 86 .7% in control group ,which showed no significant differences (χ2 = 0 .29 ,0 .13 ,P> 0 .05) .There were no significant group differences in incidences of adverse reactions (P>0 .05) .Conclusion Amisulpride has an efficacy equivalent to risperidone ,higher safety and better compliance in the treatment of schizophrenia .%目的:探讨氨磺必利与利培酮治疗精神分裂症的临床疗效和安全性。方法将60例精神分裂症患者随机分为两组,每组30例,研究组口服氨磺必利治疗,对照组口服利培酮治疗,观察8周。采用阳性与阴性症状量表评定临床疗效,副反应量表评定不良反应。结果治疗后两组阳性与阴性症状量表总分及各因子分均较治疗前呈持续性下降(P<0.01),治疗各时段两组评分比较差异均无显著性( P>0.05);治疗8周末研究组显效率60.0%、有效率83.3%,对照组分别为66.7%、86.7%,两组比较差异无显著性(χ2=0.29、0.13,P>0.05)。两组不良反应发生率比较差异均无显著性(P>0.05)。结论氨磺必利治疗精神分裂症的疗效与利培酮相当,安全性高,依从性好。

  17. Excessive weight gain after remission of depression in a schizophrenic patient treated with risperidone: case report

    Directory of Open Access Journals (Sweden)

    Psarros Constantin

    2006-09-01

    Full Text Available Abstract Background The use of atypical antipsychotics in schizophrenic patients has been associated with a risk of weight gain. Similarly, recovery from depression is often followed by improved appetite, greater food intake and potential increase in weight. Case presentation A Caucasian 33-year-old schizophrenic female patient was being treated with 6 mg/day of risperidone and 15 mg/day of clorazepate. She developed depressive symptomatology and 40 mg/day of fluoxetine was gradually added to her treatment regimen for about 9 months. After the remission of depression, and the discontinuation of fluoxetine, she experienced an increase in appetite and subsequently excessive weight gain of 52 kg. Re-administration of fluoxetine did not reverse the situation. The patient developed diabetes mellitus, which was successfully controlled with metformin 1700 mg/day. The addition at first of orlistat 360 mg/day and later of topiramate 200 mg/day has helped her to lose a significant part of the weight gained (30 kg. Conclusion The case suggests a probable association between the remission of depressive symptomatology and weight gain in a schizophrenic patient.

  18. Long-term stability, biocompatibility and oral delivery potential of risperidone-loaded solid lipid nanoparticles.

    Science.gov (United States)

    Silva, A C; Kumar, A; Wild, W; Ferreira, D; Santos, D; Forbes, B

    2012-10-15

    A solid lipid nanoparticles (SLN) formulation to improve the oral delivery of risperidone (RISP), a poorly water-soluble drug, was designed and tested. Initially, lipid-RISP solubility was screened to select the best lipid for SLN preparation. Compritol(®)-based formulations were chosen and their long-term stability was assessed over two years of storage (at 25 °C and 4 °C) by means of particle size, polydispersity index (PI), zeta potential (ZP) and encapsulation efficiency (EE) measurements. SLN shape was observed by transmission electron microscopy (TEM) at the beginning and end of the study. The oxidative potential (OP) of the SLN was measured and their biocompatibility with Caco-2 cells was evaluated using the (4,5-dimethylthiazol-2-yl)2,5-dyphenyl-tetrazolium bromide (MTT) assay. In vitro drug release and transport studies were performed to predict the in vivo release profile and to evaluate the drug delivery potential of the SLN formulations, respectively. The RISP-loaded SLN systems were stable and had high EE and similar shape to the placebo formulations before and after storage. Classical Fickian diffusion was identified as the release mechanism for RISP from the SLN formulation. Biocompatibility and dose-dependent RISP transport across Caco-2 cells were observed for the prepared SLN formulations. The viability of SLN as formulations for oral delivery of poorly water-soluble drugs such as RISP was illustrated.

  19. Synthesis, recognition and evaluation of molecularly imprinted polymer nanoparticle using miniemulsion polymerization for controlled release and analysis of risperidone in human plasma samples

    Energy Technology Data Exchange (ETDEWEB)

    Asadi, Ebadullah; Azodi-Deilami, Saman; Abdouss, Majid [Amirkabir University of Technology, Tehran (Iran, Islamic Republic of); Kordestani, Davood [Razi University, Kermanshah (Iran, Islamic Republic of); Rahimi, Alireza [Research Institute of Petroleum Industry (RIPI), Tehran (Iran, Islamic Republic of); Asadi, Somayeh [Kermanshah University of Medical Sciences, Kermanshah (Iran, Islamic Republic of)

    2014-06-15

    We prepared high selective imprinted nanoparticle polymers by a miniemulsion polymerization technique, using risperidone as the template, MAA as the functional monomers, and TRIM as the cross-linker in acetonitrile as solvent. The morphology of the nanoparticles determined by scanning electron microscopy (SEM) images and drug release, binding properties and dynamic light scattering (DLS) of molecularly imprinted polymers (MIPs) were studied. Controlled release of risperidone from nanoparticles was investigated through in 1% wt sodium dodecyl sulfate aqueous solution and by measuring the absorbance by HPLC-UV. The results showed that the imprinted nanoparticles exhibited a higher binding level and slower release rate than non-imprinted nanoparticles, which contributed to interaction of risperidone with imprinted cavities within nanoparticles. Furthermore, the results from HPLC showed good precision (5% for 50.0 µg L{sup -1}) and recoveries (between 86-91) using MIP from human plasma samples.

  20. Dopamine transporter density assessed with [{sup 123}]IPT SPECT before and after risperidone treatment in children with tourette's disorder

    Energy Technology Data Exchange (ETDEWEB)

    Ryu, Young Hoon; Kim, Tae Hoon; Ryu, Won Gee [College of Medicine, Yonsei Univ., Seoul (Korea, Republic of)] [and others

    2004-02-01

    Tourette's disorder (TD), which is characterized by multiple waxing and waning motor tics and one or more vocal tics, is known to be associated with abnormalities in the dopaminergic system. To testify our hypothesis that risperidone would improve tic symptoms of TD patients through the change of the dopaminergic system, we measured the dopamine transporter (DAT) densities between drug-naive children with TD and normal children, and investigated the DAT density before and after treatment with risperidone in drug-naive children with TD, using iodine-123 labelled N-(3-iodopropen-2-yl)-2{beta}-carbomethoxy-3beta-(4-chlorophenyl)tropane ([{sup 123}I]IPT) single photon emission computed tomography (SPECT). [{sup 123I}]IPT SPECT imaging and Yale Global Tic Severity Scale-Korean version (YGTSS-K) for assessing the tic symptom severity were carried out before and after treatment with risperidone for 8 weeks in nine drug-naive children with TD. Eleven normal children also underwent SPECT imaging 2 hours after an intravenous administration of [{sup 123}I]IPT. Drug-naive children with TD had a significantly greater increase in the specific/nonspecific DAT binding ratio of both basal ganglia compared with the normal children. However, no significant difference in the specific/nonspecific DAT binding ratio of the basal ganglia before and after treatment with risperidone in children with TD was found, although tic symptoms were significantly improved with risperidone. These findings suggest that DAT densities are directly associated with the pathophysiology of TD, however, that the effect of risperidone on tic symptoms in children with TD is not attributed to the change of dopaminergic system.

  1. 氨磺必利与利培酮治疗精神分裂症对照研究%Comparative Study of Amisulpride and Risperidone in Treating 60 Cases of Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    曹国兴; 古淑敏; 程雪

    2014-01-01

    Objective To observe the efficacy and safety of amisulpride in the treatment of schizophrenia. Methods 60 cases of first episode schizophrenia were randomly divided into the amisulpride group and the risperidone group with 30 cases in each group and treated for 8 weeks. The positive and negative symptom scale ( PANSS ) was adopted to evaluate the efficacy and the treatment emergent symptoms effect scale ( TESS ) was used to evaluate the adverse reactions. Results The total effective rate after treatment in the amisul-pride group was 83. 33%, while which in the risperidone group was 80. 00% without statistically significant difference between the two groups ( P > 0. 05 ) . The weight gain of the amisulpride group was significantly less than that of the rispefidone group ( P < 0. 05 ) . Conclusion Amisulpride and rispefidone have a similar therapeutic effect, but the case number of weight gain caused by amisulpride is significantly decreased, amisulpride deserves to be clinically popularized.%目的:观察氨磺必利治疗精神分裂症的临床疗效与安全性。方法将60例首发精神分裂症患者,随机分为氨磺必利组30例,利培酮组30例,疗程8周。采用阳性与阴性症状量表( PANSS )评定疗效,采用副反应量表( TESS )评定治疗中出现的不良反应。结果氨磺必利组的治疗总有效率为83.33%,利培酮组为80.00%,两组疗效差异无统计学意义( P>0.05);氨磺必利组的体重增加明显少于利培酮组( P<0.05)。结论氨磺必利与利培酮治疗精神分裂症疗效相当,且氨磺必利引起体重增加数例明显较少,值得临床推广。

  2. Efficacy and safety of Trichosanthes kirilowii Maxim Injections in the treatment of coronary heart disease%瓜蒌皮注射液治疗心绞痛安全性和有效性的Meta分析

    Institute of Scientific and Technical Information of China (English)

    赵先; 宁泽琼; 王婧雯; 钱小亮; 胡冬梅; 封小娜; 爱东

    2016-01-01

    Objective To evaluate the efficacy and safety of Trichosanthes kirilowii Maxim Injections in the treatment of coronary heart disease .Methods Wanfang ,VIP ,CNKI ,PubMed and Medline database were searched and analyzed .The quality of includ-ed trials was evaluated by the criterion in Cochrane Handbook .Meta-analysis was conducted by using RevMan 5 .1 .The results of angina symptoms ,ECG ST-T period of change ,the change of hemorheology and adverse reactions were recorded .Results The study included 10 randomized controlled clinical trials ,a total of 1 345 cases of patients .In the respect of angina significant effi-ciency [OR=2 .03 ,95% CI (1 .60 ,2 .57) ,P <0 .01] ,ECG significant efficiency [OR=1 .64 ,95% CI (1 .10 ,2 .42) ,P=0 .01] , angina frequency [MD= -0 .59 ,95% CI (-0 .74 ,-0 .44) ,P <0 .01] ,and ST segment down [MD= -0 .68 ,95% CI (-1 .28 ,-0 .09) ,P=0 .02] ,the treatment group was better than the control group .The duration of angina was [MD=2 .56 ,95% CI (-0 .11 ,5 .22) ,P=0 .06] and the adverse reactions [OR=1 .06 ,95% CI (0 .56 ,2 .00) ,P=0 .85] showed no statistically signifi-cant .Conclusion Trichosanthes kirilowii Maxim Injections improves the symptoms of angina significantly and also has a certain effect on the improvement of electrocardiogram .%目的:评价瓜蒌皮注射液用于治疗心绞痛的安全性和有效性。方法计算机检索中国知网(CNKI)数据库,万方(Wanfang )数据库,维普(VIP)数据库,PubMed数据库和Medline数据库,采用Cochrane Handbook推荐的标准对纳入文献进行质量评价;使用RevMan 5.1进行Meta分析。选取心绞痛治疗显效率、心绞痛发作次数和持续时间、心电图疗效结果、心电图ST-T 段改变、不良反应作为观察指标。结果本研究纳入10项随机对照临床试验,共1345例。心绞痛治疗显效率[OR=2.03,95% CI (1.60,2.57),P<0.01],心电图显效率[OR=1.64,95% CI(1.10,2.42

  3. A case of psychosis due to Fahr's syndrome and response to behavioral disturbances with risperidone and oxcarbazepine

    Science.gov (United States)

    Faye, Abhijeet Dhawalram; Gawande, Sushil; Tadke, Rahul; Kirpekar, Vivek C.; Bhave, Sudhir H.

    2014-01-01

    Calcification of basal ganglia or Fahr's syndrome is a rare disease characterized by bilateral and symmetrical intracranial deposition of calcium mainly in cerebral basal ganglia. Motor and neuropsychiatric symptoms are prominent features. We report a case presented with a few motor symptoms, features of delirium and prominent psychiatric symptoms (disorganized behavior) predominantly evident after the improvement in delirium. Radiological findings were suggestive of bilateral basal ganglia calcification. Parathyroid hormone levels were low with no significant findings in other investigations and negative family history. Patient showed significant improvement in behavioral disturbances with risperidone, low dose of lorazepam, oxcarbazepine, and memantine. PMID:24891710

  4. A control study of aripiprazole vs .risperidone in type II schiz-ophrenia%阿立哌唑与利培酮治疗Ⅱ型精神分裂症对照研究

    Institute of Scientific and Technical Information of China (English)

    徐烨; 何益群

    2013-01-01

    目的:探讨阿立哌唑与利培酮治疗Ⅱ型精神分裂症患者的临床疗效和安全性。方法将120例Ⅱ型精神分裂症患者随机分为两组,观察组口服阿立哌唑治疗,对照组口服利培酮治疗,观察12周。于治疗前后采用阳性与阴性症状量表评定临床疗效,采用韦氏成人智力量表、韦氏记忆量表及韦斯康星卡片分类测验评定认知功能,副反应量表评定不良反应。结果治疗后两组阳性与阴性症状量表总分及各因子分均较治疗前有显著下降,言语量表、操作量表、全量表和记忆量表评分均较治疗前显著升高( P<0.01);治疗12周末,观察组有效率为85.0%,对照组为88.3%,两组比较差异无显著性( P>0.05)。两组不良反应均轻微,但观察组锥体外系反应、泌乳/闭经、体质量增加、血糖升高发生率显著低于对照组( P<0.05或0.01)。结论阿立哌唑治疗Ⅱ型精神分裂症疗效显著,总体疗效与利培酮相当,但阿立哌唑治疗安全性更高,依从性更好。%Objective To explore the efficacy and safety of aripiprazole vs .risperidone in type II schizo-phrenia .Methods A total of 120 patients with type Ⅱ schizophrenia were randomly divided into two groups ,observation group took orally aripiprazole and control group did risperidone for 12 weeks .Before and after treatment efficacies were assessed with the Positive and Negative Syndrome Scale (PANSS) ,cog-nitive fundions with the WAIS-R ,WMS and WCST and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results After treatment the total and each factor scores of both groups lowered more significantly compared with pre-treatment ,verbal ,performance ,full and memory scale score height-ened (P 0 .05) .Adverse reactions of both groups were mild ,but the incidence of extrapyramidal reaction ,lactation/amenorrhea ,weight gain ,blood glu-cose elevation were

  5. 齐拉西酮与利培酮治疗精神分裂症对照研究%A control study of ziprasidone vs risperidone in the treatment of schizophrenia

    Institute of Scientific and Technical Information of China (English)

    陈卉

    2009-01-01

    Objective To explore the efficacy and safety of ziprasidone vs risperidone in the treatment of schizophrenia. Methods 78 schizophrenics were randomly divided into two groups of 36 patients each, research group took orally ziprasidone and control group did risperidone for 8 weeks. Clinical efficacies were assessed with the Positive and Negative Syndrome Scale( PANSS) and Clinical Global Impression(CGI), adverse reactions with the Treatment Emergent Symptom Scale(TESS) before treatment and at the end of the 8th week. Results At the end of the 8th week,total effective rate was 83.33% in the research and 77.78% in the control group, which showed no significant difference(χ2=0.355,P>0.05).After treatment, the CGI total,PANSS total and each factor score of both groups lowered more significantly compared with pretreatment(P0.05). Adverse reactions of both groups were mild,mostly emerged in initial stage of treatment and could relieve with time of therapy lasting or by symptomatic treatment. Incidences of weight gain,galactorrhea and menstrual disorder were significantly lower in the research than in the control group. Conclusion Ziprasidone is more effective in first-episode schizophrenia equivalent to risperidone, scarcely causes weight gain and changes of serum prolaction,blood sugar and fat, its adverse reactions are mild and is a safe and effective novel antipsychotic.%目的 探讨齐拉西酮与利培酮治疗精神分裂症的临床疗效及安全性. 方法 将72例精神分裂症患者随机分为两组,每组36例,研究组口服齐拉西酮治疗,对照组口服利培酮治疗,观察8 w.于治疗前及治疗8 w末采用阳性与阴性症状量表、临床总体印象量表评定临床疗效,副反应量表评定不良反应.结果治疗8 w末,研究组总有效率为83.33%,对照组为77.78%,两组总有效率无显著性差异(χ2=0.355,P>0.05).治疗后两组临床总体印象量表总分、阳性与阴性症状量表总分及各因子分均

  6. Influences of risperidone,quetiapine,or ziprasidone on metabolic parameters of first-episode schizophrenics%利培酮喹硫平齐拉西酮对首发精神分裂症患者代谢指标的影响

    Institute of Scientific and Technical Information of China (English)

    王明进; 张宗顺; 寻广磊

    2016-01-01

    Objective To explore the influences of risperidone ,quetiapine ,or ziprasidone on metabolic parameters of first‐episode schizophrenics .Methods A total of 120 first‐episode schizophrenics were ran‐domly divided into 3 groups taking orally risperidone ,quetiapine or ziprasidone for 12 weeks .Efficacies were assessed with the Positive and Negative Syndrome Scale (PANSS) before and after treatment ,the changes of blood pressure (BP) ,waist circumference (WC) ,fasting plasma glucose (FPG) ,triacylglycer‐ol (TG) and high density lipoprotein cholesferol (HDL‐c) detected at the same time ,and the incidences of metabolism syndrome at each time point were added up .Results After treatment the total effective rate was respectively 89 .2% in risperidone ,88 .9% in quetiapine and 86 .5% in ziprasidone group ,which showed no significant group differences (P> 0 .05) .Since the end of the 4th week WC ,TG and FPG levels heightened more significantly in risperidone and quetiapine group compared with pretreatment ,so did those of the 3 groups at the end of the 12th week (P<0 .05 or 0 .01) ,HDL‐c levels lowered more significantly in risperidone and quetiapine group compared with pretreatment (P<0 .05);WCs ,TGs and the incidences of metabolic syndrome were significantly higher in risperidone and quetiapine than in ziprasidone group at each time point (P<0 .05 or 0 .01) .Conclusion Risperidone ,quetiapine and ziprasidone are all effective in first‐epi‐sode schizophrenia ,their total efficacies equivalent ,but have different influences on metabolism , risperidone and quetiapine influences are obvious .%目的:探讨利培酮、喹硫平、齐拉西酮对首发精神分裂症患者代谢指标的影响。方法将120例首发精神分裂症患者按随机数字表法分为3组,分别口服利培酮、喹硫平、齐拉西酮治疗,观察12周。于治疗前后采用阳性与阴性症状量表评定临床疗效,同时检测血压、腰围及空腹血糖、三酰

  7. Development of Nutraceutical Emulsions as Risperidone Delivery Systems: Characterization and Toxicological Studies.

    Science.gov (United States)

    Igartúa, Daniela Edith; Calienni, María Natalia; Feas, Daniela Agustina; Chiaramoni, Nadia Silvia; Valle Alonso, Silvia Del; Prieto, María Jimena

    2015-12-01

    Emulsions are gaining increasing interest to be applied as drug delivery systems. The main goal of this work was the formulation of an oil/water nutraceutical emulsion (NE) for oral administration, enriched in omega 3 (ω3) and omega 6 (ω6), and able to encapsulate risperidone (RISP), an antipsychotic drug widely used in the treatment of autism spectrum disorders (ASD). RISP has low solubility in aqueous medium and poor bioavailability because of its metabolism and high protein binding. Coadministration of ω3, ω3, and vitamin E complexed with RISP might increase its bioavailability and induce a synergistic effect on the treatment of ASD. Here, we developed an easy and quick method to obtain NEs and then optimized them. The best formulation was chosen after characterization by particle size, defects of the oil-in-water interface, zeta potential (ZP), and in vitro drug release. The formulation selected was stable over time, with a particle size of around 3 μm, a ZP lower than -20 mV and controlled drug release. To better understand the biochemical properties of the formulation obtained, we studied in vitro toxicity in the Caco-2 cell line. After 4 h of treatment, an increase in cellular metabolism was observed for all RISP concentrations, but emulsions did not change their metabolic rate, except at the highest concentration without drug (25 μg/mL), which showed a significant reduction in metabolism respect to the control. Additionally, locomotor activity and heart rate in zebrafish were measured as parameters of in vivo toxicity. Only the highest concentration (0.625 μg/mL) showed a cardiotoxic effect, which corresponds to the decrease in spontaneous movement observed previously. As all the materials contained in the formulations were US FDA approved, the NE selected would be good candidate for clinical trials.

  8. Distinct neurobehavioral consequences of prenatal exposure to sulpiride (SUL) and risperidone (RIS) in rats.

    Science.gov (United States)

    Zuo, Jing; Liu, Zhening; Ouyang, Xuan; Liu, Haihong; Hao, Yihui; Xu, Lin; Lu, Xiao-Hong

    2008-02-15

    Antipsychotic treatment during pregnancy is indicated when risk of drug exposure to the fetus is outweighed by the untreated psychosis in the mother. Although increased risk of congenital malformation has not been associated with most available antipsychotic drugs, there is a paucity of knowledge on the subtle neurodevelopmental and behavioral consequences of prenatal receptor blockade by these drugs. In the present study, antipsychotic drugs, sulpiride (SUL, a selective D2 receptor antagonist) and risperidone (RIS, a D2/5HT2 receptor antagonist) were administered to pregnant Sprague-Dawley dams from gestational day 6 to 18. Both RIS and SUL prenatal exposed rats had lower birth body weights compared to controls. RIS exposure had a significant main effect to retard body weight growth in male offspring until postnatal day (PND) 60. Importantly, water maze tests revealed that SUL prenatal exposure impaired visual cue response in visual task performance (stimulus-response, S-R memory), but not place response as reflected in hidden platform task (spatial memory acquisition and retention). In addition, prenatal SUL treatment reduced spontaneous activity as measured in open field. Both behavioral deficits suggest that SUL prenatal exposure may lead to subtle disruption of striatum development and related learning and motor systems. RIS exposure failed to elicit deficits in both water maze tasks and increased rearing in open field test. These results suggest prenatal exposure to SUL and RIS may produce lasting effects on growth, locomotion and memory in rat offspring. And the differences may exist in the effects of antipsychotic drugs which selectively block dopamine D2 receptors (SUL) as compared to second generation drugs (RIS) that potently antagonize serotonin and dopamine receptors.

  9. Inflammation in Patients with Schizophrenia: the Therapeutic Benefits of Risperidone Plus Add-On Dextromethorphan

    Science.gov (United States)

    Chen, Shiou-Lan; Lee, Sheng-Yu; Chang, Yun-Hsuan; Chen, Shih-Heng; Chu, Chun-Hsieh; Tzeng, Nian-Sheng; Lee, I-Hui; Chen, Po-See; Yeh, Tzung Lieh; Huang, San-Yuan; Yang, Yen-Kuang; Lu, Ru-Band; Hong, Jau-Shyong

    2013-01-01

    Objectives Increasing evidence suggests that inflammation contributes to the etiology and progression of schizophrenia. Molecules that initiate inflammation, such as virus- and toxin-induced cytokines, are implicated in neuronal degeneration and schizophrenia-like behavior. Using therapeutic agents with anti-inflammatory or neurotrophic effects may be beneficial for treating schizophrenia. Methods One hundred healthy controls and 95 Han Chinese patients with schizophrenia were tested in this double-blind study. Their PANSS scores, plasma interleukin (IL)-1β, TNF-α and brain-derived neurotrophic factor (BDNF) levels were measured before and after pharmacological treatment. Results Pretreatment, plasma levels of IL-1β and TNF-α were significantly higher in patients with schizophrenia than in controls, but plasma BDNF levels were significantly lower. Patients were treated with the atypical antipsychotic risperidone (Risp) only or with Risp+add-on dextromethorphan (DM). PANSS scores and plasma IL-1β levels significantly decreased, but plasma TNF-α and BDNF levels significantly increased after 11 weeks of Risp treatment. Patients in the Risp+DM group showed a greater and earlier reduction of symptoms than did those in the Risp-only group. Moreover, Risp+DM treatment attenuated Risp-induced plasma increases in TNF-α. Conclusion Patients with schizophrenia had a high level of peripheral inflammation and a low level of peripheral BDNF. Long-term Risp treatment attenuated inflammation and potentiated the neurotrophic function but also produced a certain degree of toxicity. Risp+DM was more beneficial and less toxic than Risp-only treatment. PMID:22730040

  10. 肝切除术前PEIT治疗小肝癌28例%THE EFFICACY OF PRE-OPERATIVE PERCUTANEOUS ETHANOL INJECTION THERAPY FOR SMALL HEPATOCELLULAR CARCINOMA, 28 CASES REPORT

    Institute of Scientific and Technical Information of China (English)

    晏建军; 沈军; 黄亮; 周飞国; 张向化; 严以群

    2011-01-01

    Objective This study was designed to investigate the efficacy of pie-operative percutaneous ethanol injection therapy (PEIT) for small hepatocellukr carcinoma(small HCC). Methods From January 2000 to November 2002,67 patients with re-sectable samll HCC were proepectively randomized into two groups:preoperative PEIT group(n =28) and one-stage operation group (n = 39). All patients were proven HCC histologically after hepatectomy. The pathological changes of resected specimens were compared between two groups including tumor necrosis, capsular containment,daughter nodules,blood thrombus in portal vein and liver cirrhosis. Results All of the patients received liver resection and no operative death occurred. The main tumor necrosis areas was more extensive and the rates of encapsulation was higher in preoperab've PEIT group than those in one-stage operation group, and the formation of blood thrombus in portal vein was found in 8(28. 6% ) patients' lesion in preoperative PEIT group, but none in one-stage operation group. For the preoperative PEIT group,the l-,3-,and 5-year recurrent rates were 10.7% 、14. 3% and 25% respectively, and for the one-stage operation group,the l-,3-,and 5-year recurrent rates were 11.3% 、24.5% and 36.7% respectively;For preoperative PEIT group ,the l-,3-,5-,and 10-year survival rates were 83.9% 、78.6% 、71.4% and 53. 6% .respectively, and for the one-stage operation group,the l-,3-,5-,and 10-year survival rates were89.7% 、69.2% 、61.5% and 41% , respectively. Conclusions preoperative PEIT is safety and practical for the treatment of small HCC, and it can prevent tumor recurrence and improve the long-lenn results.%目的 探讨可切除的小肝癌术前PEIT的临床价值.方法 2000年1月~2002年11月收治的67例可切除小肝癌患者随机分成术前PEIT组(n=28)与Ⅰ期手术组(n=39)所有患者术后病理均证实为肝细胞癌.对比两组标本间肿瘤坏死、纤维包膜、子灶、门静脉血栓、肝硬化

  11. 痰热清注射液治疗成人重症肺炎疗效及安全性分析%Efficacy and Safety of Tanreqing Injection on Treating Adults Severe Pneumonia

    Institute of Scientific and Technical Information of China (English)

    张炜; 孟庆阳; 孙丽丹; 王利菊

    2016-01-01

    Objective:We want to analyze the treatment effect and safety of Tanreqing Injection on treating adults' severe pneumonia.Methods:We searched before 2015-08-01 Cochrane Library,Medline,Embase,OVID,VIP and CNKI-Chinese Academic Journal (1980--2015)was published at home and abroad about Tanreqing treatment of adults severe pneumonia abult clinical efficacy of randomized controlled clinical trials literature (randomized clinical trial,RCT).Jadad quality score using the evaluation criteria for inclusion of literature using Review Manager 5.3 software Mate analysis.Results:A total of 10 randomized controlled trials,a total of 762 cases of patients met the inclusion criteria,included in this Meta analysis.Meta-analysis showed:The homogeneity test included seven studies homogeneity (x 2=3.49,P=0.75.,I2=0),using the fixed effects model,the results show Tanreqing group treatment of adults with severe pneumonia,the cure rate than the control group,the comprehensive advantages of ratio (OR)was 0.49,95% CI (0.31,0.76),the overall effectiveness of inspection and Z=3.14,P<0.002; 10studies included homogeneity (x 2=7.16,P=0.62,I2=0),using the fixed effects model,the results show Tanreqing treatment of adults with severe pneumonia group total efficiency than the control group,the comprehensive advantages of the ratio (OR)was 0.31,95% CI (0.21,0.47),the overall effectiveness of inspection and Z=5.56,P<0.00001.Conclusion:The limited evidence suggests Tanreqing treatment of adults with severe pneumonia have a good therapeutic effect and safety plays an important role in the clinical treatment.Because high-quality RCTs lack this study,so the application Tanreqing treatment of adults with severe pneumonia have a good therapeutic effect and safety needs more high-quality clinical studies to be further confirmed.%目的:研究分析痰热清注射液治疗成人重症肺炎的治疗效果及安全性.方法:在Cochrane Librarv、Medline、Embase、OVID、VIP和CNKI

  12. Risk of Hyperprolactinemia and Sexual Side Effects in Males 10-20 Years Old Diagnosed with Autism Spectrum Disorders or Disruptive Behavior Disorder and Treated with Risperidone

    NARCIS (Netherlands)

    Roke, Yvette; Buitelaar, Jan K.; Boot, Annemieke M.; Tenback, Diederik; van Harten, Peter N.

    2012-01-01

    Objective: The aim of this study was to investigate the long-term treatment effects of risperidone on prolactin levels and prolactin-related side effects in pubertal boys with autism spectrum disorders (ASD) and disruptive behavior disorders (DBD). Method: Physical healthy 10-20-year-old males with

  13. Risperidone-Induced Weight Gain in Referred Children with Autism Spectrum Disorders Is Associated with a Common Polymorphism in the 5-Hydroxytryptamine 2C Receptor Gene

    NARCIS (Netherlands)

    Hoekstra, Pieter J.; Troost, Pieter W.; Lahuis, Bertine E.; Mulder, Hans; Mulder, Erik J.; Franke, Barbara; Buitelaar, Jan K.; Anderson, George M.; Scahill, Lawrence; Minderaa, Ruud B.

    2010-01-01

    Weight gain is an important adverse effect of risperidone, but predictors of significant weight gain have yet to be identified in pediatric patients. Here, we investigated differences between age-and gender-normed body mass index-standardized z scores at baseline and after 8 weeks of open-label, fle

  14. Risperidone-Induced Weight Gain in Referred Children with Autism Spectrum Disorders Is Associated with a Common Polymorphism in the 5-Hydroxytryptamine 2C Receptor Gene.

    NARCIS (Netherlands)

    Hoekstra, P.J.; Troost, P.W.; Lahuis, B.E.; Mulder, H.; Mulder, E.J.H.; Franke, B.; Buitelaar, J.K.; Anderson, G.M.; Scahill, L.; Minderaa, R.B.

    2010-01-01

    Abstract Weight gain is an important adverse effect of risperidone, but predictors of significant weight gain have yet to be identified in pediatric patients. Here, we investigated differences between age- and gender-normed body mass index-standardized z scores at baseline and after 8 weeks of open-

  15. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders.

    NARCIS (Netherlands)

    Reyes, M.; Buitelaar, J.K.; Toren, P.; Augustyns, I.; Eerdekens, M.

    2006-01-01

    OBJECTIVE: The authors compared the effects of maintenance versus withdrawal of risperidone treatment in children and adolescents with symptoms of disruptive behavior disorder. METHOD: Patients with disruptive behavior disorder (5-17 years of age and a range of intellect) who had responded to risper

  16. Literature Analysis of 153 Cases of Adverse Drug Reactions Induced by Risperidone%153例利培酮致不良反应的文献分析

    Institute of Scientific and Technical Information of China (English)

    周秋娟; 吴晓燕; 陈颖; 巢楠; 瞿发林; 黄家富

    2014-01-01

    Objective To study the clinical features of adverse reaction induced by risperidone. Methods 122 case reports of adverse drug reaction due to risperidone from 2000 to 2012 in China were collected and analyzed, which involved 153 patients. Results The adverse reactions of risperidone were correlated with individual differences, which mainly occurred in central and peripheral nervous system. Conclusion Pay attention to physical status of patients when use risperidone,slowly increase the dose and comply with the individualized principle.%目的:综合分析利培酮所致不良反应的临床特征。方法对2000~2012年国内文献中有关利培酮所致不良反应的病例报道122篇涉及153例患者进行汇总分析。结果利培酮所致不良反应主要累及的系统-器官为中枢及外周神经系统,不良反应的发生与患者的个体差异有关。结论利培酮用药时应注意给药速度不宜过快,遵循个体化原则,关注患者的身体状况。

  17. Schizophrenic patients treated with clozapine or olanzapine perform better on theory of mind tasks than those treated with risperidone or typical antipsychotic medications.

    Science.gov (United States)

    Savina, Ioulia; Beninger, Richard J

    2007-08-01

    Theory of mind (ToM), the ability to attribute mental states to others, is associated with medial prefrontal cortical (mPFC) activity and is impaired in schizophrenia. Olanzapine or clozapine but not typical antipsychotics or risperidone preferentially affect c-fos expression in mPFC in animals. We tested the hypothesis that schizophrenic patients treated with different antipsychotics would perform differently on ToM tasks. Groups receiving Typicals (n=23), Clozapine (n=18), Olanzapine (n=20) or Risperidone (n=23) and a Control group of healthy volunteers (n=24) were matched for age, gender, handedness and education. ToM functioning was assessed with picture sequence, second-order belief and faux-pas tests. Schizophrenic groups performed similarly to controls on non-ToM conditions. The Olanzapine and Clozapine groups performed similarly to Controls on ToM tasks. The Typicals and Risperidone groups performed worse than the other groups on ToM tasks. We concluded that ToM performance of schizophrenic patients is influenced by the antipsychotic they are taking. Our results suggest that olanzapine or clozapine but not typicals or risperidone may improve or protect ToM ability.

  18. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia

    OpenAIRE

    Honey, Garry D; Edward T Bullmore; Soni, William; Varatheesan, Malini; Williams, Steve C.R.; Sharma, Tonmoy

    1999-01-01

    Antipsychotic drug treatment of schizophrenia may be complicated by side effects of widespread dopaminergic antagonism, including exacerbation of negative and cognitive symptoms due to frontal cortical hypodopaminergia. Atypical antipsychotics have been shown to enhance frontal dopaminergic activity in animal models. We predicted that substitution of risperidone for typical antipsychotic drugs in the treatment of schizophrenia would be associated with enhanced functional activation of frontal...

  19. Alginate gel-coated oil-entrapped alginate-tamarind gum-magnesium stearate buoyant beads of risperidone.

    Science.gov (United States)

    Bera, Hriday; Boddupalli, Shashank; Nandikonda, Sridhar; Kumar, Sanoj; Nayak, Amit Kumar

    2015-01-01

    A novel alginate gel-coated oil-entrapped calcium-alginate-tamarind gum (TG)-magnesium stearate (MS) composite floating beads was developed for intragastric risperidone delivery with a view to improving its oral bioavailability. The TG-blended alginate core beads containing olive oil and MS as low-density materials were accomplished by ionotropic gelation technique. Effects of polymer-blend ratio (sodium alginate:TG) and crosslinker (CaCl2) concentration on drug entrapment efficiency (DEE, %) and cumulative drug release after 8 h (Q8h, %) were studied to optimize the core beads by a 3(2) factorial design. The optimized beads (F-O) exhibited DEE of 75.19±0.75% and Q8h of 78.04±0.38% with minimum errors in prediction. The alginate gel-coated optimized beads displayed superior buoyancy and sustained drug release property. The drug release profiles of the drug-loaded uncoated and coated beads were best fitted in Higuchi kinetic model with Fickian and anomalous diffusion driven mechanisms, respectively. The optimized beads yielded a notable sustained drug release profile as compared to marketed immediate release preparation. The uncoated and coated Ca-alginate-TG-MS beads were also characterized by SEM, FTIR and P-XRD analyses. Thus, the newly developed alginate-gel coated oil-entrapped alginate-TG-MS composite beads are suitable for intragastric delivery of risperidone over a prolonged period of time.

  20. Use of haloperidol and risperidone in highly aggressive Swiss Webster mice by applying the model of spontaneous aggression (MSA).

    Science.gov (United States)

    Fragoso, Viviane Muniz da Silva; Hoppe, Luanda Yanaan; de Araújo-Jorge, Tânia Cremonini; de Azevedo, Marcos José; Campos, Jerônimo Diego de Souza; Cortez, Célia Martins; de Oliveira, Gabriel Melo

    2016-03-15

    Aggression is defined as the act in which an individual intentionally harms or injures another of their own species. Antipsychotics are a form of treatment used in psychiatric routine. They have been used for decades in treatment of patients with aggressive behavior. Haloperidol and risperidone promote the control of psychiatric symptoms, through their respective mechanisms of action. Experimental models are obtained by behavioral, genetic, and pharmacological manipulations, and use a reduced number of animals. In this context, we applied the model of spontaneous aggression (MSA), originating the presence of highly aggressive mice (AgR) when reassembled in adulthood. We administered haloperidol and risperidone in escalating doses, for ten consecutive days. Using positive and negative control groups, we evaluated the effectiveness of these drugs and the reversal of the aggressive behavior, performing the tail suspension test (TST) and open field test (OFT) on 10th day of treatment and 10 days after its discontinuation. The results showed that both antipsychotic drugs were effective in AgR and reversed the aggressive phenotype, reducing the number of attacks by AgR and the extent of lesions in the subordinate mice (AgD) exposed to the pattern of aggressive behavior (PAB) of the aggressors. This conclusion is based on the reduction in the animals' motor and exploratory activity, and on the reversal of patterns of aggressive behavior. The association between the MSA and experiments with other therapeutic protocols and different antipsychotics can be an important methodology in the study of aggressive behavior in psychiatric patients.

  1. 关节腔注射医用三氧和透明质酸钠治疗膝关节骨性关节炎的疗效%Efficacy of medical ozone combined with sodium hyaluronate intra-articular injection in the treatment of patients with knee osteoarthritis

    Institute of Scientific and Technical Information of China (English)

    姚发利; 佘淑华; 李海涛; 高华

    2015-01-01

    目的 探讨医用三氧结合透明质酸钠治疗膝关节骨性关节炎的临床疗效.方法 膝关节骨性关节炎患者84例,随机分为注射组和传统组,各组42例.注射组使用医用三氧结合透明质酸钠关节腔内注射方法治疗,传统组使用针灸、特定电磁波谱(TDP)、中频、微波、中药敷贴等传统治疗方法治疗,于治疗前及治疗后5周记录VAS评分及Lysholm膝关节评分,并于治疗后5周评定治疗效果,观察治疗后的临床疗效.结果 与治疗前比较,两组患者治疗后VAS评分均下降,且注射组较传统组下降更明显,差异均有统计学意义(P<0.05);与治疗前比较,治疗后两组患者Lysholm评分均升高,且注射组升高更明显,差异均有统计学意义(P<0.05).注射组的有效率(92.8%,39/42例)高于传统组(81.0%,34/42例),差异有统计学意义(P<0.05).结论 医用三氧结合透明质酸钠治疗膝关节骨性关节炎疗效较传统方法好.%Objective To explore the clinical efficacy of medical ozone combined with sodium hyaluronate intra-articular injection in the treatment of patients with knee osteoarthritis.Methods Eighty-four patients with knee osteoarthritis were divided into medical ozone combined with intra-articular sodium hyaluronate injection group (injection group) and traditional group, 42 cases in each group.Patients in the injection group were received medical ozone combined with sodium hyaluronate intra-articular injection, while the others in the traditional group were received acupuncture, TDP, midfrequency, microwave, traditional Chinese medicine.VAS and Lysholm score were recorded before and after the treatment, and the effective rates were evaluated after the treatment.Results Compared with pre-treatment, VAS was decreased significantly after the treatment in both two groups, and that in injection group was better than that in traditional group (P< 0.05).Lysholm score was significantly increased after the treatment

  2. 推拿、针灸、复位、水针四联疗法治疗腰椎间盘突出症45例疗效分析%Efficacy Analysis of Quadruple Therapy with Massage, Acupuncture, Manipulative Reduction and Acupoint Injection on Lumbar Disc Herniation in 45 Cases

    Institute of Scientific and Technical Information of China (English)

    张云会; 朱丽华

    2013-01-01

    Objective:To observe the curative effects of acupuncture, massage, manipulative reduction and acupoint injection on lumbar disc hernia-tion. Methods:45 patients were treated with quadruple therapy of massage, acupuncture, manipulative reduction and acupoint injection. Results:32 cases were cured, 10 cases improved, 3 cases ineffective, the total efficiency was 93.33%. Conclusion:Efficacy of quadruple therapy with massage, acupuncture, manipulative reduction and acupoint injection on lumbar disc herniation is significant, meanwhile avoiding pains of operation and easi-ly accepted by patients.%目的:观察推拿、针灸、复位、水针四联疗法治疗腰椎间盘突出症的疗效。方法:45例患者均采用推拿、针灸、复位、水针四联疗法治疗。结果:痊愈32例,好转10例,无效3例,总有效率93.33%。结论:推拿、针灸、复位、水针四联疗法治疗腰椎间盘突出症疗效显著,同时避免了手术痛苦,患者容易接受。

  3. Paliperidone ER in the Treatment of Borderline Personality Disorder: A Pilot Study of Efficacy and Tolerability

    Directory of Open Access Journals (Sweden)

    Silvio Bellino

    2011-01-01

    Full Text Available Antipsychotics are recommended for the treatment of impulsive dyscontrol and cognitive perceptual symptoms of borderline personality disorder (BPD. Three reports supported the efficacy of oral risperidone on BPD psychopathology. Paliperidone ER is the metabolite of risperidone with a similar mechanism of action, and its osmotic release reduces plasmatic fluctuations and antidopaminergic effects. The aim of this study is to evaluate efficacy and safety of paliperidone ER in BPD patients. 18 outpatients with a DSM-IV-TR diagnosis of BPD were treated for 12 weeks with paliperidone ER (3–6 mg/day. They were assessed at baseline, week 4, and week 12, using the CGI-Severity item, the BPRS, the HDRS, the HARS, the SOFAS, the BPD Severity Index (BPDSI, and the Barratt Impulsiveness Scale (BIS-11. Adverse events were evaluated with the DOTES. Paliperidone ER was shown to be effective and well tolerated in reducing severity of global symptomatology and specific BPD symptoms, such as impulsive dyscontrol, anger, and cognitive-perceptual disturbances. Results need to be replicated in controlled trials.

  4. No change of dopamine transporter density in basal ganglia after risperidone treatment in drug-naive children with Tourette's disorder

    Energy Technology Data Exchange (ETDEWEB)

    Ryu, W. K.; Ryu, Y. H.; Yoon, M. J.; Chun, K. A.; Lee, J. D. [College of Medicine, Univ. of Yonsei, Seoul (Korea, Republic of); Zee, D. Y. [Univ. of Inhwa, Incheon (Korea, Republic of); Choi, T. H. [Korea Cancer Center Hospital, Seoul (Korea, Republic of)

    2003-07-01

    Tourette's disorder (TD), which is characterized by multiple waxing and waning motor tics and one or more vocal tics, is known to be associated with abnormalities in the dopaminergic system. To testify our hypothesis that risperidone would improve tic symptoms of TD patients through the change of the dopaminergic system, we measured the DAT densities between drug-naive children with TD and normal children investigated the DAT density before and after treatment with risperidone in drug-naive children with TD, using lodine-123 labelled N-(3-iodopropen-2-yl)-2beta-carbomethoxy-3beta-(4-chlorophenyl) tropane(I-123 IPT) single photon emission computed tomography (SPECT). I-123 IPT SPECT imaging and Yale Global Tic Severity Scale-Korean version (YGTSS-K) for assessing the tic symptom severity were carried out before and after treatment with risperidone for 8 weeks in eight drug-naive children with TD. Eight normal children also underwent SPECT imaging 2 hours after an intravenous administration of I-123 IPT and carried out both quantitative and qualitative analyses using the obtained SPECT data, which were reconstructed for the assessment of the specific/non-specific DAT binding ratio in the basal ganglia. The drug-naive children with TD had a significantly greater increase in the specific/nonspecific DAT binding ratio of both basal ganglia compared with the normal children. However, no significant difference in the specific/nonspecific DAT binding ratio of the basal ganglia before and after treatment with riperidone in children with TD was not found, although tic symptoms were significantly improved with risperidone. These findings suggest that DAT densities are directly associated with the pathophysiology of TD, however, that the effect of risperidone on tic symptoms in children with TD is not attributed to the change of dopaminergic system.

  5. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia

    Science.gov (United States)

    Honey, Garry D.; Bullmore, Edward T.; Soni, William; Varatheesan, Malini; Williams, Steve C. R.; Sharma, Tonmoy

    1999-01-01

    Antipsychotic drug treatment of schizophrenia may be complicated by side effects of widespread dopaminergic antagonism, including exacerbation of negative and cognitive symptoms due to frontal cortical hypodopaminergia. Atypical antipsychotics have been shown to enhance frontal dopaminergic activity in animal models. We predicted that substitution of risperidone for typical antipsychotic drugs in the treatment of schizophrenia would be associated with enhanced functional activation of frontal cortex. We measured cerebral blood oxygenation changes during periodic performance of a verbal working memory task, using functional MRI, on two occasions (baseline and 6 weeks later) in two cohorts of schizophrenic patients. One cohort (n = 10) was treated with typical antipsychotic drugs throughout the study. Risperidone was substituted for typical antipsychotics after baseline assessment in the second cohort (n = 10). A matched group of healthy volunteers (n = 10) was also studied on a single occasion. A network comprising bilateral dorsolateral prefrontal and lateral premotor cortex, the supplementary motor area, and posterior parietal cortex was activated by working memory task performance in both the patients and comparison subjects. A two-way analysis of covariance was used to estimate the effect of substituting risperidone for typical antipsychotics on power of functional response in the patient group. Substitution of risperidone increased functional activation in right prefrontal cortex, supplementary motor area, and posterior parietal cortex at both voxel and regional levels of analysis. This study provides direct evidence for significantly enhanced frontal function in schizophrenic patients after substitution of risperidone for typical antipsychotic drugs, and it indicates the potential value of functional MRI as a tool for longitudinal assessment of psychopharmacological effects on cerebral physiology. PMID:10557338

  6. Results and analysis of the 2008-2009 Insulin Injection Technique Questionnaire survey

    NARCIS (Netherlands)

    De Coninck, Carina; Frid, Anders; Gaspar, Ruth; Hicks, Debbie; Hirsch, Larry; Kreugel, Gillian; Liersch, Jutta; Letondeur, Corinne; Sauvanet, Jean-Pierre; Tubiana, Nadia; Strauss, Kenneth

    2010-01-01

    Background: The efficacy of injection therapy in diabetes depends on correct injection technique and, to provide patients with guidance in this area, we must understand how they currently inject. Methods: From September 2008 to June 2009, 4352 insulin-injecting Type 1 and Type 2 diabetic patients fr

  7. Efficacy and safety of phloroglucinol injection in the treatment of renal colic: a randomized, multicenter clinical trial%间苯三酚治疗肾绞痛的多中心随机对照临床研究

    Institute of Scientific and Technical Information of China (English)

    章传华; 刘双林; 陈志强; 王珅; 高文喜; 周洁; 郭永连; 李国灏; 张景宇

    2015-01-01

    Objective To evaluate the efficacy and safety of phloroglucinol injection in the treatment of renal colic by a multicentre,prospective,randomized trial.Methods From June 2013 to July 2014,a total of 200 patients with renal colic were enrolled from 5 medical centers as subjects for the study.The patients who met the following inclusion criteria were consecutively enrolled:age range of 18-70 years,emergency admission for renal colic,and a radiopaque or radiolucent urinary stone diagnosed with plain abdominal radiography,urinary system ultrasonography or non-contrast CT.Exclusion criteria included urinary tract infection,confirmed or suspected pregnancy,uncontrollable hypotension,cardiac insufficiency,arrhythmias,presence of fever,gastric ulcer and alcoholism.According to a computer-generated randomization table,patients were randomized 1 ∶ 1 assigned to phloroglucinol group (receive intravenous phloroglucinol 120 mg plus diclofenac sodium suppositories 50 mg once daily) or anisodamine group (intravenous anisodamine hydrochloride 20 mg plus diclofenac sodium suppositories 50 mg once daily).After 72 h,patients were asked about the number of colic episodes and lasting time of each episode.Pain intensity was recorded using a visual analog scale before drug administration and after treatment.Overall analgesics consumption,stone-expulsion rate and the side-effects of the drugs were also recorded.Results Among 200 patients enrolled in the study,100 patients received intravenous phloroglucinol 120 mg plus diclofenac sodium suppositóries 50 mg once daily and 100 patients received intravenous anisodamine hydrochloride 20 mg plus diclofenac sodium suppositories 50 mg once daily.There were no significant differences between the 2 groups for age,gender,stone size and stone location (P>0.05).There were no differences in the pain intensity and the drug effectiveness between the 2 groups (P>0.05).During the 72 h,there was spontaneous stone expulsion in 11 cases from

  8. C型臂引导下等离子髓核低温消融术联合臭氧治疗包容性腰椎间盘突出症的对比观察%CLINICAL OBSERVATION OF THE EFFICACY OF CONTAINED LUMBAR DISC HERNIATION TREATMENT USING PLASMA-MEDIATED COBLATION COMBINED WITH OZONE INJECTION THERAPY UNDER C-ARM GUIDANCE

    Institute of Scientific and Technical Information of China (English)

    王君; 夏庆来; 杨连海; 郑宝森

    2011-01-01

    Objective: To observe the efficacy of contained lumbar disc herniation using the technique of plasma-mediated coblation combined with ozone injection therapy under C-arm guidance.Methods: 90 patients diagnosed as contained lumbar disc herniation by MRI were randomly dividied into A, B, C group, with 30 patients each.The technique of plasma-mediated coblation combined with ozone injection therapy was applied in group A.Plasma-mediated coblation technique alone was applied in group B and ozone injection therapy alone in group C.Visual analogue score(VAS) was used to evaluate the degree of pain and improved MacNab criteria were used to evaluate the clinical efficacy during the time point 9 days, 18 days and 1 month after surgery.Results: The efficacy rate of group A 1 month after surgery was 96.6%, which was significantly higher than the other two groups of 76.6% in group B and 70% in group C ( P < 0.05 ).Conclusion: The efficacy of the technique of plasma-mediated coblation combined with ozone injection therapy to treat lumbar disc herniation have more advantage than the technique of PlasmaMediated Coblation or Ozone injection therapy alone.%目的:观察在C型臂引导下,应用等离子髓核低温消融术联合注射臭氧治疗包容性腰椎间盘突出症的临床疗效.方法:回顾性分析90例包容性腰椎间盘突出症,随机分为A、B、C三组,每组30例.A组采用等离子髓核低温消融术联合臭氧治疗,B组采用等离子髓核低温消融术治疗,C组采用腰椎间盘注射臭氧治疗.采用VAS视觉模拟疼痛评分作为疼痛水平评价指标,改良Mac-Nab标准评估治疗效果.观察三组患者术后9天、18天、1个月的临床疗效.结果:术后1个月A组治疗优良率为96.6%(29/30例),B组治疗的优良率为76.6%(23/30例),C组治疗后优良率为70%(21/30例).A组优良率高于B组和C组(P<0.05).结论:等离子髓核低温消融术联合臭氧治疗包容性腰椎间盘突出症疗效优于单独应

  9. 阿立哌唑治疗利培酮所致精神分裂症女性患者高催乳素血症的研究%Aripiprazole in treatment of female schizophrenics with risperidone induced hyperprolactinemia

    Institute of Scientific and Technical Information of China (English)

    纪菊英; 宋梓祥; 徐乐平; 孙剑; 施建安; 赵汉清; 王焕林

    2008-01-01

    Objective To explore the efficacy and safety of aripiprasole in treatment of female schizophrenics with risperidone induced hyperprolactinemia. Methods All 117 female schizophrenics with hyperprolactinemia after fixed dose risperidone treatment were randomly assigned to aripiprazole group (n=60) and control group (n=57), and received additional aripiprazole 5 nag daily or placebo for 6 weeks respectively. The plasma prolactin (PBL) level was measured at weeks 0 and 6, and the Brief Psychiatric Bating Scale (BPBS) and Treatment Emergent Symptom Scale (TESS) were assessed. Results (1)Plasma prolactin levels were significantly reduced after the study compared with the baseline [(26±6) μg/L vs. (112±40)μg/L] in aripiprazole group (P= 0.000), however there were no significant difference between pre- and post treatment in control group (P =0.180). (2) At weeks 6, the decline rate and the normal ratio of plasma prolactin levels were significantly higher in aripiprazole group [(75±8) % vs. 82%]than in control group [(5±30) % vs. 4%] respectively (beth P = 0.000 ). (3) Compared with the baseline, the BPRS score showed significant reduction in both groups at the end of the study (both P=0.045). The incidence of side effects showed no significant difference between aripiprazole and control group(P =0.553). Conclusion The results indicate that aripiprazole may be effective and safe for the treatment of female schizophrenics with risperidone induced hyperprolactinemis.%目的 探讨阿立哌唑治疗利培酮所致女性患者高催乳素血症的疗效及安全性.方法 117例利培酮所致高催乳素血症的女性患者,随机分为治疗组(60例)和对照组(57例).维持原有利培酮治疗不变,治疗组加用阿立哌唑5 mg,对照组加用安慰剂治疗,疗程均为6周.于治疗第0,6周末检测催乳素,评定简明精神病量表(BPRS)、治疗中需处理的不良反应症状量表(TESS).结果 (1)治疗第6周末,治疗组催乳素[(26±6)

  10. Synergistic function study of risperidone combined buspirone in the treatment of homeless patients with mental disorders%利培酮合并丁螺环酮治疗流浪精神障碍患者的效果分析

    Institute of Scientific and Technical Information of China (English)

    王勇健

    2016-01-01

    Objective To investigate the synergistic function and safety of risperidone combined buspirone in the treatment of homeless patients with mental disorders.Methods 96 homeless patients with mental disorders were divided into the control group and the observation group according to the random number table,48 cases in each group.The control group was given ris-peridone and the observation group was given buspirone based on the control group.After 8 weeks,the clinical efficacy was com-pared between two groups by the reduction rate of PANSS scale and symptom group score of PANSS,and the side effects of the two groups were also evaluated.Results Total efficiencies of the two groups had significant difference (P 0.05).Conclusion Risperidone combined buspirone treatment for homeless patients with mental disorders have syn-ergistic function and better security,and it should be widely applied.%目的:探讨利培酮合并丁螺环酮对流浪精神障碍患者治疗的增效作用及安全性。方法选取96例流浪精神障碍患者,根据数字法随机分为对照组和研究组,每组48例。对照组给予利培酮治疗,研究组在对照组基础上合并丁螺环酮,8周后根据 PANSS 量表减分率及 PANSS 量表症状群评分比较两组临床疗效,同时观察两组不良反应发生情况。结果研究组总有效率明显高于对照组,差异统计学意义(P <0.05)。两组治疗前后 PANSS 症状群评分比较,差异有统计学意义(P <0.05),研究组 PANSS 症状群评分下降更明显(P <0.05),两组不良反应发生率比较,差异无统计学意义(P >0.05)。结论利培酮合并丁螺环酮对流浪精神障碍患者治疗有明显的增效作用,且安全性较好,值得推广应用。

  11. Penicillin G Procaine Injection

    Science.gov (United States)

    Penicillin G procaine injection is used to treat certain infections caused by bacteria. Penicillin G procaine injection should not be used to treat ... in the treatment of certain serious infections. Penicillin G procaine injection is in a class of medications ...

  12. Toothbrushing efficacy

    NARCIS (Netherlands)

    Rosema, N.A.M.

    2015-01-01

    This thesis will explore the most meaningful aspects which are considered to be of interest regarding the efficacy of toothbrushes. One could discuss efficacy by means of plaque removal as well as by means of the effect on gingival inflammation. Plaque removal may be considered as a surrogate effect

  13. 甲氨蝶呤妊娠囊内注射联合清宫术治疗子宫瘢痕处妊娠的效果%Influence of Methotrexate Gestation Injection Combined with Curettage Treating Cesarean Scar Pregnancy on Clinical Efficacy,β-hCG and Adverse Reactions

    Institute of Scientific and Technical Information of China (English)

    颜红丽; 田燕妮; 刘嗣超; 王彩英

    2016-01-01

    Objective:To research the influence of methotrexate gestation injection combined with curet-tage treating cesarean scar pregnancy on clinical efficacy,β-hCG and adverse reactions. Methods:The clini-cal data of 150 patients with cesarean scar pregnancy treated in our hospital from April 2015 to April 2016 were analyzed retrospectively. The control group was treated with methotrexate gestation injection, based on which, the observation group was treated with curettage. The efficacy of two groups was compared. Results:The fertile function, efficacy indicators andβ-hCG of the observation group was better than that of the control group , and the total incidence rate of adverse reactions of the observation group was lower than that of the con-trol group( P<0.05) . Conclusion:Methotrexate gestation injection combined with curettage in treating cesare-an scar pregnancy has evident effect.%目的::研究子宫瘢痕处妊娠患者行甲氨蝶呤妊娠囊内注射和清宫术联合治疗对临床疗效、β-hCG及不良反应的影响。方法:资料取本院2015年4月至2016年4月收治子宫瘢痕处妊娠150例患者予回顾分析,对照组行甲氨蝶呤妊娠囊内注射治疗,观察组联合清宫术,对比两组疗效。结果:观察组生育功能及相关疗效指标、β-hCG比对照组优,且总不良反应率比对照组低,差异具有统计学意义( P<0.05)。结论:子宫瘢痕处妊娠行甲氨蝶呤妊娠囊内注射和清宫术联合治疗效果显著。

  14. Iron Dextran Injection

    Science.gov (United States)

    ... allergic to iron dextran injection; any other iron injections such as ferric carboxymaltose (Injectafer), ferumoxytol (Feraheme), iron sucrose (Venofer), or sodium ferric gluconate (Ferrlecit);any other ...

  15. 不同剂量利培酮治疗首发精神分裂症的疗效观察%Clinical observation of various dosages of risperidone in treatment of first episode schizophrenia

    Institute of Scientific and Technical Information of China (English)

    隗春玲

    2015-01-01

    Objective To observe the effect of various dosages of Risperidone Tablets in treatment of first episode schizophrenia and safety evaluation.Methods Patients (127 cases) with first episode schizophrenia from Beijing Fangshan District Mental Health Care Hospital from April 2012 to April 2014 were randomly divided into high-dosage group ( 62 cases) and low-dosage group (65 cases). The patients in the high-dosage group werepo administered with Risperidone Tablets 0.5 — 1 mg/d at beginning, then gradually added to 6 mg/d according to patient's condition and adverse reactions in the second and third day, and maintained the dosage of 6 mg/d. The patients in the low-dosage group were same to those in the high-dosage group except added dosage and maintenance dosage of 3 mg/d. Two groups were treated for 8 weeks. After treatment, the efficacy was evaluated, and PANSS score, EPS occurrence and TESS scores in two groups were compared.Results The efficacies in the high-dosage and low-dosage groups were 93.85% and 82.26%, respectively, and there were differences between two groups (P < 0.05). After treatment, negative symptom scale scores, positive symptom scale score, the psychopathology scale scores, and PANSS total score in two groups were significantly lower, and the difference was statistically significant in the same group (P < 0.05). The observational indexes of the low-dosage group were significantly lower than those in the same period in the high-dosage group treated for 4 and 8 weeks, with significant difference between two groups (P < 0.05). The incidence of EPS and TESS scores at 4 and 8 week in the low-dosage group were obviously lower than those in the high-dosage group, and the difference was statistically significant between two groups (P < 0.05).Conclusion Low-dosage of Risperidone Tablets has curative effect in treatment of first episode schizophrenia with better clinical efficacy, less PANSS score, incidence of EPS, and TESS scores, which be superior to

  16. The Comparison of the Effectiveness of Risperidone and Fluoxetine in Combination with Impulse Control Group Therapy on Improving of Impulsivity, and Relapse in Heroin Crack Addicts under Methadone Maintenance Therapy

    OpenAIRE

    Rohoallah Hadadi; Hamid reza Fathinaz; Mehdi Karimi; Saeed Akbari; Nafiseh Soltannejad

    2013-01-01

    Aim: The aim of the study was to compare the effectiveness of Risperidone and Fluoxetine in combination with impulse control group therapy on improving of impulsivity, and relapse in heroin crack addicts under methadone maintenance therapy. Method: In a semi-experimental study, 39 heroin crack addicts who were under Methadone maintenance treatment selected of addiction withdrawal centers in Tehran. The selected sample was randomly assigned to three groups. First group was under (Risperidone 1...

  17. Corticosteroid injection for de Quervain's tenosynovitis

    NARCIS (Netherlands)

    Peters-Veluthamaningal, Cyriac; van der Windt, Danielle A. W. M.; Winters, Jan C.; Jong, Betty Meyboom-de

    2009-01-01

    Back ground De Quervain's tenosynovitis is a disorder characterised by pain on the radial (thumb) side of the wrist and functional disability of the hand. It can be treated by corticosteroid injection, splinting and surgery. Objectives To summarise evidence on the efficacy and safety of corticostero

  18. Observation on the efficacy of monosialotetrahexosylganglioside sodium injection combined with brain protein hydrolysate for the treatment of Parkinson disease%单唾液酸四己糖神经节苷脂钠联合脑蛋白水解物治疗帕金森病的疗效观察

    Institute of Scientific and Technical Information of China (English)

    尹忠平; 邓雷梅; 罗昌菊; 晓菲

    2014-01-01

    目的:探讨单唾液酸四己糖神经节苷脂钠联合脑蛋白水解物治疗帕金森病的疗效。方法按照随机数字表法将86例帕金森病患者均分为实验组和对照组,对照组患者单用单唾液酸四己糖神经节苷脂钠注射液治疗,实验组患者采取单唾液酸四己糖神经节苷脂钠注射液联合注射用脑蛋白水解物治疗,比较两组患者治疗效果。结果两组患者治疗后UPDRS总评分均显著下降,与治疗前比较,差异具有统计学意义(P<0.05);实验组患者UPDRS总评分显著低于对照组,总有效率显著高于对照组,差异具有统计学意义(P<0.05);两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论单唾液酸四己糖神经节苷脂钠联合脑蛋白水解物能够显著改善帕金森病患者UPDRS评分,临床疗效显著。%Objective To explore the efficacy of monosialotetrahexosylganglioside sodium injection combined with brain protein hydrolysate for the treatment of parkinson disease.Methods 86 cases of patients with parkinson disease were randomly divided into experiment group and control group. The control group were treated by monosialotetrah exosylganglioside sodium injection, the experiment group were treated by monosialotetrahexosylganglioside sodium injection combined with brain protein hydrolysate. The clinical effects were compared for the two groups.Results The scores of UPDRS posttreatment for the two groups were lower than prior treatment(P0.05). ConclusionThe efficacy of monosialotetrahexosylganglioside sodium injection combined with brain protein hydrolysate for the treatment of parkinson disease is good, it can improve the scores of UPDRS. The clinical curative effect is distinct.

  19. Efficacy and tolerance of an injectable medical device containing stable hybrid cooperative complexes of high- and low-molecular-weight hyaluronic acid: a monocentric 16 weeks open-label evaluation

    Directory of Open Access Journals (Sweden)

    Sparavigna A

    2016-09-01

    Full Text Available Adele Sparavigna, Beatrice Tenconi DermIng srl, Clinical Research and Bioengineering Institute, Monza, MB, Italy Background: An injectable medical device containing stable hybrid cooperative complexes of high- and low-molecular-weight hyaluronic acid (HA has been developed with characteristics suited for a global improvement of facial esthetics. Objective: To evaluate the HA product performance in improving some key facial esthetic features. The study employed clinical scales, subjective evaluations, and facial skin objective measurements. Methods: A single Italian site treated 64 female subjects aged 38–60 years, with injections at five predetermined points, on each side of the face, with a 4-week time lapse between the first and the second product administration. Subjects were evaluated after 4, 8, 12, and 16 weeks, using validated clinical scales, subjective evaluation, and objective quantitative outcome measures. Assessment of esthetic results included photographic documentation. Results: Both the clinical and subjective assessments, and the majority of objective instrumental parameters indicated an improvement throughout the study and were already significant at week 4 or 8 and were still significant at week 16 (3 months after the second treatment. Minor and temporary local skin reactions were observed in 23% of subjects at the site of the injections, and the global judgment on tolerability was good or excellent, both in the investigators’ opinion and volunteers’ self-evaluation. Conclusion: Both subjective and objective improvement of the facial parameters was consistent with the bio-remodeling purpose, and persistent and still statistically significant at the end of the study. The tolerability and safety profile of the product were judged good or excellent both by investigators and volunteers. This study supports the claim for bio-remodeling of these stable hybrid cooperative complexes of low- and high-molecular-weight HA. Keywords

  20. Efficacy and tolerance of an injectable medical device containing stable hybrid cooperative complexes of high- and low-molecular-weight hyaluronic acid: a monocentric 16 weeks open-label evaluation

    Science.gov (United States)

    Sparavigna, Adele; Tenconi, Beatrice

    2016-01-01

    Background An injectable medical device containing stable hybrid cooperative complexes of high- and low-molecular-weight hyaluronic acid (HA) has been developed with characteristics suited for a global improvement of facial esthetics. Objective To evaluate the HA product performance in improving some key facial esthetic features. The study employed clinical scales, subjective evaluations, and facial skin objective measurements. Methods A single Italian site treated 64 female subjects aged 38–60 years, with injections at five predetermined points, on each side of the face, with a 4-week time lapse between the first and the second product administration. Subjects were evaluated after 4, 8, 12, and 16 weeks, using validated clinical scales, subjective evaluation, and objective quantitative outcome measures. Assessment of esthetic results included photographic documentation. Results Both the clinical and subjective assessments, and the majority of objective instrumental parameters indicated an improvement throughout the study and were already significant at week 4 or 8 and were still significant at week 16 (3 months after the second treatment). Minor and temporary local skin reactions were observed in 23% of subjects at the site of the injections, and the global judgment on tolerability was good or excellent, both in the investigators’ opinion and volunteers’ self-evaluation. Conclusion Both subjective and objective improvement of the facial parameters was consistent with the bio-remodeling purpose, and persistent and still statistically significant at the end of the study. The tolerability and safety profile of the product were judged good or excellent both by investigators and volunteers. This study supports the claim for bio-remodeling of these stable hybrid cooperative complexes of low- and high-molecular-weight HA. PMID:27713647

  1. The efficacy of preventive parasternal single injection of bupivacaine on intubation time, blood gas parameters, narcotic requirement, and pain relief after open heart surgery: A randomized clinical trial study

    Directory of Open Access Journals (Sweden)

    Mahmoud Saeidi

    2011-01-01

    Full Text Available Background: Postsurgical pain usually results in some complications in the patients. This study has tried to investigate the effects of parasternal single injection of bupivacaine on postoperative pulmonary and pain consequences in patients after open heart surgery. Methods: : In a prospective double blind clinical study, 100 consenting patients undergoing elective open heart surgery were randomized into two groups. In case group, bupivacaine was injected at both sides of sternum, immediately before sternal closure. In the control group, no intervention was performed. Then, the patients were investigated regarding intubation period, length of ICU stay, arterial blood gas (ABG parameters, morphine requirement, and their severity of postoperative pain using a visual analogue scale (VAS device. Results: No differences were found between the two groups regarding to age, sex, pump time, operation time, and body mass index and preoperative cardiac ejection fraction. Mean intubation length in case group was much shorter than that in control group. Mean PaO 2 in case group was lower in different checking times in postoperative period. The patients in the case group needed less morphine compared to those in the control group during the 24-hour observation period in the ICU. Finally, mean VAS scores of pain in case group were significantly lower than those in control group at 6, 12, and 24 hours postoperatively. Conclusions: Patients′ pain relief by parasternal single injection of bupivacaine in early postoperative period can facilitate earlier ventilator weaning and tracheal extubation after open heart surgery as well as achieving lower pain scores and narcotic requirements.

  2. 痰热清注射液不同给药途径治疗慢性支气管炎的疗效%Efficacy of Tanreqing Injection in different administration routes in the treatment of chronic bronchitis

    Institute of Scientific and Technical Information of China (English)

    邹少雁; 谷小云

    2013-01-01

    Objective To observe the clinical effects of Tangreqing injection in diferent ways on chronic bronchitis. Methods 94 cases with chronic bronchitis were randomly divided into three groups (the control group;the aerosol inhalation group; the intravenous drip group). The control group was given conventional treatment. On the basis of conventional therapy, the aerosol inhalation group received aerosol inhalation of Tanreqing injection, and the intravenous drip group received intravenous drip of Tanreqing injection. To compare the difference among the three groups. Results The total effective rate of the aerosol inhalation group, the intravenous drip group, and the control group was 94.29%, 83.33%, and 75.86%, respectively. There was a significant difference among the three groups (P<0.05). Conclusion The use of aerosol inhalation of Tanreqing injection is safe and effective in the treatment of chronic bronchitis, which is worth spreading.%目的观察痰热清注射液不同给药途径治疗慢性支气管炎的临床疗效。方法将94例患者随机分为三组,各组均予基础治疗,雾化组另予痰热清注射液雾化吸入,注射组给予痰热清注射液静滴,比较三组的治疗效果。结果雾化组、注射组及对照组的总有效率分别为94.29%、83.33%及75.86%。组间比较差异有显著性(P<0.05)。结论痰热清注射液雾化吸入治疗慢性支气管炎疗效满意,安全性好,值得临床推广使用。

  3. Efficacy of Reduning Injection in the Treatment of 90 Cases with Children Upper Respiratory Tract Infection%热毒宁注射液治疗儿童上呼吸道感染90例

    Institute of Scientific and Technical Information of China (English)

    杜维平; 周泽伟

    2012-01-01

    目的 观察热毒宁注射液治疗儿童急性上呼吸道感染的疗效.方法 将180例急性上呼吸道感染患儿随机分成两组,根据临床表现均给予常规治疗,包括止咳、退热等,合并细菌感染者均给予适当的抗生素,治疗组给予热毒宁注射液0.5 ~0.8mL/(kg·d)静脉滴注,对照组给予利巴韦林注射液10~15 mg/(kg·d)静脉滴注,疗程均为3d.结果 治疗组总有效率为92.22%,对照组总有效率为75.56%,两组比较差异有统计学意义(P<0.05).结论 热毒宁注射液治疗儿童上呼吸道感染,起效快,疗程短,疗效确切,安全可靠.%Objective To observe the effects of Redlining Injection on children with acute upper respiratory tract infection. Methods 180 patients with acute upper respiratory tract infection were randomly divided into two groups. According to clinical manifestations, they were given conventional treatment. Patients with bacterial infection treated with antibiotics, the treatment group received Redlining Injection by intravenous infusion,the control group received ribavirin injection (10-15 mg/(kg ? D)) by intravenous infusion for 3 days. Results The total effective rate was 92.22% in the treatment group, and was 75.56% in the control group. There were significant differences between the two groups (P < 0. 05). Conclusion Redlining Injection for the treatment of children with upper respiratory tract infection is rapid, effective, safe and reliable.

  4. Clinical efficacy observation on treating infantile HFMD with Tanreqing injection%痰热清注射液治疗小儿手足口病的临床疗效观察

    Institute of Scientific and Technical Information of China (English)

    孙珺; 刘宏瑞; 邸顺祥

    2013-01-01

    Objective:To observe the clinical effect of Tanreqing injection on treating infantile HFMD. Methods:122 children with HFMD were randomly divided into two groups, 62 children in the treatment group, 60 children in the control group. The treatment group was given Tanreqing injection 0.3~0.5ml/kg, while the control group was injected with Vidarabine Monophosphate. To observe and record the pyretolysis time ,rash dissipated time, appetite improve time and curative effect evaluation of disease in both groups. Results:The total effective rate in the treatment group was higher than that in the control group, and the pyretolysis time and rash dissipated time were significantly shorter than those in the control group, with significant differences (P0.05). Conclusion: Tanreqing injection had definite clinical effect on treating children's HFMD, safe and effective.%  目的:观察痰热清注射液治疗小儿手足口病的临床疗效.方法:将122例手足口病患儿随机分为治疗组62例,对照组60例.治疗组给予痰热清注射液0.3~0.5ml/kg加入5%葡萄糖注射液100~200ml,静脉滴注,1次/d;对照组给予注射用单磷酸阿糖腺苷.观察并记录两组退热时间、退疹时间、食欲改善时间及疾病疗效评价.结果:治疗组总有效率高对照组,退热和退疹时间明显短对照组,比较差异均有统计学意义(P0.05).结论:痰热清注射液治疗小儿手足口病临床疗效确切,安全有效.

  5. Intraurethral Injection of Autologous Minced Skeletal Muscle

    DEFF Research Database (Denmark)

    Gräs, Søren; Klarskov, Niels; Lose, Gunnar

    2014-01-01

    PURPOSE: Intraurethral injection of in vitro expanded autologous skeletal muscle derived cells is a new regenerative therapy for stress urinary incontinence. We examined the efficacy and safety of a simpler alternative strategy using freshly harvested, minced autologous skeletal muscle tissue...... with its inherent content of regenerative cells. MATERIALS AND METHODS: A total of 20 and 15 women with uncomplicated and complicated stress urinary incontinence, respectively, received intraurethral injections of minced autologous skeletal muscle tissue and were followed for 1 year. Efficacy was assessed...... noted. CONCLUSIONS: Intraurethral injection of minced autologous muscle tissue is a simple surgical procedure that appears safe and moderately effective in women with uncomplicated stress urinary incontinence. It compares well to a more complicated regenerative strategy using in vitro expanded muscle...

  6. Technical aspects of the piezo, laser-assisted, and conventional methods for nuclear transfer of mouse oocytes and their efficiency and efficacy: Piezo minimizes damage of the ooplasmic membrane at injection.

    Science.gov (United States)

    Chen, Shee-Uan; Chao, Kuang-Han; Chang, Chia-Yi; Hsieh, Fon-Jou; Ho, Hong-Nerng; Yang, Yu-Shih

    2004-04-01

    Assessment of the advantages and disadvantages of the piezo, laser, and conventional methods for nuclear transfer has remained elusive. Furthermore, although the piezo method had been used by some investigators for research of sperm injection and nuclear transfer for several years, many researchers have failed to operate the technique smoothly and achieve reproducible results. The procedures of nuclear transfer using piezo were ascertained and described in detail. Mouse oocytes were enucleated, and injected with cumulus cells using the piezo, laser, or conventional methods. We investigated the time needed and survival of nuclear transfer. Development was compared among the three methods and parthenogenetic control specimens. The average time of nuclear transfer for each oocyte was significantly shorter using the piezo (118 +/- 9 s) and laser methods (120 +/- 11 s) than using the conventional method (170 +/- 11 s). The damage rate was smaller for the piezo group (10%) than the laser (37%) and conventional (40%) groups. The percentages of blastocyst formation (14%, 12%, and 11%) and the number of nuclei of blastocysts (54 +/- 13, 51 +/- 11, and 52 +/- 12) were similar among the piezo, laser, and conventional groups, but significantly lower than for the control group (83%, 105 +/- 14). The piezo technique is more efficient than the conventional method for nuclear transfer. The laser method is easy to operate, but the equipment is expensive. In addition, piezo induced fewer traumas while breaking the membrane than the aspiration techniques used in the laser and conventional methods.

  7. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study.

    Science.gov (United States)

    Bobes, J; Garc A-Portilla, M P; Rejas, J; Hern Ndez, G; Garcia-Garcia, M; Rico-Villademoros, F; Porras, A

    2003-01-01

    Atypical antipsychotics seem to differ mainly in their tolerability profile. The aim of this cross-sectional study, the Estudio de Investigaci n de Resultados en Esquizofrenia (Outcomes Research Study in Schizophrenia; EIRE study), was to assess in a clinical setting the frequency of several side-effects related to haloperidol, risperidone, olanzapine, and quetiapine. This article addresses sexual dysfunction and other reproductive side-effects (gynecomastia, menorrhage, amenorrhea, and galactorrhea). We recruited outpatients diagnosed with schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders (DSM-IV; American Psychiatric Association, 1994) criteria and who had received a single antipsychotic (risperidone, olanzapine, quetiapine, or haloperidol) for at least 4 weeks. During a single visit, we collected data, including demographic and clinical characteristics, current antipsychotic and concomitant treatment, and adverse effects listed in a modified version of the UKU Scale. We used a Chi-squared test to determine pairs comparisons of the frequency of adverse reactions between treatments. To estimate risk of a given adverse reaction with a given treatment, we used a logistic regression method. We assessed 636 evaluable patients out of 669 recruited. Frequency of sexual dysfunction was high with haloperidol (38.1%) and also with olanzapine (35.3%), quetiapine (18.2%), and risperidone (43.2%). We found the frequency of other reproductive side-effects to be relatively low with all four drugs: haloperidol (6.9%), olanzapine (6.4%), quetiapine (2.7%), and risperidone (11.7%). Sexual dysfunction appeared to be dose-related with haloperidol, risperidone, and olanzapine. Risperidone and olanzapine showed a higher risk of sexual dysfunction and other reproductive sideeffects than haloperidol. Quetiapine showed a lower risk of sexual dysfunction during short-term treatment ( 12 weeks) are lacking. Our results suggest that none of the atypical

  8. Solid lipid nanoparticles (SLN)--based hydrogels as potential carriers for oral transmucosal delivery of risperidone: preparation and characterization studies.

    Science.gov (United States)

    Silva, A C; Amaral, M H; González-Mira, E; Santos, D; Ferreira, D

    2012-05-01

    Two different solid lipid nanoparticles (SLN)-based hydrogels (HGs) formulations were developed as potential mucoadhesive systems for risperidone (RISP) oral transmucosal delivery. The suitability of the prepared semi-solid formulations for application on oral mucosa was assessed by means of rheological and textural analysis, during 30 days. Plastic flows with thixotropy and high adhesiveness were obtained for all the tested systems, which predict their success for the oral transmucosal application proposed. The SLN remained within the colloidal range after HGs preparation. However, after 30 days of storage, a particle size increase was detected in one type of the HGs formulations. In vitro drug release studies revealed a more pronounced RISP release after SLN hydrogel entrapment, when compared to the dispersions alone. In addition, a pH-dependent release was observed as well. The predicted in vivo RISP release mechanism was Fickian diffusion alone or combined with erosion.

  9. Sipuleucel-T Injection

    Science.gov (United States)

    Sipuleucel-T injection is used to treat certain types of advanced prostate cancer. Sipuleucel-T injection is in a class of medications called ... Sipuleucel-T injection comes as a suspension (liquid) to be injected over about 60 minutes into a vein ...

  10. Costi ed effetti di Risperidone Long Acting (RLA rispetto ad antipsicotici atipici nel trattamento dei soggetti schizofrenici in Italia

    Directory of Open Access Journals (Sweden)

    Lorenzo G. Mantovani

    2004-03-01

    Full Text Available Objective: to estimate the costs and effects of long-acting risperidone (LAR in the treatment of schizophrenic patients in Italy, as compared to conventional and oral atypical antipsychotics. Methods: a discrete event model was used. The model simulates patients. history for every single therapeutic alternative and selects incident events, on the basis of pre-defined probability distribution-powered, randomized repetitions. The model operates on two types of parameters: patient characteristics and time-dependent variables. Patient characteristics (age, sex, illness profile and severity, probability of incurring in an adverse event and potential dangerousness remain fixed during the 5 simulated years. Time-dependent variables are subject to changes and include outpatient visits, severity of psychotic episodes, symptom-scores, compliance, incidence of adverse effects, site of treatment and dangerousness. Three treatments have been selected: scenario 1 begins with LAR, switches to olanzapine and then to clozapine; scenario 2 starts with olanzapine, switches to oral risperidone and ends with clozapine. Direct medical costs have been computed on the basis of psychiatric visits, drug costs and costs of the institution in which the patient is treated (hospital, rehabilitation clinic, etc. Outcome measures were number of psychotic episodes in 5 years, total time spent during these episodes and cumulative score of positive and negative symptoms at 5 years. Information on alternatives, transition probabilities, model structure and health resources utilization were derived from the literature and from a panel of experts. Results: it has been estimated that LAR is economically dominant (more effective at lower cost respect to oral atypical antipsychotics, being able to prevent 0.87 psychotic episodes per patient, with a net cost saving of 4,773 euro per patient. Sub-group analysis indicate that LAR is always more effective than the considered alternatives

  11. Risperidone Effects on Brain Dynamic Connectivity—A Prospective Resting-State fMRI Study in Schizophrenia

    Science.gov (United States)

    Lottman, Kristin K.; Kraguljac, Nina V.; White, David M.; Morgan, Charity J.; Calhoun, Vince D.; Butt, Allison; Lahti, Adrienne C.

    2017-01-01

    Resting-state functional connectivity studies in schizophrenia evaluating average connectivity over the entire experiment have reported aberrant network integration, but findings are variable. Examining time-varying (dynamic) functional connectivity may help explain some inconsistencies. We assessed dynamic network connectivity using resting-state functional MRI in patients with schizophrenia, while unmedicated (n = 34), after 1 week (n = 29) and 6 weeks of treatment with risperidone (n = 24), as well as matched controls at baseline (n = 35) and after 6 weeks (n = 19). After identifying 41 independent components (ICs) comprising resting-state networks, sliding window analysis was performed on IC timecourses using an optimal window size validated with linear support vector machines. Windowed correlation matrices were then clustered into three discrete connectivity states (a relatively sparsely connected state, a relatively abundantly connected state, and an intermediately connected state). In unmedicated patients, static connectivity was increased between five pairs of ICs and decreased between two pairs of ICs when compared to controls, dynamic connectivity showed increased connectivity between the thalamus and somatomotor network in one of the three states. State statistics indicated that, in comparison to controls, unmedicated patients had shorter mean dwell times and fraction of time spent in the sparsely connected state, and longer dwell times and fraction of time spent in the intermediately connected state. Risperidone appeared to normalize mean dwell times after 6 weeks, but not fraction of time. Results suggest that static connectivity abnormalities in schizophrenia may partly be related to altered brain network temporal dynamics rather than consistent dysconnectivity within and between functional networks and demonstrate the importance of implementing complementary data analysis techniques. PMID:28220083

  12. 奥氮平与利培酮治疗老年痴呆伴精神行为症状对照观察%A control study of olanzapine vs .risperidone in senile demen-tia with behavioral and psychological symptoms

    Institute of Scientific and Technical Information of China (English)

    韩曙林; 孟红凤

    2015-01-01

    目的:比较奥氮平与利培酮治疗老年痴呆伴精神行为症状患者的疗效及安全性。方法将52例老年痴呆伴精神行为症状患者随机分为奥氮平组与利培酮组,分别予以奥氮平与利培酮治疗,观察8周。治疗前后采用痴呆病理行为评定量表、副反应量表评定临床疗效及不良反应。结果奥氮平组治疗第2周末起,利培酮组治疗第4周末起痴呆病理行为评定量表评分较治疗前显著降低(P<0.01),治疗第2周末奥氮平组显著低于利培酮组(P<0.05或0.01);奥氮平组有效率为92.3%,利培酮组为88.5%,两组比较差异无显著性( P>0.05);奥氮平组不良反应发生率显著低于利培酮组(P<0.05)。结论奥氮平与利培酮治疗老年痴呆伴精神行为症状患者疗效显著且相当,但奥氮平起效更快,安全性更高。%Objective To compare the efficacy and safety between olanzapine and risperidone in senile de‐mentia with behavioral and psychological symptoms (BPS) .Methods Fifty‐two senile dementia patients with BPS were randomly assigned to olanzapine and risperidone group treated with olanzapine or risperi‐done for 8 weeks .Efficacies were assessed with the Rating Scale of the Behavioral Pathology in Alzheime‐r′s Disease (BEHAVE‐AD) before and after treatment and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results The BEHAVE‐AD score lowered more significantly since the end of the 2nd week in olanzapine group and since the 4th in risperidone group compared with pretreatment (P0 .05);the incidence of adverse reactions was significantly lower in olanzapine than in ris‐peridone group (P<0 .05) .Conclusion Both olanzapine and risperidone have an equivalent and evident effect in senile dementia with BPS ,but the former takes effect more rapidly and has higher safety .

  13. 氨磺必利与利培酮治疗首发精神分裂症的随机双盲双模拟平行对照试验%Parallel Control Method with Random Double-blind and Double-simulation in Treatment with Amisulpride and Risperidone of First-onset Schizophrenia

    Institute of Scientific and Technical Information of China (English)

    韩刚亚; 严冬梅; 张新风

    2012-01-01

    [目的]:探讨氨磺必利与利培酮治疗精神分裂症的疗效及安全性.[方法]:采用随机、双盲、双模拟、平行对照试验方法,将34例符合诊断标准的首发精神分裂症患者随机分为氨磺必利组和利培酮组,每组17例.氨磺必利和利培酮的治疗剂量分别为800~1 200 mg·d-1和2 ~6 mg·d-1.疗程均为8周.于治疗前及治疗第1,2,4,8周末采用阳性和阴性症状评定量表(PANSS)评定疗效,采用治疗中出现的症状量表(TESS)及实验室检查来评价安全性.[结果]:治疗后第2,4,8周末,两组PANSS总分较治疗前均显著降低(P<0.05);氨磺必利组和利培酮组总有效率分别为88.2%和82.4%,差异无统计学意义(P>0.05).两组不良反应发生率比较差异亦无统计学意义(P>0.05).[结论]:氨磺必利和利培酮对治疗精神分裂症的疗效相当,不良反应轻,值得临床应用.%Objective:To explore the efficacy and safety of amisulpride and risperidone in treatment of schizophrenia. Methods: A randomized, double blind, double-dummy, parallel controlled clinical trial was conducted. The 34 rases of first episode schizophrenia patients met the diagnostic criteria were randomly divided into amisulpride group and risperidone group, 17 cases in each group. The doses range of amisulpride and risperidone were 800-1200 mg and 2-6 mg per day, respectively. The treatment was 8 weeks. The efficacy and adverse events were assessed with the Positive and Negative Symptom Scale (PANSS), Treatment Emergent Symptom Scale(TESS) and the laboratory tests before and at 1st, 2nd, 4th, 8th weekend after treatment. Results :The scores of PANSS in the two groups decreased significantly compared with ihe baseline at 2nd, 4th, 8th weekend after treatment( P 0.05). Conclusion: Amisulpride is as effective as risperidone for the treatment of schizophrenia with fewer side effects and worth clinical application.

  14. Eficácia do resfriamento da pele no alívio da dor desencadeada pela injeção de toxina botulínica tipo A nas distonias faciais Skin cooling efficacy on pain relief in periocular injections with botulinum toxin A in facial dystonias

    Directory of Open Access Journals (Sweden)

    Paula Barros Bandeira de Mello Monteiro

    2012-12-01

    Full Text Available OBJETIVO: Avaliar a eficácia do resfriamento da pele com gelo no alívio da dor desencadeada pela injeção de toxina botulínica tipo A na região periocular em pacientes portadores de distonia facial. MÉTODOS: Neste estudo prospectivo, 13 pacientes receberam injeção de toxina botulínica tipo A em região glabelar (m. prócero e periocular (m. orbicular para tratamento de distonia facial. Antes das aplicações, um lado da região glabelar foi resfriado com gelo durante 5 minutos, enquanto no outro lado foi aplicada pomada Epitezan®, funcionando como placebo. A aplicação foi feita primeiramente no lado resfriado. Após a aplicação em cada um dos lados os pacientes foram instruídos a dar uma nota para a dor desencadeada pela injeção, em uma escala de 0 a 10 onde 0 era ausência de dor e 10 a dor mais intensa. RESULTADOS: A média das notas dadas pelos pacientes à dor desencadeada pela injeção no lado onde foi aplicado placebo foi 3,92 ± 3,28. No local onde foi aplicado gelo a média das notas foi de 2,92 ± 2,18 (p PURPOSE: To evaluate the efficacy of skin cooling with ice on pain relief in periocular injection with botulinum toxin type A in patients with facial dystonias. METHODS: In this prospective study, 13 patients received botulinum toxin type A injection in glabela (procerus m. and periocular region (orbicular m. for facial dystonias treatment. Before the injections, one side of the glabela was submitted to a 5-minute cooling period, while the opposite side had Epitezan® cream applied, as a placebo. The application was done at the cooled side first. After the application on each side the patients were instructed to rate the pain associated with the injection on a scale from 0 to 10, with 0 indicating no pain and 10 the worst pain. RESULTS: The average pain score on the side where cold was applied was 3,92 ± 3,28, while on the control side the average pain score was 2,92 ± 2,18 (p < 0,0166. CONCLUSION: In this study

  15. The exploration of clinical effectiveness of haloperidol and risperidone on improving behavioral and psycho-logical symptoms of dementia%氟哌啶醇与利培酮改善痴呆患者行为症状和精神状态的临床实效性探讨

    Institute of Scientific and Technical Information of China (English)

    穆军山; 叶建新; 林航; 林敏; 崔晓萍; 张敏

    2016-01-01

    Objective To observe and explore the effect of haloperidol and risperidone on improving behavioral and psy-chological symptoms of dementia (BPSD).Methods Eighty cases with dementia in the hospital from August 201 1 to October 2013 were selected,who were randomly divided into observation group treated by risperidone and control group treated with haloperidol,40 patients in each group.PANSS-EC and PANSS Rating Scale were used as the primary methods to effciently e-valuate the efficacy of two groups.Results After 6-week therapy,no significant difference was observed in two groups in terms of PANSS total score and PANSS-EC scores (P >0.05)between two groups,we found statistical difference when compared with before treatment in both groups (P 0.05)。而给药6周后与治疗前2组比较差异均具有统计学意义(P <0.05)。用药后观察组、对照组锥体外系不良反应发生率分别为42.5%、67.5%,差异有统计学意义(P <0.05)。观察组有效率为87.5%,对照组为65.0%,2组比较差异有统计学意义(P <0.05)。结论RPD 口服对改善 BPSD 与 HPL 疗效相当,但 RPD 的临床实效性更好,锥体外系不良反应发生率低,值得临床推广应用。

  16. Analysis on Characteristics and Regularities of Efficacies of Acupoint Injection by Using Data Mining Technique%基于数据挖掘技术的穴位注射疗法效应特点研究

    Institute of Scientific and Technical Information of China (English)

    许晓康; 贾春生; 王建岭; 石晶; 覃亮; 张莘; 张选平

    2012-01-01

    Objective To analyze the potential learning and regularity characters of clinical application of acupoint injection In modern literature of Chinese medicine by using data mining technique, so as to provide a reference for clinical application of this therapy- Methods A database was established first by computer recording of the standardized information data after collection of papers about acupoint injection therapy published in modern medical journals, collections of theses of medical academic conferences, dissertations for medical master's and doctor's degrees. Then, the data mining technique was employed to conduct cross link design about the types or categories of illnesses or clinical conditions, categories of departments, selection of Chinese materia medica, acupoint recipes, and clinical outcomes, etc. At last, the rules and characteristics of the acupoint injection were summarized and analyzed. Results The acupoint injection therapy enjoys the first rank of therapies for the treatment of diseases or clinical conditions of the internal medicine, and the second rank in the treatment of surgical problems. With respect to the types of illnesses or clinical conditions, it is used most frequently for hiccup and backleg pain. Generally, about 4 acupoints and 2 categories of medicines (Chinese herbal medicine or western medicine preparations) are selected in one session of treatment by using the acupoint injection therapy. The acupoints used are those close to and remote to the loci. The drugs predominately employed are single or compound western medicine preparations. The total effective rate is up to more than 93%. Conclusion The acupoint injection therapy has some obvious advantages in the treatment of clinical conditions or illness of the internal medicine and surgical problems, especially for hiccup and backleg pain. It is simple in clinical application and has a higher therapeutic effect.%目的:应用数据挖掘技术,发现穴位注射临床运用中潜

  17. The therapeutic efficacy of Lipo PGE combined with Shuxuetong injection in treatment of diabetic peripheral neuropathy%前列地尔联合疏血通治疗糖尿病周围神经病变的疗效观察

    Institute of Scientific and Technical Information of China (English)

    张小东; 陈岚

    2010-01-01

    目的 观察前列地尔(凯时)联合疏血通静脉滴注对糖尿病周围神经病变(DPN)的疗效.方法 将68名DPN患者分为两组,治疗组凯时+疏血通静脉滴注;对照组为疏血通静脉滴注,疗程均为14 d.结果 治疗组患者四肢疼痛、麻木、感觉异常等症状较对照组明显减轻(P<0.01),同时正中神经、腓肠神经的传导速度较治疗前明显加快(P<0.05),对照组治疗前后变化差异无统计学意义(P<0.05).结论 凯时联合疏血通治疗DPN是安全有效的方法.%Objective To observe the efficacy of Lipo PGE combined with Shuxuetong injection in treatment of diabetic peripheral neuropathy (DPN). Methods The 68 DPN patients were randomly divided into treatment group with Lipo PGE plus Shuxuetong injection and comparison group with Shuxuetong alone. The treatment period was 14 days. Results The pain, numbness,paresthesia and other symptoms in the limbs of patients were significantly reduced in treatment group than in comparison group (P<0. 01). At the same time, the conduction velocity of median nerve and sural nerve was significantly increased in treatment group after treatment (P<0.05), there were no significant differences in comparison group before and after the treatment. Conclusions The treatment of DPN with Lipo PGE combined with Shuxuetong injection is safe and effective.

  18. Role of Long-Acting Injectable Second-Generation Antipsychotics in the Treatment of First-Episode Schizophrenia: A Clinical Perspective

    Directory of Open Access Journals (Sweden)

    Radovan Přikryl

    2012-01-01

    Full Text Available Approximately 80% of patients with the first-episode schizophrenia reach symptomatic remission after antipsychotic therapy. However, within two years most of them relapse, mainly due to low levels of insight into the illness and nonadherence to their oral medication. Therefore, although the formal data available is limited, many experts recommend prescribing long-acting injectable second-generation antipsychotics (mostly risperidone or alternatively paliperidone in the early stages of schizophrenia, particularly in patients who have benefited from the original oral molecule in the past and agree to receive long-term injectable treatment. Early application of long-acting injectable second-generation antipsychotics can significantly reduce the risk of relapse in the future and thus improve not only the social and working potential of patients with schizophrenia but also their quality of life.

  19. 黄芪注射液联合超声雾化吸入治疗小儿支气管炎急性发作的临床效果和安全性%Clinical